

Analytical Epidemiology

Statistical and Causal Inference for Public Health

Eben Kenah

April 1, 2025

Table of contents

Preface	3
Who this book is for	4
How to use this book	4
Acknowledgements	4
 I Defining and Measuring Disease Occurrence	 6
 1 Probability, Random Variables, and Disease Occurrence	 7
1.1 Sets, experiments, and events	7
1.1.1 Experiments and events	8
1.1.2 Set operations and logic	9
1.1.3 Venn diagrams	10
1.1.4 Sequences of events*	12
1.1.5 Algebra of sets*	13
1.2 Probability	13
1.2.1 Probability calculations	14
1.3 Random variables	15
1.3.1 Indicator variables	16
1.4 R	16
1.4.1 Probability distributions	16
1.4.2 Mean	17
1.5 R	18
1.5.1 Variance	18
1.5.2 Bernoulli distribution	18
1.6 Joint and marginal distributions	19
1.7 R	20
1.7.1 Linear combinations*	20
1.7.2 Variance and covariance*	21
1.8 Probability and disease occurrence	22
1.8.1 Prevalence	23
1.9 R	24
1.9.1 Risk (cumulative incidence) and the survival function	24
1.10 R	24
1.10.1 Prevalence and the duration of disease	25

1.10.2	Descriptive and analytic epidemiology	26
2	Conditional Probability and Diagnostic Tests	34
2.1	Contingency tables	34
2.1.1	2x2 tables	35
2.1.2	Joint and marginal probabilities	35
2.1.3	Conditional probabilities	36
2.2	Multiplication of conditional probabilities	37
2.2.1	Decision trees	37
2.2.2	Independence of events	37
2.3	Sensitivity and specificity	39
2.4	R	40
2.4.1	Example: Diabetes testing	40
2.5	R	41
2.5.1	Receiver operating characteristic (ROC) curves*	41
2.6	R	44
2.7	Law of total probability	44
2.7.1	Example: probability of a positive or negative test	45
2.7.2	Standardization	47
2.8	Bayes' rule	48
2.8.1	Positive and negative predictive values	48
2.8.2	Likelihood ratios*	51
3	Maximum Likelihood Estimation	58
3.1	Binomial likelihood	58
3.1.1	Binomial distribution	59
3.2	R	60
3.2.1	Likelihood and log likelihood	60
3.2.2	Score function	62
3.2.3	Expected and observed information*	63
3.3	Large-sample theory	64
3.3.1	Sample mean (average)	64
3.3.2	Law of large numbers and consistency	64
3.3.3	Central limit theorem and the normal distribution	66
3.4	R	69
3.4.1	Efficiency of maximum likelihood estimators*	71
3.5	Hypothesis testing	72
3.5.1	Hypothesis tests and diagnostic tests	73
3.5.2	Wald, score, and likelihood ratio tests	74
3.5.3	Critical values and p-values	76
3.6	Confidence intervals	76
3.6.1	Wald confidence intervals and the delta method	77
3.6.2	Score (Wilson) confidence intervals	79

3.7	R	80
3.8	Small-sample estimation*	80
3.8.1	Median unbiased estimate	81
3.8.2	Exact (Clopper-Pearson) and mid-p confidence intervals	81
3.9	R	82
4	Bayesian Estimation	90
4.1	Prior and posterior distributions	90
4.1.1	Posterior point and interval estimation	91
4.1.2	Bayesian interpretation of confidence intervals	92
4.1.3	Posterior probability of H_0 and p-values	92
4.2	Bayesian estimation of a probability	95
4.2.1	Beta distribution	95
4.2.2	Posterior point and interval estimates	96
4.2.3	Jeffreys confidence interval	98
4.3	Comparison of binomial confidence intervals	98
4.4	R	99
5	Longitudinal Data, Rates, and Counts	102
5.1	Incomplete follow-up	104
5.1.1	Right censoring	104
5.1.2	Delayed entry (left truncation)	105
5.1.3	Left censoring and right truncation	105
5.2	Failure time distributions	105
5.2.1	Survival function	106
5.2.2	Hazard function	107
5.2.3	Cumulative hazard function	108
5.2.4	Likelihoods for right-censored and left-truncated data	109
5.3	Exponential distribution	110
5.3.1	Mean and variance	111
5.3.2	Incidence rates	111
5.4	R	112
5.4.1	Memoryless property	113
5.4.2	Prevalence, incidence, and duration of disease*	114
5.5	Poisson distribution	115
5.5.1	Mean and variance	116
5.5.2	Incidence rates via count data	116
5.6	R	117
5.6.1	Small-sample estimation of incidence rates	117
5.7	R	118
5.7.1	Poisson approximation to the binomial for rare events*	118
5.8	Bayesian estimation of incidence rates	119
5.8.1	Gamma conjugate distribution	120

5.8.2	Jeffreys confidence interval	121
5.9	R	122
6	One-Sample Survival Analysis	129
6.1	Empirical cumulative distribution function	130
6.2	Kaplan-Meier estimator	131
6.2.1	At-risk process and risk sets	131
6.2.2	Survival via multiplication of conditional probabilities	132
6.3	R	133
6.3.1	Greenwood formula and confidence intervals	134
6.3.2	Cumulative incidence and cumulative hazard	136
6.4	Nelson-Aalen estimator	136
6.4.1	Cumulative hazard via addition of expected values	136
6.5	R	137
6.5.1	Variance and confidence intervals	138
6.5.2	Survival and cumulative incidence functions	140
6.6	Parametric failure time distributions	142
6.6.1	Weibull distribution	143
6.7	R	144
6.7.1	Log-logistic distribution	144
6.8	R	146
6.8.1	Cox-Snell residuals	147
II	Study Design and Measures of Association	156
7	Cohort and Case-Control Studies	157
7.1	Sampling from a population	157
7.1.1	Hypergeometric distribution*	158
7.1.2	Multinomial distribution	159
7.2	Hypothesis tests for independence in a 2x2 table	160
7.2.1	Equality of conditional probabilities	160
7.2.2	Hypergeometric chi-squared test	161
7.2.3	Pearson's chi-squared test	163
7.2.4	Small samples and exact tests*	164
7.3	Cohort studies	165
7.3.1	Selection by exposure	166
7.3.2	Score test for independence in a cohort study*	167
7.3.3	Optimal sampling by exposure	168
7.4	R	171
7.5	Case-control studies	171
7.5.1	Selection by disease	171
7.5.2	Score test for independence in a case-control study*	173

7.5.3	Optimal sampling by disease	174
7.6	Choice of study design	174
7.6.1	Odds ratio	175
7.6.2	Imbalance and efficiency on a fixed budget	176
8	Internal and External Validity	182
8.1	Misclassification	183
8.1.1	Nondifferential misclassification of disease	183
8.1.2	Nondifferential misclassification of exposure	187
8.1.3	Simultaneous nondifferential misclassification	190
8.2	Selection bias	191
8.2.1	Selection bias in cohort studies	192
8.2.2	Selection bias in case-control studies	192
8.2.3	Prospective and retrospective studies	193
8.2.4	Generalizability and transportability	193
8.2.5	Example: Berkson's bias	194
8.3	R	196
9	Measures of Association in Cohort Studies	199
9.1	Measures of association	199
9.1.1	Risk difference	200
9.2	R	200
9.2.1	Risk ratio	201
9.3	R	202
9.3.1	Odds ratio	202
9.4	R	204
9.4.1	Incidence rate ratio	204
9.5	R	205
9.6	Generalized linear models	205
9.6.1	Risk differences and the identity link	206
9.7	R	209
9.7.1	Risk ratios and the log link	209
9.8	R	212
9.8.1	Odds ratios and the logit link	212
9.9	R	213
9.9.1	Cumulative hazard ratio and the complementary log-log link*	214
9.10	R	215
9.10.1	Poisson GLMs for incidence rate ratios	215
9.11	R	216
9.11.1	Poisson GLMs for risks	216
9.12	Rothman diagrams	217
9.12.1	Contour lines	217
9.12.2	Relationships among the RR, OR, and HR	220

9.12.3 Relationships between changes in the RD, RR, and OR*	220
10 Two-Sample Survival Analysis and the Cox Model	239
10.1 Measures of association in survival analysis	239
10.1.1 Rate ratios and hazard ratios	240
10.1.2 Risk differences, risk ratios, and odds ratios	241
10.2 Accelerated failure time models	244
10.2.1 Exponential AFT model	245
10.3 R	245
10.3.1 Weibull AFT model	246
10.4 R	246
10.4.1 Log-logistic AFT model	246
10.5 R	246
10.6 Log-rank test	247
10.6.1 Observed and expected failures among the exposed	247
10.6.2 Chi-squared statistic	247
10.6.3 Weighted log-rank tests	248
10.7 R	249
10.8 Cox model	249
10.8.1 Proportional hazards assumption	249
10.8.2 Partial likelihood	250
10.8.3 Correction for ties*	251
10.8.4 Estimation of baseline survival and cumulative hazard*	253
10.9 R	255
11 Design and Analysis of Case-Control and Case-Cohort studies	263
11.1 Case-control studies for rare diseases	264
11.1.1 Cumulative case-control studies and the odds ratio	264
11.2 R	266
11.2.1 Density case-control studies and risk-set sampling	267
11.3 R	269
11.4 Case-cohort studies	269
11.4.1 Rare diseases with rare exposures	270
11.4.2 Estimation without the rare disease assumption*	270
11.5 Nested case-control studies	272
11.5.1 Conditional logistic regression	273
11.6 R	273
12 Bayesian analysis of cohort and case-control studies	278
12.1 Prior distributions	278
12.2 Posterior distributions	279
12.2.1 Markov chain Monte Carlo	279
12.2.2 Hamiltonian Monte Carlo	280

12.2.3	Laplace approximation	281
12.2.4	Inference with samples from the posterior	281
12.3	Cohort studies	281
12.3.1	Risk ratios	281
12.4	R	281
12.4.1	Odds ratios	281
12.5	R	281
12.5.1	Accelerated failure time models	282
12.5.2	Proportional hazards models	282
12.6	Case-control studies	282
12.6.1	Conditional logistic regression	282
III	Principles of Causal Inference	285
13	Causality in Public Health	286
13.1	Koch's postulates	286
13.1.1	Lack of sufficiency: cholera	287
13.1.2	Lack of necessity: the common cold	288
13.2	Chronic diseases	289
13.2.1	Specificity	289
13.2.2	Strength of association	290
13.2.3	Biological plausibility	291
13.2.4	Multiple causation	292
13.3	Hill Criteria	293
13.3.1	Statistics in causal inference	294
13.4	Observation versus experiments	295
13.4.1	Intervention	296
14	Potential Outcomes and Attributable Risk	297
14.1	Potential outcomes	297
14.1.1	Measures of causal effect	298
14.1.2	Confounding and exchangeability	298
14.1.3	Selection bias and the analytic cohort condition	299
14.2	Attributable risk	301
14.2.1	Sufficient-component cause model (causal pies)	301
14.2.2	Attributable risk among the exposed	302
14.2.3	Population attributable risk	302
14.2.4	Dependence on time interval	303
14.2.5	Adding up attributable risks	303
14.3	Excess and etiologic cases	303
14.3.1	Excess and etiologic fractions	304
14.3.2	Limitations of the etiologic fraction	305

14.4	Sensitivity analysis	306
14.4.1	Cornfield's inequality	306
14.4.2	E-values	307
15	Confounding and Selection Bias on DAGs	308
15.1	Simpson's paradox	308
15.2	Directed acyclic graphs	309
15.2.1	Adding variables and arrows	310
15.2.2	Paths and causal paths	311
15.3	R	312
15.3.1	Ancestors and descendants	312
15.4	R	312
15.4.1	Joint distributions consistent with a DAG*	313
15.4.2	Open paths and associations	313
15.5	R	314
15.5.1	Conditional associations	314
15.6	R	315
15.7	Confounding and selection bias	316
15.7.1	Confounding and open backdoor paths	316
15.7.2	Selection bias and colliders	316
15.7.3	Simpson's paradox revisited	316
15.7.4	Berkson's bias	316
16	Confounding and Selection Bias on SWIGs	326
17	Causal Effects and Standardization	327
17.1	Measures of association in a cohort study with bias	327
17.1.1	Confounding and selection bias	328
17.1.2	Crude measures	329
17.1.3	Marginal causal effects	329
17.1.4	Stratum-specific measures	330
17.1.5	Conditional causal effects	331
17.2	Standardization	331
17.2.1	Reconstructing marginal causal risks	331
17.2.2	Standardized risks and measures of association	332
17.2.3	Treatment effects	333
17.2.4	Confidence limits	334
17.3	Simpson's paradox standardized	335
17.3.1	Crude risks and measures of association	335
17.4	R	336
17.4.1	Conditional risks and measures of association	336
17.5	R	337
17.5.1	Standardized risks and measures of association	337

17.6 R	338
18 Geometry of Causal Inference	344
18.1 Rothman diagrams	344
18.1.1 Example: smoking and 20-year mortality	344
18.2 R	346
18.2.1 Causal points	346
18.2.2 Association points	347
18.2.3 Standardization and line segments	348
18.3 Confounding	352
18.3.1 Confounding rectangle	352
18.3.2 Confounders with more than two levels*	353
18.4 Effect measure modification	355
18.4.1 Contour lines	356
18.4.2 Interaction	357
18.5 R	359
18.6 Collapsibility	361
18.6.1 Definition in terms of standardized measures	361
18.6.2 Straight contour lines	361
18.6.3 Noncollapsibility and changes upon adjustment	364
 IV Epidemiologic and Statistical Methods for Causal Inference	 374
19 Stratified Analysis	375
19.1 Pooled measures of association	376
19.1.1 Woolf estimators	376
19.1.2 Mantel-Haenszel estimators	377
19.2 Testing homogeneity	379
19.2.1 Wald χ^2 tests	380
19.2.2 Interaction terms	380
19.2.3 Testing the null hypothesis	380
19.3 Regression models	381
19.3.1 Conditional logistic regression	381
19.3.2 Stratified AFT models	382
19.4 R	382
19.4.1 Stratified Cox model	382
19.5 R	384
 20 Matching in Cohort and Case-Control Studies	 387
20.0.1 Matching in a cohort study	388
20.0.2 Matching on non-confounders	389
20.0.3 Matching and efficiency	389

20.1 Matching in a case-control study	390
20.1.1 Matching on non-confounders	390
20.1.2 Matching and efficiency	391
20.2 Overmatching	391
References	395
Appendices	408
A Calculus	408

Preface




Figure 1: Areas of London supplied by the Southwark & Vauxhall (blue, now green) and Lambeth (red) water companies during the 1849-1854 cholera epidemic in London (Snow 1855). Source: Wellcome Collection via [Wikimedia Commons](#).

One day at lunch at the Harvard School of Public Health, I overheard Professor Murray Mittleman say: “I love epidemiology. It all fits together like a diamond.” As a second-year doctoral student in epidemiology, I was surprised to hear the subject described with such unstrained enthusiasm. It has taken years of study and experience for me to understand what he meant. On the way, I too have fallen in love.

Who this book is for

This book is intended primarily for two audiences:

- Epidemiologists are often protected from the mathematical foundations of their field. The long-term price of this is “dogmatism, that is, a tendency to rigidly protect a partially understood theoretical heritage” (Morabia 2004). The mathematics needed for a deeper understanding of epidemiologic methods is within reach of anyone who has come far enough to need it. Whether you master this material or just learn to approach it with more patience than fear, you will be doing a service to epidemiology and to public health.
- Biostatisticians are familiar with probability and statistical inference, but applying statistics to solve scientific problems in public health requires skills different from those needed to prove that a method works under given assumptions. Epidemiology is a living example of the interplay between theory and applications in statistics, and epidemiologists have shown integrity, courage, and ingenuity in confronting causal questions with statistical tools.

Beyond these audiences, I hope to explain the logic of epidemiology to any interested reader. It is possible that epidemiologic research has already helped save your life.

How to use this book

Difficult chapters, sections, subsections, and exercises are marked with an asterisk (*). These can be skipped without harming the logical flow of the book, but none of them is beyond the reach of a determined reader. The starring is recursive: Starred sections can be skipped within a starred chapter, starred subsections can be skipped within a starred section, and so on. Footnotes offer context or hint at more advanced material, and they can be ignored if they do not seem useful or interesting.

This is a work in progress. You may find that some parts are unfinished or just bad. Please report errors (including typos) or submit suggestions (especially good examples) at:

<https://github.com/ekenah/analyticalepi/issues>.

Acknowledgements

This book is written in [LaTeX](#) and [Quarto](#) with calculations and figures generated in [R](#), [Python](#), and [Inkscape](#). I have also included many links to [Wikipedia](#). A good text editor and code editor are important, and I use [vim](#) and [VSCode](#). All of these are free, open-source, and publicly available thanks to the work of many contributors. I am also grateful to [Google Scholar](#), [PubMed](#), and the libraries at [Ohio State](#), the [University of Florida](#), the [University](#)

of Washington, and Harvard University for giving me access to the scientific literature in epidemiology, statistics, public health, and medicine.

Tony Barry, Devesh Kapur, Paul Farmer, and James H. Maguire guided me to a career in public health when I was an undergraduate. James Robins, Miguel A. Hernán, Marc Lipsitch, and Stephen P. Luby helped me become an epidemiologist, biostatistician, and epidemic modeler in graduate school. My career began under the mentorship of Ira M. Longini, Jr., and M. Elizabeth Halloran as a postdoctoral fellow at the University of Washington and an assistant professor at the University of Florida. My colleagues Yang Yang, Grzegorz Rempała, Forrest Crawford, and Patrick Schnell have all provided useful comments. For their patience with early versions of this material, I am grateful to the students of STA 6177/PHC 6937 (Applied Survival Analysis) at the University of Florida from 2013 to 2016 and PUBHEPI 8430 (Epidemiology 4) at The Ohio State University from 2019 to the present.

My parents, Chris and Kate Kenah, courageously allowed me to travel to places they had never been to and do things I had been told to avoid. These experiences in the United States, India, South Africa, and especially Bangladesh opened my eyes to the terrible importance of clear thinking in public health. My wife, Asma Aktar, and our sons Rafi, Rayhan, and Rabi remind me every day how important it is to destroy everything that stifles humanity. To that end, I hope this book is useful.

Any mistakes are my own, and God knows best). (

Part I

Defining and Measuring Disease Occurrence

1 Probability, Random Variables, and Disease Occurrence

One sees, from this essay, that probability theory is basically common sense reduced to calculation; it makes us appreciate with exactitude that which fair minds sense with a sort of instinct, often without being able to account for it. (Laplace 1820)¹

To begin at the beginning, we will start with probability. Morabia (2004) accurately observed that “Epidemiology came late in human history because it had to wait for the emergence of probability.” This is probably the most difficult chapter of the book, but it will make all subsequent chapters easier. You can use it as a reference and come back to the difficult parts when you need them. Learning to think clearly about probability will give you a compass to find your way through difficult terrain in epidemiology.

1.1 Sets, experiments, and events

To speak clearly about probabilities, we need some basic notation for sets. If A is a set that contains an **element** a , we write

$$a \in A. \tag{1.1}$$

If A and B are sets such that every element of A is also an element of B , we write

$$A \subseteq B. \tag{1.2}$$

to indicate that A is a **subset** of B . Sets A and B are equal if and only if $A \subseteq B$ and $B \subseteq A$, which means they contain exactly the same elements. The *empty set* with no elements is denoted \emptyset . For any set A , it is true that $A \subseteq A$ and $\emptyset \subseteq A$.

¹[Pierre-Simone, marquis de Laplace](#) (1749-1827) is often called the Newton of France. He proved that the solar system is stable, developed theories of ocean tides and gravitational potential, proved one of the first general versions of the central limit theorem, and pioneered the Bayesian interpretation of probability. His is one of the 72 names on the Eiffel Tower.

We use \mathbb{R} to denote the real numbers. Intervals are subsets of \mathbb{R} that take one of the following forms:

$$(a, b) = \{x \in \mathbb{R} : a < x < b\}, \quad (1.3)$$

$$(a, b] = \{x \in \mathbb{R} : a < x \leq b\}, \quad (1.4)$$

$$[a, b) = \{x \in \mathbb{R} : a \leq x < b\}, \quad (1.5)$$

$$[a, b] = \{x \in \mathbb{R} : a \leq x \leq b\}. \quad (1.6)$$

$$(1.7)$$

An endpoint with a square bracket is included in the interval; an endpoint with a round bracket is not. We can have $a = -\infty$ or $b = \infty$ as long as we use a round bracket for the corresponding endpoint. For example, it is true that $\mathbb{R} = (-\infty, \infty)$. However, $\mathbb{R} \neq [-\infty, \infty]$ because $\pm\infty$ are not real numbers.

1.1.1 Experiments and events

In probability, an **experiment** is any process that will produce one outcome out of a set of possible outcomes. The set of possible outcomes is called the **sample space** and is traditionally denoted Ω . An experiment produces a single outcome $\omega \in \Omega$. For example, the sample space for a single coin flip is

$$\Omega = \{H, T\}, \quad (1.8)$$

where $\omega = H$ if we get heads and $\omega = T$ if we get tails.

The outcomes in the sample space must determine everything about the random outcome of the experiment. If we flip a coin twice, the sample space cannot be $\{H, T\}$ because each $\omega \in \Omega$ must specify the outcome of both coin flips. Instead,

$$\Omega = \{HH, HT, TH, TT\} \quad (1.9)$$

where $\omega = XY$ if we get X on the first flip and Y on the second. This helps us see, for example, that there are two ways to get one H and one T in two coin flips.

The purpose of probability is to summarize uncertainty about the outcomes of experiments. However, the outcomes themselves do not have probabilities. Probabilities are assigned to **events**, which are subsets of the sample space Ω . If A is an event, then A occurs if and only if the outcome ω produced by our experiment is an element of A (i.e., if and only if $\omega \in A$). If we flip a coin twice, the event that we get two heads is $\{HH\}$, the event that we get one head is $\{HT, TH\}$, and the event that we get zero heads is $\{TT\}$. By definition, the event Ω always occurs and the event \emptyset never occurs.

In experiments with a finite or countably infinite sample space,² the distinction between the outcome ω and the event $\{\omega\}$ can be safely ignored. In more complex experiments (e.g., taking a random sample from a standard normal distribution), this distinction is important.³ In all cases, experiments have outcomes and events have probabilities.

In epidemiology, it is often useful to think of the sample space Ω as being a population and each $\omega \in \Omega$ as an individual in this population. In this context, our experiment is to sample a person from Ω and ask them questions, take measurements, or follow them over time to ascertain disease occurrence. Events would be subpopulations of Ω , such as $\{\omega \in \Omega : \omega \text{ lives in Ohio}\}$. This event occurs if the sampled individual ω lives in Ohio, and it does not occur if they live somewhere else.

1.1.2 Set operations and logic

There are three basic set operations that take one or more sets and define another set: complement, intersection, and union. Each operation has a simple interpretation in terms of logic.

- The **complement** of a set A is

$$A^c = \{\omega \in \Omega : \omega \notin A\}, \quad (1.10)$$

which can be interpreted logically as **not** A . If A is an event, then the event A^c occurs if $\omega \notin A$. For the same reason that “not not A ” means “ A ”, we have $(A^c)^c = A$.

- The **intersection** of two sets A and B is

$$A \cap B = \{\omega \in \Omega : \omega \in A \text{ and } \omega \in B\}, \quad (1.11)$$

which can be interpreted logically as A **and** B . If A and B are events, then the event $A \cap B$ occurs if $\omega \in A$ and $\omega \in B$.

- The **union** of two sets A and B is

$$A \cup B = \{\omega \in \Omega : \omega \in A \text{ or } \omega \in B\}, \quad (1.12)$$

which can be interpreted logically as A **or** B as long as we use an *inclusive* “or” (i.e., and/or). If A and B are events, then the event $A \cup B$ occurs if $\omega \in A$ or $\omega \in B$.

²The natural numbers $\mathbb{N} = \{0, 1, 2, \dots\}$ are *countably infinite*, as are the integers \mathbb{Z} and the rational numbers \mathbb{Q} . The real numbers \mathbb{R} are *uncountably infinite*, as are the real numbers in any nonempty interval (a, b) and the irrational numbers. Uncountably infinite sets are infinitely larger than countably infinite sets. This distinction was discovered in the 1870s by the German mathematician [Georg Cantor](#) (1845–1918). It was considered shocking, but it has become a cornerstone of modern mathematics.

³In experiments with uncountably infinite sample spaces, the probability of an event A cannot always be calculated by adding up the probabilities of $\{\omega\}$ for all $\omega \in A$. For example: If we choose a number at uniformly at random in $[0, 1]$, the probability of getting any particular number ω is zero. The sum of the probabilities of all $\{\omega\} \subseteq A$ is zero (if A is countable) or undefined (if A is uncountable). By maintaining a distinction between outcomes and events and by limiting probability calculations to countable (i.e., finite or countably infinite) sums, we end up with something coherent and useful.

If $A \subseteq B$, then $A \cap B = A$ and $A \cup B = B$. An important special case is that

$$A \cap A = A \cup A = A. \quad (1.13)$$

For the empty set \emptyset , we get $A \cap \emptyset = \emptyset$ and $A \cup \emptyset = A$. For the sample space Ω , we get $A \cap \Omega = A$ and $A \cup \Omega = \Omega$.

Union and intersection are *commutative* operations like addition and multiplication, so the order of A and B does not matter:

$$A \cup B = B \cup A$$

and

$$A \cap B = B \cap A.$$

Events A and B are **disjoint** or **mutually exclusive** when $A \cap B = \emptyset$. If A and B are disjoint, then at most one of them can occur in a single experiment. Any set and its complement are disjoint, and the empty set \emptyset is disjoint with itself and all other sets.

If Ω is a population, these set operations allow us to define subpopulations in terms of multiple traits. If the event $A = \{\omega \in \Omega : \omega \text{ lives in Ohio}\}$, then its complement A^c contains all individuals in Ω who live outside Ohio. If the event $B = \{\omega \in \Omega : \omega \text{ is 42 years old}\}$, then the intersection $A \cap B$ contains everyone in Ω who is 42 years old and lives in Ohio. If Ω does not contain any 42-year-old Ohio residents, then A and B are disjoint. The union $A \cup B$ contains everyone in Ω who lives in Ohio or is 42 years old. This could include both a 24-year-old who lives Ohio and a 42-year-old who lives Michigan.

1.1.3 Venn diagrams

A useful tool for understanding events and set operations is the **Venn diagram**.⁴ An example is shown in Figure 1.1. The rectangle represents Ω , and the circles A and B represent events. A^c is everything in Ω outside the circle A , and B^c is everything outside the circle B . Their intersection $A \cap B$ is the area where the two circles overlap. Their union $A \cup B$ is everything contained in at least one of A or B .

⁴Named after [John Venn](#) (1834-1923), an English logician and philosopher who was one of the pioneers of the frequentist interpretation of probability. He was ordained as an Anglican priest in 1859 but resigned from the church in 1883. He was a prize-winning gardener of roses and white carrots and a prominent supporter of women's right to vote. From 1903 until his death, he was President of Fellows in Gonville and Caius College at the University of Cambridge, where he is commemorated with a Venn diagram in a stained glass window.




Figure 1.1: Venn diagram showing events A and B . The area contained in both events is their intersection $A \cap B$. The union $A \cup B$ is all area contained in at least one of A and B , including $A \cap B$.

1.1.4 Sequences of events*

Intersections can be written for more than two events. The intersection of A_1, A_2, \dots, A_n is

$$I_n = \bigcap_{i=1}^n A_i. \quad (1.14)$$

Because set intersection is commutative and associative, any ordering of A_1, \dots, A_n produces the same intersection. The event I_n occurs if and only if all of the events A_1, \dots, A_n occur. Each new event makes the intersection smaller (i.e., never larger) in the sense that

$$\bigcap_{i=1}^{n+1} A_i \subseteq I_n.$$

whenever A_{n+1} is another event.

Similarly, unions can be written for more than two events. If A_1, A_2, \dots, A_n is a set of events, then their union is

$$U_n = \bigcup_{i=1}^n A_i. \quad (1.15)$$

Because set union is commutative and associative, any ordering of A_1, \dots, A_n produces the same union. The event U_n occurs if and only if at least one of the events A_i occurs. Each new event makes the union bigger (i.e., never smaller) in the sense that

$$U_n \subseteq \bigcup_{i=1}^{n+1} A_i$$

whenever A_{n+1} is another event.

Both unions and intersections can be defined for infinite sequences of events.⁵ To describe this, we let $n = \infty$ in the notation from Equation 1.14 or Equation 1.15. The union of any finite sequence of events can be turned into the union of an infinite sequence of events by adding an endless sequence of empty sets to the finite sequence. The new sequence is still a sequence of disjoint events, and each empty set \emptyset leaves the union unchanged. If (A_1, A_2, \dots) is an infinite sequence of events such that $A_i = \emptyset$ for all $i > n$, then

$$\bigcup_{i=1}^{\infty} A_i = \bigcup_{i=1}^n A_i.$$

This turns out to be useful when we try to give a mathematically rigorous definition of probability.

⁵In probability, we only consider unions and intersections of finite or countably infinite sets of events. Although unions and intersections can be defined for uncountably infinite sets of events, it can be impossible to assign probabilities to the resulting sets (see the [Banach-Tarski paradox](#)). As an epidemiologist, this should not keep you up at night.

1.1.5 Algebra of sets*

Unions, intersections, and complements can be combined in complex ways. Fortunately, there are a few basic principles that can be used to simplify these calculations. We have already seen that unions and intersections are commutative. Unions and intersections are also *associative*, so

$$A \cup (B \cup C) = (A \cup B) \cup C$$

and

$$A \cap (B \cap C) = (A \cap B) \cap C$$

for any sets A , B , and C .

De Morgan's laws describe how complements affect unions and intersections. If A and B are sets, then

$$(A \cap B)^c = A^c \cup B^c \quad (1.16)$$

because you are outside $A \cap B$ if and only if you are outside A or outside B . Similarly,

$$(A \cup B)^c = A^c \cap B^c. \quad (1.17)$$

because you are outside $A \cup B$ if and only if you are outside A and outside B . Note that each of these equations implies the other if we replace $A = (A^c)^c$ with A^c and replace $B = (B^c)^c$ with B^c . They are two sides of the same coin, but it is helpful to remember them both.

The *distributive properties* describe how unions and intersections interact with each other. Recall that multiplication distributes over addition, so $a(b + c) = ab + ac$. For any sets A , B , and C , we have the following distributive properties:

- Intersections distribute over unions, so

$$A \cap (B \cup C) = (A \cap B) \cup (A \cap C).$$

- Unions distribute over intersections, so

$$A \cup (B \cap C) = (A \cup B) \cap (A \cup C).$$

Intersections and unions also distribute over themselves. However, this is a consequence of commutativity, associativity, and Equation 1.13, not a separate property like the distributive rules above.

1.2 Probability

A *probability measure* is a function that takes an event $A \subseteq \Omega$ and returns a number $\Pr(A) \in [0, 1]$ in any way that conforms to the following rules:

- $\Pr(\Omega) = 1$.
- $\Pr(A) \in [0, 1]$ for any event $A \subseteq \Omega$.⁶
- The **addition rule**: If (A_1, A_2, \dots) is any sequence of disjoint events, then

$$\Pr\left(\bigcup_{i=1}^{\infty} A_i\right) = \sum_{i=1}^{\infty} \Pr(A_i).$$

The addition rule is stated in terms of an infinite sequence of disjoint events because this implies the addition rule for any finite sequence of disjoint events (see Section 1.1.4).

It is useful to think of probability as a generalization of our intuitions about area or volume. When there is no overlap in a set of two-dimensional shapes, we can get the total area they cover by adding up the areas of the individual shapes. Similarly, we can get the total volume taken up by a set of bowling balls by adding up their individual volumes.

There is a lot of debate about the meaning of probability, but its definition does not assume any particular interpretation. Probability calculations are based on the rules above no matter what we think it all means, and any interpretation consistent with these rules is valid.

1.2.1 Probability calculations

Several useful properties of probability follow immediately from the definition above. A short proof follows each result. To follow the proofs, it helps to draw Venn diagrams.

Theorem 1.1. *If A is an event, $\Pr(A^C) = 1 - \Pr(A)$.*

Proof. Because $\Omega = A \cup A^C$ and A and A^C are disjoint, we have

$$\Pr(A) + \Pr(A^C) = \Pr(\Omega) = 1$$

by the addition rule. The result follows when we subtract $\Pr(A)$ from both sides. \square

Theorem 1.2. *If A and B are events such that $A \subseteq B$, then $\Pr(A) = \Pr(B) - \Pr(B \cap A^C)$. This implies that $\Pr(A) \leq \Pr(B)$.*

⁶Technically, we assign probabilities only to events in a class \mathcal{F} of subsets of Ω that is required to contain Ω and to be closed under complements and countable unions. “Closed under complements” means that $A^C \in \mathcal{F}$ whenever $A \in \mathcal{F}$. For example, $\emptyset = \Omega^C$ must be in \mathcal{F} because $\Omega \in \mathcal{F}$. “Closed under countable unions” means that $\bigcup_{i=1}^{\infty} A_i \in \mathcal{F}$ whenever (A_1, A_2, \dots) is a sequence of events in \mathcal{F} . The class \mathcal{F} is called a σ -algebra or σ -field, and this restriction on the domain of probability helps avoid internal contradictions like the [Banach-Tarski paradox](#).

Proof. Each element of B either is or is not in A , so

$$B = (B \cap A) \cup (B \cap A^c) = A \cup (B \cap A^c).$$

where the second equality follows from the fact that $B \cap A = A$ because $A \subseteq B$. The two sets on the right-hand side are disjoint, so we have

$$\Pr(B) = \Pr(A) + \Pr(B \cap A^c)$$

by the addition rule. The result follows if we subtract $\Pr(B \cap A^c)$ from both sides. This implies that $\Pr(A) \leq \Pr(B)$ because $\Pr(B \cap A^c) \geq 0$. \square

Theorem 1.3. *If A and B are events, $\Pr(A \cup B) = \Pr(A) + \Pr(B) - \Pr(A \cap B)$.*

Proof. We can break $A \cup B$ into three disjoint sets: elements of A and not B , elements of B and not A , and elements of both A and B . In set notation, this is

$$A \cup B = (A \cap B^c) \cup (B \cap A^c) \cup (A \cap B).$$

By the addition rule,

$$\Pr(A \cup B) = \Pr(A \cap B^c) + \Pr(B \cap A^c) + \Pr(A \cap B). \quad (1.18)$$

By Theorem 1.2, we have

$$\Pr(A \cap B^c) = \Pr(A) - \Pr(A \cap B),$$

because $A \cap B \subseteq A$ and

$$\Pr(B \cap A^c) = \Pr(B) - \Pr(A \cap B).$$

because $A \cap B \subseteq B$. The result follows from substituting these back into Equation 1.18 and collecting terms involving $\Pr(A \cap B)$. Intuitively, $\Pr(A) + \Pr(B)$ includes the overlap $\Pr(A \cap B)$ twice, so we have to subtract out one of them. This can be seen clearly in Figure 1.1. \square

1.3 Random variables

The outcomes of an experiment can be anything, not just numbers. A **random variable** is a real-valued function defined on a sample space Ω . In other words, a random variable X is a function that takes an *argument* $\omega \in \Omega$ as input and returns a *value* $X(\omega) \in \mathbb{R}$. Traditionally, random variables are written as capital letters and possible values are written as lower-case letters, so $\Pr(X = x)$ denotes the probability of the event

$$\{\omega \in \Omega : X(\omega) = x\}.$$

For simplicity, random variables are usually written without the argument ω .

The distinction between outcomes and random variables is useful because we can define multiple random variables on the same sample space. For example, the height, weight, and age of an individual ω sampled from a population Ω are different random variables defined on the same sample space.

1.3.1 Indicator variables

The simplest random variables are **indicator variables**. For an event A , the indicator variable

$$\mathbb{1}_A(\omega) = \begin{cases} 1 & \text{if } \omega \in A, \\ 0 & \text{if } \omega \notin A. \end{cases}$$

Indicator variables are **binary** random variables, which take exactly two values. In practice, these values should be zero and one unless there is a specific reason to do otherwise. When sampling from a population, we can define indicator variables for membership in different subpopulations.

All of the basic set operations above can be expressed in terms of indicator variables for sets.

- The indicator function for the complement of A is

$$\mathbb{1}_{A^c} = 1 - \mathbb{1}_A. \quad (1.19)$$

- If B is another event and $\mathbb{1}_B$ is its indicator variable, then the indicator variable for the intersection A and B is the product of their indicator variables:

$$\mathbb{1}_{A \cap B} = \mathbb{1}_A \mathbb{1}_B. \quad (1.20)$$

- The indicator variable for the union $A \cup B$ is

$$\mathbb{1}_{A \cup B} = 1 - (1 - \mathbb{1}_A)(1 - \mathbb{1}_B) = \mathbb{1}_A + \mathbb{1}_B - \mathbb{1}_{A \cap B}. \quad (1.21)$$

This follows from Equation 1.17 because $A \cup B = (A^c \cap B^c)^c$.

1.4 R

1.4.1 Probability distributions

The set of possible values of a random variable X is called the *support* of X and denoted $\text{supp}(X)$.⁷ For example, the support of an indicator variable is $\{0, 1\}$. In this section, we will focus on **discrete** random variables, which have a support on a finite or countably infinite set. There are two standard ways to describe the distribution of a discrete random variable:

⁷Technically, the support of X is the smallest closed set S_X such that $\Pr(X \in S_X) = 1$. For a discrete random variable with support on a finite set, it is just the set of possible values. For a discrete random variable with support on a countably infinite set, it can include points whose probability mass is zero—a pathological case that we can safely ignore. For a continuous random variable, it can include values whose probability density is zero—a case that is not unusual or pathological.

- The **probability mass function** (PMF) of a discrete random variable X is

$$f(x) = \begin{cases} \Pr(X = x) > 0 & \text{if } x \in \text{supp}(X), \\ 0 & \text{if } x \notin \text{supp}(X). \end{cases}$$

Because $\Pr(\Omega) = 1$, we always have

$$\sum_{x \in \text{supp}(X)} f(x) = 1.$$

- The **cumulative distribution function** (CDF) of X is

$$F(x) = \Pr(X \leq x).$$

$F(x)$ is monotonically increasing in x , which means that $F(a) \leq F(b)$ whenever $a < b$. It has a jump upward of size $f(x)$ at each $x \in \text{supp}(X)$, and its value at each such x is the value that it jumps to—not the value that it jumps up from. For sufficiently small x , $F(x)$ can be made arbitrarily close to zero. For sufficiently large x , $F(x)$ can be made arbitrarily close to one. More formally, we say that $\lim_{x \downarrow -\infty} F(x) = 0$ and $\lim_{x \uparrow \infty} F(x) = 1$.

The PMF and CDF provide equivalent descriptions of the distribution of X in the sense that either of these functions can be used to calculate the other. Given the PMF f , the CDF is defined by

$$F(x) = \sum_{\substack{v \in \text{supp}(X): \\ v \leq x}} f(v).$$

where the sum is taken over all $u \in \text{supp}(X)$ such that $u \leq x$. Given the CDF F , the PMF is defined by

$$f(x) = F(x) - \max_{v \leq x} F(v)$$

where the maximum is $F(v)$ for the largest $v \in \text{supp}(X)$ such that $v < x$.

1.4.2 Mean

The **mean** or *expected value* of a random variable X is

$$\mathbb{E}(X) = \sum_{x \in \text{supp}(X)} x \Pr(X = x) = \sum_{x \in \text{supp}(X)} x f(x),$$

where f is the PMF of X . The mean is often written μ , and it is often described as a measure of the “location” or “central tendency” of X .

Indicators are an extremely useful for calculating probabilities using means. For any event A , its probability is the mean of the indicator variable $\mathbb{1}_A$:

$$\Pr(A) = 0 \Pr(\mathbb{1}_A = 0) + 1 \Pr(\mathbb{1}_A = 1) = \mathbb{E}(\mathbb{1}_A).$$

This is a common way to calculate probabilities in data analyses.

1.5 R

1.5.1 Variance

If X has $\mathbb{E}(X) = \mu$, then $(X - \mu)^2$ is another random variable. The **variance** of X is the expected value of $(X - \mu)^2$:

$$\text{Var}(X) = \mathbb{E}[(X - \mu)^2] = \sum_{x \in \text{supp}(X)} (x - \mu)^2 f(x).$$

{eq-Var} Because $(x - \mu)^2 \geq 0$ with equality if and only if $x = \mu$, we always have $\text{Var}(X) \geq 0$. We have $\text{Var}(X) = 0$ if and only if $X = \mu$ with probability one. An equivalent expression for the variance that is often easier to use is:

$$\text{Var}(X) = \mathbb{E}(X^2) - \mu^2 \tag{1.22}$$

where $\mathbb{E}(X^2)$ is the expected value of the random variable X^2 . The variance is often written σ^2 , and it is often described as a measure of the dispersion of X around the mean.

The square root of the variance is called the **standard deviation**, which is often written σ . If a random variable X has units (e.g., length, weight, or time), the mean and the standard deviation have the same units as X . For example, the mean and standard deviation of a length in meters both have units of meters but the variance has units of meters².

1.5.2 Bernoulli distribution

The distribution of an indicator variable is called the **Bernoulli distribution**.⁸ A random variable with the Bernoulli(p) distribution has the PMF

$$f(x) = p^x(1-p)^{1-x} = \begin{cases} 1-p & \text{if } x = 0 \\ p & \text{if } x = 1. \end{cases}$$

Equivalently, it has the CDF

$$F(x) = \begin{cases} 0 & \text{if } x < 0 \\ 1-p & \text{if } x \in [0, 1) \\ 1 & \text{if } x \geq 1. \end{cases}$$

⁸Named after [Jacob Bernoulli](#) (1655-1705), a Swiss mathematician who derived the first version of the law of large numbers and discovered the constant $e \approx 2.718281828$, which is the base for natural logarithms. He and his younger brother Johann Bernoulli (1667-1748) were some of the first mathematicians to try to understand and apply calculus, but their relationship eventually curdled into a jealous rivalry. A lunar impact crater called Bernoulli is named jointly after them.

If a random variable X has a Bernoulli(p) distribution, we write $X \sim \text{Bernoulli}(p)$. The indicator variable for an event A has a Bernoulli distribution with $p = \Pr(A)$.

If $X \sim \text{Bernoulli}(p)$, then it has mean

$$\mathbb{E}(X) = 0 \times (1 - p) + 1 \times p = p$$

and variance

$$\text{Var}(X) = (0 - p)^2(1 - p) + (1 - p)^2p = p(1 - p).$$

Its standard deviation is $\sqrt{p(1 - p)}$, which is greater than zero unless $p = 0$ or $p = 1$. If $p = 0$, then $X = 0$ with probability one. If $p = 1$, then $X = 1$ with probability one.

1.6 Joint and marginal distributions

If X and Y are random variables defined on the same probability space, then their **joint** probability mass function is

$$f(x, y) = \Pr(X = x \text{ and } Y = y) = \Pr(\{\omega : X(\omega) = x \text{ and } Y(\omega) = y\}).$$

The **marginal** probability mass functions are the PMFs of X or Y individually, which can be calculated from the joint PMF. The marginal PMF of X is

$$f_X(x) = \sum_{y \in \text{supp}(Y)} f(x, y),$$

and the marginal PMF of Y is

$$f_Y(y) = \sum_{x \in \text{supp}(X)} f(x, y).$$

These are called marginal distributions by analogy to the margins of a table. The distinction between joint and marginal distributions is extremely important in epidemiology and other applications of probability.

For example, Table 1.1 shows the joint and marginal PMFs for two binary random variables X and Y . By definition,

$$f(0, 0) + f(0, 1) + f(1, 0) + f(1, 1) = 1.$$

In the table, it is clear that the joint distribution determines the marginal distributions. However, there are many different joint distributions that are consistent with the same marginal distributions. Thus, the marginal distributions do not determine the joint distribution.⁹

⁹This becomes a fundamental insight when we discuss hypothesis tests for independence as well as confounding and selection bias.

Table 1.1: Joint and marginal PMFs for binary random variables X and Y .

	$Y = 0$	$Y = 1$	X margin
$X = 0$	$f(0, 0)$	$f(0, 1)$	$f_X(0) =$ $f(0, 0) + f(0, 1)$
$X = 1$	$f(1, 0)$	$f(1, 1)$	$f_X(1) =$ $f(1, 0) + f(1, 1)$
Y margin	$f_Y(0) =$ $f(0, 0) + f(1, 0)$	$f_Y(1) =$ $f(0, 1) + f(1, 1)$	1

1.7 R

Joint distributions can be defined for more than two random variables. If X_1, X_2, \dots, X_n are random variables defined on the same sample space, then their joint PMF is

$$f(x_1, x_2, \dots, x_n) = \Pr(X_1 = x_1, X_2 = x_2, \dots, X_n = x_n).$$

The marginal distribution of each X_i can be found by adding up the PMF over the support of all the other random variables. For example,

$$f_{X_2}(x_2) = \sum_{x_1 \in \text{supp}(X_1)} \sum_{x_3 \in \text{supp}(X_3)} f(x_1, x_2, x_3).$$

when $n = 3$. In this same case, we can talk about the joint distribution of any two variables marginalized over the third. For example,

$$f_{X_2, X_3}(x_2, x_3) = \sum_{x_1 \in \text{supp}(X_1)} f(x_1, x_2, x_3).$$

For larger n , the formulas gets uglier but the ideas are the same.

1.7.1 Linear combinations*

If a and b are constants, then $aX + bY$ is another random variable on Ω . It is called a *linear combination* of X and Y . Linear combinations can be defined for more than two random variables. If X_1, \dots, X_n are random variables defined on a sample space and a_1, \dots, a_n are constants, then

$$\sum_{i=1}^n a_i X_i = a_1 X_1 + a_2 X_2 + \dots + a_n X_n$$

is a linear combination of X_1, \dots, X_n . The constants can be any real numbers, including one and zero.

Section 1.3.1 contains both examples and non-examples of linear combinations of random variables.

- The indicator function for A^C in Equation 1.19 is a linear combination of $\mathbb{1}_A$ and the random variable $\mathbb{1}_\Omega$, which equals one for all $\omega \in \Omega$.
- The indicator function for $A \cup B$ in Equation 1.21 is linear combination of the indicator variables $\mathbb{1}_A$, $\mathbb{1}_B$, and $\mathbb{1}_{A \cap B}$.
- The indicator function for $A \cap B$ in Equation 1.20 is not a linear combination of $\mathbb{1}_A$ and $\mathbb{1}_B$ because we have to multiply these two variables.

If X and Y are random variables defined on the same sample space and a and b are constants, the mean of the linear combination $aX + bY$ is

$$\mathbb{E}(aX + bY) = a \mathbb{E}(X) + b \mathbb{E}(Y). \quad (1.23)$$

This is a direct consequence of the definition of expected value:

$$\begin{aligned} \mathbb{E}(aX + bY) &= \sum_{x \in \text{supp}(X)} \sum_{y \in \text{supp}(Y)} (ax + by) f(x, y) \\ &= a \sum_{x \in \text{supp}(X)} \left(x \sum_{y \in \text{supp}(Y)} f(x, y) \right) + b \sum_{y \in \text{supp}(Y)} \left(y \sum_{x \in \text{supp}(X)} f(x, y) \right) \\ &= a \sum_{x \in \text{supp}(X)} x f_X(x) + b \sum_{y \in \text{supp}(Y)} y f_Y(y). \end{aligned}$$

The algebra is not pretty, but the logic is straightforward. We split up the sum into parts depending only on x and only on y outside the joint PMF. In each part, we factor out a constant and find the marginal PMF. This same logic extends to a linear combination of any number of random variables.

1.7.2 Variance and covariance*

The variance of $aX + bY$ is

$$\text{Var}(aX + bY) = a^2 \text{Var}(X) + b^2 \text{Var}(Y) + 2ab \text{Cov}(X, Y) \quad (1.24)$$

where

$$\text{Cov}(X, Y) = \mathbb{E}[(X - \mathbb{E}(X))(Y - \mathbb{E}(Y))]$$

is called the **covariance** of X and Y . Note that $\text{Cov}(X, Y) = \text{Cov}(Y, X)$. Because $\text{Var}(X) = \text{Cov}(X, X)$, variance is a special case of covariance. When X and Y are *independent* in the sense that the value of one tells us nothing about the value of the other, then $\text{Cov}(X, Y) = 0$ and $\text{Var}(aX + bY) = a^2 \text{Var}(X) + b^2 \text{Var}(Y)$.¹⁰

¹⁰Discrete random variables X and Y are independent if $\Pr(X = x \text{ and } Y = y) = \Pr(X = x) \Pr(Y = y)$ for any possible values $x \in \text{supp}(X)$ and $y \in \text{supp}(Y)$. We will discuss independence more rigorously when we discuss conditional probabilities in Chapter 2.

The joint distribution of X and Y has a **covariance matrix** which is

$$\begin{bmatrix} \text{Var}(X) & \text{Cov}(X, Y) \\ \text{Cov}(X, Y) & \text{Var}(Y) \end{bmatrix}$$

The variances are along the diagonal of the matrix, and the covariances appear off the diagonal. Because $\text{Cov}(X, Y) = \text{Cov}(Y, X)$, covariance matrices are always symmetric (i.e., symmetric across the diagonal). Covariance matrices are an extremely useful tool for calculating the variances of linear combinations of random variables. For example:

$$\text{Var}(aX + bY) = \begin{pmatrix} a & b \end{pmatrix} \begin{bmatrix} \text{Var}(X) & \text{Cov}(X, Y) \\ \text{Cov}(X, Y) & \text{Var}(Y) \end{bmatrix} \begin{pmatrix} a \\ b \end{pmatrix}$$

in matrix and vector notation from [linear algebra](#). This logic extends to linear combinations of any number of random variables.

The covariance is the numerator of the *Pearson correlation coefficient*,¹¹ which is

$$\rho_{XY} = \rho_{YX} = \frac{\text{Cov}(X, Y)}{\sqrt{\text{Var}(X) \text{Var}(Y)}}.$$

Because of the [Cauchy-Schwarz inequality](#), it turns out that $\rho_{XY} \in [-1, 1]$.

- We get $\rho_{XY} = -1$ if and only if $Y = cX$ for some negative constant c .
- We get $\rho_{XY} = 1$ if and only if $Y = cX$ for some positive constant c . For example, $\rho_{XX} = 1$ for any random variable X .
- We get $\rho_{XY} = 0$ if (but not only if) X and Y are independent. However, it is possible to have $\rho_{XY} = 0$ when X and Y are not independent.

If we divide each entry $\text{Cov}(X, Y)$ in a covariance matrix by $\sqrt{\text{Var}(X) \text{Var}(Y)}$, when we get a *correlation matrix*. Any correlation matrix is symmetric, and the entries along its diagonals are all ones.

1.8 Probability and disease occurrence

In epidemiology, there are two fundamental measures of disease occurrence that are probabilities: **prevalence** and **risk**. In both cases, our experiment is to sample an individual ω from a population Ω . The *disease outcome* is a binary random variable

$$D(\omega) = \begin{cases} 1 & \text{if } \omega \text{ has the disease outcome,} \\ 0 & \text{otherwise.} \end{cases}$$

¹¹Named after [Karl Pearson](#) (1857-1936), an English mathematician who founded the modern discipline of mathematical statistics. In 1911, he started the world's first university department of statistics at University College London. He was an outspoken socialist and supporter of women's rights, but he was also a vocal proponent of social Darwinism and eugenics who opposed Jewish immigration into Britain.

The set of individuals in Ω who have $D(\omega) = 1$ is an event in Ω , and our measure of disease occurrence is

$$\Pr(\{\omega \in \Omega : D(\omega) = 1\}).$$

The most important difference between prevalence and risk is the role of time in the definition of D .

There is an important technical detail to remember when we talk about disease onset and recovery. When a person has disease onset at time t^{onset} and recovers at time t^{rec} , they have disease for each $t \in [t^{\text{onset}}, t^{\text{rec}})$. We assume that $t^{\text{rec}} > t^{\text{onset}}$ so this interval is nonempty. We let the onset and recovery times for person i be t_i^{onset} and t_i^{rec} , respectively. If a person has multiple episodes of the disease, each episode has its own t^{onset} and t^{rec} . For example, the j^{th} episode in person i would have onset time t_{ij}^{onset} and recovery time t_{ij}^{rec} .

The time scale used to define disease onset is flexible, and this flexibility is useful. The most obvious time scale is *calendar time* or *absolute time*. Another common time scale is age, which is an important determinant of the risk of many diseases. In some cases, time since an event is a useful time scale. The event that defines time scale could be a single event (e.g., exposure to contaminated food at a party) or an event that occurs at different times for different individuals (e.g., time since menopause). In general, it is wise to choose the time scale that corresponds to the most important time-varying determinant of disease onset. The chosen time scale is often called the *analysis time scale*.

1.8.1 Prevalence

For prevalence, the disease outcome is defined by choosing a time t and letting

$$D(\omega) = \begin{cases} 1 & \text{if } \omega \text{ has disease at time } t, \\ 0 & \text{otherwise.} \end{cases}$$

In other words, it is the proportion of the population Ω that disease at time t . This includes individuals who have disease onset at time $t^{\text{onset}} = t$ but not individuals who recover from disease at time $t^{\text{rec}} = t$. This is often called the **point prevalence** at time t .

Another version of prevalence is **period prevalence**. For period prevalence, we choose a nonempty time interval $(t_a, t_b]$ and define

$$D(\omega) = \begin{cases} 1 & \text{if } \omega \text{ has disease at any time } t \in (t_a, t_b], \\ 0 & \text{otherwise.} \end{cases}$$

In other words, it is the proportion of the population that has disease at any time in the interval $(t_a, t_b]$. This includes prevalent cases at time t_a and cases with disease onset in $(t_a, t_b]$. The period prevalence in $(t_a, t_b]$ is the point prevalence at t_a plus the risk of disease onset in $(t_a, t_b]$, to which we now turn.

1.9 R

1.9.1 Risk (cumulative incidence) and the survival function

To define **risk** or **cumulative incidence**, we first choose a nonempty time interval $(t_a, t_b]$. The disease outcome is defined as

$$D(\omega) = \begin{cases} 1 & \text{if } \omega \text{ has } t^{\text{onset}} \in (t_a, t_b], \\ 0 & \text{otherwise.} \end{cases}$$

In the population that is disease-free and at risk of disease at time t_a , it is the proportion who have disease onset at $t^{\text{onset}} \leq t_b$. The risk is sometimes called the *incidence proportion*.

The risk depends on a specified interval $(t_a, t_b]$. We can always define our time scale so that $t_a = 0$, so the risk in $(t_a, t_b]$ on the original time scale is the same as the risk in the interval $(0, t_b - t_a]$ on the analysis time scale. On the analysis time scale, the **cumulative incidence function** $F(t)$ is the risk of disease in $(0, t]$ for any possible t . The corresponding **survival function** is

$$S(t) = 1 - F(t),$$

which is the probability of no disease onset in $(0, t]$. In practice, it is often easier to calculate the survival function than to calculate the cumulative incidence function directly. There is only one way to survive disease-free through the interval $(0, t]$, but you can have disease onset at any time.

1.10 R

The survival function has several important properties:

- $S(0) = 1$ because $(0, 0]$ is an empty interval where no one can have disease onset.
- Because $S(t)$ is a probability, $S(t) \in [0, 1]$ for all t .
- $S(t)$ monotonically decreases (i.e., never increases) with increasing t . If $t_a < t_b$, then the time interval $(0, t_a]$ is contained $(0, t_b]$. Everyone who survives disease-free through $(0, t_b]$ must have survived disease-free through $(0, t_a]$, but some people who survived through $(0, t_a]$ might not make it all the way through $(0, t_b]$. Thus, $S(t_a) \geq S(t_b)$ whenever $t_a < t_b$.
- If the disease or event occurs eventually for all individuals in our population Ω (e.g., death), then $S(t) \rightarrow 0$ as $t \rightarrow \infty$.

Each of these probabilities follows directly from the definition of $S(t)$. Similarly, the cumulative incidence function F has $F(0) = 0$ and $F(t) \in [0, 1]$, and it is monotonically increasing (i.e., never decreasing) with increasing t . If the disease or event occurs eventually in all individuals, then $F(t) \rightarrow 1$ as $t \rightarrow \infty$. Figure 1.2 shows the survival and cumulative hazard curves for the data generated in the prevalence example above.




Figure 1.2: Survival and cumulative incidence curves for the data from the prevalence example.

Here, I will generally use the word “risk” to refer to the probability of disease onset in a specified interval. When there is possible confusion about the meaning of “risk”, I will use “cumulative incidence” instead. The terms “cumulative incidence function” and “survival function” are standard in survival analysis, which is the branch of statistics that studies times to events. The creative use of “risk” in public health and medicine should not make you shy away from using the word correctly.

1.10.1 Prevalence and the duration of disease

Point and period prevalence are both affected by the duration of disease. Both measures will increase if the duration of disease increases. A simple illustration of this is given in Figure 1.3. For a fixed set of onset times, the point prevalence of disease at any time t either stays the same or increases when the duration of disease increases. The prevalence at time $t = 5$ is $\frac{2}{5} = 0.4$ under the shorter duration of disease but $\frac{3}{5} = 0.6$ under the longer duration of disease. Period prevalence over any interval $(t_a, t_b]$ is affected by the duration of disease because it is the point prevalence at t_a (which is affected by disease duration) plus the risk of disease onset over $(t_a, t_b]$. In a given population, the relationship between prevalence, frequency of disease onset (incidence), and the duration of disease can be complex (Freeman and Hutchison 1980; Preston 1987; Keiding 1991; Alho 1992). The risk of disease in any given interval is not affected by the duration of disease.




Figure 1.3: Each black horizontal line shows the onset of disease and recovery from disease in a single individual. The gray lines show recoveries from disease if the disease duration increases.

1.10.2 Descriptive and analytic epidemiology

Prevalence is often a useful measure for **descriptive epidemiology**, which measures the distribution of disease over person, place, and time. Because prevalence depends on both incidence and duration of disease, a change in the prevalence of disease can generally be explained several different ways (MacMahon and Terry 1958; Dunn Jr 1962). For example, an increase in prevalence of human immunodeficiency virus (HIV) infection could be caused by an increase in the incidence of HIV infection (which is bad) or an increase in the life expectancy of HIV-infected people (which is good).

Risk (cumulative incidence) is generally more useful than prevalence for **analytic epidemiology**, which attempts to identify the causes of a disease. Another advantage of risk is that it can be used for outcomes that begin and end very quickly (e.g., traffic accidents or being hit by lightning) and for outcomes that remove individuals from the population (e.g., emigration or death). Prevalence is not a useful measure of the public health impact of these events.

Listing 1.1 indicators.R

```
## Indicator variables for events A and B, etc.

# Setting the seed ensures that everyone gets the same random samples.
# Functions are called using parentheses (round brackets).
# The function rbinom() is a random sample from a binomial distribution.
set.seed(42)
n <- 100
dat <- data.frame(A = rbinom(n, 1, 0.3))
dat$B <- rbinom(n, 1, 0.6)

# inspecting a data frame
names(dat) # variables in the data frame
nrow(dat)  # number of rows (individuals)
ncol(dat)  # number of columns (variables)
dim(dat)   # rows and columns in the data frame
str(dat)   # summary of the data frame structure (variables and types)

# inspecting columns of a data frame (or vectors)
# Our sample space or population consists of 100 individuals.
# Square brackets are used for indices, which can be numbers or TRUE/FALSE.
dat$A      # indicator for A for all 100 individuals
dat$A[10]   # indicator for A in individual 10
dat$A[2:6]  # indicator variables for individuals 2 to 6
dat$A[c(10, 20, 30)] # A indicators for individuals 10, 20, and 30
which(dat$A == 1)  # which individuals are in event A
which(dat$A == 0)  # which individuals are not in event A

# indicator variable for A complement
# In R (and many other languages), "!" means "not".
# The function as.integer() changes TRUE/FALSE to 1/0.
dat$Acomp <- as.integer(!dat$A)

# indicator variable for A intersection B
# In R (and many other languages), "&" means "and".
dat$ABintersect <- as.integer(dat$A & dat$B)

# indicator variable for A union B
# In R (and many other languages), "|" means "or".
dat$ABunion <- as.integer(dat$A | dat$B)

# save the data frame as a CSV file
# The file argument can be a path (e.g., "./data/indicators.csv" in Linux).
write.csv(dat, file = "indicators.csv", row.names = FALSE)
```

Listing 1.2 probabilities.R

```
## Indicator variables and probability calculations

# read in CSV file with indicator variables using the function read.csv()
# The argument can be a path (e.g., "./data/indicators.csv" in Linux).
dat <- read.csv("indicators.csv")

# calculate probabilities from indicator variables using the function mean()
# This will also work with TRUE/FALSE (i.e., logical) variables, which are
# converted to TRUE = 1 and FALSE = 0 in calculations.
prob_A <- mean(dat$A)
prob_B <- mean(dat$B)
prob_Acomp <- mean(dat$Acomp)
prob_ABintersect <- mean(dat$ABintersect)
prob_ABunion <- mean(dat$ABunion)

# Pr(A complement) = 1 - Pr(A)
prob_Acomp
1 - prob_A

# Pr(A union B) = Pr(A) + Pr(B) - Pr(A intersect B)
prob_ABunion
prob_A + prob_B - prob_ABintersect

# Beware of numerical error when comparing floating-point numbers!
# This example is from The R Inferno by Patrick Burns.
# https://www.burns-stat.com/pages/Tutor/R_inferno.pdf
0.1 == 0.3 / 3
sprintf("%.20f", 0.1)
sprintf("%.20f", 0.3 / 3)

# math can be more accurate than computers (which is not their fault)
prob_ABunion == prob_A + prob_B - prob_ABintersect
sprintf("%.20f", prob_ABunion)
sprintf("%.20f", prob_A + prob_B - prob_ABintersect)
```

Listing 1.3 jointdist.R

```
## Joint and marginal distributions of indicators for events A and B

# read indicator variable data from the CSV file
dat <- read.csv("indicators.csv")
n <- nrow(dat)

# tables of counts
# Putting "<name> = " before the vector creates a label.
table(A = dat$A)
table(B = dat$B)

# joint table of counts
# In table(), the first argument defines rows and the second defines columns.
# The addmargins() functions adds the row, column, and overall sums.
table(A = dat$A, B = dat$B)
addmargins(table(A = dat$A, B = dat$B))

# tables of probabilities
# Table margins match the distributions of A (rows) and B (columns).
table(Adist = dat$A) / n      # marginal distribution of A indicator
table(Bdist = dat$B) / n      # marginal distribution of B indicator
addmargins(table(A = dat$A, B = dat$B)) / n  # joint distribution
```

Listing 1.4 prevalence.R

```
## Point and period prevalence

# generate onset and recovery data for 100 individuals
# Setting the seed ensures that everyone gets the same random numbers,
# but it is strictly optional.
# The function rexp() randomly samples from an exponential distribution.
set.seed(42)
cohort <- data.frame(onset = rexp(100, rate = 0.4))
cohort$duration <- rexp(100, rate = 2)
cohort$recovery <- cohort$onset + cohort$duration

# statistical summaries (mean, quartiles, range)
summary(cohort$onset)
summary(cohort$duration)
summary(cohort$recovery)

# highest and lowest recovery times
# The function sort() sorts the vector from lowest to highest.
# head() returns the first 6 values of a vector; tails() returns the last 6.
min(cohort$onset)
head(sort(cohort$onset))      # lowest 6 values (first 6 in the sorted vector)
tail(sort(cohort$onset))      # highest 6 values (last 6 in the sorted vector)
max(cohort$onset)

# With a long vector, sorting repeatedly can be slow.
# You can also control the number of elements returned by head() or tail().
onset_ordered <- sort(cohort$onset)
head(onset_ordered, n = 10)
tail(onset_ordered, n = 10)

# seeing rows and columns of the data frame
cohort[1:10, c("onset", "duration", "recovery")]
cohort[c(10, 20, 50), c("onset", "recovery")]
cohort[which(cohort$recovery < 1), c("onset", "recovery")]
cohort[, c("onset", "recovery")]      # all rows
cohort[c(2, 3, 5, 7, 11), ]          # all columns

# point prevalence
prev <- function(t) {
  # vector of TRUE/FALSE for prevalent cases at time t
  prevalent <- cohort$onset <= t & cohort$recovery > t
  mean(prevalent)
}

prev(0)
prev(1)
prev(2)
prev(6)

# period prevalence
# The parentheses around the logical tests are just for readability.
```

Listing 1.5 risk.R

```
## Risk, survival function, and cumulative incidence function

# read data from CSV file
# Change or remove ".R/" in the path as needed to locate the cohort.csv file.
# You can also re-generate the data as in prevalence.R using the same seed.
cohort <- read.csv("./R/cohort.csv")

# risk (cumpulative incidence)
risk <- function(t) {
  # vector of TRUE/FALSE for incident cases in (0, t]
  incident <- cohort$onset <= t
  mean(incident)
}

risk(0)
risk(1)
risk(2)
risk(6)

# cumulative incidence function
# Vectorize() takes a function like risk() that takes a single number as input
# and creates a function that can take a number or vector as input.
cuminc <- Vectorize(risk)
cuminc(c(0, 1, 2, 6))

# survival function
# A simple function can be put on one line.
# It takes the same input as cuminc(), so it can take a vector
surv <- function(t) 1 - cuminc(t)
surv(c(0, 1, 2, 6))

# plot the survival and cumulative incidence functions
t <- seq(0, 20, by = 0.1)
plot(t, surv(t), type = "l",
      xlab = "Time", ylab = "Probability")
lines(t, cuminc(t), lty = "dashed")
grid()
legend("right", bg = "white", lty = c("dashed", "solid"),
      legend = c("Cumulative incidence", "Survival"))
```

Listing 1.6 surv-fig.R

```
## Plot of survival and cumulative incidence functions

# read data from CSV file
# Change or remove ".R/" in the path as needed to locate the cohort.csv file.
# You can also re-generate the data as in prevalence.R using the same seed.
cohort <- read.csv("./R/cohort.csv")

# risk (cumpulative incidence)
risk <- function(t) {
  # vector of TRUE/FALSE for incident cases in (0, t]
  incident <- cohort$onset <= t
  mean(incident)
}

# cumulative incidence function
cuminc <- Vectorize(risk)

# survival function
surv <- function(t) 1 - cuminc(t)

# plot the survival and cumulative incidence functions
t <- seq(0, 20, by = 0.1)
plot(t, surv(t), type = "l",
      xlab = "Time", ylab = "Probability")
lines(t, cuminc(t), lty = "dashed")
grid()
legend("right", bg = "white", lty = c("dashed", "solid"),
      legend = c("Cumulative incidence", "Survival"))
```

Listing 1.7 prevdur-fig.R

```
## R code for prevalence and duration plot
plot(0, 0, type = "n", xlim = c(0, 10), ylim = c(0, 5.5),
     xlab = "Time", ylab = "Individual", yaxt = "n")
Axis(side = 2, at = 1:5, labels = 1:5)
grid()
start <- c(4, 1, 3, 2, 6)
stop1 <- c(7, 3, 6, 4, 7)
stop2 <- c(9, 4, 8, 7, 9)
arrows(x0 = start, y0 = 1:5, x1 = stop1, code = 3, length = 0.2, angle = 90)
arrows(x0 = stop1, y0 = 1:5, x1 = stop2, code = 2, length = 0.2, angle = 90,
      col = "darkgray")
abline(v = 5, lty = "dashed")
text(5.5, 0.5, label = "t = 5")
```

2 Conditional Probability and Diagnostic Tests

The probability that two subsequent events will happen is a ratio compounded of the probability of the 1st and the probability of the 2d on supposition the 1st happens. (Bayes 1763)¹

Suppose we know that an event A occurred and want calculate the probability that B also occurred. The **conditional probability** of B given A is

$$\Pr(B|A) = \frac{\Pr(A \cap B)}{\Pr(A)}. \quad (2.1)$$

Note that this is well-defined only if $\Pr(A) > 0$. Conditional probabilities given A are just probabilities where the original sample space Ω has been replaced with an event $A \subseteq \Omega$. Everything we have learned about probabilities applies to all of the conditional probabilities given the same event A . Conditional probability is arguably the most important mathematical tool in epidemiology.

2.1 Contingency tables

In statistics, a **contingency table** classifies individuals by two discrete variables, one that defines the rows and one that defines the columns. Each cell in the table contains the number of individuals who are in the intersection of the corresponding categories of the row and column variables. These numbers are called *cell counts*. The margins of the table contain row or column totals.

¹Thomas Bayes (1701-1761) was an English Presbyterian minister from a family of Nonconformists (i.e., Protestants who did not observe the rules of the Church of England). He studied logic and theology at the University of Edinburgh and served as a minister in Tunbridge Wells near Kent, England. He was elected a Fellow of the Royal Society in 1742 for his defense of Newton's calculus against a 1734 book called *The Analyst: A Discourse Addressed to an Infidel Mathematician* by Bishop George Berkeley (1685-1753). Late in life, Bayes became interested in probability and "inverse probability" (statistics). This essay was published posthumously, and it has had a profound effect on modern statistics.

Table 2.1: 2x2 table of exposure (X) and disease (D).

	$D = 1$	$D = 0$	Total
$X = 1$	a	b	$r_1 = a + b$
$X = 0$	c	d	$r_0 = c + d$
Total	$k_1 = a + c$	$k_0 = b + d$	$n = a + b + c + d$

2.1.1 2x2 tables

In epidemiology, a **2x2 table** is a contingency table based on a binary exposure variable and a binary disease outcome. We denote exposure by $X = 1$ and no exposure by $X = 0$, and we denote disease by $D = 1$ and no disease by $D = 0$. The precise definition of “disease” depends on context. In descriptive epidemiology, $D_i = 1$ might mean that person i is a prevalent case of disease. In analytic epidemiology, $D_i = 1$ might mean that person i had an onset of disease in an interval $(t_{\text{start}}, t_{\text{stop}}]$ on a relevant time scale. We put exposure in the rows and disease in the columns,² and the exposure and disease categories are ordered so that individuals with $X = 1$ and $D = 1$ go in the top left corner. This is the most common arrangement in epidemiologic research, but it is not universal.

Table 2.1 shows an example of a 2x2 table. There are a individuals with both exposure and disease, b individuals with exposure but not disease, c individuals with disease but no exposure, and d individuals with neither. In the rows, there are $r_1 = a + b$ exposed individuals and $r_0 = c + d$ unexposed individuals. In the columns, there are $k_1 = a + c$ individuals who had a disease onset and $k_0 = b + d$ individuals who did not. The row and column totals are called the *margins* of the table. The total number of individuals is $n = a + b + c + d$.

2.1.2 Joint and marginal probabilities

Here, we assume that Table 2.1 represents our entire population Ω and our experiment is to randomly sample an individual $\omega \in \Omega$ and measure their exposure status $X(\omega)$ and their disease status $D(\omega)$. Probabilities involving both X and D are called **joint probabilities**, and they can be calculated using the cell counts. In Table 2.1, the four joint probabilities are

$$\begin{aligned}\Pr(X = 1 \text{ and } D = 1) &= a/n, \\ \Pr(X = 1 \text{ and } D = 0) &= b/n, \\ \Pr(X = 0 \text{ and } D = 1) &= c/n, \\ \Pr(X = 0 \text{ and } D = 0) &= d/n.\end{aligned}$$

²This is partly to respect the linear algebra convention that rows come before columns in matrix indices, so M_{ij} is the entry in row i and column j of the matrix M . In analytic epidemiology, exposure must occur before any disease that it causes, so we let the exposure define the rows.

Together, these probabilities defined the joint distribution of the random variables X and D via their joint probability mass function (PMF).

Probabilities involving X or D alone are called **marginal probabilities** because they are calculated using the margins of the table. In Table 2.1, the marginal probabilities for exposure X are

$$\begin{aligned}\Pr(X = 1) &= r_1/n, \\ \Pr(X = 0) &= r_0/n.\end{aligned}$$

Together, these define the marginal distribution of X , which is Bernoulli(r_1/n). The marginal probabilities for disease D are

$$\begin{aligned}\Pr(D = 1) &= k_1/n, \\ \Pr(D = 0) &= k_0/n.\end{aligned}$$

Together, these define the marginal distribution of D , which is Bernoulli(k_1/n).

2.1.3 Conditional probabilities

Joint and marginal probabilities can be used to calculate conditional probabilities, which have a joint probability in the numerator and a marginal probability in the denominator. As before, we assume that Table 2.1 represents our entire population Ω and our experiment is to randomly sample an individual $\omega \in \Omega$ and measure $X(\omega)$ and $D(\omega)$. In Table 2.1, the conditional probability of disease given exposure is

$$\Pr(D = 1 | X = 1) = \frac{\Pr(D = 1 \text{ and } X = 1)}{\Pr(X = 1)} = \frac{a/n}{r_1/n} = \frac{a}{r_1},$$

and the conditional probability of disease given no exposure is

$$\Pr(D = 1 | X = 0) = \frac{\Pr(D = 1 \text{ and } X = 0)}{\Pr(X = 0)} = \frac{c/n}{r_0/n} = \frac{c}{r_0},$$

Similarly, the conditional probability of exposure given disease is

$$\Pr(X = 1 | D = 1) = \frac{\Pr(X = 1 \text{ and } D = 1)}{\Pr(D = 1)} = \frac{a/n}{k_1/n} = \frac{a}{k_1},$$

and the conditional probability of exposure given no disease is

$$\Pr(X = 1 | D = 0) = \frac{\Pr(X = 1 \text{ and } D = 0)}{\Pr(D = 0)} = \frac{b/n}{k_0/n} = \frac{b}{k_0}.$$

In all cases, the table total cancels out and we get a calculation in one row (for conditional probabilities given X) or one column (for conditional probabilities given D).

2.2 Multiplication of conditional probabilities

Equation 2.1 can be rearranged into

$$\Pr(A \cap B) = \Pr(B | A) \Pr(A), \quad (2.2)$$

exactly as described by Bayes at the beginning of this chapter (if we let A be the “1st event” and B be the “2d”). This depends only on the definition of conditional probability in Equation 2.1, not on any assumptions about the relationship between the events A and B . This multiplication rule for conditional probabilities extends to any number of events. For three events A , B , and C such that $B \cap C$ and C have probabilities greater than zero, we have

$$\Pr(A \cap B \cap C) = \Pr(A | B \cap C) \Pr(B \cap C) \quad (2.3)$$

$$= \Pr(A | B \cap C) \Pr(B | C) \Pr(C). \quad (2.4)$$

To ensure that all of these conditional probabilities are well-defined, we need $B \cap C$ and C to have probabilities greater than zero. In practice, $\Pr(A | B \cap C)$ is usually written $\Pr(A | B, C)$.

2.2.1 Decision trees

Figure 2.1 shows an example of a **decision tree**. The *root* of the tree is on the left and the *leaves* of the tree are on the right. Each node where two or more branches meet represents a decision. In the example, the root represents the decision A or A^C (i.e., not A). The two nodes connected to the root each represent the decision B or B^C (i.e., not B). Each branch of the tree is labeled with the conditional probability of the branch given the event that it branches out from. Because of the multiplication rule for conditional probabilities, the probability of each leaf is equal to the product of the probabilities along the branches connecting it to the root.

2.2.2 Independence of events

The events A and B are **independent** if

$$\Pr(A \cap B) = \Pr(A) \Pr(B). \quad (2.5)$$

When two events are independent, the occurrence (or not) of one event tells us nothing about whether the other event occurred: If $\Pr(A) > 0$, equation Equation 2.5 is equivalent to $\Pr(B | A) = \Pr(B)$. If $\Pr(B) > 0$, it is equivalent to $\Pr(A | B) = \Pr(A)$. If A and B are not independent, the occurrence of A contains information about the occurrence of B and vice versa.




Figure 2.1: A decision tree for events A and B . The probability of each leaf is found by multiplying the probabilities along the branches leading from the leaf back to the root.

Table 2.2: Disease status (D^+/D^-) and test result (T^+/T^-).

	T^+	T^-
D^+	True positive	False negative
D^-	False positive	True negative

Independence of events A and B implies that the events A and B^C are also independent:

$$\begin{aligned}
 \Pr(A \cap B^C) &= \Pr(A) - \Pr(A \cap B) \\
 &= \Pr(A) - \Pr(A) \Pr(B) \\
 &= \Pr(A)(1 - \Pr(B)) \\
 &= \Pr(A) \Pr(B^C).
 \end{aligned}$$

A similar argument shows that A^C and B are independent. Because $A^C \cap B^C = (A \cup B)^C$ by DeMorgan's laws (see Section 1.1.5),

$$\begin{aligned}
 \Pr(A^C \cap B^C) &= 1 - \Pr(A \cup B) \\
 &= 1 - \Pr(A) - \Pr(B) + \Pr(A \cap B) \\
 &= 1 - \Pr(A) - \Pr(B) + \Pr(A) \Pr(B) \\
 &= (1 - \Pr(A))(1 - \Pr(B)) \\
 &= \Pr(A^C) \Pr(B^C).
 \end{aligned}$$

Therefore, independence of two events implies independence between any combination of themselves or their complements.

2.3 Sensitivity and specificity

In the epidemiology of screening and diagnostic tests, several of the most important concepts are conditional probabilities. If we classify disease status into diseased (D^+) and nondiseased (D^-) and the test result into positive (T^+) and negative (T^-), we have the four possible combinations Table 2.2.

The **sensitivity** of a test is the conditional probability that the test is positive given that the individual tested has the disease:

$$\text{sens} = \Pr(T^+ \mid D^+).$$

The **specificity** of a test is the conditional probability that the test is negative given that the individual tested does not have the disease:

$$\text{spec} = \Pr(T^- \mid D^-).$$

In both cases, we are conditioning on the disease status of the individual being tested. These concepts were introduced by Yerushalmy (1947) in a comparison of different types of chest X-rays for tuberculosis case detection.

2.4 R

Listing 2.1 sensspec.R

```
## Sensitivity and specificity

# generate diagnostic testing data
set.seed(42)
n <- 500
dtdat <- data.frame(disease = rbinom(n, 1, 0.5))
dtdat$testpos <- ifelse(dtdat$disease,
                        rbinom(n, 1, 0.85), rbinom(n, 1, 0.05))

# prevalence
mean(dtdat$disease)
# Pr(T+)
mean(dtdat$testpos)

# sensitivity
mean(dtdat$testpos[dtdat$disease == TRUE])
sum(dtdat$disease & dtdat$testpos) / sum(dtdat$disease)

# specificity
1 - mean(dtdat$testpos[dtdat$disease == FALSE])
mean(!dtdat$testpos[dtdat$disease == FALSE])
```

Maximizing either sensitivity or specificity alone does not necessarily lead to good screening or diagnostic test: A test where everyone tests positive has perfect sensitivity but zero specificity, and a test where everyone tests negative has perfect specificity but zero sensitivity. There is almost always a tradeoff where higher sensitivity leads to lower specificity and vice versa.

2.4.1 Example: Diabetes testing

Remein and Wilkerson (1961) describe an early study of diabetes screening conducted by the United States Public Health Service in Boston City Hospital between 1954 and 1957. They

Table 2.3: Sensitivity and specificity of the Somogyi-Nelson blood glucose test for diabetes where T^+ corresponds to a concentration above 130 mg/dL.

	T^+	T^-	Sensitivity and specificity
<i>Before meal</i>			
D^+	31	39	sens = $31/70 \approx 0.443$
D^-	5	505	spec = $505/510 \approx 0.990$
<i>One hour after meal</i>			
D^+	55	15	sens = $55/70 \approx 0.786$
D^-	48	462	spec = $462/510 \approx 0.906$
<i>Two hours after meal</i>			
D^+	45	25	sens = $45/70 \approx 0.643$
D^-	16	494	spec = $494/510 \approx 0.969$
<i>Three hours after meal</i>			
D^+	34	36	sens = $34/70 \approx 0.486$
D^-	1	509	spec = $509/510 \approx 0.998$

recruited early-morning patients who were not febrile or acutely ill. Those willing to participate gave urine and blood samples. Next, they were given a meal meant to approximate an average breakfast or light lunch (a sandwich, 5 grams of butter, 60 grams of cheese, and three filled cookies). After the meal, they gave further urine and blood samples at one, two, and three hours after eating. The samples were analyzed using four different blood tests and six different urine tests. Participants returned for a follow-up visit between 3 and 21 days after the screening tests, where a definitive diagnosis of diabetes was made using an oral glucose tolerance test and a physical examination according to criteria established by a group of experts.

A total of 595 participants completed both visits. Table 2.3 is a reconstruction of the data for the Somogyi-Nelson blood test based on the 580 participants (70 with diabetes and 510 without) who took the test at all four time points. In the table, a positive test is defined as a blood glucose concentration above 130 mg/dL (milligrams per deciliter).

2.5 R

2.5.1 Receiver operating characteristic (ROC) curves*

The tradeoff between sensitivity and sensitivity in choosing a clinical measurement cutoff to distinguish positive and negative tests can be seen using a **receiver operating characteristic** (ROC) curve (Lusted 1971a, 1971b; Swets 1988; Zweig and Campbell 1993). These curves were

Listing 2.2 RWtable.R

```
## Table 2 from Remein and Wilkerson (Journal of Chronic Disease, 1961)

# function to generate numbers based on sensitivity and specificity
RWtable <- function(sens, spec, n1=70, n0=510) {
  # arguments:  sensitivity, specificity,
  #             n1 is number of diabetics, n0 is number of nondiabetics
  tp <- round(sens * n1)
  fp <- round((1 - spec) * n0)
  tn <- round(spec * n0)
  fn <- round((1 - sens) * n1)
  return(c(truepos = tp, falsepos = fp, trueneg = tn, falseneg = fn))
}

RWtable(0.443, 0.990)  # before meal
RWtable(0.786, 0.906)  # one hour after
RWtable(0.643, 0.969)  # two hours after
RWtable(0.486, 0.998)  # three hours after
```

originally used in World War II to analyze the performance of radar systems locating ships and airplanes. They were applied to diagnostic tests in the late 1950s in the first attempt to automate the classification of Pap smears to detect cervical cancer (Bostrom, Sawyer, and Tolles 1959; Lusted 1984; Bengtsson and Malm 2014).

Each combination of a clinical measurement and a cutoff between positive and negative tests defines a diagnostic or screening test that has a sensitivity $\text{sens} \in [0, 1]$ and a specificity $\text{spec} \in [0, 1]$. The horizontal axis of an ROC curve plots

$$1 - \text{spec} = \Pr(T^+ | D^-),$$

and its vertical axis plots $\text{sens} = \Pr(T^+ | D^+)$. The test corresponds to a point $(1 - \text{spec}, \text{sens})$ in the unit square $[0, 1] \times [0, 1]$. The best tests correspond to points close to the top left corner $(0, 1)$, which represents a test with perfect specificity (so $1 - \text{spec} = 0$) and perfect sensitivity.

For a sequence of cutoffs, a given clinical measurement produces a curve connecting the points produced by the tests based on it. Figure 2.2 shows four ROC curves based on data from Remein and Wilkerson (1961): one for the Somogyi-Nelson blood glucose measurement before the meal and one each for the measurements one, two, and three hours after the meal. For all four measurements, the curves are based on the combinations of sensitivity and specificity for glucose concentration cutoffs from 70 mg/dL to 200 mg/dL. In these tests, using a higher glucose concentration cutoff to define a positive test leads to lower sensitivity and higher specificity.




Figure 2.2: ROC curves for Somogyi-Nelson blood tests conducted before the meal and at 1-3 hours after the meal. Cutoff values for the before-meal curve are labeled, and the points corresponding to the 130 mg/dL cutoff along the curve for each blood glucose measurement are circled.

ROC curves for different clinical measurements can be compared using the area under the curve (AUC), which is the area between the x-axis $[0, 1]$ and the ROC curve. Greater AUC corresponds to a measurement that is better able to distinguish between disease and no disease (Bamber 1975; Hanley and McNeil 1982). For a test that is positive when a clinical measurement is above a given cutoff, the AUC is the probability that a person with disease

has a higher value than a person without disease.³ In this example, it is the probability that a true diabetic has a higher blood glucose concentration than a true nondiabetic at the time blood glucose concentration is measured. A measurement that was always higher (or always lower) for individuals with disease than individuals without disease would have $AUC = 1$. The AUCs in Figure 2.2 show clearly that the tests one and two hours after the meal, which have curves above and to the left of the other two curves, better distinguish between diabetics and nondiabetics than the tests before and three hours after the meal. This is biologically plausible: Before the meal, there is no glucose load. Three hours after the meal, the glucose from the meal has largely been absorbed.

2.6 R

The test one hour after the meal with a 130 mg/dL cutoff has a good combination of sensitivity and specificity. It is near the top left corner, where perfect tests live. If a diagnostic test was completely useless, the test results (T^+ or T^-) would be independent of disease status (D^+ or D^-). In that case,

$$\Pr(T^+ | D^+) = \Pr(T^+ | D^-) = \Pr(T^+).$$

Thus, the ROC curve for a useless test follows the diagonal line from the lower left corner $(0,0)$ to the upper right corner $(1,1)$, and it has an AUC of 0.5. Tests below the diagonal on an ROC curve are worse than useless: the definitions of positive and negative should be reversed.

The sensitivity and specificity of a test tell us how accurate it is with a given definition of positive and negative. The ROC curve shows us how this accuracy depends on the cutoff between positive and negative tests, and the area under the curve shows us how well the underlying clinical measurement (e.g., blood glucose concentration) can distinguish between people with and without disease. However, the best cutoff for a test depends on its purpose, the population to be tested, and the benefit of identifying a true positive or negative versus the harm of a false positive or negative (Blumberg 1957; Kessel 1962).

2.7 Law of total probability

Suppose A_1, \dots, A_n are disjoint events such that their union is Ω . This is called a **partition** of Ω . An important special case is when we partition Ω into A and A^c .

³For a test that is positive when a clinical measurement is below a given cutoff, it is the probability that a person with disease has a lower value than a person without disease. Bamber (1975) showed that the AUC is closely related to the Wilcoxon rank sum statistic for the null hypothesis that the diseased and nondiseased have the same distribution for the measurement on which the test is based.

Let B be another event. Every $\omega \in B$ is in exactly one of the A_i . For each i , $B \cap A_i$ is the part of B that is contained in A_i . The event B is the union of these subsets:

$$B = \bigcup_{i=1}^n (B \cap A_i).$$

Because A_i are disjoint, so are the subsets $B \cap A_i$. By the addition rule for probabilities of disjoint sets, we have

$$\Pr(B) = \sum_{i=1}^n \Pr(B \cap A_i)$$

which is the sum of the $\Pr(B \cap A_i)$.⁴ Using the multiplication rule for conditional probabilities in Equation 2.2 on each $\Pr(B \cap A_i)$, we get

$$\Pr(B) = \sum_{i=1}^n \Pr(B | A_i) \Pr(A_i).$$

This is called the **law of total probability**.

2.7.1 Example: probability of a positive or negative test

We can use the law of total probability to calculate the probability of a positive or negative test based on the sensitivity and specificity of the test and the prevalence of disease. Because all individuals either do or do not have the disease,⁵ we have

$$T^+ = (T^+ \cap D^+) \cup (T^+ \cap D^-).$$

These two groups are mutually exclusive, so

$$\Pr(T^+) = \Pr(T^+ \cap D^+) + \Pr(T^+ \cap D^-).$$

We can calculate each probability on the right-hand side using the multiplication rule in Equation 2.2:

$$\begin{aligned} \Pr(T^+ \cap D^+) &= \Pr(T^+ | D^+) \Pr(D^+) = \text{sensitivity} \times \text{prevalence}, \\ \Pr(T^+ \cap D^-) &= \Pr(T^+ | D^-) \Pr(D^-) = (1 - \text{specificity}) \times (1 - \text{prevalence}). \end{aligned}$$

Putting everything together, we get

$$\begin{aligned} \Pr(T^+) &= \Pr(T^+ | D^+) \Pr(D^+) + \Pr(T^+ | D^-) \Pr(D^-) \\ &= \text{sensitivity} \times \text{prevalence} + (1 - \text{specificity}) \times (1 - \text{prevalence}). \end{aligned} \tag{2.6}$$

⁴The symbol Σ , which is an upper-case Greek letter σ (sigma), stands for a sum. For products, we use Π , which is an upper-case Greek letter π (pi).

⁵Many diseases are complex processes (Rothman 1981), making any binary classification of disease status somewhat arbitrary. Here, we assume that we have an operational definition of disease status that allows a reasonable binary classification.

A similar chain of reasoning shows that

$$\Pr(T^-) = (1 - \text{sensitivity}) \times \text{prevalence} + \text{specificity} \times (1 - \text{prevalence}),$$

which equals $1 - \Pr(T^+)$.

Figure 2.3 shows how the probability of a positive test depends on the prevalence of disease using the example of the Somogyi-Nelson test one hour after the meal in Table 2.3. With a cutoff of 130 mg/dL, the test has a sensitivity of 0.786 and a specificity of 0.906. At low prevalences, the test overestimates the prevalence of diabetes due to imperfect specificity. At high prevalences, it underestimates the prevalence of diabetes due to imperfect sensitivity. The errors cancel out somewhere near a prevalence of 30%.




Figure 2.3: The probability of a positive Somogyi-Nelson diabetes test one hour after the meal as a function of the hypothetical prevalence of diabetes. The black dotted line shows the true prevalence of diabetes.

2.7.2 Standardization

In epidemiology, it is often useful to think of our sample space Ω as a population and the outcomes $\omega \in \Omega$ as individuals. The sets A_1, \dots, A_n into which we partition the sample space are disjoint subpopulations (e.g., age groups). Let $\Pr(D | A_i)$ be the prevalence of disease in

subpopulation A_i at a given time point. Then the overall prevalence of disease is

$$\Pr(D) = \sum_{i=1}^n \Pr(D | A_i) \Pr(A_i). \quad (2.7)$$

This application of the law of total probability is called **standardization**. By changing the $\Pr(A_i)$, we can use the subpopulation prevalences to calculate the prevalence of disease in a population with any desired composition of subpopulations. Equation 2.7 can also be used to calculate population-level risk from the subpopulation-specific risks in any given time interval. In the form of standardization, the law of total probability is one of the most important tools in epidemiology.

2.8 Bayes' rule

Bayes' rule (Bayes 1763) relates the conditional probabilities $\Pr(A | B)$ and $\Pr(B | A)$:

$$\Pr(A | B) = \frac{\Pr(B \cap A)}{\Pr(B)} = \frac{\Pr(B | A) \Pr(A)}{\Pr(B)}. \quad (2.8)$$

In the denominator, the law of total probability is often used to calculate $\Pr(B)$ via partitioning Ω into A and A^c . This gives us

$$\Pr(A | B) = \frac{\Pr(B | A) \Pr(A)}{\Pr(B | A) \Pr(A) + \Pr(B | A^c) \Pr(A^c)}.$$

Bayes' rule is an incredibly useful application of conditional probabilities, and it forms the theoretical foundation for Bayesian statistical inference.

2.8.1 Positive and negative predictive values

Sensitivity and specificity tell us how disease status predicts the result of a test, but they do not tell us how to interpret a test result. If you test positive, it is important to know the conditional probability that you truly have disease given that you tested positive. This is called the **positive predictive value** (PPV):

$$\text{PPV} = \Pr(D^+ | T^+).$$

If you test negative, it is important to know the conditional probability that you are truly disease-free given that you tested negative. This is called the **negative predictive value** (NPV):

$$\text{NPV} = \Pr(D^- | T^-).$$

These terms were introduced by Vecchio (1966). Table 2.4 shows the PPV and NPV for the Somogyi-Nelson diabetes tests from Table 2.3.

Table 2.4: PPV and NPV of the Somogyi-Nelson blood glucose test for diabetes where T^+ corresponds to a concentration above 130 mg/dL.

	T^+	T^-	PPV and NPV
<i>Before meal</i>			
D^+	31	39	PPV = $31/36 \approx 0.861$
D^-	5	505	NPV = $505/544 \approx 0.928$
Total	36	544	
<i>One hour after meal</i>			
D^+	55	15	PPV = $55/103 \approx 0.534$
D^-	48	462	NPV = $462/477 \approx 0.969$
Total	103	477	
<i>Two hours after meal</i>			
D^+	45	25	PPV = $45/61 \approx 0.738$
D^-	16	494	NPV = $494/519 \approx 0.952$
Total	61	519	
<i>Three hours after meal</i>			
D^+	34	36	PPV = $34/35 \approx 0.971$
D^-	1	509	NPV = $509/545 \approx 0.934$
Total	35	545	

Vecchio (1966) showed that the PPV and NPV depend on the prevalence of disease as well as the sensitivity and specificity of the test. To calculate the PPV and NPV, we use Bayes' rule to switch the conditional probabilities from $\Pr(T | D)$ to $\Pr(D | T)$. From the definition of PPV and Bayes' rule, we get

$$\Pr(D^+ | T^+) = \frac{\Pr(T^+ \cap D^+)}{\Pr(T^+)} = \frac{\Pr(T^+ | D^+) \Pr(D^+)}{\Pr(T^+)}.$$

The sensitivity of the test and the prevalence of disease are in the numerator, and $\Pr(T^+)$ is in Equation 2.6. Putting this all together, we get

$$\text{PPV} = \frac{\text{sensitivity} \times \text{prevalence}}{\text{sensitivity} \times \text{prevalence} + (1 - \text{specificity}) \times (1 - \text{prevalence})}.$$

The numerator is the probability of a true positive test, and the denominator is the probability of a (true or false) positive test. By a similar argument,

$$\text{NPV} = \frac{\text{specificity} \times (1 - \text{prevalence})}{\text{specificity} \times (1 - \text{prevalence}) + (1 - \text{sensitivity}) \times \text{prevalence}}.$$

The numerator is the probability of a true negative test, and the denominator is the probability of a (true or false) negative test.

Figure 2.4 shows how the positive and negative predictive values of a test depend on the prevalence of disease for the Somogyi-Nelson test before the meal and one hour after the meal in Remein and Wilkerson (1961). With a cutoff of 130 mg/dL, the sensitivity and specificity are 0.443 and 0.990 before the meal and 0.786 and 0.906 one hour after the meal. If prevalence equals zero, the PPV is zero and the NPV equals one because no one has disease. As prevalence increases, PPV increases and NPV decreases. If the prevalence equals one, the PPV is one and the NPV is zero because everyone has disease. A perfect test would have PPV and NPV equal to one at all prevalences.




Figure 2.4: Positive and negative predictive values of the Somogyi-Nelson diabetes test before the meal (gray) and one hour after the meal (black) as a function of diabetes prevalence.

2.8.2 Likelihood ratios*

For a probability p , the **odds** is

$$\theta = \frac{p}{1-p}.$$

While a probability lives in $[0, 1]$, the odds can go from zero (for $p = 0$) to infinity (as p approaches one). There is a one-to-one relationship between probabilities and odds, so we can

calculate the probability of an event if we know the odds. If the odds is θ , the corresponding probability is

$$p = \frac{\theta}{1 + \theta}.$$

Odds and odds ratios have an important role in epidemiology and statistical inference. In a Bayesian statistical framework, odds ratios give us a simple way to update our knowledge about the probability of an event given new information.

Suppose we know the prevalence of a disease in a population Ω . We randomly sample an individual $\omega \in \Omega$ and give them a diagnostic test. If we randomly sample an individual ω from a population Ω , the odds that ω has disease is

$$\frac{\Pr(D^+)}{1 - \Pr(D^+)} = \frac{\Pr(D^+)}{\Pr(D^-)}.$$

where $\Pr(D^+)$ is the prevalence of disease. This is called the **prior odds** of disease. If ω tests positive for the disease, the conditional odds that they have disease is

$$\frac{PPV}{1 - PPV} = \frac{\Pr(D^+ | T^+)}{\Pr(D^- | T^+)} = \frac{\Pr(D^+ \cap T^+)}{\Pr(D^- \cap T^+)},$$

where we have cancelled out $\Pr(T^+)$ from the numerator and the denominator in the last expression. This is called the **posterior odds** of disease. The second expression above shows that the probability corresponding to the posterior odds is the PPV.

Using the multiplication rule for conditional probabilities, we get

$$\frac{\Pr(D^+ \cap T^+)}{\Pr(D^- \cap T^+)} = \frac{\Pr(T^+ | D^+) \Pr(D^+)}{\Pr(T^+ | D^-) \Pr(D^-)} = \frac{\text{sensitivity}}{1 - \text{specificity}} \times \frac{\Pr(D^+)}{\Pr(D^-)}.$$

The term $\text{sensitivity}/(1 - \text{specificity})$ is called the **likelihood ratio**. If our individual ω tests positive for disease,

$$\text{posterior odds of } D^+ = \text{likelihood ratio} \times \text{prior odds of } D^+.$$

The likelihood ratio is a measure of how much we learn from a positive test result, and it does not depend on the prevalence of disease [Lusted (1971b); Swets (1973); Fagan (1975); Albert (1982); Zweig and Campbell (1993)]. Because an ROC curve plots sensitivity on the vertical axis and $1 - \text{specificity}$ on the horizontal axis, the likelihood ratio for a given test is the slope of the line from the point $(0, 0)$ to the point representing the test.

Table 2.5 shows the prior odds, likelihood ratio, posterior odds, and PPV for the Somogyi-Nelson blood glucose tests for diabetes from 580 participants (70 with diabetes and 510 without) in Remein and Wilkerson (1961). Note that the tests with the highest likelihood ratios come from the glucose measurements that had the lowest AUCs in Figure 2.2. These tests have high likelihood ratios despite their low sensitivity because they have specificities near one. The test with the best combination of sensitivity and specificity in Table 2.3 has the lowest likelihood ratio. Like other summaries of diagnostic test performance, the likelihood ratio by itself does not determine the best test for a given purpose.

Table 2.5: Prior odds, likelihood ratios, posterior odds, and PPV for the Somogyi-Nelson blood glucose test for diabetes where T^+ corresponds to a concentration above 130 mg/dL.

Test	Prior odds	Likelihood ratio	Posterior odds	PPV
Before meal	$70/510 \approx 0.137$	45.171	$31/5 = 6.200$	$31/36 \approx 0.861$
1 hour after	$70/510 \approx 0.137$	8.348	$55/48 \approx 1.146$	$55/103 \approx 0.534$
2 hours after	$70/510 \approx 0.137$	20.491	$45/16 \approx 2.813$	$45/61 \approx 0.738$
3 hours after	$70/510 \approx 0.137$	247.714	$34/1 = 34.000$	$34/35 \approx 0.971$

Listing 2.3 ROCcurve.R

```
# data from Table 2 in Remein and Wilkerson (Journal of Chronic Disease, 1961)
SNdat <- data.frame(cutoff = seq(70, 200, by = 10))
SNdat$sens_pre <- c(95.7, 91.4, 82.9, 65.7, 54.3, 50.0, 44.3, 37.1, 30.0,
  25.7, 25.7, 22.9, 21.4, 17.1) / 100
SNdat$spec_pre <- c(11.0, 36.3, 65.7, 84.7, 92.7, 96.7, 99.0, 99.6, 99.8,
  99.8, 99.8, 99.8, 100.0, 100.0) / 100
SNdat$sens_1hr <- c(100.0, 97.1, 97.1, 95.7, 92.9, 88.6, 78.6, 68.6, 57.1,
  52.9, 47.1, 40.0, 34.3, 28.6) / 100
SNdat$spec_1hr <- c(8.2, 22.4, 39.0, 57.3, 70.6, 83.3, 90.6, 95.1, 97.8,
  99.4, 99.6, 99.8, 100.0, 100.0) / 100
SNdat$sens_2hr <- c(98.6, 97.1, 94.3, 88.6, 85.7, 71.4, 64.3, 57.1, 50.0,
  47.1, 42.9, 38.6, 34.3, 27.1) / 100
SNdat$spec_2hr <- c(8.8, 25.5, 47.6, 69.8, 84.1, 92.5, 96.9, 99.4, 99.6,
  99.8, 100.0, 100.0, 100.0, 100.0) / 100
SNdat$sens_3hr <- c(94.3, 91.4, 82.9, 70.0, 60.0, 51.4, 48.6, 41.4, 32.9,
  28.6, 28.6, 28.6, 24.3, 20.0) / 100
SNdat$spec_3hr <- c(8.6, 34.7, 67.5, 86.5, 95.3, 98.2, 99.8,
  rep(100.0, 7)) / 100
# write.csv(SNdat, "SNdat.csv", row.names = FALSE)

# ROC curves with labels
plot(1 - SNdat$spec_pre, SNdat$sens_pre, type = "n",
  xlim = c(0, 1), ylim = c(0, 1),
  xlab = "1 - Specificity = Pr(T+ | D-)",
  ylab = "Sensitivity = Pr(T+ | D+)")
grid()
lines(1 - SNdat$spec_pre, SNdat$sens_pre, col = "darkgray")
lines(1 - SNdat$spec_1hr, SNdat$sens_1hr, lty = "solid")
lines(1 - SNdat$spec_2hr, SNdat$sens_2hr, lty = "dashed")
lines(1 - SNdat$spec_3hr, SNdat$sens_3hr, lty = "dotted")
points(1 - SNdat[SNdat$cutoff == 130, c(3, 5, 7, 9)],
  SNdat[SNdat$cutoff == 130, c(2, 4, 6, 8)])
points(1 - SNdat$spec_pre[seq(2, 12, by = 2)],
  SNdat$sens_pre[seq(2, 12, by = 2)], pch = 8)
text(1 - SNdat$spec_pre[seq(2, 12, by = 2)] + c(0, .09, .09, .1, .1, .1),
  SNdat$sens_pre[seq(2, 12, by = 2)] + c(-.05, -.02, -.02, 0, 0, -.01),
  labels = c("80 mg/dL", "100 mg/dL", "120 mg/dL", "140 mg/dL",
    "160 mg/dL", "180 mg/dL"))
abline(0, 1, lty = "dotted", col = "darkgray")
text(.51, .49, adj = c(.5, 1), srt = 42,
  label = "Useless tests (T and D independent)")
points(c(0, 0, 1), c(0, 1, 1), pch = 3)
text(.01, .99, adj = c(0, 1), label = "Perfect test")
text(.01, .01, adj = c(0, 0), label = "Everyone tests negative")
text(.99, .99, adj = c(1, 0), srt = 90, label = "Everyone tests positive")
legend("bottomright", bg = "white",
  lty = c("solid", "solid", "dashed", "dotted", NA),
  col = c("darkgray", rep("black", 4)), pch = c(rep(NA, 4), 1),
  legend = c("Before meal (AUC = 0.825)",
    "1 hour after (AUC = 0.923)",
    "2 hours after (AUC = 0.904)",
```

Listing 2.4 auc.R

```
## areas under the ROC curves

# load Somogyi-Nelson test data generated for Figure 2.2 (if needed)
# The argument can contain a path before the file name.
SNdat <- read.csv("SNdat.csv")

auc <- function(x, y) {
  # x is an increasing list of specificities
  # y is a decreasing list of sensitivities
  roc <- approxfun(c(1, 1 - x, 0), c(1, y, 0), ties = "max")
  area <- integrate(function(x) roc(x), 0, 1)
  return(area)
}

auc(SNdat$spec_pre, SNdat$sens_pre)
auc(SNdat$spec_1hr, SNdat$sens_1hr)
auc(SNdat$spec_2hr, SNdat$sens_2hr)
auc(SNdat$spec_3hr, SNdat$sens_3hr)
```

Listing 2.5 testpos.R

```
## probability of testing positive as a function of prevalence

# function to generate testing data
tdat <- function(prev, sens=0.786, spec=0.906) {
  # defaults are sensitivity and sensitivity one hour after the meal
  truepos <- sens * prev
  falsepos <- (1 - spec) * (1 - prev)
  trueneg <- spec * (1 - prev)
  falseneg <- (1 - spec) * prev
  pos <- truepos + falsepos
  neg <- 1 - pos
  ppv <- truepos / pos
  npv <- trueneg / neg
  return(data.frame(prev = prev, sens = sens, spec = spec,
                    truepos = truepos, falsepos = falsepos,
                    trueneg = trueneg, falseneg = falseneg,
                    pos = pos, neg = neg, ppv = ppv, npv = npv))
}
tdat_1hr <- tdat(seq(0, 1, by = .01))
write.csv(tdat_1hr, "R/tdat_1hr.csv", row.names = FALSE)

# plot
plot(tdat_1hr$prev, tdat_1hr$pos, type = "n", xlim = c(0, 1), ylim = c(0, 1),
     xlab = "Prevalence of disease = Pr(D+)",
     ylab = "Probability of positive test = Pr(T+)")
polygon(c(tdat_1hr$prev, 1, 0), c(tdat_1hr$pos, 0, 0),
        border = NA, col = "gray")
polygon(c(tdat_1hr$prev, 1, 0), c(tdat_1hr$falsepos, 0, 0),
        border = NA, col = "darkgray")
grid()
lines(tdat_1hr$prev, tdat_1hr$falsepos, col = "gray")
lines(tdat_1hr$prev, tdat_1hr$pos)
abline(0, 1, lty = "dotted")
text(0.1, 0.02, adj = c(0, 0), label = "False positives")
text(0.2, 0.1, adj = c(0, 0), label = "True positives")
```

Listing 2.6 predval.R

```
## Predictive values as a function of prevalence

# uses tdat_1hr data and tdat() function from Figure 2.3 (testpos.R)
# tdat_1hr <- read.csv("tdat_1hr.csv")
# generate data using the sensitivity and specificity of the pre-meal test
tdat_pre <- tdat(seq(0, 1, by = .01), sens = 0.443, spec = 0.990)

# plot of PPV and NPV as a function of diabetes prevalence
plot(tdat_1hr$prev, tdat_1hr$ppv, type = "n", xlim = c(0, 1), ylim = c(0, 1),
     xlab = "Prevalence of disease = Pr(D+)",
     ylab = "Predictive value = Pr(D | T)")
grid()
lines(tdat_1hr$prev, tdat_1hr$ppv)
lines(tdat_1hr$prev, tdat_1hr$npv, lty = "dashed")
lines(tdat_pre$prev, tdat_pre$ppv, col = "darkgray")
lines(tdat_pre$prev, tdat_pre$npv, lty = "dashed", col = "darkgray")
legend("bottom", lty = c("solid", "dashed", "solid", "dashed"),
     col = c("darkgray", "darkgray", "black", "black"),
     bg = "white", inset = 0.05,
     legend = c("PPV before meal", "NPV before meal",
                "PPV 1 hour after", "NPV 1 hour after"))
```

3 Maximum Likelihood Estimation

Far better an approximate answer to the *right* question, which is often vague, than an *exact* answer to the wrong question, which can always be made precise. (Tukey 1962)¹

In probability, we are told the rules of the game and then we predict what it will look like. In statistics, we watch the game and try to figure out the rules. Roughly speaking, statistics (game to rules) is the reverse of probability (rules to game). When done well, statistics helps us learn from observations while accounting honestly for uncertainty. An outstanding early example of statistics applied to public health is the work of [Florence Nightingale](#) (1820-1910), who collected data and developed statistical graphics to demonstrate the need for public health reforms in the British Army in the 1850s (I. B. Cohen 1984; Winkelstein Jr 2009).²

Here, we will use estimation of a probability as an example of **maximum likelihood estimation**, which is used for parameter estimation throughout **frequentist** statistical inference, where the probability of an event A is interpreted as the limiting value of the proportion of n repetitions of an experiment in which A occurs as $n \rightarrow \infty$. Maximum likelihood estimation gives us a way to find point estimates of parameters that are optimal in large samples. It is also the foundation for three types of hypothesis tests and confidence intervals that are widely used to quantify uncertainty in frequentist inference.

3.1 Binomial likelihood

In Section 3.1.1, we used the prevalence p in our population to figure out the distribution of the number X of diseased individuals in a sample of size n . This is probability. The corresponding statistical problem would be to estimate the prevalence p after seeing $X = x$ infected individuals in a sample of size n .

When our experiment is to sample multiple individuals from a population, the analogy between the outcomes $\omega \in \Omega$ and the individuals in the population breaks down. Recall that when we flip a coin twice, each $\omega \in \Omega$ must specify the outcomes of both flips. When the experiment

¹[John Tukey](#) (1915-2000) was an American mathematician and statistician who worked at Bell Labs and Princeton University. He developed the box plot, Tukey's range test for multiple comparisons, and the [fast Fourier transform](#). In 1947, he coined the term "bit" as shorthand for "binary digit".

²She was elected a member of the Royal Statistical Society in 1859, where she was the first woman to be a member. In 1860, she founded the world's first modern nursing school at St. Thomas Hospital in London.

is to sample n individuals from a population, the entire sample is a single outcome ω and Ω contains all possible samples of n individuals from the population. If the population size is N , then the number of possible samples of size n is given by the *binomial coefficient*

$$\binom{N}{n} = \frac{N!}{n!(N-n)!},$$

where $k!$ denotes k factorial. **Factorials** are defined by $0! = 1$ and $k! = k \cdot (k-1)!$ for any integer $k > 0$. For example, $1! = 1$, $2! = 2$, $3! = 6$, $4! = 24$, $5! = 120$, and so on. For $k > 0$, $k!$ is the product of all positive integers up to and including k , which grows extremely fast as k increases.

3.1.1 Binomial distribution

Suppose we sample n individuals from a population Ω and test them for disease. For simplicity, we assume that the diagnostic test has perfect sensitivity and specificity. Let Y_i denote whether person i in the sample has disease, and let X be the total number who have disease. Then

$$X = \sum_{i=1}^n Y_i,$$

so it is a linear combination of the Y_i . Each Y_i is a Bernoulli(p) random variable, where p is the prevalence of disease in the population. When N is much larger than n (for which we write $N \gg n$), the test results for each person in the sample are approximately independent.

The distribution of a sum of n independent Bernoulli(p) random variables is called a **binomial(n, p) distribution**.³ The probability $Y_1 = 1$ is p , and the probability that $Y_1 = 0$ is $(1-p)$, so we can handle both cases by writing

$$\Pr(Y_1 = y_1) = p^{y_1}(1-p)^{1-y_1}.$$

When the Y_i are independent, each Y_i has a Bernoulli(p) distribution (see Section 1.5.2) and

$$\Pr(Y_1 = y_1, Y_2 = y_2, \dots, Y_n = y_n) = \prod_{i=1}^n \Pr(Y_i = y_i) = \prod_{i=1}^n p^{y_i}(1-p)^{1-y_i}$$

by the multiplication rule for independent events. Substituting $x = \sum_{i=1}^n y_i$, we get

$$\Pr(Y_1 = y_1, Y_2 = y_2, \dots, Y_n = y_n) = p^x(1-p)^{n-x}.$$

³For finite N , X actually has a *hypergeometric distribution* because the test results are not exactly independent. If the first person in our sample has disease, the probability that the next person we sample has disease is slightly less than p . If the first person in our sample does not have disease, the probability that the next person we sample has disease is slightly greater than p . When $N \gg n$, this hypergeometric distribution is approximately binomial(n, p).

The value of x depends only on the sum of the y_i , and there are $\binom{n}{x}$ different ways to get x cases of disease out of n sampled individuals. By the addition rule for disjoint events, we get

$$\Pr(X = x) = \binom{n}{x} p^x (1 - p)^{n-x}. \quad (3.1)$$

This is the probability mass function (PMF) of the binomial distribution. The set of possible values of a binomial(n , p) random variable X is $\text{supp}(X) = \{0, 1, \dots, n\}$.

Section 1.5.2 showed that a Bernoulli(p) random variable has expected value p and variance $p(1 - p)$. Because a binomial(n , p) random variable is the sum of n independent Bernoulli(p) random variables, its expected value is

$$\mathbb{E}(X) = np.$$

by the rule for expectations of linear combinations in Equation 1.23. Its variance is

$$\text{Var}(X) = np(1 - p)$$

by the rule for variances of linear combinations in Equation 1.24. The covariances are all zero because the Y_i are independent.

3.2 R

3.2.1 Likelihood and log likelihood

In probability, we know the prevalence of disease p and we deduce the distribution of the number of diseased individuals X in a sample of size n . In statistics, we observe $X = x$ and use this to estimate p . To do this, we rewrite the binomial PMF Equation 3.1 as a function of p instead of x :

$$L(p) = \binom{n}{x} p^x (1 - p)^{n-x}. \quad (3.2)$$

This is the binomial **likelihood function**. The right-hand sides of Equation 3.1 and Equation 3.2 are identical, and they produce exactly the same value given the same x and p . However, the two equations define different functions. In binomial PMF in Equation 3.1, the prevalence p is fixed and the number of diseased individuals x is the argument of the function. In the binomial likelihood function in Equation 3.2, the number of diseased individuals x is fixed and the prevalence p is the argument of the function. The PMF belongs to probability, and the likelihood belongs to statistics.

Listing 3.1 binomdist.R

```
## binomial distribution

# binomial PMF
# The second and third arguments are n ("size") and p ("prob").
dbinom(2, 10, 0.4)
dbinom(0:10, 10, 0.4)
sum(dbinom(0:10, 10, 0.4))

# binomial CDF
pbinom(0:10, 10, 0.4)
cumsum(dbinom(0:10, 10, 0.4))

# binomial quantiles
qbinom(c(0.25, 0.5, 0.75, 1), 10, 0.4)

# random samples
rbinom(20, 10, 0.4)
x <- rbinom(1000, 10, 0.4)
mean(x)
var(x)
```

The **log likelihood** is the natural logarithm (i.e., the logarithm to base $e = 2.718281828\dots$)⁴ of the likelihood function. For binomial log likelihood is

$$\ell(p) = \ln \binom{n}{x} + x \ln p + (n - x) \ln(1 - p).$$

Because the logarithm turns products into sums, it is generally much easier to handle the log likelihood than the likelihood itself. The term $\ln \binom{n}{x}$ does not depend on p , so it can be ignored. Intuitively, this tells us that the total number $x = y_1 + y_2 + \dots + y_n$ of individuals with disease in our sample contains the same information about the prevalence of disease as the sequence y_1, y_2, \dots, y_n of disease indicators.

For any given p , we can think of $\ell(p)$ as a random variable whose value is determined by our

⁴**Euler's number** e is named after [Leonhard Euler](#) (1707–1783), a Swiss mathematician who introduced the notation $f(x)$ for mathematical functions and the letter i to denote the imaginary unit $\sqrt{-1}$. He spent most of his life in Berlin and St. Petersburg, and he is widely considered the greatest mathematician of the 18th century. The number e was first discovered in 1683 by Jacob Bernoulli (the namesake of the Bernoulli distribution) when studying compound interest, where $e = \lim_{n \rightarrow \infty} (1 + 1/n)^n$. In 1748, Euler proved that $e = \frac{1}{0!} + \frac{1}{1!} + \frac{1}{2!} + \frac{1}{3!} + \dots$.

sample of size n . Let p_{true} be the true prevalence of disease. By *Gibb's inequality*,⁵

$$\mathbb{E}[\ell(p_{\text{true}})] > \mathbb{E}[\ell(p)]$$

for all $p \neq p_{\text{true}}$. This inequality is about the expected value of the log likelihood over all possible samples of size n . For any given sample, it is possible that $\ell(p_{\text{true}})$ is not the maximum of the log likelihood. However, this inequality is an important part of the justification for estimating p by maximizing the log likelihood (Boos and Stefanski 2013). Because function $v \mapsto \ln(v)$ is strictly increasing in v , the likelihood $L(p)$ and the log likelihood $\ell(p)$ are maximized at exactly the same value of p .

3.2.2 Score function

To find the maximum of the log likelihood, we find the value of p where its slope is zero. This is the mathematical version of the insight that the ground at the top of a hill is level. The **score function** is the first derivative of the log likelihood

$$U(p) = \frac{d}{dp} \ell(p) = \frac{x}{p} - \frac{n-x}{1-p},$$

which is the slope of $\ell(p)$ at p . To find where the slope equals zero, we solve the *score equation*

$$U(\hat{p}) = \frac{x}{\hat{p}} - \frac{n-x}{1-\hat{p}} = 0 \quad (3.3)$$

where \hat{p} denotes the maximum likelihood estimate (MLE) of p_{true} . When the dust settles, we get

$$\hat{p} = \frac{x}{n}$$

so our MLE of the prevalence is just the proportion of our sample who has disease.

To confirm that this is a maximum instead of a minimum, we need to look at the second derivative of ℓ . When we walk across the top of a hill, we go from walking uphill to walking downhill so the slope is decreasing. If $\ell(p)$ is maximized at \hat{p} , then the slope of the slope (i.e., the second derivative) should be negative. The second derivative of $\ell(p)$ at \hat{p} is

$$\frac{d}{dp} U(p) = \frac{d^2}{dp^2} \ell(p) = -\frac{x}{p^2} - \frac{n-x}{(1-p)^2}. \quad (3.4)$$

This is negative for any $p \in (0, 1)$. Thus, the log likelihood is maximized at \hat{p} if $x > 0$ and $x < n$.

When $x = 0$ or $x = n$, the log likelihood $\ell(p)$ has no maximum at any $p \in (0, 1)$. Instead, the maximum occurs at one of the boundaries of the set of possible p . When $x = 0$, our MLE of p_{true} is $\hat{p} = 0$. When $x = n$, our maximum likelihood estimate is $\hat{p} = 1$.

⁵This is named for [Josiah Willard Gibbs](#) (1839–1903), an American scientist who earned the first American doctorate in engineering in 1863 and went on to work on statistical mechanics, thermodynamics, optics, and vector calculus as a professor of physics at Yale. Albert Einstein called him the greatest mind in American history.

3.2.3 Expected and observed information*

For any given p , we can think of the score $U(p)$ as a random variable that has an expected value and a variance. If $p_{\text{true}} = p$, the expected value of the score is always zero:

$$\mathbb{E}_p[U(p)] = \mathbb{E}_p \left[\frac{X}{p} - \frac{n-X}{1-p} \right] = \frac{\mathbb{E}_p(X)}{p} - \frac{\mathbb{E}_p(n-X)}{1-p} = \frac{np}{p} - \frac{n(1-p)}{1-p} = 0$$

where we use the subscript p to indicate that the expected value is calculated assuming that $p_{\text{true}} = p$. Because $\mathbb{E}_p[U(p)] = 0$, the corresponding variance of the score is

$$\mathcal{J}(p) = \text{Var}_p[U(p)] = \mathbb{E}_p[U(p)^2],$$

by Equation 1.22. This is called the **expected Fisher information** or **expected information**.⁶ It can be used to calculate confidence limits for p_{true} .

Under *regularity conditions* that are met when $p_{\text{true}} \in (0, 1)$, the Fisher information $\mathcal{J}(p)$ can be calculated using the second derivative of the log likelihood $\ell(p)$ from Equation 3.4.⁷ Specifically, $\mathcal{J}(p)$ is the expected value of the negative second derivative of $\ell(p)$:

$$\mathcal{J}(p) = \mathbb{E}_p \left[-\frac{d^2}{dp^2} \ell(p) \right] = \mathbb{E}_p \left[\frac{X}{p^2} + \frac{n-X}{(1-p)^2} \right], \quad (3.5)$$

where the subscript p indicates that the expected value is calculated assuming that $p_{\text{true}} = p$. Using Equation 1.23 and the binomial(n, p) distribution for X , this simplifies to

$$\mathcal{J}(p) = \frac{\mathbb{E}(X)}{p^2} + \frac{\mathbb{E}(n-X)}{(1-p)^2} = \frac{n}{p} + \frac{n}{1-p} = \frac{n}{p(1-p)}.$$

Because p_{true} is unknown, the expected information is often evaluated at \hat{p} . In some models, the expected information can be difficult to calculate.

The negative second derivative of $\ell(p)$ inside the expectation in Equation 3.5 evaluated is the **observed Fisher information** or **observed information**

$$I(p) = -\frac{d^2}{dp^2} \ell(p) = \frac{x}{p^2} + \frac{n-x}{(1-p)^2}. \quad (3.6)$$

⁶Named after [Ronald Fisher](#) (1890–1962), who established the foundations of maximum likelihood inference between 1912 and 1922. He was the most important statistician of the 20th century, and he was one of the founders of population genetics. He had poor eyesight for his entire life, which led him to develop a formidable sense of geometry in his head. However, he was also a leading eugenicist and one of the most vocal opponents of the hypothesis that smoking causes lung cancer.

⁷For estimating a parameter θ , the conditions are these: (1) The set of possible values of the observed data X does not depend on θ . (2) Each θ produces a different distribution of X . (3) The true value of θ is in the interior of the set of possible values. (4) The log likelihood $\ell(\theta)$ has continuous first and second derivatives with respect to θ in a neighborhood of θ_{true} . These conditions are met by the binomial likelihood when $p_{\text{true}} \in (0, 1)$.

For the binomial distribution $I(\hat{p}) = \mathcal{J}(\hat{p})$ but this equality does not hold at other values of p . The observed information is an unbiased estimator of the expected information, and it can always be calculated from the data. It often produces more accurate variance estimates than the expected information (Efron and Hinkley 1978; Kenward and Molenberghs 1998; Reid 2003). However, it is generally safe to use whichever is most convenient (Boos and Stefanski 2013).

3.3 Large-sample theory

The log likelihood, the score function, and the Fisher and observed information give us all of the pieces we need to calculate point and interval estimates of p_{true} . To put them together, we use two fundamental results from probability theory about the behavior of sample means. The law of large numbers justifies point estimates and the central limit theorem justifies hypothesis tests and interval estimates, which can be obtained in three standard ways.

3.3.1 Sample mean (average)

If Y_1, Y_2, \dots, Y_n are random variables, then the **sample mean** or **average** is

$$\hat{\mu}_n = \frac{1}{n} \sum_{i=1}^n Y_i.$$

This sample mean can be thought of as a random variable whose value is determined when we observe $Y_1 = y_1, Y_2 = y_2, \dots, Y_n = y_n$. If each Y_i has $\mathbb{E}(Y_i) = \mu$, then

$$\mathbb{E}[\hat{\mu}_n] = \frac{1}{n} \sum_{i=1}^n \mathbb{E}[Y_i] = \frac{1}{n} n\mu = \mu \quad (3.7)$$

by Equation 1.23. Thus, the sample mean $\hat{\mu}_n$ is an **unbiased** estimate of μ for any sample size n . When the Y_i are indicator variables, $\hat{\mu}_n$ is just the proportion of the sample with $Y_i = 1$.

3.3.2 Law of large numbers and consistency

If the Y_i are independent and each has $\text{Var}(Y_i) = \sigma^2$, then

$$\text{Var}(\hat{\mu}_n) = \frac{1}{n^2} \sum_{i=1}^n \text{Var}(Y_i) = \frac{1}{n^2} n\sigma^2 = \frac{\sigma^2}{n} \quad (3.8)$$

by Equation 1.24. Thus, the variance of $\hat{\mu}_n$ decreases as the sample size n increases. The standard deviation of $\hat{\mu}_n$ is proportional to $1/\sqrt{n}$. As $n \rightarrow \infty$, we should have $\hat{\mu}_n \rightarrow \mu$. This is called the **law of large numbers**, and it holds even when $\sigma^2 = \infty$.

Theorem 3.1 (Law of Large Numbers). *If Y_1, Y_2, \dots is an infinite sequence of independent and identically-distributed (IID) random variables with mean $\mu < \infty$ and variance $\sigma^2 \leq \infty$, then*

$$\hat{\mu}_n \rightarrow \mu$$

as $n \rightarrow \infty$.⁸

Our maximum likelihood estimate \hat{p}_n is a sample mean:

$$\hat{p}_n = \frac{X}{n} = \frac{1}{n} \sum_{i=1}^n Y_i.$$

where each $Y_i \sim \text{Bernoulli}(p_{\text{true}})$ and the Y_i are independent. Therefore, the LLN implies that

$$\hat{p}_n \rightarrow p_{\text{true}}$$

as $n \rightarrow \infty$. This convergence is shown in Figure 3.1. An estimate that converges to its true value as $n \rightarrow \infty$ is called **consistent**. Intuitively, this means that \hat{p}_n is guaranteed to be close to p_{true} in a large sample. However, the LLN does not specify how close or how large a sample we need.

Listing 3.2 lln.R

```
## Law of large numbers

n <- 1000
x <- seq(n)
plot(x, cumsum(rbinom(n, 1, .5)) / x, type = "n", ylim = c(0, 1),
     xlab = "Number of samples", ylab = "Sample mean")
grid()
lines(x, cumsum(rbinom(n, 1, .5)) / x, lty = "solid")
lines(x, cumsum(rbinom(n, 1, .5)) / x, lty = "dashed")
lines(x, cumsum(rbinom(n, 1, .5)) / x, lty = "dotted")
abline(h = .5)
```

⁸For simplicity, we are being vague about what we mean by $\hat{\mu}_n \rightarrow \mu$. Probability has several different notions of convergence/. The *weak* LLN guarantees convergence *in probability*, which means that $\lim_{n \rightarrow \infty} \Pr(|\hat{\mu}_n - \mu| > \varepsilon) = 0$ for any $\varepsilon > 0$. The *strong* LLN guarantees convergence *almost surely*, which means that $\Pr(\lim_{n \rightarrow \infty} \hat{\mu}_n = \mu) = 1$.




Figure 3.1: The LLN at work. Each line traces the sample means calculated from a sequence of random samples x_1, x_2, x_3, \dots from a Bernoulli(0.5) distribution. For each sequence, the y-coordinate above n is the sample mean from the first n random samples in the sequence. The true mean of 0.5 is marked by a solid horizontal line.

3.3.3 Central limit theorem and the normal distribution

When both the mean and variance of the Y_i are finite, the **central limit theorem** (CLT) allows us to say something about how far away our sample mean $\hat{\mu}_n$ is from the true value μ . It is the most important result in all of probability and statistics.

Theorem 3.2 (Central Limit Theorem). *If Y_1, Y_2, \dots is an infinite sequence of IID random variables with finite mean μ and variance $\sigma^2 < \infty$, then*

$$Z_n = \frac{\hat{\mu}_n - \mathbb{E}(\hat{\mu}_n)}{\sqrt{\text{Var}(\hat{\mu}_n)}} = \frac{\sqrt{n}(\hat{\mu}_n - \mu)}{\sqrt{\sigma^2}}$$

*has a distribution that converges to a **normal distribution** or **Gaussian distribution** with mean zero and variance one as $n \rightarrow \infty$.*⁹ *Because of this, we say that $\hat{\mu}_n$ is **asymptotically normal**.*

The normal distribution is a distribution for a **continuous random variable**, which can take any value on an interval or even on all of \mathbb{R} . Instead of a PMF, a continuous random variable Z has a **probability density function** (PDF). If Z is a continuous random variable with PDF $f(z)$ and $[a, b]$ is an interval, then

$$\Pr(Z \in [a, b]) = \int_a^b f(z) \, dz.$$

The integral on the right-hand side represents the area under $f(z)$ over the interval $[a, b]$. The cumulative distribution function of Z is

$$F(z) = \int_{-\infty}^z f(u) \, du,$$

where the integral on the right-hand side represents the area under $f(z)$ over the interval $(-\infty, u]$. For the same reason that the values of the PMF for any discrete random variable add up to one, we have

$$\Pr(Z \in \mathbb{R}) = \int_{-\infty}^{\infty} f(z) \, dz = 1$$

for any continuous random variable Z . Like the PMF and CDF of a discrete random variable, the PDF and CDF of a continuous random variable contain the same information about the distribution of Z .

The PDF of the normal distribution with mean μ and variance σ^2 is

$$f(z, \mu, \sigma^2) = \frac{1}{\sqrt{2\pi\sigma^2}} e^{-\frac{(z-\mu)^2}{2\sigma^2}}.$$

The **standard normal distribution** has $\mu = 0$ and $\sigma^2 = 1$. It is such an important distribution that its PDF and CDF have special notation. The standard normal PDF is

$$\phi(z) = \frac{1}{\sqrt{2\pi}} e^{-\frac{z^2}{2}},$$

and its CDF is $\Phi(z)$. These functions and the relationship between them are illustrated in Figure 3.2. A normal distribution is denoted $N(\mu, \sigma^2)$, so the standard normal distribution is written $N(0, 1)$.

⁹Named after [Carl Friedrich Gauss](#) (1777-1855), a German mathematician who is widely considered one of the greatest mathematicians of all time. He discovered the normal distribution in 1809, but the CLT itself was first proved by Laplace in 1810 (see Chapter 1).




Figure 3.2: The PDF (top) and CDF (bottom) of a standard normal random variable Z . If $X \sim N(0, 1)$, then $\Pr(0 < X < 2)$ equals the shaded area under the PDF as well as the change in the CDF from 0 to 2. This same relationship between the CDF and the PDF holds for all continuous random variables and any interval (a, b) .

3.4 R

For our estimated probability \hat{p}_n is a sample mean of IID Y_i with $\mathbb{E}(Y_i) = p_{\text{true}}$ and $\text{Var}(Y_i) = p_{\text{true}}(1 - p_{\text{true}})$. When n is large,

$$Z_n = \frac{\sqrt{n}(\hat{p}_n - p_{\text{true}})}{\sqrt{p_{\text{true}}(1 - p_{\text{true}})}} = \frac{\hat{p}_n - p_{\text{true}}}{\sqrt{\mathcal{I}(p_{\text{true}})^{-1}}} \quad (3.9)$$

has a distribution that is close to a standard normal distribution. Figure 3.3 shows this convergence is shown for sample means where $Y_i \sim \text{Bernoulli}(0.1)$. The CLT does not guarantee that the distribution of Z_n is approximately normal in any given sample. It only guarantees that the normal approximation holds eventually as n increases. When the $Y_i \sim \text{Bernoulli}(p)$, the normal approximation is typically good when $np(1 - p) > 5$.




Figure 3.3: The CLT at work. The dashed lines show the PMF of the distribution of the average from a sample of size n from a Bernoulli(0.1) distribution. The solid line is the standard normal PDF.

3.4.1 Efficiency of maximum likelihood estimators*

We have used the LLN and the CLT to show that \hat{p}_n is consistent and asymptotically normal, which are both wonderful properties for an estimator to have. However, they do not prove

that \hat{p}_n is the best estimator of p_{true} in any particular sense. In Equation 3.9, the variance of \hat{p}_n was

$$\mathcal{J}(p_{\text{true}})^{-1} = \frac{p_{\text{true}}(1 - p_{\text{true}})}{n},$$

which is the inverse of the Fisher information. It turns out that no other unbiased estimator of p_{true} can have lower variance, so \hat{p}_n is the minimum-variance unbiased estimator of p_{true} .

Suppose θ is a parameter for a family of PMFs or PDFs $f(y, \theta)$ such that the true PMF or PDF is $f(y, \theta_{\text{true}})$. When we observe $Y_1 = y_1, Y_2 = y_2, \dots, Y_n = y_n$, the likelihood is

$$L(\theta) = \prod_{i=1}^n f(y_i, \theta),$$

and the log likelihood is

$$\ell(\theta) = \ln L(\theta) = \sum_{i=1}^n \ln f(y_i, \theta).$$

The score function is

$$U(\theta) = \frac{d}{d\theta} \ell(\theta),$$

and the MLE is the solution of the score equation $U(\hat{\theta}) = 0$. The Fisher information is

$$\mathcal{J}(\theta) = \mathbb{E}_{\theta} \left[\frac{d^2}{d\theta^2} \ell(\theta) \right],$$

and $\text{Var}(\hat{\theta}) = \mathcal{J}(\theta)^{-1}$. If $\bar{\theta}$ is any unbiased estimator of the true value θ_{true} , then

$$\text{Var}(\bar{\theta}) \geq \mathcal{J}(\theta_{\text{true}})^{-1}.$$

This result is called the *Cramér-Rao lower bound* (Rao 1945; Cramér 1946),¹⁰ No unbiased estimator of θ_{true} can have smaller variance than the MLE $\hat{\theta}$. Maximum likelihood estimates are consistent, asymptotically normal, and asymptotically efficient when the likelihood is correct (Boos and Stefanski 2013).

3.5 Hypothesis testing

In a **hypothesis test**, we specify a **null hypothesis** and then decide whether to reject it based on the value of a **test statistic**. A null hypothesis often takes the form

$$H_0 : \theta_{\text{true}} = \theta_0. \tag{3.10}$$

We reject H_0 if the test statistic appears inconsistent with its distribution under H_0 . Otherwise, we *fail to reject* H_0 . It is traditional to avoid saying that H_0 was accepted.

¹⁰Named after Swedish statistician [Harald Cramér](#) (1893–1985), who was a professor at Stockholm University, and Indian-American statistician [Calyampudi Radhakrishna \(C. R.\) Rao](#) (1920–2023), who was a professor at the Indian Statistical Institute, the University of Cambridge, the University of Pittsburgh, and Pennsylvania State University.

Table 3.1: Truth of H_0 and hypothesis test results.

	Reject H_0 (T^+)	Fail to reject H_0 (T^-)
H_0 false (D^+)	True positive	False negative = type II error
H_0 true (D^-)	False positive = type I error	True negative

Table 3.2: Truth of H_0 and hypothesis test results

3.5.1 Hypothesis tests and diagnostic tests

If we think of H_0 as not having the disease and rejecting H_0 as testing positive for the disease, a hypothesis test is analogous to a diagnostic test. Table 3.1 shows the possible outcomes of a hypothesis test, and its margins show the correspondence to diagnostic testing (Diamond and Forrester 1983). A false positive occurs when we reject H_0 when it is true, which is called a **type I error**. A false negative occurs when we fail to reject H_0 when it is false, which is called **type II error**.

A hypothesis test has analogs of sensitivity and specificity. The equivalent of specificity is $1 - \alpha$ where

$$\alpha = \Pr(\text{reject } H_0 \mid H_0 \text{ true})$$

is the probability of a type I error. This is also called the **significance level** of the test. The equivalent of sensitivity is the **power** of the test, which is $1 - \beta$ where

$$\beta = \Pr(\text{fail to reject } H_0 \mid H_0 \text{ false})$$

is the probability of a type II error.

A hypothesis test also has analogs of positive and negative predictive values (PPV and NPV). Just like the PPV and NPV of a diagnostic test depend on the prevalence of disease, the PPV and NPV of a hypothesis test depend on the **prior probability** that H_0 is true, which is the probability that H_0 is true based on what we know before we see the test result. For a hypothesis test, the PPV is

$$\Pr(H_0 \text{ false} \mid H_0 \text{ rejected}) = \frac{(1 - \beta) \Pr(H_0 \text{ false})}{(1 - \beta) \Pr(H_0 \text{ false}) + \alpha \Pr(H_0 \text{ true})} \quad (3.11)$$

by Bayes' rule. Similarly, the NPV of the hypothesis test is

$$\Pr(H_0 \text{ true} \mid H_0 \text{ not rejected}) = \frac{(1 - \alpha) \Pr(H_0 \text{ true})}{(1 - \alpha) \Pr(H_0 \text{ true}) + \beta \Pr(H_0 \text{ false})}. \quad (3.12)$$

The conditional probability that H_0 is true given the result of the hypothesis test is called the **posterior probability** of H_0 .

3.5.2 Wald, score, and likelihood ratio tests

In a maximum likelihood framework, there are three classical tests for a null hypothesis of the form

$$H_0 : p_{\text{true}} = p_0.$$

These tests are asymptotically equivalent, which means that they produce similar results in large samples. The best way to visualize the different tests is to look at a graph of the log likelihood function. Figure 3.4 shows the log likelihood function for a binary outcome with $x = 60$ events out of $n = 100$ trials and a null hypothesis $H_0 : p_{\text{true}} = 0.5$. All three tests generalize to null hypotheses involving multiple parameters (Boos and Stefanski 2013).

The **Wald test** (Wald 1943) of H_0 looks at the distance between the MLE \hat{p} and the hypothesized value p_0 (Wald 1943), rejecting H_0 when this distance is sufficiently large.¹¹ An example is shown in Figure 3.4. The Wald test statistic is

$$W = \frac{(\hat{p} - p_0)^2}{I(\hat{p})} = \frac{n(\hat{p} - p_0)^2}{\hat{p}(1 - \hat{p})} \stackrel{\text{approx}}{\sim} \chi_1^2 \quad (3.13)$$

under H_0 , where $I(\hat{p})$ is the observed information from Equation 3.6. The χ_1^2 distribution is the distribution of Z^2 if $Z \sim N(0, 1)$.

The **score test** looks at the slope of the log likelihood at p_0 , rejecting H_0 if this slope is sufficiently far from zero (Rao 1948; Aitchison and Silvey 1958). An example is shown in Figure 3.4. Its score test statistic is

$$S = \frac{U(p_0)^2}{\mathcal{I}(p_0)} = \frac{n(\hat{p} - p_0)^2}{p_0(1 - p_0)} \stackrel{\text{approx}}{\sim} \chi_1^2 \quad (3.14)$$

under H_0 , where $\mathcal{I}(p_0)$ is the expected information from Equation 3.5. The numerator of the score statistic is the same as for the Wald statistic in Equation 3.13, but the denominator uses the expected information at p_0 instead of the observed information at \hat{p} . In score tests, it is generally better to use the expected information than the observed information (D. A. Freedman 2007). The most important advantage of the score test is that it only needs the hypothesized null value p_0 , so it can be done without finding the maximum likelihood estimate \hat{p} .

The **likelihood ratio test** looks at the vertical distance between $\ell(\hat{p})$ (which is the maximum) and $\ell(p_0)$, rejecting H_0 if this distance is sufficiently large Wilks (1938).¹² An example is shown in Figure 3.4. The likelihood ratio test statistic is

$$L = 2(\ell(\hat{p}) - \ell(p_0)) \stackrel{\text{approx}}{\sim} \chi_1^2 \quad (3.15)$$

¹¹Named after [Abraham Wald](#) (1902–1950), a Jewish Hungarian mathematician who was invited to move from Vienna to the United States in 1938 after Nazi Germany annexed Austria. He worked at the Statistical Research Group at Columbia University during World War II. In 1950, he and his wife were killed in a plane crash in India, where he was visiting the Indian Statistical Institute.

¹²[Samuel S. Wilks](#) (1906–1964) was an American mathematician and statistician who grew up on a farm in Texas, got a Ph.D. at the University of Iowa, and went on to be a professor at Princeton University.

under H_0 . The *Neyman-Pearson lemma* (Neyman and Pearson 1933) shows that the likelihood ratio test is the most powerful of all hypothesis test for comparing two hypotheses $H_0 : p_{\text{true}} = p_0$ and $H_1 : p_{\text{true}} = p_1$ at a fixed significance level.

Tests of the null hypothesis $p = 0.5$




Figure 3.4: Binomial log likelihood function for $x = 60$ and $n = 100$. The null value of p is $p_0 = 0.5$ and the maximum likelihood estimate is $\hat{p} = 0.6$.

3.5.3 Critical values and p-values

The Neyman-Pearson approach to hypothesis testing fixes the significance level α before calculating the test statistic and deciding whether to reject H_0 .¹³ The decision to reject the null hypothesis depends on the value of the test statistic, which is compared to a **critical value** calculated based on the distribution of the test statistic under H_0 . If $Z \sim N(0, 1)$ under H_0

$$\Pr(|Z| \geq z_{1-\frac{\alpha}{2}} | H_0 \text{ true}) = 1 - \alpha.$$

Because $Z^2 \sim \chi_1^2$ when $Z \sim N(0, 1)$, this is equivalent to

$$\Pr(Z^2 \geq z_{1-\frac{\alpha}{2}}^2 | H_0 \text{ true}) = 1 - \alpha.$$

In the Wald, score, and likelihood ratio tests above, H_0 is rejected if the test statistic is larger than the critical value $z_{1-\frac{\alpha}{2}}^2$. For $\alpha = 0.05$, we have $z_{0.975} \approx 1.96$ so critical value for the χ_1^2 distribution is $1.96^2 \approx 3.84$. The test statistic and critical value in a hypothesis test are analogous to the clinical measurement and cutoff in a diagnostic test.

Instead of making a binary decision, it is more informative to calculate a measure of the evidence against H_0 . The **p-value** for a given test statistic is the lowest value of α at which the test would still fail to reject H_0 . A hypothesis test with significance level α rejects H_0 if the p-value is $\leq \alpha$. For the Wald, score, or likelihood ratio tests above,

$$\text{p-value} = 1 - F_{\chi_1^2}(\text{test statistic})$$

where $F_{\chi_1^2}$ is the CDF of the χ_1^2 distribution. If we think of the test statistic as the clinical measurement underlying a diagnostic test, the p-value equals $1 - \text{spec}_{\max}$ where spec_{\max} is the highest specificity under which we would still get a positive test (i.e., reject H_0).

3.6 Confidence intervals

A p-value is more informative than a binary decision whether to reject H_0 , but it is still more useful to know what values of p are plausibly consistent with the data we observed (Rothman 1978). The $1 - \alpha$ **confidence interval** for p_{true} is the set of all possible null values p_0 such that we would fail to reject $H_0 : p_{\text{true}} = p_0$ in a hypothesis test with significance level α . The endpoints of the confidence interval are called *confidence limits*. Just as different clinical measurements lead to different diagnostic tests, different hypothesis tests lead to different confidence intervals.

¹³This approach to hypothesis testing was pioneered in the 1920s by [Jerzy Neyman](#) (1894–1981), a Polish mathematician and statistician who founded the first department of statistics in the United States at the University of California, Berkeley in 1938, and [Egon Pearson](#) (1895–1980), a British statistician who was a professor at University College London like his father Karl Pearson.

If we calculate a confidence interval many times with independent data sets, the $1-\alpha$ confidence interval should contain p_{true} with probability $1-\alpha$. The actual probability that the confidence interval contains p_{true} is called the **coverage probability**. A good confidence interval should have a coverage probability close to $1-\alpha$ while being as narrow as possible. The Wald, score, and likelihood ratio tests from Section 3.5.2 are large-sample tests because they rely on consistency and asymptotic normality of the maximum likelihood estimate \hat{p} . All three tests can be inverted to produce confidence intervals that perform well in large samples. In smaller samples, the score and likelihood ratio confidence intervals often have better coverage probability and width than the Wald confidence interval (Agresti and Coull 1998; Brown, Cai, and DasGupta 2001).

3.6.1 Wald confidence intervals and the delta method

The Wald confidence limits come from solving the equation

$$\frac{(\hat{p} - p)^2}{\hat{p}(1 - \hat{p})/n} = z_{1-\frac{\alpha}{2}}^2. \quad (3.16)$$

for p , which gives us

$$\hat{p} \pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{\hat{p}(1 - \hat{p})}{n}}. \quad (3.17)$$

The coverage probabilities of Wald confidence intervals can be much lower than $1-\alpha$, especially when p_{true} is close to zero or one (Agresti and Coull 1998; Brown, Cai, and DasGupta 2001).

Another problem with the Wald confidence interval for p_{true} is that it can have bounds outside $[0, 1]$. One way to avoid this is to calculate confidence limits for a transformation of \hat{p} using the **delta method**. A good transformation $g(p)$ should have continuous first derivatives and be strictly increasing or decreasing, so each value of $g(p)$ corresponds to a single value of p (i.e., g is *one-to-one*). The delta method derives the approximate normal distribution $g(\hat{p})$ using the approximation

$$g(\hat{p}) \approx g(p_{\text{true}}) + g'(p_{\text{true}})(\hat{p} - p_{\text{true}}).$$

where $g'(p_{\text{true}})$ is the slope of g at p_{true} . An example of this approximation is shown in Figure 3.5. The key insight is that

$$\text{Var}[g(\hat{p})] \approx g'(p_{\text{true}})^2 \text{Var}(\hat{p}),$$

which is a generalization of the fact that $\text{Var}(c\hat{p}) = c^2 \text{Var}(\hat{p})$ for any constant c . If \hat{p} has an approximate $N(p_{\text{true}}, \text{Var}(\hat{p}))$ distribution in large samples, then

$$g(\hat{p}) \overset{\text{approx}}{\sim} N(g(p_{\text{true}}), g'(p_{\text{true}})^2 \text{Var}(\hat{p})).$$

in large samples. Because our estimator \hat{p} is consistent, we can replace the unknown p_{true} with \hat{p} . Because g is one-to-one, we can calculate confidence limits for p_{true} using the confidence limits for $g(p_{\text{true}})$.




Figure 3.5: The approximation used by the delta method using the logistic transformation for a binomial confidence interval near $\hat{p} = 0.6$. The black curve is $\text{logit}(p)$, and the dashed line shows the tangent line at $p = 0.6$.

A widely used transformation for probabilities is the **logit transformation**

$$\text{logit}(p) = \ln\left(\frac{p}{1-p}\right). \quad (3.18)$$

The **odds** corresponding to the probability p is $\frac{p}{1-p}$, so the logit is the natural logarithm of the odds. The logit transformation maps the interval $(0, 1)$ onto all of \mathbb{R} :

- As $p \rightarrow 0$, the odds $p/(1-p) \rightarrow 0$ and $\text{logit}(p) \rightarrow -\infty$.

- When $p = 1/2$, the odds $p/(1-p) = 1$ and $\text{logit}(p) = 0$.
- As $p \rightarrow 1$, the odds $p/(1-p) \rightarrow \infty$ and $\text{logit}(p) \rightarrow \infty$.

To use the delta method, we need to calculate the derivative of $\text{logit}(p)$. By the chain rule,

$$\text{logit}'(p) = \frac{1-p}{p} \frac{1}{(1-p)^2} = \frac{1}{p(1-p)},$$

which is continuous and strictly positive for all $p \in (0, 1)$. By the delta method, the variance of $\text{logit}(\hat{p})$ is approximately

$$\text{logit}'(p_{\text{true}})^2 \frac{p_{\text{true}}(1-p_{\text{true}})}{n} = \frac{1}{p_{\text{true}}^2(1-p_{\text{true}})^2} \frac{p_{\text{true}}(1-p_{\text{true}})}{n} = \frac{1}{np_{\text{true}}(1-p_{\text{true}})}.$$

When we replace the unknown p_{true} with our MLE \hat{p} , we get the following confidence limits for $\text{logit}(p_{\text{true}})$:

$$\text{logit}(\hat{p}) \pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{1}{n\hat{p}(1-\hat{p})}}.$$

To get confidence limits for p_{true} , we use the inverse function for the logit, which is

$$\text{expit}(v) = \frac{e^v}{1+e^v} = \frac{1}{1+e^{-v}}. \quad (3.19)$$

This is also called the *logistic function*. If the confidence limits for $\text{logit}(p_{\text{true}})$ are a and b , then the confidence limits for p_{true} are $\text{expit}(a)$ and $\text{expit}(b)$. These are guaranteed to be in $(0, 1)$ because $\text{expit}(v) \in (0, 1)$ for any $v \in \mathbb{R}$. The logit-transformed confidence interval can have narrower width and a coverage probability closer to $1 - \alpha$ than the untransformed Wald confidence interval (Agresti 2013).

3.6.2 Score (Wilson) confidence intervals

The **score** or **Wilson** confidence limits come from solving the equation

$$\frac{(\hat{p} - p)^2}{p(1-p)/n} = z_{1-\frac{\alpha}{2}}^2. \quad (3.20)$$

for p (Wilson 1927). This differs from Equation 3.16 for the Wald confidence interval because it uses p instead of \hat{p} in the denominator. It is a quadratic equation in p , so it has two solutions. The center of the resulting confidence interval is

$$\tilde{p} = \hat{p} \left(\frac{n}{n + z_{1-\frac{\alpha}{2}}^2} \right) + \frac{1}{2} \left(\frac{z_{1-\frac{\alpha}{2}}^2}{n + z_{1-\frac{\alpha}{2}}^2} \right) = \frac{x + \frac{1}{2} z_{1-\frac{\alpha}{2}}^2}{n + z_{1-\frac{\alpha}{2}}^2}, \quad (3.21)$$

where x is the number of diseased individuals in our sample. This is a weighted average of \hat{p} and $1/2$ with weights proportional to n and $z_{1-\frac{\alpha}{2}}^2$, respectively. The resulting confidence interval is

$$\tilde{p} \pm z_{1-\frac{\alpha}{2}} \sqrt{\tilde{V}}$$

where

$$\tilde{V} = \frac{\hat{p}(1-\hat{p})}{n + z_{1-\frac{\alpha}{2}}^2} \left(\frac{n}{n + z_{1-\frac{\alpha}{2}}^2} \right) + \frac{\left(\frac{1}{2}\right)^2}{n + z_{1-\frac{\alpha}{2}}^2} \left(\frac{z_{1-\frac{\alpha}{2}}^2}{n + z_{1-\frac{\alpha}{2}}^2} \right).$$

This variance is a weighted average of the variances of sample proportions equal to \hat{p} and $1/2$ with the same weights as in \tilde{p} and with $n + z_{1-\frac{\alpha}{2}}^2$ instead of n in the denominator. Wilson confidence intervals are narrower than the corresponding Wald intervals, and they have coverage probabilities much closer to $1 - \alpha$ (Agresti and Coull 1998; Brown, Cai, and DasGupta 2001).

The *Agresti-Coull confidence interval* is a simplification of the Wilson confidence interval that replaces \hat{p} with \tilde{p} in the Wald confidence interval to get the confidence limits

$$\tilde{p} \pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{\tilde{p}(1-\tilde{p})}{n}}.$$

Because $z_{0.975} \approx 1.96$, we have $\tilde{p} \approx \frac{k+2}{n+4}$ for a 95% confidence interval. In this case, the Agresti-Coull interval is often implemented as follows: “Add two successes and two failures and then use the Wald formula” (Agresti and Coull 1998). This interval is only slightly wider than the score confidence interval, and the two intervals are nearly identical for $n > 40$ (Brown, Cai, and DasGupta 2001).

The likelihood ratio test can also be inverted to get confidence intervals, but these can only be calculated numerically. For the binomial model, the likelihood ratio and score confidence intervals are nearly identical (Agresti and Coull 1998; Brown, Cai, and DasGupta 2001). The score intervals are more common in practice because they are easier to calculate.

3.7 R

3.8 Small-sample estimation*

Maximum likelihood estimates are consistent, asymptotically normal, and asymptotically efficient. However, they are not guaranteed to perform well in any finite sample. For a sample of n independent Bernoulli(p) random variables, the sum has a binomial(n, p) distribution and this can be used to find the finite-sample distribution of the sample mean. This distribution can be used directly to calculate point estimates, p-values, and confidence limits.

Confidence limits calculated using the finite-sample distribution of a test statistic under H_0 are called **exact confidence limits**. They can often be constructed to have a coverage probability of at least $1 - \alpha$. However, their coverage probabilities are often higher than $1 - \alpha$, and they can be much wider than approximate $1 - \alpha$ confidence intervals for the same parameter (Agresti and Coull 1998).

If the finite-sample distribution of the test statistic is not known exactly, it is possible to calculate point estimates, p-values, or confidence limits using simulations. This is the basic idea behind the *bootstrap* (Efron and Tibshirani 1994) and *Monte Carlo methods* (Robert and Casella 2004).

3.8.1 Median unbiased estimate

The **median unbiased estimate** of p_{true} is the value of p that makes

$$\Pr_p(X < x) = \Pr_p(X > x)$$

where we use the subscript p to indicate that these probabilities are calculated assuming $p_{\text{true}} = p$. If p_{med} is the median unbiased estimate, then

$$\sum_{k=0}^{x-1} \binom{n}{k} p_{\text{med}}^k (1 - p_{\text{med}})^{n-k} + \frac{1}{2} \binom{n}{x} p_{\text{med}}^x (1 - p_{\text{med}})^{n-x} = \frac{1}{2},$$

and

$$\frac{1}{2} \binom{n}{x} p_{\text{med}}^x (1 - p_{\text{med}})^{n-x} + \sum_{k=x+1}^n \binom{n}{k} p_{\text{med}}^k (1 - p_{\text{med}})^{n-k} = \frac{1}{2}.$$

The median of the distribution of p_{med} is always p_{true} (Birnbaum 1964), which is a slightly different notion of unbiasedness than the unbiasedness of \hat{p} where $\mathbb{E}(\hat{p}) = p_{\text{true}}$.

3.8.2 Exact (Clopper-Pearson) and mid-p confidence intervals

The **exact** or **Clopper-Pearson** confidence limits for p_{true} use the finite-sample distribution of the sample mean \hat{p} Clopper and Pearson (1934). When $x > 0$, the lower $1 - \alpha$ confidence limit is the solution to

$$\sum_{k=x}^n \binom{n}{k} p_{\text{lower}}^k (1 - p_{\text{lower}})^{n-k} = \frac{\alpha}{2}, \quad (3.22)$$

so the *upper tail* of the $\text{binomial}(n, p_{\text{lower}})$ distribution has probability $\alpha/2$. When $x = 0$, we set $p_{\text{lower}} = 0$. When $x < n$, the upper confidence limit is the solution to

$$\sum_{k=0}^x \binom{n}{k} p_{\text{upper}}^k (1 - p_{\text{upper}})^{n-k} = \frac{\alpha}{2}, \quad (3.23)$$

so the *lower tail* of the binomial(n, p_{upper}) distribution has probability $\alpha/2$. When $x = n$, we set $p_{\text{upper}} = 1$. This interval is guaranteed to have a coverage probability of at least $1 - \alpha$, but the price for this is that it is always wider than the Wald and Wilson confidence intervals (Agresti and Coull 1998; Brown, Cai, and DasGupta 2001). In general, the score or likelihood ratio confidence intervals have better combinations of coverage probability and width.

To make exact confidence limits less conservative, we can include only $\frac{1}{2} \Pr(X = x)$ instead of $\Pr(X = x)$ in the calculation of the tail probabilities in Equation 3.23 and Equation 3.22. The resulting confidence intervals are called **mid-p exact confidence intervals** (Lancaster 1961, berry1995mid). The lower $1 - \alpha$ mid-p exact confidence limit is the solution to

$$\frac{1}{2} \binom{n}{x} p_{\text{lower}}^x (1 - p_{\text{lower}})^{n-x} + \sum_{k=x+1}^n \binom{n}{k} p_{\text{lower}}^k (1 - p_{\text{lower}})^{n-k} = \frac{\alpha}{2}.$$

and the upper limit is the solution to

$$\sum_{k=0}^{x-1} \binom{n}{k} p_{\text{upper}}^k (1 - p_{\text{upper}})^{n-k} + \frac{1}{2} \binom{n}{x} p_{\text{upper}}^x (1 - p_{\text{upper}})^{n-x} = \frac{\alpha}{2}.$$

The mid-p exact confidence limits are have good combinations of coverage probability and width as well as good performance in small samples (Brown, Cai, and DasGupta 2001).

3.9 R

Listing 3.3 normplots.R

```
## Normal distribution PDF and CDF

# set grid of plots
par(mfrow = c(2, 1), mar = c(2, 5, 2, 2) + 0.1)

# define variables
x <- seq(-3.5, 3.5, by = 0.01)
a <- 0
b <- 2

# plot of PDF
plot(x, dnorm(x), type = "n",
     ylab = expression(paste("PDF ", phi1(z))))
grid()
lines(x, dnorm(x))
polygon(x = c(b, a, seq(a, b, by = 0.01)),
       y = c(0, 0, dnorm(seq(a, b, by = 0.01))),
       lty = "dashed", col = "darkgray")
text(0.4, 0.18, labels = "Area = Pr(0 < Z < 2)", srt = 90)

# plot of CDF
plot(x, pnorm(x), type = "n",
     ylab = expression(paste("CDF ", Phi(z))))
grid()
lines(x, pnorm(x))
segments(c(-4, -4), pnorm(c(a, b)), c(a, b), pnorm(c(a, b)),
       lty = "dashed")
segments(c(a, b), c(-1, -1), c(a, b), pnorm(c(a, b)), lty = "dashed")
arrows(-3, pnorm(a), -3, pnorm(b), code = 3, length = 0.1)
text(-1.7, sum(pnorm(c(a, b))) / 2, labels = "Change = Pr(0 < Z < 2)")
```

Listing 3.4 normdist.R

```
## normal (Gaussian) distribution

# normal PDF
# Second and third arguments are mean and SD (not variance).
# The defaults are mean = 0 and SD = 1.
dnorm(2, 1.2, 5)

# normal CDF (using default mean and variance)
pnorm(1.96)
pnorm(1.96) - pnorm(-1.96)

# normal quantiles
qnorm(0.975)
pnorm(qnorm(0.975))

# random samples (using named arguments)
rnorm(25, mean = 2.3, sd = 3)
```

Listing 3.5 clt.R

```
## Central limit theorem

# probability mass function for sample mean
dblline <- function(n, p=.5, ...) {
  x <- (seq(-.5, n + .5) / n - p) * sqrt(n / (p * (1 - p)))
  y <- c(0, dbinom(0:n, n, p), 0) * sqrt(p * (1 - p) * n)
  lines(stepfun(x, y), pch = NA, ...)
}

# define grid of plots
par(mfrow = c(2, 2))
x <- seq(-4, 4, by = .01)

# n = 20
plot(x, dnorm(x), type = "n", ylim = c(0, .5),
     main = "n = 20", xlab = "Z score", ylab = "Probability density")
grid()
dblline(20, p = .1, lty = "dashed")
lines(x, dnorm(x), col = "darkgray")

# n = 50
plot(x, dnorm(x), type = "n", ylim = c(0, .5),
     main = "n = 50", xlab = "Z score", ylab = "Probability density")
grid()
dblline(50, p = .1, lty = "dashed")
lines(x, dnorm(x), col = "darkgray")

# n = 100
plot(x, dnorm(x), type = "n", ylim = c(0, .5),
     main = "n = 100", xlab = "Z score", ylab = "Probability density")
grid()
dblline(100, p = .1, lty = "dashed")
lines(x, dnorm(x), col = "darkgray")

# n = 250
plot(x, dnorm(x), type = "n", ylim = c(0, .5),
     main = "n = 250", xlab = "Z score", ylab = "Probability density")
grid()
dblline(250, p = .1, lty = "dashed")
lines(x, dnorm(x), col = "darkgray")
```

Listing 3.6 htests.R

```
## Hypothesis tests based on the log likelihood

# binomial log likelihood, score, and information functions
bin_loglik <- function(p, k=60, n=100) {
  k * log(p) + (n - k) * log(1 - p)
}
bin_score <- function(p, k=60, n=100) {
  k / p - (n - k) / (1 - p)
}
bin_information <- function(p, k=60, n=100) {
  k / p^2 + (n - k) / (1 - p)^2
}

# plot showing Wald, score, and likelihood ratio tests
p <- seq(0.4, 0.8, length.out = 200)
plot(p, bin_loglik(p), type = "n",
      xlim = c(0.40, 0.70), ylim = c(-72, -66),
      main = "Tests of the null hypothesis p = 0.5",
      xlab = "p", ylab = "ln L(p)")
grid()
lines(p, bin_loglik(p))
abline(v = c(0.5, 0.6), lty = "dotted")
abline(h = c(bin_loglik(0.5), bin_loglik(0.6)), lty = "dashed")
abline(a = bin_loglik(0.5) - bin_score(0.5) * 0.5, b = bin_score(0.5),
      col = "darkgray")
text(c(0.5, 0.6), c(-67.05, -67),
      labels = c(expression(p[0]), expression(hat(p))))
text(0.55, -70.7, labels = "Wald test")
arrows(0.5, -70.5, 0.6, code = 3, length = 0.1)
arrows(0.475, bin_loglik(0.5), y1 = bin_loglik(0.6),
      code = 3, length = 0.1)
text(0.45, -68.3, labels = "LRT")

# The slope is the tangent of the angle to the x-axis.
# We also must account for the different scales on the x- and y-axes.
# 0.3 / 6 is xdist / ydist (see xlim and ylim above)
score_angle <- atan(bin_score(0.5) * 0.3 / 6)
angles <- seq(0, score_angle, by = 0.01)
score_x <- 0.5 + 0.04 * cos(angles)
score_y <- bin_loglik(0.5) + 0.04 * (6 / 0.3) * sin(angles)
lines(score_x, score_y)
text(0.56, -68.8, "Score test")
arrows(score_x[2], score_y[2], score_x[1], score_y[1], length = 0.1)
arrows(rev(score_x)[2], rev(score_y)[2], rev(score_x)[1], rev(score_y)[1],
      length = 0.1)
```

Listing 3.7 delta.R

```
## Approximation used by the delta method

p <- seq(0.02, 0.98, by = 0.01)
logit <- function(p) log(p) - log(1 - p)

# plot
plot(p, logit(p), type = "n",
      xlab = "p", ylab = "logit(p)")
grid()
lines(p, logit(p))
points(0.6, logit(0.6))
abline(logit(0.6) - 2.5, 1 / 0.24, lty = "dashed")
text(0.6, -1,
      labels = expression(paste("logit(p) - ", logit(0.6) %~~% logit,
                                "'(0.6) (p - 0.6)"))))
```

Listing 3.8 binconf.R

```
## Binomial confidence intervals

# using BinomCI() function from the DescTools package
library(DescTools)
BinomCI(15, 22, method = "wald")          # Wald confidence interval
BinomCI(15, 22, method = "logit")         # logit-transformed Wald CI
BinomCI(15, 22, method = "wilson")        # score CI (default)
BinomCI(15, 22, method = "agresti-coull") # Agresti-Coull CI
BinomCI(15, 22, method = "lik")          # likelihood ratio CI

# using binconf() function from the Hmisc package
library(Hmisc)
binconf(15, 22, method = "asymptotic")    # Wald CI
binconf(15, 22, method = "wilson")        # score CI (default)

# using prop.test in base R (stats package)
# Wilson confidence interval with continuity correction by default
# The continuity correction is not generally recommended. Like the exact CI,
# it can be too wide and have a coverage probability greater than 1 - \alpha.
prop.test(15, 22)
names(prop.test(15, 22))
prop.test(15, 22, correct = FALSE)        # score CI

# using binom.test (exact confidence interval)
binom.test(15, 22)    # same as binconf with method = "exact"
names(binom.test(15, 22))

# changing the confidence level (1 - alpha) to 80%
# All are score (Wilson) confidence intervals by default.
BinomCI(15, 22, conf.level = 0.8)
binconf(15, 22, alpha = 0.2)
prop.test(15, 22, conf.level = 0.8, correct = FALSE)

# writing a function to get Wald confidence limits
bconf_wald <- function(x, n, level=0.95) {
  # x is number of successes out of n trials
  p_hat <- x / n
  alpha <- 1 - level
  pvar <- p_hat * (1 - p_hat) / n
  p_int <- p_hat + c(-1, 1) * qnorm(1 - alpha / 2) * sqrt(pvar)

  # return named vector (names do not need quotes)
  return(c(point = p_hat, lower = p_int[1], upper = p_int[2]))
}

bconf_wald(15, 22)
bconf_wald(15, 22, level = 0.80)
```

Listing 3.9 binomial-small.R

```
## Small-sample binomial point and interval estimates

# median unbiased estimate
medp_binom <- function(k, n) {
  # k = number of successes, n = number of trials

  # binomial lower tail probability
  lower_tail <- function(p) pbinom(k, n, p) - dbinom(k, n, p) / 2

  # median unbiased estimate
  med <- uniroot(function(p) lower_tail(p) - 1 / 2, interval = c(0, 1))
  med$root
}
medp_binom(15, 22)

# exact (Clopper-Pearson) confidence intervals
binom.test(15, 22) # base R (stats)
names(binom.test(15, 22))
binom.test(15, 22, conf.level = 0.8)

library(Hmisc)
binconf(15, 22, method = "exact")
binconf(15, 22, method = "exact", alpha = 0.2)

library(DescTools)
BinomCI(15, 22, method = "clopper-pearson") # exact CI
BinomCI(15, 22, method = "midp") # mid-p exact CI
```

4 Bayesian Estimation

In the null hypothesis schema we are trying only to nullify something: “The null hypothesis is never proved or established but is possibly disproved in the course of experimentation.” But ordinarily evidence does not take this form. With the *corpus delicti* in front of you, you do not say, “Here is evidence against the hypothesis that no one is dead.” You say, “Evidently someone has been murdered.” (Berkson 1942)¹

In **Bayesian** inference, probability distributions are used to summarize our knowledge about the possible values of an unknown parameter θ_{true} . The distribution of possible values of θ_{true} before we have seen our data is called the **prior distribution**, and the distribution of possible values of θ_{true} after we see the data is called the **posterior distribution**. Most parameters we are interested in estimating (such as probabilities) are continuous, so they have a probability density function (PDF) instead of a probability mass function (PMF). The posterior PDF is proportional to the prior PDF times the likelihood function, and the posterior distribution can be used to get point and interval estimates of an unknown parameter. The interval estimates are called **credible intervals**, and they have important advantages over confidence intervals. The Bayesian approach to statistics is more logically consistent and more intuitive than the frequentist approach, but it can be more computationally complex. While large-sample theory can be useful in Bayesian inference, it does not rely on asymptotic normality to the same degree that maximum likelihood estimation does.

4.1 Prior and posterior distributions

The value of a PDF is not a probability (it can be greater than one), but PDFs can be handled like probabilities in terms of the addition rule and the multiplication of conditional probabilities Boos and Stefanski (2013). Let $\pi(\theta)$ be the **prior** PDF of θ . Before we see our data, we believe that $\theta_{\text{true}} \in [a, b]$ with probability

$$\Pr(a \leq \theta \leq b) = \int_a^b \pi(\theta) d\theta.$$

¹Joseph Berkson (1899–1982) was an American physician and statistician at the Mayo Clinic in Rochester, Minnesota. He helped develop and popularize the use of logistic regression for binary outcomes, coining the term “logit” for the log odds in 1944. He also pioneered the study of selection bias, a special case of which is called “Berkson’s bias”. In the late 1950s and the 1960s, he argued that scientific evidence did not establish that smoking causes lung cancer.

This integral is the area under the graph of $\pi(\theta)$ between $\theta = a$ and $\theta = b$. For a given value of θ , the likelihood of our data is $L(\theta) = \pi(\text{data} | \theta)$. By Bayes' rule, the **posterior** PDF is

$$\pi(\theta | \text{data}) = \frac{L(\theta)\pi(\theta)}{\pi(\text{data})} \propto L(\theta)\pi(\theta).$$

where \propto denotes “proportional to.” Calculating $\pi(\text{data})$ is difficult and almost always unnecessary. As long as we can calculate $\pi(\theta | \text{data})$ up to a constant of proportionality, we can normalize it to ensure that we have a posterior PDF whose integral over \mathbb{R} equals one. After we see our data, we believe that $\theta_{\text{true}} \in [a, b]$ with probability

$$\Pr(a \leq \theta \leq b | \text{data}) = \int_a^b \pi(\theta | \text{data}) d\theta.$$

Bayesian point and interval estimates of θ_{true} are based on the posterior PDF.

Bayesian methods are often simpler, easier to interpret, and more robust to small sample sizes than frequentist methods like maximum likelihood estimation. In the limit of a large sample size, Bayesian and frequentist methods almost always give equivalent results. The Bayesian approach is also valuable because it emphasizes estimation and the accumulation of knowledge rather than binary decisions (Tukey 1960). However, the adoption of Bayesian methods has been impeded by a historical lack of the computational power needed to use them and by the widespread hesitation to specify prior distributions among epidemiologists, statisticians, and other scientists. The first problem is largely solved, but the latter problem remains with us today.

A common approach to specifying a prior distribution is to use a **noninformative prior** that places few or no restrictions on the value of θ . This lets the data “speak for itself” at the price of ignoring existing knowledge about the underlying scientific question. The ability to incorporate an informative prior distribution in the Bayesian approach to statistical inference should be viewed as a feature, not a bug (Greenland 2006; Greenland and Poole 2013).

4.1.1 Posterior point and interval estimation

The mean, median, or mode of the posterior distribution of θ can be used as a point estimate of θ_{true} . We will use $\bar{\theta}$ to denote the posterior mean and $\tilde{\theta}$ to denote the posterior median. In large samples, the posterior distribution converges to a normal distribution with mean θ_{true} and variance $I(\theta_{\text{true}})^{-1}$ (Le Cam 1953; Gelman et al. 2014),² which is the same as the limiting normal distribution of the MLE $\hat{\theta}$. In this limit, the posterior mean, median, and mode are all equal to $\hat{\theta}$.

²This convergence follows from the *Laplace approximation* to the posterior distribution (Gelman et al. 2014). It occurs when the likelihood $L(\theta)$ has a continuous second derivative with respect to θ and θ_{true} is not on the boundary of the support of the prior distribution. These are similar to the regularity conditions for maximum likelihood estimation.

A $1 - \alpha$ **credible interval** is an interval $[a, b]$ such that

$$\Pr(a \leq \theta \leq b \mid \text{data}) = \int_a^b \pi(\theta \mid \text{data}) d\theta = 1 - \alpha.$$

Given our data, we believe that $\theta_{\text{true}} \in [a, b]$ with probability $1 - \alpha$. There are many different ways that a credible interval can be defined. The one that is conceptually closest to a confidence interval is the **central posterior interval** or **equal-tailed interval**, where

$$\Pr(\theta < a \mid \text{data}) = \Pr(\theta > b \mid \text{data}) = \frac{\alpha}{2}.$$

Thus, the $1 - \alpha$ confidence limits are the $\alpha/2$ and $1 - \alpha/2$ quantiles of the posterior distribution of θ_{true} . Unlike confidence intervals, credible intervals can accurately be interpreted as containing θ_{true} with probability $1 - \alpha$. Like confidence intervals, credible intervals are only reliable if the likelihood is approximately correct. An equal-tailed credible interval is guaranteed to contain the posterior median $\tilde{\theta}$. It will usually contain the posterior mean $\bar{\theta}$, but this is not guaranteed in small samples.

4.1.2 Bayesian interpretation of confidence intervals

Bayesian credible intervals actually have the properties that people intuitively but naively expect of frequentist confidence intervals. In finite samples, a $1 - \alpha$ equal-tailed credible interval and a $1 - \alpha$ confidence interval will be similar when the posterior density $\pi(\theta \mid \text{data})$ is proportional to the likelihood $L(\theta) = \pi(\theta \mid \text{data})$. This occurs when $\pi(\theta)$ is constant, as in some uninformative priors. In the limit of a large sample, the credible interval and the confidence interval are nearly identical. In general, a frequentist confidence interval can be interpreted as an approximation to a Bayesian credible interval when there is a large sample and a prior distribution that is flat across the range of the confidence interval (Pratt 1965; Greenland and Poole 2013). However, credible intervals do not rely on large-sample approximations, and they are able to incorporate prior knowledge about the possible values of θ_{true} .

4.1.3 Posterior probability of H_0 and p-values

The idea of prior and posterior probabilities from Bayesian inference gives us a useful perspective on the interpretation of p-values, which is a source of much confusion in epidemiology (Diamond and Forrester 1983; Greenland et al. 2016; Baduashvili, Evans, and Cutler 2020). The most common error is to interpret the p-value as the posterior probability that H_0 is true. By Bayes' rule,

$$\Pr(H_0 \text{ true} \mid \text{data}) = \frac{\Pr(\text{data} \mid H_0 \text{ true}) \Pr(H_0 \text{ true})}{\Pr(\text{data})}.$$

The p-value is analogous to $\Pr(\text{data} \mid H_0 \text{ true})$, but the posterior probability $\Pr(H_0 \text{ true} \mid \text{data})$ depends on its prior probability $\Pr(H_0)$. It should take more data to convince us of a null

hypothesis that seemed very unlikely than to convince us of a null hypothesis that seemed very likely.

For a null hypothesis of the form $H_0 : \theta_{\text{true}} = \theta_0$ where θ ranges over an interval, it can be difficult to assign a prior probability to H_0 . For any continuous distribution of θ , the probability that it takes any particular value is zero. One way around this difficulty is to assign a prior probability mass to the null value θ_0 . A more difficult problem is to assign a prior probability to the alternative hypothesis H_1 , which is often not clearly specified. This means that the posterior probability of the null hypothesis is often not clearly defined.

However, it is not difficult to calculate a lower bound on the probability that H_0 is true given the data (Edwards, Lindman, and Savage 1963; Berger and Sellke 1987). Let π_0 be the prior probability of H_0 , and suppose we have a single alternative hypothesis $H_1 : \theta_{\text{true}} = \theta_1$ with prior probability $1 - \pi_0$. Then the posterior probability of H_0 is

$$\Pr(H_0 | \text{data}) = \frac{L(\theta_0)\pi_0}{L(\theta_0)\pi_0 + L(\theta_1)(1 - \pi_0)} = \left(1 + \frac{1 - \pi_0}{\pi_0} \frac{L(\theta_1)}{L(\theta_0)}\right)^{-1}.$$

Given the data, the posterior probability of H_0 is minimized if we happen to get the MLE $\hat{\theta} = \theta_1$, so

$$\Pr(H_0 \text{ true} | \text{data}) \geq \left(1 + \frac{1 - \pi_0}{\pi_0} \frac{L(\hat{\theta})}{L(\theta_0)}\right)^{-1}.$$

From Wilk's theorem (Wilks 1938) for the likelihood ratio test, twice the log likelihood ratio has an approximate χ_1^2 distribution in large samples. To get a p-value of α from the likelihood ratio test, we need

$$2(\ell(\hat{\theta}) - \ell(\theta_0)) = z_{1-\frac{\alpha}{2}}^2 \Rightarrow \frac{L(\hat{\theta})}{L(\theta_0)} = e^{\frac{1}{2}z_{1-\frac{\alpha}{2}}^2}.$$


Figure 4.1 shows the minimum posterior probability of H_0 if $\pi_0 = 0.5$ for different p-values. The p-value is almost always much lower than the lower bound of the posterior probability of the null. For $\pi_0 = 0.5$, the lower bounds for $\Pr(H_0 \text{ true} | \text{data})$ are approximately 0.205 for $p = 0.10$, 0.128 for $p = 0.05$, and 0.035 for $p = 0.01$. In practice, the posterior probability of H_0 can be much larger than its lower bound (Berger and Sellke 1987).

Listing 4.1 postH0.R

```
## Posterior probability of the null hypothesis (H0)

# function to calculate lower bound
lowerb <- function(pi0=0.5, pval=0.05) {
  # args: pi0 = prior probability of H0, pval = p-value
  # return: lower bound on posterior probability of H0
  z <- qnorm(1 - pval / 2)
  1 / (1 + (1 - pi0) / pi0 * exp(0.5 * z^2))
}

# plot of lower bounds for p-value = 0.01, 0.05, and 0.1
x <- seq(0, 1, by = .01)
plot(x, lowerb(x), type = "n", xlim = c(0, 1), ylim = c(0, 1),
     xlab = expression("Prior probability of H"[0]),
     ylab = expression("Minimum posterior probability of H"[0])),
     grid()
abline(0, 1, col = "gray")
lines(x, lowerb(x))
lines(x, lowerb(x, pval = .01), lty = "dashed")
lines(x, lowerb(x, pval = .1), lty = "dotted")
legend("topleft", bg = "white", lty = c("dotted", "solid", "dashed"),
      legend = c("p = 0.10", "p = 0.05", "p = 0.01"))
```



4.2 Bayesian estimation of a probability

When estimating a probability p_{true} , our likelihood will be the binomial likelihood

$$L(p) = \binom{n}{k} p^k (1-p)^{n-k}$$

when k out of n samples equal one. Because we only need to calculate the likelihood up to a constant of proportionality, we can safely ignore the $\binom{n}{k}$ because it does not depend on p . The posterior distribution of p will be

$$\pi(p | \text{data}) \propto p^k (1-p)^{n-k} \pi(p)$$

where $\pi(p)$ is the prior distribution of p . When $\pi(p | \text{data})$ and $\pi(p)$ are from the same family of distributions, the prior $\pi(p)$ is said to be a **conjugate** distribution for the binomial likelihood. Conjugate distributions exist for many likelihoods used in epidemiology.

4.2.1 Beta distribution

The conjugate distribution for the binomial likelihood is the **beta distribution**. It has a support on $[0, 1]$ (where p_{true} must live) with the PDF

$$f(x, \alpha, \beta) = \frac{\Gamma(\alpha + \beta)}{\Gamma(\alpha)\Gamma(\beta)} x^{\alpha-1} (1-x)^{\beta-1} \propto x^{\alpha-1} (1-x)^{\beta-1}.$$

where $\alpha > 0$ and $\beta > 0$ are shape parameters and $\Gamma(v)$ is the gamma function.³ Because we will only need to calculate PDFs up to a multiplicative constant, the gamma function term can be safely ignored. If $X \sim \text{beta}(\alpha, \beta)$, then

$$\mathbb{E}[X] = \frac{\alpha}{\alpha + \beta}$$

and

$$\text{Var}(X) = \frac{\alpha\beta}{(\alpha + \beta)^2(\alpha + \beta + 1)}.$$

The beta distribution has a number of important special cases:

- When $\alpha = \beta = 1$, it is a $\text{uniform}(0, 1)$ distribution.
- The beta distribution with $\alpha = \beta = 1/2$ is the **Jeffreys prior** for the binomial likelihood.⁴ A Jeffreys prior is proportional to the square root of the expected information $\mathcal{I}_1(\theta)$ of a single observation (Jeffreys 1946). They are widely used as noninformative priors. For the binomial likelihood, $\mathcal{I}_1(p) = \frac{1}{p(1-p)}$.

³The **gamma function** is $\Gamma(v) = \int_0^\infty y^{v-1} e^{-y} dy$. It is used to define the gamma distribution, of which the chi-squared distributions (including χ_1^2) are special cases. If v is a positive integer, then $\Gamma(v) = (v-1)!$.

⁴**Harold Jeffreys** (1891–1989) was an English mathematician, statistician, geophysicist, and astronomer. He helped revive the Bayesian notion of probability as an expression of our knowledge about an unknown quantity, wrote a classic textbook on mathematical physics with his wife Bertha (also a mathematician and physicist), and was a prominent opponent of the theory of plate tectonics.

4.2.2 Posterior point and interval estimates

If the prior distribution of p is a $\text{beta}(\alpha, \beta)$ distribution, then

$$\begin{aligned}\pi(p \mid \text{data}) &\propto p^k(1-p)^{n-k} \times p^{\alpha-1}(1-p)^{\beta-1} \\ &= p^{k+\alpha-1}(1-p)^{n-k+\beta-1}\end{aligned}$$

so the posterior distribution of p is a $\text{beta}(k + \alpha, n - k + \beta)$ distribution. The posterior mean is

$$\bar{p} = \frac{k + \alpha}{(k + \alpha) + (n - k + \beta)} = \frac{k + \alpha}{n + \alpha + \beta},$$

and the posterior variance is

$$\frac{(k + \alpha)(n - k + \beta)}{(n + \alpha + \beta)^2(n + \alpha + \beta + 1)} = \frac{\bar{p}(1 - \bar{p})}{n + \alpha + \beta + 1}.$$

The endpoints of the $1 - \alpha$ central credible interval are the $\alpha/2$ and $1 - \alpha/2$ quantiles of the $\text{beta}(k + \alpha, n - k + \beta)$ distribution. Figure 4.2 shows prior and posterior distributions for 15 successes out of 22 trials. Although the prior distributions are quite different, the posterior distributions are quite similar. With large samples, the prior distribution disappears into the likelihood.




Figure 4.2: Prior and posterior distributions for p after observing 15 successes out of 22 trials. The uniform prior and the resulting posterior distribution are shown in black with the 2.5% tails shaded. The central 95% credible interval includes all values of p between the two tails. The Jeffreys prior and the corresponding posterior distribution are shown in dark gray.

As $n \rightarrow \infty$, we have $\bar{p} - \hat{p} \rightarrow 0$ and

$$\frac{\bar{p}(1 - \bar{p})}{n + \alpha + \beta + 1} - \frac{\hat{p}(1 - \hat{p})}{n} \rightarrow 0. \quad (4.1)$$

Thus, the posterior distribution approaches approximate normal distribution of the maximum

Table 4.1: 95% confidence intervals for the sensitivity, specificity, PPV, and NPV of diabetes test in Remein and Wilkerson (1961).

	Sensitivity	Specificity	PPV	NPV
95% CI type	55/70 \approx 0.786	462/510 \approx 0.906	55/103 \approx 0.534	462/477 \approx 0.969
Wald	(0.690, 0.882)	(0.881, 0.931)	(0.438, 0.630)	(0.953, 0.984)
Logit	(0.674, 0.866)	(0.877, 0.928)	(0.438, 0.628)	(0.949, 0.981)
Agresti-Coull	(0.675, 0.867)	(0.877, 0.928)	(0.438, 0.627)	(0.948, 0.981)
Score	(0.676, 0.866)	(0.877, 0.928)	(0.438, 0.627)	(0.949, 0.981)
Likelihood ratio	(0.680, 0.871)	(0.879, 0.929)	(0.438, 0.629)	(0.950, 0.982)
Exact	(0.671, 0.875)	(0.877, 0.930)	(0.433, 0.633)	(0.949, 0.982)
Mid-p	(0.678, 0.870)	(0.878, 0.929)	(0.437, 0.629)	(0.950, 0.982)
Jeffreys	(0.679, 0.869)	(0.878, 0.929)	(0.438, 0.628)	(0.950, 0.982)

likelihood estimate \hat{p} in large samples. However, the Bayesian posterior distribution is valid for any sample size, not just large samples.

4.2.3 Jeffreys confidence interval

The $1 - \alpha$ Jeffreys confidence interval is the central credible interval with a $\text{beta}(1/2, 1/2)$ prior, which is the Jeffreys prior for a binomial model. When $k > 0$ and $k < n$, its endpoints are the $\alpha/2$ and $1 - \alpha/2$ quantiles of the $\text{beta}(k + 1/2, n - k + 1/2)$ posterior distribution that we get if we see k successes in n trials. When $k = 0$, the lower endpoint is 0. When $k = n$, the upper endpoint is 1. For a binomial proportion, the Jeffreys confidence interval has width and coverage probability similar to the score (Wilson) and mid-p exact confidence intervals (Brown, Cai, and DasGupta 2001).

4.3 Comparison of binomial confidence intervals

Table 4.1 shows eight types of confidence intervals for a probability that we have discussed. These are calculated for the sensitivity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) of the diabetes test one hour after the meal, where a positive test was defined as a blood glucose concentration above 130 mg/dL.

Because of their good coverage probabilities and narrow widths, the score (Wilson), likelihood ratio, and Jeffreys intervals are recommended by Agresti and Coull (1998) and Brown, Cai, and DasGupta (2001). The Agresti-Coull intervals are slightly wider than these intervals, but they have slightly higher coverage probabilities and are simpler to calculate. Mid-p exact confidence intervals are similar to the Jeffreys intervals, but they are more difficult to calculate. Exact intervals are too wide, and the Wald intervals have coverage probabilities that are often too

low. The logit-transformed Wald interval has good coverage probabilities, but it can be even wider than the exact interval. In large samples (with larger samples required for probabilities near zero or one), all of the intervals are similar.

4.4 R

Listing 4.2 normplots.R

```
## Bayesian prior and posterior distributions for a probability

# beta prior and posterior distributions
# The prior is beta(1, 1), which is the uniform(0, 1) distribution.
# Because k = 15 and n = 22, the posterior is beta(15 + 1, 22 - 15 + 1)
p <- seq(0.01, 0.99, by = 0.01)
plot(p, dbeta(p, 16, 8), type = "n", ylim = c(0, 5),
     xlab = "p", ylab = "Probability density")
grid()
lines(p, dbeta(p, 1, 1), lty = "dashed") # prior PDF
lines(p, dbeta(p, 16, 8))                # posterior PDF
postlower <- qbeta(0.025, 16, 8)          # 95% credible interval lower bound
postupper <- qbeta(0.975, 16, 8)         # 95% credible interval upper bound
polygon(c(0, seq(0, postlower, by = 0.01), postlower),
        c(0, dbeta(seq(0, postlower, by = 0.01), 16, 8), 0),
        col = "darkgray")
polygon(c(postupper, seq(postupper, 1, by = 0.01), 1),
        c(0, dbeta(seq(postupper, 1, by = 0.01), 16, 8), 0),
        col = "darkgray")
legend("topleft", bg = "white",
      lty = c("dashed", "solid", NA, "dashed", "solid"),
      col = c("black", "black", NA, "darkgray", "darkgray"),
      fill = c(NA, NA, "darkgray", NA, NA),
      border = c(NA, NA, "black", NA, NA),
      legend = c("uniform prior", "posterior (uniform)",
                  "2.5% tails (uniform)", "Jeffreys prior",
                  "posterior (Jeffreys)"))
lines(p, dbeta(p, 0.5, 0.5), lty = "dashed", col = "darkgray")
lines(p, dbeta(p, 15.5, 7.5), col = "darkgray")
```

Listing 4.3 binconf-table.R

```
## Comparison of binomial confidence limits
library(DescTools)

# Sensitivity (55 / 70)
# Use round() to get rounded numbers shown in the table.
round(BinomCI(55, 70, method = "wald"), 3)
round(BinomCI(55, 70, method = "logit"), 3)
round(BinomCI(55, 70, method = "agresti-coull"), 3)
round(BinomCI(55, 70, method = "wilson"), 3)
round(BinomCI(55, 70, method = "lik"), 3)
round(BinomCI(55, 70, method = "clopper-pearson"), 3)
round(BinomCI(55, 70, method = "midp"), 3)
round(BinomCI(55, 70, method = "jeffreys"), 3)

# Specificity (462 / 510)
round(BinomCI(462, 510, method = "wald"), 3)
round(BinomCI(462, 510, method = "logit"), 3)
round(BinomCI(462, 510, method = "agresti-coull"), 3)
round(BinomCI(462, 510, method = "wilson"), 3)
round(BinomCI(462, 510, method = "lik"), 3)
round(BinomCI(462, 510, method = "clopper-pearson"), 3)
round(BinomCI(462, 510, method = "midp"), 3)
round(BinomCI(462, 510, method = "jeffreys"), 3)

# PPV (55 / 103)
round(BinomCI(55, 103, method = "wald"), 3)
round(BinomCI(55, 103, method = "logit"), 3)
round(BinomCI(55, 103, method = "agresti-coull"), 3)
round(BinomCI(55, 103, method = "wilson"), 3)
round(BinomCI(55, 103, method = "lik"), 3)
round(BinomCI(55, 103, method = "clopper-pearson"), 3)
round(BinomCI(55, 103, method = "midp"), 3)
round(BinomCI(55, 103, method = "jeffreys"), 3)

# NPV (462 / 477)
round(BinomCI(462, 477, method = "wald"), 3)
round(BinomCI(462, 477, method = "logit"), 3)
round(BinomCI(462, 477, method = "agresti-coull"), 3)
round(BinomCI(462, 477, method = "wilson"), 3)
round(BinomCI(462, 477, method = "lik"), 3)
round(BinomCI(462, 477, method = "clopper-pearson"), 3)
round(BinomCI(462, 477, method = "midp"), 3)
round(BinomCI(462, 477, method = "jeffreys"), 3)
```

5 Longitudinal Data, Rates, and Counts

The *mortality* and *force of mortality* will readily be distinguished, by comparing cholera with consumption; the *mortality* of the latter is 90–100 per cent, but its mean duration is two years, and the *force of mortality* is consequently nearly 0.50; the mortality in cholera is not 50 per cent, while the force of mortality is 2415, for cholera destroys in a week as many as phthisis consumes in a year. Phthisis is more dangerous than cholera; but cholera, probably, excites the greatest terror. (Farr 1838)¹

The meaning of a risk or cumulative incidence depends on the time interval over which it is observed. William Farr observed that a risk of death slightly less than 50% over one week for cholera patients was widely considered more alarming than a risk of death greater than 90% over two years for tuberculosis patients. In public health, it matters a great deal how quickly things happen. How rapidly an event occurs is measured using a **rate**, which has units of events per unit time (Elandt-Johnson 1975; Morgenstern, Kleinbaum, and Kupper 1980). To estimate a risk or a rate, we use **longitudinal data** where individuals are followed over time. The analysis of longitudinal data is complicated by the fact that individuals can come and go during the study period.

To estimate the risk of disease onset in a time interval $(t_a, t_b]$, we would follow individuals from time t_a to time t_b to ascertain disease onset. From Section 1.9.1, the risk of disease onset in the time interval $(t_a, t_b]$ is

$$\Pr(\{\omega \in \Omega : D(\omega) = 1\})$$

where

$$D(\omega) = \begin{cases} 1 & \text{if } \omega \text{ has } t^{\text{onset}} \in (t_a, t_b], \\ 0 & \text{otherwise.} \end{cases}$$

and t^{onset} denotes the onset time of the disease. In practice, the population Ω is often defined to consist only of individuals who are at risk of disease at time t_a . If we have complete follow-up of the entire population Ω over the entire interval $(t_a, t_b]$, then we know the cumulative incidence exactly.

¹William Farr (1807–1883) was a British pioneer of epidemiology. As the first statistician in the General Register Office, he was responsible for the collection of medical statistics in England and Wales. He set up a system for recording causes of death that allowed comparison of mortality rates. In the quote, “consumption” and “phthisis” both refer to tuberculosis.

More often, we follow a sample of individuals from the population. If selection into the sample is independent of disease onset during $(t_a, t_b]$ and we have complete follow-up over the entire interval, then we can get point and interval estimates of the true cumulative incidence using methods for a binomial proportion from Chapter 3 or Chapter 4. In practice, almost all longitudinal studies have individuals entering or leaving the study during the follow-up period. When this occurs, methods for binomial proportions can produce inefficient or biased estimates of risk.

The analysis of incomplete longitudinal data is called **survival analysis**, and it is the theoretical foundation for many epidemiologic methods. To analyze survival data, it is important to have clear definitions of the following that can be applied equally to all study participants:

- The **time origin**: This is the beginning of the time-to-event, and it defines the time scale used in the analysis. It could be a particular calendar time, a particular age, or the occurrence of a particular event (see Table 5.1).
- The **failure time** or **event time**: This is the end of the time-to-event. Both the outcome and its occurrence time need careful but practical operational definitions that can be applied equally to all participants in the study.
- The **observation process** and **at-risk process**: For their disease onset time to be observed, individual i must be both at risk of the outcome and under observation at t_i^{onset} . The observation and at-risk processes are required to be *predictable*, which means that their value at any time t is determined just before time t .² For example, if observation begins at time t , you are under observation just after time t but not at time t itself. If observation ends at time t , then you are under observation up to and including time t .
- The **entry time** t_i^{entry} is the earliest time at which the individual i is both at risk of the outcome and under observation. If the entry time occurs after the origin, we have **delayed entry**, which is also called **left truncation**.
- The **exit time** or **follow-up time** t_i is the last time the individual is both at risk of the outcome and under observation. If the exit time occurs before the failure time, we have **right censoring** (loss to follow-up).

In complex data, an individual can have multiple entry, exit, and failure times and even multiple time origins (e.g., time to heart attack after vigorous exercise or ingestion of cocaine). The time scale is usually defined so that $t = 0$ at the origin time, and we will assume that the origin and population are defined so that all individuals in the population are at risk of the event at $t = 0$.

²To be predictable, it is sufficient for a process to be left-continuous. The disease onset process is assumed to be right-continuous with left-hand limits (cadlag) and hence unpredictable.

Table 5.1: Time scales and time origins adapted from Clayton and Hills (1993).

Time scale	Origin
Calendar time	Fixed date
Time since exposure	Exposure time
Time under treatment	Start of treatment
Time since diagnosis	Time of diagnosis
Age	e.g., 65th birthday
Time in hospital	Hospital admission

5.1 Incomplete follow-up

Let t^{event} be the failure time of individual i and t^{cens} be the last time at which they would be under observation if they had no disease onset. We assume all times are defined so that $t = 0$ at the time origin.

5.1.1 Right censoring

When $t_i^{\text{cens}} < t_i^{\text{event}}$, the outcome in person i is **right censored** at time t_i^{cens} . We know that individual i does not have an event at or before t_i^{cens} , but we do not know when or if the event will occur after that. In right-censored data, we see the exit time

$$t_i = \min(t_i^{\text{event}}, t_i^{\text{cens}})$$

and the **event indicator**

$$\delta_i = \begin{cases} 0 & \text{if } t_i^{\text{exit}} = t_i^{\text{cens}}, \\ 1 & \text{if } t_i^{\text{exit}} = t_i^{\text{event}}. \end{cases}$$

Right censoring is often just called *censoring*. There are many reasons that person i might be censored: Perhaps we can no longer find person i (loss to follow-up), person i is no longer at risk of failure (e.g., a woman who has a hysterectomy is no longer at risk of uterine cancer), or observation ends. Different individuals in the same study can be censored for different reasons.

Independent right censoring occurs if those who remain under observation at any given time are a random sample of all of those who would be under observation if there were no right censoring. Censoring is not independent if those who remain under observation have systematically different failure times than those who are censored. There are three canonical types of independent censoring:

- *Type I censoring* occurs when observation of each individual ends at a predetermined time under the control of the investigators.

- *Type II censoring* occurs when observation ends after a predetermined number of events have been observed.
- *Random censoring* occurs when each person i has a random censoring time t_i^{cens} that is independent of his or her failure time t_i^{event} and not under the control of the investigators.

As long as all censoring is independent, different censoring mechanisms can occur within the same study. All of the methods we will discuss assume independent censoring, and they become biased under *dependent* or *informative* censoring.

5.1.2 Delayed entry (left truncation)

Whereas right censoring concerns the observation of failure times, truncation concerns the selection of study participants. **Delayed entry** or **left truncation** occurs when an individual i has an entry time $t_i^{\text{entry}} > 0$ where $t = 0$ denotes the origin. If person i had disease onset before t_i^{entry} , he or she would have been excluded from the study. Person-time prior to entry cannot be included as time at risk; it is called **immortal person-time**. Delayed entry can be handled easily by all of the methods we will discuss. As with independent right censoring, we require that the set of individuals under observation are a random sample of the individuals who would be under observation if we had no right censoring or left truncation. You can think of this as **independent left truncation**.

5.1.3 Left censoring and right truncation

Given that we have right censoring and left truncation (delayed entry), it is natural to wonder whether there is also left censoring and right truncation. Unfortunately, the answer is yes:

- *Left censoring* means that we know an individual had an event before a left-censoring time but we do not know when.
- *Right truncation* means that our sample contains only individuals who have already had the event.

Both of these must be handled using strong assumptions or specialized methods. Some areas of epidemiology must contend with left censoring (e.g., we know that a birth defect occurred prior to birth but not exactly when) or right truncation. Usually, they can be prevented or minimized by good study design.

5.2 Failure time distributions

Failure time distributions are described in terms of survival functions, cumulative hazard functions, and hazard functions. Any one of these is sufficient to specify the distribution of the

time to an event, but each has a different and useful interpretation. We denote the failure time as a positive random variable T . For simplicity, we will assume that T is continuous.

5.2.1 Survival function

The **survival function** for a failure time T is

$$S(t) = \Pr(T > t),$$

which is the probability that the event does not occur up to and including time t . Several properties follow from this definition:

- Because it is a probability, $S(t) \in [0, 1]$ for all t .
- Because $T > 0$, $S(0) = 1$.
- $S(t)$ is monotonically decreasing, which means that it cannot increase. If $u > t$, you can survive to time u only if you survive to time t , so $S(t) \geq S(u)$.

The survival function $S(t)$ tells us everything there is to know about the distribution of the time-to-event T . The **cumulative incidence function** is

$$F(t) = 1 - S(t) = \Pr(T \leq t),$$

which is also the cumulative distribution function (CDF) for T . If T is a continuous random variable, then

$$-S'(t) = F'(t) = f(t), \quad (5.1)$$

where $f(t)$ is the probability density function (PDF) of T . If T is a discrete or continuous failure time with survival function $S(t)$, it turns out that

$$\mathbb{E}[T] = \int_0^\infty S(t) dt. \quad (5.2)$$

This is often easier to calculate than the integral $\mathbb{E}[T] = \int_0^\infty tf(t)dt$ that is normally used to define the mean of a positive random variable.³ The p th quantile of the failure time distribution is the solution to the equation

$$p = F(t_p) = 1 - S(t_p), \quad (5.3)$$

³Using integration by parts, we get that

$$\int_0^\infty tf(t) dt = -tS(t)\Big|_0^\infty + \int_0^\infty S(t) dt = \int_0^\infty S(t) dt$$

when $tS(t) \rightarrow 0$ as $t \rightarrow \infty$.

so higher quantiles correspond to longer times to events.⁴ When $p = 0.5$, we get the median time-to-event. Much of survival analysis is dedicated to calculating and comparing survival functions.

5.2.2 Hazard function

For any $\Delta > 0$, the probability that you have an event in the time interval $(t, t + \Delta]$ is

$$\Pr(\text{event in } (t, t + \Delta]) = S(t) - S(t + \Delta)$$

and the conditional probability that you have an event in the interval given that you survived until time t is

$$\Pr(\text{event in } (t, t + \Delta] \mid \text{survival until } t) = \frac{S(t) - S(t + \Delta)}{S(t)}. \quad (5.4)$$

The numerator is the expected number of events in $(t, t + \Delta]$ given that you remain at risk at time t . Dividing by Δ gives us

$$\frac{S(t) - S(t + \Delta)}{S(t)\Delta},$$

which is the expected number of events per unit time in the interval $(t, t + \Delta]$. The **hazard function** is the limit of this expected number of events per unit time as $\Delta \downarrow 0$ (i.e., as Δ decreases to zero):

$$h(t) = \lim_{\Delta \downarrow 0} \frac{S(t) - S(t + \Delta)}{S(t)\Delta}. \quad (5.5)$$

Because the numerator is nonnegative and the denominator is positive, $h(t) \geq 0$. The hazard function $h(t)$ measures the instantaneous expected number of events per unit time like a speedometer measures the instantaneous speed of a vehicle. When $h(t)$ is high, you are likely to have an event soon after time t if you have survived event-free until t . When $h(t)$ is low, you are relatively unlikely to have an event soon after t .

Unlike the survival function, the hazard function has units. Because we divide an expected number of events by a time interval Δ , the hazard has units of events/time. Just like the same speed can be expressed in miles per hour or kilometers per hour, using different measures of time (e.g., month, week, day, hour, minute, or second) changes the numerical value of the hazard but not its meaning.

When Δ is small, then Equation 5.4 and Equation 5.5 give us

$$h(t) \approx \frac{\Pr(\text{event in } (t, t + \Delta] \mid \text{survival until } t)}{\Delta}.$$

⁴When T is discrete (or a mixture of continuous and discrete components),

$$t_p = \inf\{t : F(t) \geq p\} = \inf\{t : S(t) \leq 1 - p\}.$$

When T is continuous, this reduces to Equation 5.3.

Rearranging, we get

$$h(t)\Delta \approx \Pr(\text{event in } (t, t + \Delta] \mid \text{survival until } t).$$

Notice how the units work:

$$h(t) \frac{\text{events}}{\text{time unit}} \Delta \text{ time units} = h(t)\Delta \text{ events.} \quad (5.6)$$

Multiplying the hazard by a time interval gives the expected number of events that would occur in that interval if the hazard remained constant.

When times to failure are continuous, the survival function is differentiable. By definition of the derivative of $S(t)$,

$$\lim_{\Delta \downarrow 0} \frac{S(t) - S(t + \Delta)}{\Delta} = -S'(t).$$

Putting this back into Equation 5.5, we get

$$h(t) = \frac{1}{S(t)} \lim_{\Delta \downarrow 0} \frac{S(t) - S(t + \Delta)}{\Delta} = \frac{-S'(t)}{S(t)}. \quad (5.7)$$

Because $-S'(t) = f(t)$ from Equation 5.1, we can multiply both sides by $S(t)$ to get

$$f(t) = h(t)S(t). \quad (5.8)$$

Thus, the PDF is the product of the hazard and survival functions. This is used to write likelihoods for right-censored and left-truncated data.

5.2.3 Cumulative hazard function

The **cumulative hazard function** for a positive random variable T is

$$H(t) = -\ln S(t). \quad (5.9)$$

Several properties follow from this definition:

- $H(0) = 0$ because $S(0) = 1$.
- $H(t)$ is monotonically increasing, which means that it cannot decrease. If $u > t$, then $H(u) \geq H(t)$.
- When $S(t) > 0$, $H(t) \in [0, \infty)$.
- $S(t) = e^{-H(t)}$.

Taking the derivative with respect to t on both sides of Equation 5.9 (using the chain rule on the right-hand side), we get

$$H'(t) = \frac{-S'(t)}{S(t)} = h(t)$$

where the final equality follows from Equation 5.7. By the fundamental theorem of calculus and the fact that $H(0) = 0$,

$$H(t) = \int_0^t h(u) du \quad (5.10)$$

so the cumulative hazard $H(t)$ is the area under the graph of h over $(0, t)$.

Equation 5.10 gives us an interesting way to interpret the cumulative hazard function. If the event is something that can be repeated (e.g., clicks on a Geiger counter), the expected number of events in $(0, t]$ is the sum of the expected numbers of events in a series of intervals $(u_0, u_1], (u_1, u_2], \dots, (u_{n-1}, u_n]$ where $u_0 = 0$ and $u_n = t$. Taking a limit as the number of subintervals grows larger and each subinterval becomes smaller,

$$\mathbb{E}[\text{number of events in } (0, t]] = \int_0^t h(u) du = H(t).$$

The units in the integral work in the same way as in Equation 5.6. For an event that cannot be repeated (e.g., death), $H(t)$ can be interpreted as the expected number of events that would occur if the event were made repeatable. After an event at time t , you would be brought back to being at risk at time t to wait for the next event to occur.

5.2.4 Likelihoods for right-censored and left-truncated data

Suppose our survival time distribution has hazard function $h(t, \theta_{\text{true}})$ and survival function $S(t, \theta_{\text{true}})$, where θ_{true} is an unknown parameter (or parameter vector). If individual i has entry time t_i^{entry} , exit time t_i , and event indicator δ_i , then their likelihood contribution is

$$L_i(\theta) = \frac{h(t_i, \theta)^{\delta_i} S(t_i, \theta)}{S(t_i^{\text{entry}}, \theta)}. \quad (5.11)$$

In the numerator, every observation contributes a survival term, but only the observed failure times ($\delta_i = 1$) contribute a hazard term. The survival term in the denominator accounts for the fact that they survived until time t_i^{entry} . When $t_i^{\text{entry}} = 0$, then the denominator equals one. Table 5.2 shows the likelihood contributions for all four possible combinations of right censoring and delayed entry (left truncation).

Taking logarithms on both sides of Equation 5.11 gives us the log likelihood contribution

$$\ell_i(\theta) = \delta_i \ln h(t_i, \theta) - [H(t_i, \theta) - H(t_i^{\text{entry}}, \theta)].$$

Table 5.2: Possible likelihood contributions for $(t_i^{\text{entry}}, t_i, \delta_i)$.

	Right censoring ($\delta_i = 0$)	No right censoring ($\delta_i = 1$)
Delayed entry ($t^{\text{entry}} > 0$)	$\frac{S(t_i, \theta)}{S(t_i^{\text{entry}}, \theta)}$	$\frac{h(t_i, \theta)S(t_i, \theta)}{S(t_i^{\text{entry}}, \theta)}$
No delayed entry ($t^{\text{entry}} = 0$)	$S(t_i, \theta)$	$h(t_i, \theta)S(t_i, \theta)$

All observations contribute a cumulative hazard term, but only observed event times contribute a hazard term. When $t_i^{\text{entry}} = 0$, then $H(0, \theta) = 0$ for all θ . When we have n independent observations, the log likelihood is the sum of the individual log likelihood contributions:

$$\ell(\theta) = \sum_{i=1}^n \ell_i(\theta).$$

The maximum likelihood estimate $\hat{\theta}$ can be found using the score function $U(\theta) = \ell'(\theta)$, and its approximate variance is $I(\hat{\theta})^{-1} = [-\ell''(\hat{\theta})]^{-1}$. The log likelihood can be used to do Wald, score, and likelihood ratio hypothesis tests and obtain the corresponding confidence intervals. For example, the Wald 95% confidence interval in large samples is

$$\hat{\theta} \pm 1.96 \sqrt{I(\hat{\theta})^{-1}}.$$

If necessary, the delta method can be used to get confidence intervals that keep $\hat{\theta}$ within an appropriate range of values. Bayesian estimation can be done using the corresponding likelihood $L(\theta) = \exp(\ell(\theta))$

5.3 Exponential distribution

The exponential distribution is the simplest and most important failure time distribution. It has a constant hazard function

$$h(t) = \lambda$$

where λ is called the **rate parameter** and has units of events/time. Its cumulative hazard function is

$$H(t) = \int_0^t h(u) \, du = \int_0^t \lambda \, du = \lambda t,$$

its the survival function is

$$S(t) = e^{-H(t)} = e^{-\lambda t}.$$

A higher rate parameter λ implies shorter survival times. The **scale parameter** is $\sigma = \lambda^{-1}$. A smaller scale parameter corresponds to shorter survival times.

5.3.1 Mean and variance

The mean of an exponential random variable T is found most easily by integrating the survival function:

$$\mathbb{E}(T) = \int_0^\infty e^{-\lambda t} dt = \frac{1}{\lambda} \int_0^\infty \lambda e^{-\lambda t} dt = \frac{1}{\lambda}, \quad (5.12)$$

In that integral, we “creatively multiplied by one” to turn the integrand into an exponential PDF and then used the fact that the total area under the PDF is one. Integration by parts can be used to show that

$$\mathbb{E}(T^2) = \int_0^\infty t^2 \lambda e^{-\lambda t} dt = \frac{2}{\lambda^2},$$

so

$$\text{Var}(T) = \mathbb{E}(T^2) - \mathbb{E}(T)^2 = \frac{2}{\lambda^2} - \frac{1}{\lambda^2} = \frac{1}{\lambda^2}.$$

by Equation 1.22. Thus, the standard deviation $\sqrt{\text{Var}(T)} = 1/\lambda$ is equal to the mean.

5.3.2 Incidence rates

Now imagine that we want to estimate an unknown rate parameter λ_{true} for an exponential distribution. Let $(t_1^{\text{entry}}, t_1, \delta_1), \dots, (t_n^{\text{entry}}, t_n, \delta_n)$ denote a set of entry times, exit times, and event indicators in a sample of size n . The likelihood is

$$L(\lambda) = \prod_{i=1}^n \lambda^{\delta_i} e^{-\lambda(t_i - t_i^{\text{entry}})},$$

and the log likelihood is

$$\ell(\lambda) = \sum_{i=1}^n (\delta_i \ln \lambda - \lambda(t_i - t_i^{\text{entry}})) = m \ln \lambda - \lambda T, \quad (5.13)$$

where

$$m = \sum_{i=1}^n \delta_i$$

is the total number of observed events and

$$T = \sum_{i=1}^n (t_i - t_i^{\text{entry}})$$

is the total **person-time**. This is the total time under observation added up over all participants in the study. The likelihood assumes that the same rate λ_{true} of events per unit time occurs in all of this person-time.

Maximum likelihood estimation of the rate λ_{true} proceeds in the same way as it did for a probability. The only difference is that we are working with an exponential likelihood for

times to events rather than a binomial likelihood for a binary outcome. Differentiating with $\ell(\lambda)$ with respect to λ , we get the score function

$$U(\lambda) = \frac{m}{\lambda} - T. \quad (5.14)$$

Solving the score equation $U(\hat{\lambda}) = 0$ gives us the point estimate

$$\hat{\lambda} = \frac{m}{T}. \quad (5.15)$$

This is called the **incidence rate** in epidemiology. The incidence rate is the maximum likelihood estimate of an exponential rate parameter.

Differentiating $U(\lambda)$ with respect to λ , we get the observed information function $I(\lambda) = m/\lambda^2$. The estimated variance is

$$I(\hat{\lambda})^{-1} = \left(\frac{m}{(\frac{m}{T})^2} \right)^{-1} = \frac{m}{T^2}, \quad (5.16)$$

so the Wald 95% confidence interval for λ_{true} is

$$\hat{\lambda} \pm 1.96 \sqrt{\frac{m}{T^2}}. \quad (5.17)$$

It has relatively poor performance in terms of width and coverage probability. The performance of the Wald confidence interval can be improved using a log transformation, which ensures that the lower bound is greater than zero. Using the delta method, the variance of $\ln \hat{\lambda}$ is approximately

$$\left(\frac{1}{\hat{\lambda}} \right)^2 \frac{m}{T^2} = \frac{1}{m},$$

which depends only on the number of events observed. An approximate 95% confidence interval for $\ln(\lambda_0)$ is

$$\ln \left(\frac{m}{T} \right) \pm 1.96 \sqrt{\frac{1}{m}}.$$

Exponentiating, we get the log-transformed Wald 95% confidence interval

$$\frac{m}{T} e^{\pm 1.96 \sqrt{\frac{1}{m}}}.$$

Better interval estimates can be obtained by inverting the score or likelihood ratio test or from Bayesian credible intervals. Among the frequentist large-sample confidence intervals, the likelihood ratio interval has the best performance (Brown, Cai, and DasGupta 2003).

5.4 R

5.4.1 Memoryless property

Given that you have reached age a , your **life expectancy at age a** is how many years you are expected to live past age a . According to the [Social Security Administration's 2019 life table](#), life expectancy at birth in the United States in 2019 was 76.22 years for males and 81.28 years for females. Life expectancy at age 40 was 38.74 years for males and 42.76 years for females, which means that the average age at death for those who survive to age 40 was 78.74 years and 82.76 years, respectively. Life expectancy at age 80 was 8.43 years for males and 9.83 years for females, so the average ages at death were 88.43 and 89.83 years, respectively. For humans, remaining life expectancy decreases with age.

Humans do not have exponential lifetimes. If your lifetime has an exponential distribution with rate λ and you survive to age t , the probability that you survive to age $t + u$ is

$$\Pr(\text{lifetime} > t + u \mid \text{lifetime} > t) = \frac{e^{-\lambda(t+u)}}{e^{-\lambda t}} = e^{-\lambda u}.$$

This does not depend on t , so your life expectancy would be constant with age. This is called the **memoryless property**.

In a population with exponential lifetimes, the old and the young would have equal hazards of death at any given time and equal risks of death over any time interval. This seems to be true of decaying radioactive isotopes and other processes from physics and chemistry, but humans are more complex. The hazard of death is typically high right after birth, drops rapidly to a minimum between the ages of roughly 5 and 30, and then slowly increases. This is called the *bathtub-shaped hazard* or the *Gompertz-Makeham law of mortality* (Gompertz 1825; Makeham 1860). Figure 5.1 shows The bathtub-shaped hazard of death for the United States population in 2019.




Figure 5.1: Mortality hazard (deaths per year) by age in the United States based on the Social Security Administration 2019 life table.

5.4.2 Prevalence, incidence, and duration of disease*

Suppose the time to disease onset in healthy individuals has an exponential(λ) distribution and the time to recovery in diseased individuals has an exponential(γ) distribution. Then the incidence rate of disease is λ and the mean duration of disease is $1/\gamma$. For simplicity, imagine a closed population where individuals move between the healthy and diseased states.

If the prevalence of disease at time t is p and the population has total size n , then the expected

number of disease onsets in any time interval $(t, t + dt]$ is $n(1 - p)\lambda dt$. The expected number of recoveries in the same interval is $np\gamma dt$. For the prevalence to remain roughly constant over time (i.e., to randomly fluctuate around an equilibrium), we need the expected number of onsets and recoveries in each time interval to be the same: Thus, we need

$$n(1 - p)\lambda = np\gamma$$

The left-hand side is the expected number of disease onsets per time unit, and the right-hand side is the expected number of recoveries per time unit. It is critical to use the same time units (e.g., day, week, month, year) for the incidence rate and the duration of disease. This equation can be rearranged to get

$$\frac{\lambda}{\gamma} = \frac{p}{1 - p},$$

so

$$\text{incidence rate} \times \text{mean duration} = \text{prevalence odds}$$

When the prevalence p is low, the prevalence and prevalence odds are roughly equal and we get

$$\text{incidence rate} \times \text{mean duration} \approx \text{prevalence}.$$

Under more realistic conditions, the relationship between prevalence, incidence, and the duration of disease is more complex (Freeman and Hutchison 1980; Preston 1987; Keiding 1991; Alho 1992).

5.5 Poisson distribution

The Poisson distribution⁵ is one of the most important distributions in probability and statistics, and it has many applications in epidemiology. Section 5.2.3 showed that the cumulative hazard $H(t)$ is the expected number of events that occur in $(0, t]$ when the event is repeatable. The number of events has a Poisson distribution with mean $H(t)$.

If events occur at a constant rate λ , then the times between events have an exponential(λ) distribution. The number X of events that occur in a time interval of length T will have a Poisson distribution with mean λT . The probability mass function (PMF) of a Poisson(λT) distribution is

$$\Pr(X = x) = \frac{(\lambda T)^x}{x!} e^{-\lambda T} \text{ for } x = 0, 1, 2, \dots \quad (5.18)$$

and $\text{supp}(X) = \{0, 1, 2, \dots\}$. This is a PMF because, by definition,

$$e^{\lambda T} = \sum_{k=0}^{\infty} \frac{(\lambda T)^k}{k!}.$$

⁵Named after [Sim'on Denis Poisson](#) (1781-1840), a French mathematician, physicist, and astronomer. He introduced the distribution in an 1837 paper in which he estimated the number of wrongful convictions that would occur over a given time period. His is one of the 72 names inscribed on the Eiffel Tower.

Multiplying $(\lambda T)^k/k!$ by $e^{-\lambda T}$ ensures that the PMF over all possible values of X equals one. The relationship between the exponential and Poisson distributions can be seen easily for $X = 0$:

$$\Pr(X = 0) = \frac{(\lambda T)^0}{0!} e^{-\lambda T} = e^{-\lambda T},$$

which is the probability that no event occurs in $(0, T]$ when the time-to-event has an exponential(λ) distribution.

5.5.1 Mean and variance

The mean of the Poisson(λT) distribution is

$$\mathbb{E}[X] = \sum_{k=0}^{\infty} k \frac{(\lambda T)^k}{k!} e^{-\lambda T} = \lambda T e^{\lambda T} e^{-\lambda T} = \lambda T.$$

A similar calculation yields

$$\mathbb{E}[X^2] = \sum_{k=0}^{\infty} k^2 \frac{(\lambda T)^k}{k!} e^{-\lambda T} = \lambda T + (\lambda T)^2.$$

Using Equation 1.22, we get

$$\text{Var}(X) = [\lambda T + (\lambda T)^2] - (\lambda T)^2 = \lambda T.$$

Thus, both the mean and the variance are λT . Because it equals the mean, the parameter λT is often written μ . Both λ and μ can be estimated using maximum likelihood or Bayesian methods.

5.5.2 Incidence rates via count data

Suppose we observe n individuals in whom the time to disease onset is exponential(λ_{true}), observing a total person-time of T during which m disease onsets occur. If we string together all of the observations, the memoryless property of the exponential distribution guarantees that we get an interval with total length T in which m events occurred and the times between events were exponential(λ_{true}). Therefore, the total number of events that we see has a Poisson distribution with mean $\lambda_{\text{true}} T$. Using the Poisson PMF in Equation 5.18, we get the likelihood

$$L(\lambda) = \frac{(\lambda T)^m}{m!} e^{-\lambda T}.$$

The corresponding log likelihood is

$$\ell(\lambda) = \ln L(\lambda) = m(\ln \lambda + \ln T) - \ln(m!) - \lambda T.$$

Taking the derivative with respect to λ , we get the score function

$$U(\lambda) = \frac{m}{\lambda} - T,$$

which is exactly the same as the score function for λ that we got using an exponential likelihood in Equation 5.14. Taking another derivative with respect to λ , we also get the same estimated variance

$$I(\hat{\lambda})^{-1} = \frac{m}{T^2}$$

that we got in Equation 5.16. Under the Poisson model for the number of events, the Wald and log-transformed Wald confidence intervals for the unknown incidence rate λ_{true} are exactly the same as those from the exponential model for the times to events. The score and likelihood ratio tests can be inverted to get confidence intervals that perform better in terms of coverage probability and width than the Wald interval (Brown, Cai, and DasGupta 2003).

5.6 R

5.6.1 Small-sample estimation of incidence rates

The Poisson distribution can be used to calculate confidence limits for the incidence rate λ_{true} that do not rely on the approximate normality in large samples that is guaranteed by the central limit theorem (CLT). Exact confidence limits can be calculated in a manner similar to the Clopper-Pearson confidence limits for a binomial probability in Section 3.8.2. Bayesian estimation, which does not require asymptotic normality, can also be used for small samples.

If we observe m events in a total person-time T , the median unbiased estimate of λ_{true} is the value of λ that makes

$$\Pr_{\lambda}(X \leq m) = \Pr_{\lambda}(X \geq m)$$

where we use the subscript λ to indicate that the probabilities are calculated assuming $\lambda_{\text{true}} = \lambda$. If λ_{med} is the median unbiased estimate, then

$$\sum_{k=0}^{m-1} \frac{(\lambda_{\text{med}}T)^k}{k!} e^{-\lambda_{\text{med}}T} + \frac{1}{2} \frac{(\lambda_{\text{med}}T)^m}{m!} e^{-\lambda_{\text{med}}T} = \frac{1}{2}.$$

It is the value of λ that makes the tail probabilities equal. The median of the distribution of λ_{med} is always λ_{true} (Birnbaum 1964).

The lower exact $1 - \alpha$ confidence limit for λ_{true} gives the upper tail of the Poisson distribution a probability of $\alpha/2$ (Garwood 1936). It solves the equation

$$\sum_{k=m}^{\infty} \frac{(\lambda_{\text{lower}}T)^k}{k!} e^{-\lambda_{\text{lower}}T} = 1 - \left[\sum_{k=0}^{m-1} \frac{(\lambda_{\text{lower}}T)^k}{k!} e^{-\lambda_{\text{lower}}T} \right] = \frac{\alpha}{2}.$$

The upper exact $1 - \alpha$ confidence limit for λ_{true} gives the lower tail of the Poisson distribution a probability of $\alpha/2$. It solves the equation

$$\sum_{k=0}^m \frac{(\lambda_{\text{upper}} T)^k}{k!} e^{-\lambda_{\text{upper}} T} = \frac{\alpha}{2}.$$

As with the Clopper-Pearson confidence limits for a binomial probability, the exact Poisson confidence limits guarantee a coverage probability (i.e., probability that the confidence interval contains λ_{true}) of at least $1 - \alpha$. However, these confidence intervals can be wide and have a coverage probability much higher than $1 - \alpha$ (G. R. Cohen and Yang 1994; Swift 2009).

Mid-p confidence limits can produce confidence intervals that are narrower and have a coverage probability closer to $1 - \alpha$ (Lancaster 1961). The lower $1 - \alpha$ mid-p exact confidence limit for the incidence rate λ_{true} solves the equation

$$1 - \left[\sum_{k=0}^{m-1} \frac{(\lambda_{\text{lower}} T)^k}{k!} e^{-\lambda_{\text{lower}} T} + \frac{1}{2} \frac{(\lambda_{\text{lower}} T)^m}{m!} e^{-\lambda_{\text{lower}} T} \right] = \frac{\alpha}{2}.$$

The upper $1 - \alpha$ mid-p exact confidence limit solves the equation

$$\sum_{k=0}^{m-1} \frac{(\lambda_{\text{upper}} T)^k}{k!} e^{-\lambda_{\text{upper}} T} + \frac{1}{2} \frac{(\lambda_{\text{upper}} T)^m}{m!} e^{-\lambda_{\text{upper}} T} = \frac{\alpha}{2}.$$

The coverage probability of the mid-p confidence interval is usually very close to $1 - \alpha$ (G. R. Cohen and Yang 1994; Swift 2009).

5.7 R

5.7.1 Poisson approximation to the binomial for rare events*

Most applications of the Poisson distribution in epidemiology come from its relationship with the exponential distribution, but the Poisson distribution also has a useful relationship with the binomial distribution. When n is large and p is small, the binomial(n, p) distribution can be approximated by a Poisson(np) distribution. More specifically, imagine that n increases and p decreases such that $np = \mu$ stays constant. The binomial(n, p) probability mass function is

$$\Pr(X = k) = \binom{n}{k} p^k (1 - p)^{n-k} = \frac{n!}{(n-k)!k!} p^k (1 - p)^{n-k}.$$

When n is much larger than k , we have

$$\frac{n!}{(n-k)!k!} \approx \frac{n^k}{k!}.$$

Because $p = \mu/n$, we also have

$$p^k = \frac{\mu^k}{n^k}$$

for each n and

$$(1 - p)^{n-k} = \left(1 - \frac{\mu}{n}\right)^{n-k} \rightarrow e^{-\mu}$$

as $n \rightarrow \infty$. Putting all of this together, we get the following approximation to the binomial PMF

$$\Pr(X = k) \approx \frac{n^k \mu^k}{k! n^k} e^{-\mu} = \frac{\mu^k}{k!} e^{-\mu},$$

which is the $\text{Poisson}(\mu)$ PMF.

As an approximation to the binomial distribution, the Poisson distribution can be used for rare events in many different contexts. The number of events such as automobile accidents or number of onsets of a rare disease in a given time period or area (or both) will often have a Poisson distribution. Clarke (1946) describes an astonishing application of the Poisson distribution that occurred in London in World War II. The [V1 flying bomb](#) was a German cruise missile with an 850 kg warhead that was fired at London (and later at Belgium) in 1944 and 1945. Soon after the attacks began, many people felt that the bomb impacts were clustered in particular areas of London. British investigators used the Poisson distribution to determine whether the V1s were being aimed or fell randomly within the city.

They divided 144 square kilometers of central London into 576 squares of 0.25 square kilometers each. By then, the total number of bombs that had fallen on the entire area was 537. If the bombs were falling randomly, the number of bombs in each square should have a Poisson distribution with mean $537/576 \approx 0.932$. Grouping the squares by the number of bombs that had fallen on them yielded Table 5.3. The close fit to the Poisson distribution suggested that the bombs were falling randomly over the entire 144 square kilometers, not being aimed at particular targets within the city. Near the end of the war, analysis of captured V1s revealed that the guidance system was only accurate to a radius of about 6 kilometers, a circle large enough to encompass almost all of London at the time.

5.8 Bayesian estimation of incidence rates

As with a binomial probability, Bayesian methods can be used to estimate an incidence rate without making any large-sample assumptions. They also allow a prior distribution to be used to incorporate background knowledge about the possible values of λ_{true} .

Table 5.3: Distribution of V1 bomb impacts in London (Clarke 1946).}

Number of impacts	Expected (Poisson) number of squares	Actual number of squares
0	226.74	229
1	211.39	211
2	98.54	93
3	30.62	35
4	7.14	7
5+	1.57	1
Total squares	576.00	576

5.8.1 Gamma conjugate distribution

The conjugate distribution for the exponential(λ) and Poisson(λT) distributions is the **gamma distribution**, which has the PDF

$$f(x, \alpha, \beta) = \frac{\beta^\alpha}{\Gamma(\alpha)} x^{\alpha-1} e^{-\beta x} \quad (5.19)$$

where $\alpha > 0$ is the shape parameter, $\beta > 0$ is the rate parameter, and $\Gamma(\alpha) = \int_0^\infty x^{\alpha-1} dx$ is the *gamma function*. If X has a gamma(α, β) distribution, then

$$\mathbb{E}[X] = \frac{\alpha}{\beta}$$

and variance

$$\text{Var}(X) = \frac{\alpha}{\beta^2}$$

The exponential(β) distribution is a special case of the gamma distribution with shape $\alpha = 1$.

If the prior PDF of an unknown exponential rate λ_{true} has a gamma(α, β) distribution, then

$$p(\lambda | \text{data}) \propto (\lambda^m e^{-\lambda T})(\lambda^{\alpha-1} e^{-\beta \lambda}) = \lambda^{m+\alpha-1} e^{-\lambda(T+\beta)}.$$

After normalizing, this is a gamma($m + \alpha, T + \beta$) distribution. The posterior mean is

$$\bar{\lambda} = \frac{m + \alpha}{T + \beta}$$

and the posterior variance is

$$\frac{m + \alpha}{(T + \beta)^2} = \frac{\bar{\lambda}}{T + \beta}$$

The equal-tailed $1 - \alpha$ credible interval has its limits at the $\alpha/2$ and $1 - \alpha/2$ quantiles of this distribution. Figure 5.2 shows an example of an uninformative Bayesian prior and a posterior distribution for the incidence rate.




Figure 5.2: The PDFs of a $\text{gamma}(0.5, 0.1)$ prior distribution and the $\text{gamma}(4.5, 25.1)$ posterior distribution that results from seeing 4 events in 25 person-years of observation. The units of the incidence rate events per year.

5.8.2 Jeffreys confidence interval

If we fix the total person-time T and model the number of events as a $\text{Poisson}(\lambda T)$ random variable, the Jeffreys prior has $\alpha = 1/2$ and $\beta = 0$ (Jeffreys 1946). This is an *improper prior* because the PDF has a total area of ∞ under the curve, but we get a proper posterior distribution (i.e., a posterior PDF with a total area of 1) as long as $T > 0$. The Jeffreys confidence interval for λ_{true} is the equal-tailed credible interval from the $\text{gamma}(m + 1/2, T)$

posterior distribution. If $m = 0$, the lower limit can be set to zero. This confidence interval has good coverage probabilities and narrow widths similar to the likelihood ratio confidence interval (Brown, Cai, and DasGupta 2003; Swift 2009).

5.9 R

Listing 5.1 exponential.R

```
## Exponential rate parameter estimation

# generate right-censored exponential distribution
tevent <- rexp(1000, rate = 2)
tcens <- rexp(1000) # default rate = 1
sdat <- data.frame(texit = pmin(tcens, tevent),
                  event = ifelse(tcens < tevent, 0, 1))

# calculating incidence rate and log-transformed confidence interval
m <- sum(sdat$event)
T <- sum(sdat$texit)
m / T
m / T * exp(c(-1, 1) * qnorm(.975) * sqrt(1 / m))

# fitting intercept-only exponential regression model
# This uses the survreg() function from the survival package.
library(survival)
expfit <- survreg(Surv(texit, event) ~ 1, data = sdat,
                 dist = "exponential")
summary(expfit)
coef(expfit)
confint(expfit)

# log-transformed Wald CI for the exponential rate
# The intercept is ln(scale), which is -ln(rate).
# The rate is exp(-intercept).
exp(-coef(expfit))
exp(-confint(expfit))

# add delayed entry (left truncation) to sdat
sdat2 <- sdat
sdat2$tentry <- rexp(1000, rate = 5)
sdat2 <- subset(sdat2, tentry < texit)

# incidence rate and log-transformed confidence interval
m2 <- sum(sdat2$event)
T2 <- sum(sdat2$texit - sdat2$tentry)
m2 / T2
m2 / T2 * exp(c(-1, 1) * qnorm(.975) * sqrt(1 / m2))

# survreg() does not handle delayed entry, so use flexsurv::flexsurvreg()
library(flexsurv)
expfit2 <- flexsurvreg(Surv(tentry, texit, event) ~ 1, data = sdat2,
                     dist = "exp")
# The summary() function does not work with flexsurvreg objects.132
# Type "expfit2" or "expfit2$res" to get point and interval estimates.
# The "se" in expfit2$res is the delta method standard error.
expfit2
expfit2$res # rate parameter scale
expfit2$res.t # log rate parameter scale
```

Listing 5.2 bathtub.R

```
# life table for male and female mortality in the United State, 2019
lifetab <- read.csv(file = "R/lifetable-2019.csv")
hdat <- subset(lifetab, age <= 80)
hdat$surv_male <- 1 - hdat$mortality_male
hdat$surv_female <- 1 - hdat$mortality_female

# plot hazard (events per year) for ages 0-80
plot(hdat$age, -log(hdat$surv_male), type = "l",
      xlab = "Age (years)", ylab = "Mortality hazard (deaths per year)")
lines(hdat$age, -log(hdat$surv_female), lty = "dashed")
grid()
legend("topleft", bg = "white", lty = c("solid", "dashed"),
      legend = c("Male", "Female"))
```

Listing 5.3 Poisson-rate.R

```
## Poisson regression for incidence rates

# generate right-censored exponential distribution
tevent <- rexp(1000, rate = 2)
tcens <- rexp(1000)           # default rate = 1
sdat <- data.frame(textit = pmin(tcens, tevent),
                  event = ifelse(tcens < tevent, 0, 1))

# Poisson regression model
# Use log(time) offset to get incidence rate from Poisson(time * incidence rate)
poisreg <- glm(event ~ offset(log(textit)), data = sdat, family = poisson())
exp(coef(poisreg))
# GLMs use likelihood ratio confidence intervals in R.
exp(confint(poisreg))

# exponential regression for comparison (log-transformed Wald CI)
library(survival)
expreg <- survreg(Surv(textit, event) ~ 1, data = sdat, dist = "exponential")
exp(-coef(expreg))
exp(-confint(expreg))

# add delayed entry to sdat
sdat2 <- sdat
sdat2$tentry <- rexp(1000, rate = 5)
sdat2 <- subset(sdat2, tentry < textit)

# Poisson regression with delayed entry
poisreg2 <- glm(event ~ offset(log(textit - tentry)), data = sdat2,
               family = poisson())
exp(coef(poisreg2))
exp(confint(poisreg2))

# exponential regression with delayed entry for comparison
library(flexsurv)
expreg2 <- flexsurvreg(Surv(tentry, textit, event) ~ 1, data = sdat2,
                     dist = "exp")
expreg2$res
```

Listing 5.4 Poisson-small.R

```
## Small-sample Poisson point and interval estimation

# median unbiased estimate
medrate_pois <- function(m, T) {
  # m = number of events, T = total person-time

  # Poisson lower tail probability
  lower_tail <- function(rate) {
    mu = rate * T
    ppois(m, mu) - dpois(m, mu) / 2
  }

  # median unbiased estimate
  med <- uniroot(function(rate) lower_tail(rate) - 1 / 2, interval = c(0, 1))
  med$root
}
medrate_pois(7, 22)

# exact confidence limits
# The point estimate is the incidence rate m / T, not the median unbiased rate.
library(DescTools)
PoissonCI(7, 22, method = "exact")
PoissonCI(7, 22, method = "exact", conf.level = 0.8)

# mid-p confidence limits
midp_pois <- function(m, T, level=0.95) {
  # m = number of events, T = total person-time
  # The default confidence level (1 - type I error probability) is 0.95.

  # Poisson mid-p lower tail probability
  lower_tail <- function(rate) {
    mu = rate * T
    ppois(m, mu) - dpois(m, mu) / 2
  }

  # lower confidence limit
  alpha <- 1 - level
  lower <- uniroot(function(rate) lower_tail(rate) - (1 - alpha / 2),
    interval = c(0, 100), extendInt = "yes")
  # upper confidence limit
  upper <- uniroot(function(rate) lower_tail(rate) - alpha / 2,
    interval = c(0, 100), extendInt = "yes")

  # names for confidence limits
  lower_perc <- paste(round(alpha / 2 * 100, 3), "%", sep = "")
  upper_perc <- paste(round((1 - alpha / 2) * 100, 3), "%", sep = "")

  # return named vector of confidence limits
  conflimits <- c(lower$root, upper$root)
  names(conflimits) <- c(lower_perc, upper_perc)
  conflimits
}
```

Listing 5.5 incrate-Bayes-plot.R

```
## Bayesian estimation of incidence rates

x <- seq(0, 1, by = 0.002)
m <- 4
T <- 25

# plot of prior and posterior distributions
plot(x, dgamma(x, shape = 0.5 + m, rate = 0.1 + T), type = "n",
      xlab = expression(paste("Incidence rate (", lambda, ")")),
      ylab = "Probability density")
grid()
lines(x, dgamma(x, shape = 0.5, rate = 0.1), lty = "dashed")
lines(x, dgamma(x, shape = 0.5 + m, rate = 0.1 + T))
legend("topright", lty = c("dashed", "solid"),
      legend = c("gamma(0.5, 0.1) prior", "gamma (4.5, 25.1) posterior"))
```

Listing 5.6 `incrate-Bayes.R`

```
## Bayesian estimation of incidence rates with gamma conjugate distribution

# incidence rate posterior mean, median, and equal-tailed credible limits
incrate_bayes <- function(m, T, level=0.95, priora=0.5, priorb=0) {
  # default arguments are for the Jeffreys confidence interval
  alpha <- 1 - level
  posta <- priora + m
  postb <- priorb + T
  if (m == 0) {
    lower <- 0
  } else {
    lower <- qgamma(alpha / 2, shape = posta, rate = postb)
  }
  upper <- qgamma(1 - alpha / 2, shape = posta, rate = postb)
  postmean <- posta / postb
  postmedian <- qgamma(0.5, shape = posta, rate = postb)
  return(c(postmean = postmean, postmedian = postmedian,
           lower = lower, upper = upper,
           priora = priora, priorb = priorb, level = level))
}

# 7 events in 22 units of person-time
incrate_bayes(7, 22) # Jeffreys 95% confidence interval
incrate_bayes(7, 22, level = 0.8) # Jeffreys 80% confidence interval
incrate_bayes(7, 22, priora = 1, priorb = 1) # uniform prior
```

6 One-Sample Survival Analysis

In many estimation problems it is inconvenient or impossible to make complete measurements on all members of a random sample. For example, in medical follow-up studies to determine the distribution of survival times after an operation, contact with some individuals will be lost before their death, and others will die from causes it is desired to exclude from consideration. Similarly, observation of the life of a vacuum tube may be ended by breakage of the tube, or a need to use the test facilities for other purposes. In both examples, incomplete observations may also result from a need to get out a report within a reasonable time. (Kaplan and Meier 1958)

In **nonparametric** survival analysis, we do not assume that the failure time distributions are defined by a small number of parameters, such as the rate parameter in an exponential model for times to events or a Poisson model for the number of events. Whenever possible, it is good to incorporate existing knowledge into the estimation of unknown parameters, and the use of parametric models and Bayesian methods accomplishes this. When such knowledge is not available, nonparametric methods allow us to avoid making assumptions we cannot defend.

However, this flexibility comes at a price. For example, suppose we know that our time-to-event has an exponential distribution. If we use a nonparametric model anyway, then:

- The nonparametric estimates of the survival, cumulative hazard, or hazard functions will be less precise than the estimates from an exponential model.
- We might be unable to estimate mean or median survival times or other quantities that require extrapolation beyond the data used for estimation.

Parametric and nonparametric methods are at opposite ends of the bias-variance tradeoff. The assumptions of parametric models can induce bias, but they produce estimates with low variance when the assumptions are approximately correct. The flexibility of nonparametric models avoids bias, but they produce estimates with higher variance than an equivalent parametric method based on sound assumptions. Survival analysis has nonparametric estimators of the survival and cumulative hazard functions that can be used with relatively little loss of efficiency. Because of this combination of flexibility and efficiency, they are widely used in epidemiologic research.

6.1 Empirical cumulative distribution function

The cumulative distribution function (CDF) of a random variable X is the function

$$F(x) = \Pr(X \leq x). \quad (6.1)$$

For each value of x , $F(x)$ is a probability that we can estimate using methods for a binomial proportion. However, we can get a more complete picture of the distribution of X by linking the estimates for different x together to estimate the whole function $F(x)$.

If x_1, \dots, x_n are observations of a random variable X , the **empirical CDF** is the function

$$\hat{F}_n(x) = \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{x_i \leq x} \quad (6.2)$$

where $\mathbb{1}_{x_i \leq x} = 1$ if $x_i \leq x$ is true and zero otherwise. For a fixed value of x , $\hat{F}_n(x)$ is just the proportion of the observations that are $\leq x$. At each x , the number of observations with $X_i \leq x$ is a $\text{binomial}(n, F(x))$ random variable with expected value $nF(x)$ and variance $nF(x)(1 - F(x))$. Thus,

$$\mathbb{E}(\hat{F}_n(x)) = F(x)$$

and

$$\text{Var}(\hat{F}_n(x)) = \frac{1}{n} F(x)(1 - F(x)). \quad (6.3)$$

As $n \rightarrow \infty$, we have $\hat{F}_n(x) \rightarrow F(x)$ by the law of large numbers (LLN) and By the central limit theorem (CLT),

$$\frac{\sqrt{n}(\hat{F}_n(x) - F(x))}{\sqrt{F(x)(1 - F(x))}} \stackrel{\text{approx}}{\sim} N(0, 1) \quad (6.4)$$

by the central limit theorem (CLT).¹ Unlike a single proportion estimate \hat{p} , the empirical CDF links all of these estimated probabilities together—like beads on a necklace—through the variable x .

At any given x , interval estimates for $F(x)$ can be obtained using any of the methods we have discussed for probabilities, including the Wald, score (Wilson), likelihood ratio, exact (Clopper-Pearson), mid-p, or Jeffreys confidence intervals as well as Bayesian credible intervals. For example,

$$\hat{F}_n(x) \pm 1.96 \sqrt{\frac{1}{n} \hat{F}_n(x)(1 - \hat{F}_n(x))} \quad (6.5)$$

is the 95% Wald confidence interval. To force this confidence interval to stay inside $(0, 1)$, we can use the delta method with a logit or log-log transformation. These are called **pointwise** confidence intervals because we have a separate confidence interval for $F(x)$ at each x .

¹The *Glivenko-Cantelli theorem* guarantees that $\sup_{x \in \mathbb{R}} |\hat{F}_n(x) - F(x)| \rightarrow 0$ as $n \rightarrow \infty$, so the convergence happens simultaneously for all x (Van der Vaart 2000).

6.2 Kaplan-Meier estimator

In data with right censoring and left truncation, we cannot calculate the empirical CDF directly. The **Kaplan-Meier estimator** (Kaplan and Meier 1958) uses conditional probabilities to estimate the survival function $S(t) = 1 - F(t)$ for failure time data.² The basic idea behind the Kaplan-Meier estimator is to solve the problems of right censoring and left truncation (delayed entry) by breaking analysis time into periods where no one enters or leaves the study. In each such interval $(t_a, t_b]$, we can estimate the conditional probability of surviving to time t_b given that you were at risk of disease at time t_a .

If there are n individuals at risk throughout the interval $(t_a, t_b]$, then the number of events at time t_b can be treated like a $\text{binomial}(n, p)$ random variable where p is the risk of the event in $(t_a, t_b]$. Our point estimate of this conditional probability is

$$\hat{p} = \frac{d}{n}$$

where d is the number of failures at time t_b . Its variance is approximately

$$\text{Var}(\hat{p}) = \frac{1}{n}\hat{p}(1 - \hat{p}).$$

Given that you were at risk of disease at time t_a ,

$$\hat{q} = 1 - \hat{p}$$

is the conditional probability of surviving past time t_b .

6.2.1 At-risk process and risk sets

To estimate the risk in an interval $(t_a, t_b]$, it is critical to define who is at risk of failure at time t_a . We assume that all times are defined relative to a time origin that can differ between individuals. The **at-risk process** for individual i is

$$Y_i(t) = \begin{cases} 1 & \text{if } i \text{ is at risk and under observation at time } t, \\ 0 & \text{otherwise.} \end{cases}$$

The at-risk process is assumed to be predictable (i.e., its value at t is determined just before time t), so $Y_i(t) = 1$ even if i fails or is censored at time t . Note that a person is only at risk

²Named after American statisticians [Edward L. Kaplan](#) (1920–2006) and [Paul Meier](#) (1924–2011). Kaplan worked at Bell Telephone Laboratories, the Lawrence Radiation Laboratory (now the Lawrence Berkeley National Laboratory), and Oregon State University. Meier worked at Johns Hopkins and the University of Chicago and was an early advocate for the use of randomization in clinical trials. Both were doctoral students of John Tukey at Princeton. Their 1958 paper is one of the most-cited papers in statistics, with 66,740 citations as of 22 January 2025.

if they are both at risk of failure and under observation. If person i is not under observation until an entry time $t_i^{\text{entry}} > 0$, then $Y_i(t) = 0$ when $t \leq t_i^{\text{entry}}$.

The set of individuals under observation and at risk of failure at time t is called the **risk set** at time t and written

$$\mathcal{R}(t) = \{i : Y_i(t) = 1\}$$

The risk set $\mathcal{R}(t)$ includes everyone under observation who fails at time t , who is censored at time t , or who survives past time t .

6.2.2 Survival via multiplication of conditional probabilities

Let T denote the random failure time in the analysis time scale (i.e., with the origin as time zero), and suppose we have times $0 < t_1 < t_2$. To have $T > t_2$, we must also have $T > t_1$, so

$$\begin{aligned} \Pr(T > t_2) &= \Pr(T > t_2 \text{ and } T > t_1) \\ &= \Pr(T > t_2 \mid T > t_1) \Pr(T > t_1). \end{aligned}$$

In other words, the probability of survival in $(0, t_2]$ is the product of the survival probabilities in the intervals $(0, t_1]$ and $(t_1, t_2]$. If $t_3 > t_2$, then

$$\begin{aligned} \Pr(T > t_3) &= \Pr(T > t_3 \mid T > t_2) \Pr(T > t_2) \\ &= \Pr(T > t_3 \mid T > t_2) \Pr(T > t_2 \mid T > t_1) \Pr(T > t_1) \end{aligned}$$

which is the product of the survival probabilities in the intervals $(0, t_1]$, $(t_1, t_2]$, and $(t_2, t_3]$. This logic extends to any number of intervals. If we have distinct times $0 = t_0 < t_1 < \dots < t_m$, then

$$\Pr(T > t_m) = \prod_{i=1}^m \Pr(T > t_i \mid T > t_{i-1}).$$

This uses the multiplication rule for conditional probabilities, so it does not assume that failures in different intervals are independent. In single-failure data, an individual who fails in one interval cannot fail in a later interval, so failures in different intervals cannot be independent.

Let $0 = t_0 < t_1 < t_2 < \dots < t_m$ be the endpoints of intervals $(t_{i-1}, t_i]$ within which there are no entries or exits from the study. Let $n_j = \sum_{i=1}^n Y_i(t_j)$ be the number of people in the risk set $\mathcal{R}(t_j)$ and let $d_j \geq 0$ be the number of failures that occur at time t_j . The estimated conditional probability q_j of surviving through the interval $(t_{j-1}, t_j]$ given survival to t_{j-1} is

$$\hat{q}_j = 1 - \frac{d_j}{n_j},$$

and the Kaplan-Meier estimator of $S(t)$ is

$$\hat{S}(t) = \prod_{j: t_j \leq t} \hat{q}_j = \prod_{j: t_j \leq t} \left(1 - \frac{d_j}{n_j}\right). \quad (6.6)$$

This is the product of the conditional survival probabilities in $(t_{j-1}, t_j]$ for all intervals such that $t_j \leq t$. To survive to time t , you need to survive through all intervals up to and including time t . This makes it easier to calculate the survival function than to calculate cumulative incidence directly. The Kaplan-Meier estimator is a consistent and asymptotically normal estimator of the true survival function (Fleming and Harrington 2005; Aalen, Borgan, and Gjessing 2008). Figure 6.1 shows an example based on a right-censored sample of size 500 from a log-logistic distribution with shape $\alpha = 1$ and rate $\lambda = 2$.

6.3 R




Figure 6.1: True log-logistic survival function and Kaplan-Meier estimate with complementary log-log 95% confidence limits.

6.3.1 Greenwood formula and confidence intervals

Calculating the variance of a product is difficult and tedious, but calculating the variance of a sum is easy. Taking logarithms in Equation 6.6, we get

$$\ln \hat{S}(t) = \sum_{j: t_j \leq t} \ln \hat{q}_j.$$

For each j , the estimated variance of \hat{q}_j is

$$\text{Var}(\hat{q}_j) = \frac{1}{n_j} \hat{q}_j (1 - \hat{q}_j).$$

Since $\ln x$ has the derivative $\frac{1}{x}$,

$$\text{Var}(\ln \hat{q}_j) \approx \frac{1}{\hat{q}_j^2} \text{Var}(\hat{q}_j) = \frac{d_j}{n_j(n_j - d_j)}.$$

by the delta method from Section 3.6.1.

The estimated survival probabilities in each time interval are conditionally independent, so

$$\text{Var}(\ln \hat{S}(t)) = \sum_{t_j \leq t} \text{Var}(\ln \hat{q}_j) = \sum_{t_j \leq t} \frac{d_j}{n_j(n_j - d_j)}.$$

by Equation 1.24. Since $\hat{S}(t) = \exp(\ln \hat{S}(t))$, we can use the delta method again to get an estimated variance for $\hat{S}(t)$. The function $\exp(x) = e^x$ is its own derivative, so we get

$$\text{Var}(\hat{S}(t)) = \hat{S}(t)^2 \text{Var}(\ln \hat{S}(t)) = \hat{S}(t)^2 \sum_{t_j \leq t} \frac{d_j}{n_j(n_j - d_j)}. \quad (6.7)$$

This is called the *Greenwood formula* (Greenwood 1926).³ It was developed originally for life tables and applied later to the Kaplan-Meier estimator.

For each t , a pointwise Wald 95% confidence interval for $S(t)$ is

$$\hat{S}(t) \pm 1.96 \sqrt{\text{Var}(\hat{S}(t))}.$$

This confidence interval can have a lower bound less than zero or an upper bound greater than one, outside the possible values of $S(t)$. Better confidence intervals can be obtained using a *complementary log-log* transformation, which is

$$\ln(-\ln S(t)) = \ln H(t)$$

where $H(t)$ is the cumulative hazard. The logit (log odds) transformation can also be used.

³Major Greenwood (1880–1949) was an English epidemiologist and statistician. He worked at the Lister Institute (now part of the University of London) and joined the newly-created Ministry of Health after serving in the Royal Army Medical Corps in World War I. He studied the health effects of factory work and developed early models of infectious disease transmission. In 1928, he became the first professor of epidemiology at the London School of Hygiene and Tropical Medicine. In an obituary, Austin Bradford Hill wrote that one of Greenwood's greatest contributions "lay merely in his outlook, in his statistical approach to medicine, then a new approach and one long regarded with suspicion. And he fought this fight continuously and honestly."

6.3.2 Cumulative incidence and cumulative hazard

The Kaplan-Meier estimator of the survival function can also be used to estimate the cumulative hazard function $H(t) = -\ln S(t)$ and the cumulative incidence function $F(t) = 1 - S(t)$, which is the CDF of the time-to-event distribution. The estimated cumulative hazard function is

$$\hat{H}_{\text{KM}}(t) = -\ln \hat{S}(t), \quad (6.8)$$

which is defined whenever $\hat{S}(t) > 0$. The estimated cumulative incidence function is

$$\hat{F}_{\text{KM}}(t) = 1 - \hat{S}(t).$$

When there is no right censoring or left truncation (delayed entry), $\hat{F}(t)$ equals the empirical CDF of the times to events as in Equation 6.2 and the Greenwood variance equals the corresponding variance in Equation 6.3. Confidence limits for $F(t)$ or $H(t)$ can be obtained from the corresponding confidence limits for $S(t)$.

6.4 Nelson-Aalen estimator

The Kaplan-Meier estimator is based on estimating conditional survival probabilities in intervals within which there are no entries or exits. The **Nelson-Aalen** estimator uses the same time intervals, but it estimates an expected number of events in each interval (Nelson 1969, 1972; Altshuler 1970; Aalen 1978). It is based on the interpretation of the cumulative hazard $H(t)$ as an expected number of events in $(0, t]$ if the event could be made repeatable, and it uses the fact that the expected number of events in different intervals can be added together by Equation 1.23. The at-risk process and risk sets are defined exactly as in Section 6.2.1.

6.4.1 Cumulative hazard via addition of expected values

As above, let $0 = t_0 < t_1 < t_2 < \dots < t_m$ be the endpoints of intervals $(t_{i-1}, t_i]$ within which there are no entries or exits from the study. Let $n_j = \sum_{i=1}^n Y_i(t_j)$ be the number of people in the risk set $\mathcal{R}(t_j)$ and let $d_j \geq 0$ be the number of failures that occur at time t_j . The estimated expected number of events per individual under observation in this time interval is

$$\frac{1}{n_j} \sum_{i \in \mathcal{R}_j} \mathbb{1}_{t_i^{\text{event}} \in (t_{j-1}, t_j]} = \frac{d_j}{n_j}.$$

Adding these up over all time intervals with endpoints at or before time t , we get the Nelson-Aalen estimator

$$\hat{H}(t) = \sum_{j: t_j \leq t} \frac{d_j}{n_j}. \quad (6.9)$$

The Nelson-Aalen estimator is an unbiased, consistent, and asymptotically normal estimator of the true cumulative hazard (Fleming and Harrington 2005; Aalen, Borgan, and Gjessing 2008). Figure 6.2 shows an example based on a right-censored sample of size 500 from a log-logistic distribution with shape $\alpha = 1$ and rate $\lambda = 2$.

The **Fleming-Harrington correction for ties** (Fleming and Harrington 1984) replaces each d_j/n_j in Equation 6.9 with

$$\frac{1}{n_j} + \frac{1}{n_j - 1} + \dots + \frac{1}{n_j - (d_j - 1)} > \frac{d_j}{n_j}. \quad (6.10)$$

The resulting estimator of the cumulative hazard is sometimes called the *Fleming-Harrington estimator*. It accounts for the fact that the d_j events did not really happen at the same time. They appear to be tied because the times were defined and measured with the limited precision possible in a real study. The example in Figure 6.2 uses this correction.

6.5 R




Figure 6.2: True log-logistic cumulative hazard function and Nelson-Aalen estimate with log-transformed 95% confidence limits.

6.5.1 Variance and confidence intervals

Let D_j be the random number of events in the interval $(t_{j-1}, t_j]$ whose observed value is d_j . If an event is repeatable, the number of events per individual in any interval $(t_{j-1}, t_j]$ has a Poisson distribution with mean

$$\Delta H_j = H(t_j) - H(t_{j-1}).$$

When an event cannot be repeated, this is true in an interval sufficiently small that ΔH_j is much smaller than one (i.e., $\Delta H_j \ll 1$). Because our time intervals are defined to be small enough that no one leaves the study by having an event, $\Delta H_j \ll 1$ in each interval where n_j is large.

Because we have n_j individuals at risk in this interval,

$$D_j \sim \text{Poisson}(n_j \Delta H_j).$$

because D_j is the sum of n_j $\text{Poisson}(\Delta H_j)$ random variables. Because $\text{Var}(D_j) = n_j \Delta H_j$,

$$\text{Var}\left(\frac{D_j}{n_j}\right) = \frac{1}{n_j^2} \text{Var}(D_j) = \frac{\Delta H_j}{n_j}.$$

Replacing the unknown ΔH_j with

$$\Delta \hat{H}_j = \hat{H}(t_j) - \hat{H}(t_{j-1}) = \frac{d_j}{n_j},$$

we get the estimated variance

$$\text{Var}(\Delta \hat{H}_j) = \frac{d_j}{n_j^2}.$$

The variance of $\hat{H}(t)$ is the sum of these variances over all time intervals with endpoints on or before time t , so

$$\text{Var}(\hat{H}(t)) = \sum_{j:t_j \leq t} \text{Var}(\Delta \hat{H}_j) = \sum_{j:t_j \leq t} \frac{d_j}{n_j^2}.$$

With the Fleming-Harrington correction for ties from Equation 6.10, each d_j/n_j^2 is replaced by

$$\frac{1}{n_j^2} + \frac{1}{(n_j - 1)^2} + \dots + \frac{1}{(n_j - (d_j - 1))^2} > \frac{d_j}{n_j^2}.$$

This estimator of the variance (with or without the Fleming-Harrington correction) can be justified more rigorously using the theory of *counting processes* and *martingales* (Fleming and Harrington 2005; Aalen, Borgan, and Gjessing 2008). For our purposes, it is enough to highlight its connection to the Poisson distribution.

For each t , a pointwise Wald 95% confidence interval for $H(t)$ is

$$\hat{H}(t) \pm 1.96 \sqrt{\text{Var}(\hat{H}(t))}.$$

This can produce confidence intervals with negative lower bounds, outside the possible values of $H(t)$. A better confidence interval is produced using a log transformation. By the delta method,

$$\text{Var}(\ln \hat{H}(t)) = \frac{1}{\hat{H}(t)^2} \text{Var}(\hat{H}(t)).$$

The corresponding confidence interval for $\hat{H}(t)$ has the endpoints

$$\hat{H}(t)e^{\pm 1.96\sqrt{\text{Var}(\ln \hat{H}(t))}}. \quad (6.11)$$

Both endpoints of this confidence interval are nonnegative, and they are strictly positive for all t such that $\hat{H}(t) > 0$. Because $H(t) = -\ln S(t)$, the log transformation for the cumulative hazard function $H(t)$ corresponds to the log-log transformation for the survival function $S(t)$.

6.5.2 Survival and cumulative incidence functions

The Nelson-Aalen estimate $\hat{H}(t)$ can be used to estimate the survival function

$$S(t) = e^{-H(t)},$$

and the cumulative incidence function

$$F(t) = 1 - S(t) = 1 - e^{-H(t)}.$$

The estimated survival function is

$$\hat{S}_{\text{NA}}(t) = e^{-\hat{H}(t)},$$

and the estimated cumulative incidence function is

$$\hat{F}_{\text{NA}}(t) = 1 - \hat{S}_{\text{NA}}(t) = 1 - e^{-\hat{H}(t)}.$$

In both of these estimators, $\hat{H}(t)$ can incorporate the Fleming-Harrington correction for ties from Equation 6.10. Confidence limits for $S(t)$ and $F(t)$ can be obtained from the corresponding confidence limits for $H(t)$.

If there is any t_j where all individuals at risk have an event, the Kaplan-Meier estimator $\hat{S}(t) = 0$ for all $t > t_j$. Once you multiply by zero, there is no going back. This never happens for the estimate of $S(t)$ based on the Nelson-Aalen estimator. Because $\hat{H}(t) < \infty$, we always have

$$\hat{S}_{\text{NA}}(t) = \exp(-\hat{H}(t)) > 0.$$

This is a practical advantage of the Nelson-Aalen estimator over the Kaplan-Meier estimator.

More generally, the Kaplan-Meier estimator produces smaller estimates of $S(t)$ than the Nelson-Aalen estimator does. Similar inequalities exist for the estimated $H(t)$ and $F(t)$:

$$\begin{aligned} \hat{S}(t) &\leq \hat{S}_{\text{NA}}(t) \\ \hat{H}_{\text{KM}}(t) &\geq \hat{H}(t) \\ \hat{F}_{\text{KM}}(t) &\geq \hat{F}_{\text{NA}}(t). \end{aligned}$$

Each inequality implies the others, but the cumulative hazard inequality is the simplest. As shown in Figure 6.3,

$$-\ln\left(1 - \frac{d_j}{n_j}\right) \geq \frac{d_j}{n_j}$$

with equality only if $d_j > 0$. By Equation 6.6 and Equation 6.8,

$$\hat{H}_{KM}(t) = - \sum_{j:t_j \leq t} \ln\left(1 - \frac{d_j}{n_j}\right) \geq \sum_{j:t_j \leq t} \frac{d_j}{n_j} = \hat{H}(t).$$

with equality only when all $d_j = 0$ in the sums. The Nelson-Aalen estimate with the Fleming-Harrington correction for ties is greater than the uncorrected $\hat{H}(t)$ and less than $\hat{H}_{KM}(t)$. Although not equal, the Nelson-Aalen estimator and Kaplan-Meier estimators of the survival $S(t)$, cumulative hazard $H(t)$, and the cumulative incidence $F(t)$ produce similar results in large samples, where d_j/n_j is small for each j .




Figure 6.3: Increments in the estimated cumulative hazard in the interval $(t_{j-1}, t_j]$ based on the Kaplan-Meier and Nelson-Aalen estimators.

6.6 Parametric failure time distributions

Many times to events that are important in epidemiology cannot be accurately described using an exponential distribution. In particular, it is important to allow the hazard function $h(t)$ to change over time. Here, we introduce two simple failure time distributions where $h(t)$ is not constant. They each have a shape parameter α and a rate parameter λ . As with the exponential distribution, the scale parameter is $\sigma = 1/\lambda$. The gamma distribution from

equation Equation 5.19 is also used as a failure time distribution, but its survival and hazard functions do not have a simple closed form.

For all parametric failure time models, likelihoods are constructed as in Section 5.2.4. The rate parameter λ and shape parameter α can be estimated using frequentist methods such as maximum likelihood or Bayesian methods. When using parametric methods, it is important to evaluate goodness-of-fit to check whether the underlying assumptions are reasonable.

6.6.1 Weibull distribution

The Weibull distribution (Weibull et al. 1951) is a two-parameter generalization of the exponential distribution.⁴ It has the survival function

$$S(t, \alpha, \lambda) = \exp(-(\lambda t)^\alpha),$$

where $\alpha > 0$ is the shape parameter and $\lambda > 0$ is the rate parameter. The Weibull cumulative hazard function is

$$H(t, \alpha, \lambda) = -\ln S(t) = (\lambda t)^\alpha, \quad (6.12)$$

and its hazard function is

$$h(t, \alpha, \lambda) = \frac{\partial}{\partial t} H(t, \alpha, \lambda) = \alpha \lambda^\alpha t^{\alpha-1}. \quad (6.13)$$

The notation $\partial/\partial t$ means that we take a derivative with respect to t while holding the other arguments, α and λ , constant. Figure 6.4 shows examples of these hazard functions. The exponential distribution is a special case of the Weibull distribution with shape $\alpha = 1$.

⁴Named after [Waloddi Weibull](#) (1887-1979), a Swedish engineer and applied mathematician who was a member of the Swedish Coast Guard and invented a technique of using explosives to determine the type and thickness of sediments beneath the sea floor.




Figure 6.4: Hazard functions for the Weibull distribution with different shape parameters α . All have rate $\lambda = 1$.

6.7 R

6.7.1 Log-logistic distribution

The exponential distribution has a constant hazard, and the Weibull hazard function is increasing, decreasing, or constant. The log-logistic distribution has a more flexible hazard function.

Its survival function is

$$S(t) = \frac{1}{1 + (\lambda t)^\alpha}.$$

where $\lambda > 0$ is the rate parameter and $\alpha > 0$ is the shape parameter. Its cumulative hazard function is

$$H(t, \alpha, \lambda) = -\ln S(t) = \ln(1 + (\lambda t)^\alpha),$$

and its the hazard function is

$$h(t, \alpha, \lambda) = \frac{\partial}{\partial t} H(t, \alpha, \lambda) = \frac{\lambda \alpha (\lambda t)^{\alpha-1}}{1 + (\lambda t)^\alpha}.$$

As before, we differentiate $H(t, \alpha, \lambda)$ with respect to t while holding α and λ constant. There are three general shapes that the hazard function can take depending on the shape parameter α :

$$h(t) \begin{cases} \text{decreases from } \infty & \text{if } \alpha < 1, \\ \text{decreases from } \lambda & \text{if } \alpha = 1, \\ \text{increases then decreases} & \text{if } \alpha > 1. \end{cases}$$

Figure 6.5 shows examples of these hazard functions. The exponential distribution is not a special case of the log-logistic distribution for any shape α .




Figure 6.5: Hazard functions for the log-logistic distribution with different shape parameters α . All have rate $\lambda = 1$.

The name of the log-logistic distribution comes from the fact that the logarithm of a log-logistic random variable has a *logistic distribution* (just like the logarithm of a log-normal random variable has a normal distribution). The log-logistic distribution is used in economics to model the distribution of wealth or income (Fisk 1961), where it is known as the *Fisk distribution*.

6.8 R

6.8.1 Cox-Snell residuals

One way to check goodness-of-fit for a parametric failure time model is to use **Cox-Snell residuals** (Cox and Snell 1968). For an observation $(t_i^{\text{entry}}, t_i^{\text{exit}}, \delta_i)$, the Cox-Snell residual is

$$\left(\hat{H}(t_i^{\text{entry}}), \hat{H}(t_i^{\text{exit}}), \delta_i\right),$$

where the estimated cumulative hazards are playing the role of entry and exit times. When the parametric model is correct, the Cox-Snell residuals are a right-censored and left-truncated sample from an exponential distribution with rate $\lambda = 1$. To check this, we can plot the Nelson-Aalen estimate of the cumulative hazard for the Cox-Snell residuals and compare it to the `exponential(1)` cumulative hazard, which is $H(t) = t$.

Listing 6.1 loglogistic.R

```
## Fitting a log-logistic distribution
# To sample a log-logistic random variable in R, you sample a logistic random
# variable with location = -log(rate) and scale = 1 / shape.
# The exponential of the logistic variable has a log-logistic distribution
# with the correct rate and shape parameters.
library(survival)

# Log-logistic distribution and regression (rate = 2, shape = 3)
llsample <- exp(rlogis(1000, location = -log(2), scale = 1 / 3))
llogdat <- data.frame(time = llsample, event = 1)
llogreg <- survreg(Surv(time, event) ~ 1, data = llogdat,
                  dist = "loglogistic")
exp(-coef(llogreg))      # point estimate of rate
exp(-confint(llogreg))   # 95% confidence interval for rate
1 / llogreg$scale        # point estimate of shape

# log-transformed 95% confidence interval for the shape parameter
exp(-log(llogreg$scale) + c(-1, 1)
    * qnorm(.975) * sqrt(vcov(llogreg)["Log(scale)", "Log(scale)"])))

# plot of true and estimated log-logistic hazard functions
llrate_est <- exp(-coef(llogreg))
llshape_est <- 1 / llogreg$scale
llrate_true <- 2
llshape_true <- 3
h_llog <- function(time, rate, shape) {
  # returns last expression if there is no return() statement
  (rate * shape * (time * rate)^(shape - 1) /
   (1 + (time * rate)^shape))
}
t <- seq(0, 4, by = 0.01)
plot(t, h_llog(t, llrate_true, llshape_true), type = "n",
     xlab = "Time", ylab = "Hazard (Log-logistic)")
grid()
lines(t, h_llog(t, llrate_est, llshape_est))
lines(t, h_llog(t, llrate_true, llshape_true), lty = "dashed")
legend("topright", lty = c("solid", "dashed"), bg = "white",
     legend = c("Estimated hazard function", "True hazard function"))
```

Listing 6.2 KMcurve.R

```
## Kaplan-Meier survival curve
library(survival)

# right-censored sample from log-logistic dist with rate = 2 and shape = 1
# Uses samples from logistic distribution with location = -log(rate) and
# scale = 1 / shape.
set.seed(42)
llog_f <- exp(rlogis(500, location = -log(2), scale = 1))
llog_c <- exp(rlogis(500, location = -log(2), scale = 2))
t <- pmin(llog_f, llog_c)
d <- ifelse(llog_c < llog_f, 0, 1)
llogdat <- data.frame(time = t, delta = d)

# Kaplan-Meier estimate with complementary log-log confidence intervals
llog_km <- survfit(Surv(time, delta) ~ 1, data = llogdat,
                  conf.type = "log-log")

# Log-logistic survival function
llog_surv <- function(t, lambda=1, gamma=1) 1 / (1 + (lambda * t)^gamma)

# Kaplan-Meier curve and log-logistic survival curve
t <- seq(0, max(llogdat$time), .01)
plot(llog_km, xlim = c(0, 15),
     xlab = "Time", ylab = "Survival probability")
grid()
lines(t, llog_surv(t, 2, 1), col = "darkgray")
legend("topright", bg = "white",
     lty = c("solid", "dashed", "solid"),
     col = c("black", "black", "darkgray"),
     legend = c("Kaplan-Meier estimate", "95% confidence limits",
                "True survival function"))
```

Listing 6.3 NelsonAalen.R

```
## Nelson-Aalen estimator
# The Nelson-Aalen estimator is calculated using survival::survfit().
# Use the argument "stype = 2" to get the survival function estimated from the
# Nelson-Aalen estimate of the cumulative hazard.
# Use the argument "ctype = 2" to get the Fleming-Harrington correction.

library(survival)
?survfit          # get general help about survfit
?survfit.formula  # get help with the specific version we use below

# right-censored sample from log-logistic dist with rate = 2 and shape = 1
# Uses samples from logistic distribution with location = -log(rate) and
# scale = 1 / shape.
set.seed(42)
llog_f <- exp(rlogis(500, location = -log(2), scale = 1))
llog_c <- exp(rlogis(500, location = -log(2), scale = 2))
t <- pmin(llog_f, llog_c)
d <- ifelse(llog_c < llog_f, 0, 1)
llogdat <- data.frame(time = t, delta = d)

# Nelson-Aalen estimator with log-transformed confidence intervals
# The log transformation of H is the log-log transformation of S, so we use
# the argument conf.type = "log-log".
llog_na <- survfit(Surv(time, delta) ~ 1, data = llogdat,
                  conf.type = "log-log", stype = 2, ctype = 2)

# point and interval estimates of the survival function
summary(llog_na, times = 1:15)

# calculate point and interval estimates of the cumulative hazard function
names(summary(llog_na, times = 1:15))
summary(llog_na, times = 1:15)$cumhaz
-log(summary(llog_na, times = 1:15)$surv)
-log(summary(llog_na, times = 1:15)$lower)
-log(summary(llog_na, times = 1:15)$upper)
```

Listing 6.4 NAcurve.R

```
## Nelson-Aalen cumulative hazard curve
library(survival)

# right-censored sample from log-logistic dist with rate = 2 and shape = 1
# Uses samples from logistic distribution with location = -log(rate) and
# scale = 1 / shape.
set.seed(42)
llog_f <- exp(rlogis(500, location = -log(2), scale = 1))
llog_c <- exp(rlogis(500, location = -log(2), scale = 2))
t <- pmin(llog_f, llog_c)
d <- ifelse(llog_c < llog_f, 0, 1)
llogdat <- data.frame(time = t, delta = d)

# Nelson-Aalen estimate of the survival function with FH correction
llog_na <- survfit(Surv(time, delta) ~ 1, data = llogdat,
                  conf.type = "log-log", stype = 2, ctype = 2)

# log-logistic cumulative hazard function
llog_cumhaz <- function(t, lambda, gamma) log(1 + (lambda * t)^gamma)

# Nelson-Aalen curve and log-logistic cumulative hazard curve
t <- seq(0, max(llogdat$time), .01)
plot(llog_na, fun = "cumhaz", xlim = c(0, 20),
     xlab = "Time", ylab = "Cumulative hazard")
grid()
lines(t, llog_cumhaz(t, 2, 1), col = "darkgray")
legend("bottomright", bg = "white", lty = c("solid", "dashed", "solid"),
     col = c("black", "black", "darkgray"),
     legend = c("Nelson-Aalen estimate", "95% confidence limits",
               "True cumulative hazard function"))
```

Listing 6.5 estHineq.R

```
## Kaplan-Meier  $H(t)$  >= Nelson-Aalen  $H(t)$ 

# plot of estimated cumulative hazard function increments
x <- seq(0, 1, by = 0.01)
plot(x, x, type = "l", ylim = c(0, 1),
     xlab = expression(d[j] / n[j]),
     ylab = expression(paste("Estimated ", Delta, H[j], " = ",
                             H(t[j]) - H(t[j - 1]))))
lines(x, -log(1 - x), lty = "dashed")
grid()
text(0.75, 0.55, expression(paste("NA estimator: ", d[j] / n[j])))
text(0.25, 0.7, expression(paste("KM estimator: -ln(", 1 - d[j] / n[j], ") ",
                                   sep = "")))
```

Listing 6.6 Weibull-haz.R

```
## Weibull hazard functions

# hazard function
hweib <- function(t, shape=1, rate=1) shape * rate^shape * t^(shape - 1)

# hazard plots for shapes 2, 1, and 1 / 2
t <- seq(0, 2, by = 0.01)
plot(t, hweib(t, 2), type = "l", lty = "dashed",
     xlab = "Time", ylab = "Weibull hazard (rate = 1)")
lines(t, hweib(t))
lines(t, hweib(t, 0.5), lty = "dotted")
grid()
text(1.6, 1.2, "shape = 1 (exponential)")
text(1.25, 0.2, "shape = 1 / 2")
text(0.7, 1.9, "shape = 2")
```

Listing 6.7 Weibull.R

```
## Fitting a Weibull distribution
# In R, the shape is 1 / the "scale" parameter.
# In standard terminology, the scale is 1 / rate.
library(survival)

# Weibull distribution and regression (rate = 2, shape = 3)
# Weibull is the default distribution for survival::survreg().
wsample <- rweibull(1000, shape = 3, scale = 1 / 2)
weibdat <- data.frame(time = wsample, event = 1)
weibreg <- survreg(Surv(time, event) ~ 1, data = weibdat)
summary(weibreg)
exp(-coef(weibreg))      # point estimate of rate
exp(-confint(weibreg))   # 95% confidence interval for rate
1 / weibreg$scale        # point estimate of shape

# log-transformed Wald confidence interval for the shape parameter
# vcov() returns the estimated covariance matrix from the model
exp(-log(weibreg$scale) + c(-1, 1)
    * qnorm(.975) * sqrt(vcov(weibreg)["Log(scale)", "Log(scale)"])))

# plot of true and estimated Weibull hazard functions
wrate_est <- exp(-coef(weibreg))
wshape_est <- 1 / weibreg$scale
wrate_true <- 2
wshape_true <- 3
h_weib <- function(time, rate, shape) rate * shape * (time * rate)^(shape - 1)
t <- seq(0, 4, by = 0.01)
plot(t, h_weib(t, wrate_true, wshape_true), type = "n",
     xlab = "Time", ylab = "Hazard (Weibull)")
grid()
lines(t, h_weib(t, wrate_est, wshape_est))
lines(t, h_weib(t, wrate_true, wshape_true), lty = "dashed")
legend("topleft", lty = c("solid", "dashed"), bg = "white",
     legend = c("Estimated hazard function", "True hazard function"))
```

Listing 6.8 loglogistic-haz.R

```
## Log-logistic hazard functions

# hazard function
hllog <- function(t, shape=1, rate=1) {
  shape * rate^shape * t^(shape - 1) / (1 + (rate * t)^shape)
}

# hazard plots for shape = 2, 1, 1 / 2
t <- seq(0, 4, by = 0.01)
plot(t, hllog(t, 2), type = "l", lty = "dashed",
      xlab = "Time", ylab = "Log-logistic hazard (rate = 1)")
lines(t, hllog(t))
lines(t, hllog(t, 0.5), lty = "dotted")
grid()
text(1.5, 0.5, "shape = 1")
text(3, 0.7, "shape = 2")
text(1.5, 0.1, "shape = 1 / 2")
```

Listing 6.9 loglogistic.R

```
## Fitting a log-logistic distribution
# To sample a log-logistic random variable in R, you sample a logistic random
# variable with location = -log(rate) and scale = 1 / shape.
# The exponential of the logistic variable has a log-logistic distribution
# with the correct rate and shape parameters.
library(survival)

# Log-logistic distribution and regression (rate = 2, shape = 3)
llsample <- exp(rlogis(1000, location = -log(2), scale = 1 / 3))
llogdat <- data.frame(time = llsample, event = 1)
llogreg <- survreg(Surv(time, event) ~ 1, data = llogdat,
                  dist = "loglogistic")
exp(-coef(llogreg))      # point estimate of rate
exp(-confint(llogreg))   # 95% confidence interval for rate
1 / llogreg$scale        # point estimate of shape

# log-transformed 95% confidence interval for the shape parameter
exp(-log(llogreg$scale) + c(-1, 1)
    * qnorm(.975) * sqrt(vcov(llogreg)["Log(scale)", "Log(scale)"])))

# plot of true and estimated log-logistic hazard functions
llrate_est <- exp(-coef(llogreg))
llshape_est <- 1 / llogreg$scale
llrate_true <- 2
llshape_true <- 3
h_llog <- function(time, rate, shape) {
  # returns last expression if there is no return() statement
  (rate * shape * (time * rate)^(shape - 1) /
   (1 + (time * rate)^shape))
}
t <- seq(0, 4, by = 0.01)
plot(t, h_llog(t, llrate_true, llshape_true), type = "n",
     xlab = "Time", ylab = "Hazard (Log-logistic)")
grid()
lines(t, h_llog(t, llrate_est, llshape_est))
lines(t, h_llog(t, llrate_true, llshape_true), lty = "dashed")
legend("topright", lty = c("solid", "dashed"), bg = "white",
      legend = c("Estimated hazard function", "True hazard function"))
```

Part II

Study Design and Measures of Association

7 Cohort and Case-Control Studies

Like fire, the χ^2 test is an excellent servant and a bad master. (Hill 1965)

Some the most important questions in public health involve the association between a disease and a possible predictor or cause, which we call an exposure. Here, we consider testing the null hypothesis that exposure and disease are independent in a population based on a sample from that population. If exposure and disease are independent, an individual's exposure status contains no information about their risk of disease and vice versa. For simplicity, we focus on a binary exposure and a binary disease outcome and we focus on association, not causation. It turns out this null hypothesis can be tested most efficiently when we sample study participants according to exposure or according to disease (but not both). Sampling by exposure leads to the **cohort study** design, and sampling by disease leads to the **case-control** study design.

7.1 Sampling from a population

Suppose we take a random sample of size n from a population of size $N \gg n$ (i.e., N is much greater than n) and classify each individual in the sample by exposure and disease in a contingency table. We assume that each possible sample of size n is equally likely. Each of the cell counts in the resulting 2x2 table is a random variable in the sample space Ω_n that consists of all possible samples of size n from the population Ω . In Table 7.1, these random variables are \mathcal{A} , \mathcal{B} , \mathcal{C} , and \mathcal{D} . The random row totals are $\mathcal{R}_1 = \mathcal{A} + \mathcal{B}$ and $\mathcal{R}_0 = \mathcal{C} + \mathcal{D}$, and the random column totals are $\mathcal{K}_1 = \mathcal{A} + \mathcal{C}$ and $\mathcal{K}_0 = \mathcal{B} + \mathcal{D}$. The total sample size n is fixed, which means that it is the same for every sample $\omega_n \in \Omega_n$.

Table 7.2 shows the observed values of these random variables from a single sample. These are the values available to us for statistical inference about the independence of exposure and disease.

Table 7.1: Random 2x2 table of exposure (X) and disease (D).

	$D = 1$	$D = 0$	Total
$X = 1$	\mathcal{A}	\mathcal{B}	\mathcal{R}_1
$X = 0$	\mathcal{C}	\mathcal{D}	\mathcal{R}_0
Total	\mathcal{K}_1	\mathcal{K}_0	n

Table 7.2: Observed 2x2 table of exposure (X) and disease (D).

	$D = 1$	$D = 0$	Total
$X = 1$	a	b	r_1
$X = 0$	c	d	r_0
Total	k_1	k_0	n

7.1.1 Hypergeometric distribution*

Over all possible samples from the population Ω , the joint distribution of the cell counts \mathcal{A} , \mathcal{B} , \mathcal{C} , and \mathcal{D} in Table 7.1 is a **multivariate hypergeometric** distribution. Its probability mass function (PMF) is

$$\Pr(\mathcal{A} = a, \mathcal{B} = b, \mathcal{C} = c, \mathcal{D} = d) = \frac{\binom{Np_{\mathcal{A}}}{a} \binom{Np_{\mathcal{B}}}{b} \binom{Np_{\mathcal{C}}}{c} \binom{Np_{\mathcal{D}}}{d}}{\binom{N}{n}} \quad (7.1)$$

for all $a, b, c, d \geq 0$ such that $a + b + c + d = n$, where

$$\begin{aligned} p_{\mathcal{A}} &= \Pr(X = 1 \text{ and } D = 1) \\ p_{\mathcal{B}} &= \Pr(X = 1 \text{ and } D = 0) \\ p_{\mathcal{C}} &= \Pr(X = 0 \text{ and } D = 1) \\ p_{\mathcal{D}} &= \Pr(X = 0 \text{ and } D = 0) \end{aligned}$$

in the underlying population (i.e., where Ω is the population and we sample a single individual ω at random). The numerator in Equation 7.1 is the number of ways of getting cell counts $\mathcal{A} = a$, $\mathcal{B} = b$, $\mathcal{C} = c$, and $\mathcal{D} = d$ in a sample of size n , and the denominator is the number of samples of size n that can be chosen from our population Ω of size $N \geq n$.

The marginal distribution of each cell count is a **hypergeometric distribution**. The PMF of \mathcal{A} , which is the number of individuals who are exposed and have disease (or disease onset), is

$$\Pr(\mathcal{A} = a) = \frac{\binom{Np_{\mathcal{A}}}{a} \binom{N(1-p_{\mathcal{A}})}{n-a}}{\binom{N}{n}}.$$

where $a \geq 0$ and $a \leq n$. Its mean is

$$\mathbb{E}(\mathcal{A}) = np_{\mathcal{A}},$$

which is identical to the binomial($n, p_{\mathcal{A}}$) mean. Its variance is

$$\text{Var}(\mathcal{A}) = np_{\mathcal{A}}(1 - p_{\mathcal{A}}) \frac{N - n}{N - 1},$$

which is smaller than the binomial($n, p_{\mathcal{A}}$) variance for all $n > 1$. The factor $(N - n)/(N - 1)$ is called the *finite population correction*.

The row totals \mathcal{R}_1 and \mathcal{R}_0 and the column totals \mathcal{K}_1 and \mathcal{K}_0 from Table 7.1 also have hypergeometric distributions. For \mathcal{R}_1 , we have

$$\Pr(\mathcal{R}_1 = r_1) = \frac{\binom{N\pi}{r_1} \binom{N(1-\pi)}{n-r_1}}{\binom{N}{n}}$$

where $\pi = \Pr(X = 1)$ is the marginal probability of exposure in the population. For \mathcal{K}_1 , we have

$$\Pr(\mathcal{K}_1 = k_1) = \frac{\binom{Np}{k_1} \binom{N(1-p)}{n-k_1}}{\binom{N}{n}}$$

where $p = \Pr(D = 1)$ is the marginal prevalence or risk of disease in the population.

As the population size $N \rightarrow \infty$, the distribution of \mathcal{A} converges to a binomial($n, p_{\mathcal{A}}$) distribution. If $N \rightarrow \infty$ and $n \rightarrow \infty$ such that $n^2/N \rightarrow 0$, the distribution of

$$\frac{\mathcal{A} - \mathbb{E}(\mathcal{A})}{\sqrt{\text{Var}(\mathcal{A})}}$$

converges to the standard normal distribution $N(0, 1)$. The hypergeometric distributions of the other cell counts and marginal totals also converge to binomial or normal distributions.

7.1.2 Multinomial distribution

If we fix the sample size n and let the population size $N \rightarrow \infty$, the multivariate hypergeometric distribution converges to the **multinomial distribution**. Its PMF is

$$\Pr(\mathcal{A} = a, \mathcal{B} = b, \mathcal{C} = c, \mathcal{D} = d) = \frac{n!}{a!b!c!d!} p_{\mathcal{A}}^a p_{\mathcal{B}}^b p_{\mathcal{C}}^c p_{\mathcal{D}}^d.$$

for $a, b, c, d \geq 0$ such that $a + b + c + d = n$. This PMF is written in terms of four probabilities, but there are only three degrees of freedom because $p_{\mathcal{A}} + p_{\mathcal{B}} + p_{\mathcal{C}} + p_{\mathcal{D}} = 1$. In the multinomial distribution, the covariance of \mathcal{A} and \mathcal{B} is

$$\text{Cov}(\mathcal{A}, \mathcal{B}) = -np_{\mathcal{A}}p_{\mathcal{B}},$$

and the covariances for the other five pairs of cell counts follow the same pattern. The multinomial approximation to the multivariate hypergeometric distribution and the binomial approximation to the hypergeometric distribution can be used when N is much larger than n (i.e., $N \gg n$), which is a common situation in epidemiologic studies.¹

When the *joint* distribution of the cell counts is multinomial, the *marginal* distribution of each cell count is binomial. For example, the distribution of \mathcal{A} is binomial($n, p_{\mathcal{A}}$), so its

¹The distribution of the cell counts in Table 7.1 is exactly multinomial (and each cell count and row or column total is exactly binomial) if we sample with replacement.

mean is $np_{\mathcal{A}}$ and its variance is $np_{\mathcal{A}}(1 - p_{\mathcal{A}})$. The row and column sums also have binomial distributions. The distribution of \mathcal{R}_1 is binomial(n, π) where

$$\pi = \Pr(X = 1)$$

is the marginal prevalence of exposure. The distribution of \mathcal{K}_1 is binomial(n, p) where

$$p = \Pr(D = 1)$$

is the marginal prevalence or risk of disease.

7.2 Hypothesis tests for independence in a 2x2 table

When exposure and disease are independent, the multiplication rule for independent events implies that

$$\Pr(X = x \text{ and } D = d) = \Pr(X = x) \Pr(D = d)$$

for all possible values x of X and d of D . There are two equivalent ways to express this null hypothesis that will prove useful in thinking about epidemiologic study design: one in terms of conditional risks of disease given exposure and one in terms of conditional prevalences of exposure given disease.

7.2.1 Equality of conditional probabilities

Independence of exposure and disease can be expressed in terms of equality of conditional probabilities of disease (or disease onset) given exposure. Let

$$p_1 = \Pr(D = 1 | X = 1)$$

be the risk of disease among the exposed and

$$p_0 = \Pr(D = 1 | X = 0)$$

be the prevalence or risk of disease among the unexposed. If exposure and disease are independent, then

$$\Pr(D = 1 | X = x) = \frac{\Pr(D = 1) \Pr(X = x)}{\Pr(X = x)} = \Pr(D = 1)$$

for $x = 1$ and $x = 0$. Therefore, $p_1 = p_0$ if exposure and disease are independent. Conversely, suppose $p_1 = p_0$. By definition of p_1 and p_0 ,

$$\Pr(D = 1 | X = 1) = \Pr(D = 1 | X = 0).$$

Expanding the conditional probabilities, we get

$$\frac{\Pr(D = 1 \text{ and } X = 1)}{\Pr(X = 1)} = \frac{\Pr(D = 1 \text{ and } X = 0)}{\Pr(X = 0)}.$$

This can be rewritten as

$$\frac{\Pr(D = 1 \text{ and } X = 1)}{\Pr(X = 1)} = \frac{\Pr(D = 1) - \Pr(D = 1 \text{ and } X = 1)}{1 - \Pr(X = 1)}.$$

Cross-multiplying the numerators and denominators shows that this equality holds if and only if

$$\Pr(D = 1 \text{ and } X = 1) = \Pr(D = 1) \Pr(X = 1).$$

Because D and X are binary, this establishes that D and X are independent random variables. Therefore, $p_1 = p_0$ implies that exposure and disease are independent. Combining both results shows that $H_0 : p_1 = p_0$ is equivalent to the null hypothesis that exposure and disease are independent.

A similar argument applies to the conditional prevalence of exposure given disease status. Let

$$\pi_1 = \Pr(X = 1 \mid D = 1)$$

be the prevalence of exposure among cases and

$$\pi_0 = \Pr(X = 1 \mid D = 0)$$

be the prevalence of exposure among controls. The null hypothesis $H_0 : \pi_1 = \pi_0$ is equivalent to the null hypothesis that exposure and disease are independent.

7.2.2 Hypergeometric chi-squared test

Under the null hypothesis that exposed and disease are independent, we have

$$\begin{aligned} p_{\mathcal{A}} &= \Pr(X = 1) \Pr(D = 1) = \pi p, \\ p_{\mathcal{B}} &= \Pr(X = 1) \Pr(D = 0) = \pi(1 - p), \\ p_{\mathcal{C}} &= \Pr(X = 0) \Pr(D = 1) = (1 - \pi)p, \\ p_{\mathcal{D}} &= \Pr(X = 0) \Pr(D = 0) = (1 - \pi)p. \end{aligned}$$

The marginal prevalence of exposure π and the marginal risk of disease p are both unknown. In a score test of the null hypothesis, these are *nuisance parameters* that can be replaced by maximum likelihood estimates (Rao 1948; Boos and Stefanski 2013). Because \mathcal{R}_1 has an approximate binomial(n, π) distribution when $N \gg n$,

$$\hat{\pi} = \frac{r_1}{n}. \tag{7.2}$$

Table 7.3: 2x2 table determined by \mathcal{A} and the margins.

	$D = 1$	$D = 0$	Total
$X = 1$	\mathcal{A}	$r_1 - \mathcal{A}$	r_1
$X = 0$	$k_1 - \mathcal{A}$	$\mathcal{A} - (a - d)$	r_0
Total	k_1	k_0	n

is the maximum likelihood estimate of π based on Table 7.2. Because \mathcal{K}_1 has an approximate binomial(n, p) distribution when $N \gg n$,

$$\hat{p} = \frac{k_1}{n} \quad (7.3)$$

is the maximum likelihood estimate of p based on Table 7.2. When we use these maximum likelihood estimates of π and p to test independence, we are conditioning on the row and column totals in the observed 2x2 table in Table 7.2.

Given the margins of a 2x2 table, the entire table is determined by any one of the four cell counts. Table 7.3 shows how the cell counts in Table 7.2 are determined by \mathcal{A} and the margins. Because all cell counts must be nonnegative, we must have $\mathcal{A} \geq 0$, $\mathcal{A} \leq r_1$, and $\mathcal{A} \leq k_1$. In the bottom right cell of the 2×2 table, we must have

$$\mathcal{A} - (a - d) \geq 0.$$

Therefore,

$$a_{\min} = \max(0, a - d) \leq \mathcal{A} \leq \min(r_1, k_1) = a_{\max}.$$

Note that the cells along the diagonal of the 2×2 table (the \mathcal{A} and \mathcal{D} cells) both increase with \mathcal{A} , while the cells off the diagonal (the \mathcal{B} and \mathcal{C} cells) both decrease with \mathcal{A} . Any of the other cells could also determine the entire table given the margins, and constraints on the possible values of \mathcal{B} , \mathcal{C} , and \mathcal{D} given the margins could be found in a similar way.

The conditional distribution of the cell count \mathcal{A} given the margins of Table 7.2 is hypergeometric. Imagine our sample as a bowl of n marbles, r_1 of which are exposed and r_0 of which are unexposed. If we randomly choose k_1 marbles without replacement to represent the individuals with disease, then \mathcal{A} is the number of exposed marbles in our sample. The probability that we get a exposed marbles and $k_1 - a$ unexposed marbles is

$$\Pr(\mathcal{A} = a \mid \text{margins}) = \frac{\binom{r_1}{a} \binom{r_0}{k_1 - a}}{\binom{n}{k_1}} = \frac{\binom{r_1}{a} \binom{r_0}{c}}{\binom{n}{k_1}} = \frac{r_1! r_0! k_1! k_0!}{a! b! c! d! n!}$$

We could also view our sample as a bowl of n marbles of which k_1 have disease (or disease onset) and k_0 do not. In that case, \mathcal{A} is the number of diseased marbles in a sample of r_1 marbles that represent exposed individuals and we get exactly the same hypergeometric distribution

of \mathcal{A} . The cell counts \mathcal{B} , \mathcal{C} , and \mathcal{D} also have hypergeometric distributions given the margins of the table.

Under the null hypothesis that exposure and disease are independent, the conditional mean of \mathcal{A} given the margins of Table 7.2 is

$$\mathbb{E}(\mathcal{A} \mid \text{margins}) = n\hat{\pi}\hat{p} = \frac{r_1 k_1}{n}$$

and its conditional variance is

$$\text{Var}(\mathcal{A} \mid \text{margins}) = \frac{r_1 r_0 k_1 k_0}{n^2(n-1)}.$$

For large n , the hypergeometric distribution is approximately normal so the hypergeometric chi-squared statistic is

$$\chi_{\text{H}}^2 = \frac{(a - \mathbb{E}(\mathcal{A} \mid \text{margins}))^2}{\text{Var}(\mathcal{A} \mid \text{margins})} = \frac{(n-1)(ad-bc)^2}{r_1 r_0 k_1 k_0} \quad (7.4)$$

Under the null hypothesis, $\chi_{\text{H}}^2 \stackrel{\text{approx}}{\sim} \chi_1^2$ (i.e., the chi-squared distribution with one degree of freedom). The p-value is $1 - F(\chi_{\text{H}}^2)$ where F is the cumulative distribution function (CDF) of the χ_1^2 distribution. We reject the null hypothesis at significance level α when χ_{H}^2 is sufficiently large that the p-value is less than α . We get exactly the same hypothesis test using \mathcal{B} , \mathcal{C} , or \mathcal{D} instead of \mathcal{A} .

7.2.3 Pearson's chi-squared test

A more general approach to testing independence of the rows and columns in a contingency table is **Pearson's chi-squared test** (Pearson 1900, 1922).² Like the hypergeometric test, Pearson's chi-squared test conditions on the margins of the table. In a contingency table with I rows and J columns, let O_{ij} be the observed cell count in row i and column j . Let r_i be the total for row i and k_j be the total for column j . Under independence, the expected cell count is

$$E_{ij} = \frac{r_i k_j}{n}.$$

Pearson's chi-squared statistic is

$$\chi_{\text{P}}^2 = \sum_{i=1}^I \sum_{j=1}^J \frac{(O_{ij} - E_{ij})^2}{E_{ij}} \quad (7.5)$$

Under the null hypothesis that the variables defining the rows and the columns are independent, χ_{P}^2 has a chi-squared distribution with $(I-1)(J-1)$ degrees of freedom (Fisher 1922; Boos

²Named after [Karl Pearson](#) (1857–1936), an English statistician who appeared in the context of the Pearson correlation coefficient in Section 1.7.2.

and Stefanski 2013). In any contingency table, Pearson’s chi-squared test is the score test of the null hypothesis that the rows and columns are independent based on a multinomial model (see Section 7.1.2) for the joint distribution of the cell counts (Boos and Stefanski 2013).

In Table 7.2, we have $I = J = 2$ with $O_{11} = a$, $O_{12} = b$, $O_{21} = c$, and $O_{22} = d$. Using the multivariate hypergeometric distribution or its multinomial approximation, we have the following estimated expected cell counts under the null hypothesis that exposure and disease are independent:

$$\begin{aligned}\mathbb{E}_{11} &= \mathbb{E}(\mathcal{A} \mid \text{margins}) = n\hat{\pi}\hat{p} = \frac{r_1 k_1}{n} \\ \mathbb{E}_{12} &= \mathbb{E}(\mathcal{B} \mid \text{margins}) = n\hat{\pi}(1 - \hat{p}) = \frac{r_1 k_0}{n} \\ \mathbb{E}_{21} &= \mathbb{E}(\mathcal{C} \mid \text{margins}) = n(1 - \hat{\pi})\hat{p} = \frac{r_0 k_1}{n} \\ \mathbb{E}_{22} &= \mathbb{E}(\mathcal{D} \mid \text{margins}) = n(1 - \hat{\pi})(1 - \hat{p}) = \frac{r_0 k_0}{n}.\end{aligned}\tag{7.6}$$

As in the hypergeometric chi-squared test, we are conditioning on the margins of the table because we are using the maximum likelihood estimates of π (the prevalence of exposure) and p (the risk of disease). When the dust settles in Equation 7.5, we get

$$\chi_P^2 = \frac{n(ad - bc)^2}{r_1 r_0 k_1 k_0} = \frac{n}{n - 1} \chi_H^2.\tag{7.7}$$

When exposure and disease are independent, χ_P^2 has a chi-squared distribution with $(2 - 1)(2 - 1) = 1$ degrees of freedom. The p-value is $1 - F(\chi_P^2)$ where F is the CDF of the χ_1^2 distribution, and we reject the null hypothesis at significance level α when χ_P^2 is sufficiently large that the p-value is less than α .

The chi-squared approximation to the distribution of χ_P^2 is generally considered acceptable if the minimum expected cell count is greater than or equal to five, and it is likely to be accurate whenever the average expected cell count is greater than or equal to 7.5 (Roscoe and Byars 1971), which is equivalent to $n \geq 30$ for a 2x2 table.³ Because $\chi_H^2 < \chi_P^2$, the hypergeometric chi-squared test is slightly more conservative than Pearson’s chi-squared test in the sense that it is less likely to reject the null hypothesis of independence. For large n , there is no practical difference.

7.2.4 Small samples and exact tests*

In small samples, the hypergeometric distribution can be used to calculate “exact” p-values. For two-sided alternative hypotheses, this leads to **Fisher’s exact test** (Fisher 1935; Irwin

³These rules of thumb are for chi-squared tests with one degree of freedom and significance level $\alpha = 0.05$. Smaller α require larger average cell counts to estimate smaller p-values accurately, and chi-squared tests with more than one degree of freedom are more robust to small expected cell counts (Roscoe and Byars 1971).

et al. 1935) or **Blaker’s exact test** (Blaker 2000). These use the hypergeometric PMF to calculate a p-value for the null hypothesis of independent rows and columns. These tests differ slightly in the way that they define the tails of the distribution of \mathcal{A} , and there are two versions of Fisher’s exact test.

The *minimum likelihood* Fisher’s exact test defines the p-value as the sum of the probabilities of all possible a such that $\Pr(A = a \mid \text{margins}) \leq \Pr(\mathcal{A} = a \mid \text{margins})$. The simpler but slightly less powerful *central* Fisher’s exact test defines the p-value as twice the minimum of the tail probabilities $\Pr(\mathcal{A} \leq a \mid \text{margins})$ and $\Pr(A \geq a \mid \text{margins})$.⁴

Blaker’s exact test defines the p-value as the minimum tail probability plus the probability of an opposite tail defined so that its probability is less than or equal to that of the smaller tail. For example: If the smaller tail is $\mathcal{A} \leq a$, then the p-value is

$$\Pr(A \leq a \mid \text{margins}) + \sum_{a'=a_{\text{opp}}}^{a_{\text{max}}} \Pr(A = a' \mid \text{margins})$$

where a_{opp} is chosen so that the sum in the second term is less than or equal to $\Pr(A \leq a \mid \text{margins})$. Blaker’s test is sometimes more powerful and never less powerful than both versions of Fisher’s exact test (Blaker 2000; Fay 2010).

These tests are “exact” in the sense that they reject a true null hypothesis with probability less than or equal to the nominal significance level α . However, they are often overly conservative in that the true significance level (i.e., the actual probability of rejecting the null hypothesis when it is true) can be substantially less than α . Using mid-p values mitigates this problem, ensuring that the true significance level stays closer to α . The price of this is that the true significance level of the test can be slightly greater than α , so the mid-p tests are no longer “exact” (Lancaster 1961; Routledge 1992; Agresti 2013).

7.3 Cohort studies

Random sampling from the population is not the most efficient way to detect a departure from independence of exposure and disease. By rearranging the Pearson chi-squared statistic χ_P^2 from equation Equation 7.7, we can identify two strategies for generating a more powerful test. One is to select participants by exposure, which leads to the **cohort study** design. The other is to select participants by disease, which leads to the **case-control** study design. In both cases, a balanced study design is optimal (or near-optimal) and Pearson’s chi-squared test is the score test of the null hypothesis that exposure and disease are independent. If participation in the study involves any cost, risk, or inconvenience, then maximizing the power of the study

⁴Inversion of the minimum likelihood Fisher’s or Blaker’s exact tests can produce confidence regions for the odds ratio that consist of two disjoint intervals, but inversion of the central Fisher’s exact test always produces a confidence region that consists of a single interval (Fay 2010).

for a given number of participants is an important ethical consideration because an inefficient study will place an unnecessary burden on some participants.

7.3.1 Selection by exposure

The Pearson chi-squared statistic χ_P^2 from Equation 7.5 can be rewritten in terms of the risks of disease in exposed and unexposed individuals. As above, let p_1 be the risk of disease in the exposed and p_0 be the risk of disease in the unexposed. In Table 7.2, their maximum likelihood estimates are $\hat{p}_1 = a/r_1$ and $\hat{p}_0 = c/r_0$. The maximum likelihood estimate of $p_1 - p_0$ is

$$\hat{p}_1 - \hat{p}_0 = \frac{a}{a+b} - \frac{c}{c+d} = \frac{ad-bc}{(a+b)(c+d)} = \frac{ad-bc}{r_1 r_0}. \quad (7.8)$$

Section 7.2.1 showed that the null hypothesis that exposure and disease are independent is equivalent to $H_0 : p_1 = p_0 = p$ where p is the marginal risk of disease.

When $n \ll N$ and the null hypothesis is true, \mathcal{A} has an approximate binomial(r_1, p) conditional distribution, \mathcal{C} has an approximate binomial(r_0, p) conditional distribution, and they are conditionally independent given the row sums r_1 and r_0 . Thus, the large-sample variance of $\hat{p}_1 - \hat{p}_0$ under the null is approximately

$$\text{Var}_0(\hat{p}_1 - \hat{p}_0) = p(1-p) \left(\frac{1}{r_1} + \frac{1}{r_0} \right) = p(1-p) \frac{n}{r_1 r_0} \quad (7.9)$$

where we used $n = r_1 + r_0$. Replacing the unknown p with its maximum likelihood estimate $\hat{p} = k_1/n$, we get the estimated null variance

$$\hat{\text{Var}}_0(\hat{p}_1 - \hat{p}_0) = \hat{p}(1-\hat{p}) \frac{n}{r_1 r_0} = \frac{k_1 k_0}{r_1 r_0 n} \quad (7.10)$$

where we used $1 - \hat{p} = k_0/n$. Combining Equation 7.8 and Equation 7.9, we get

$$\frac{(\hat{p}_1 - \hat{p}_0)^2}{\hat{p}(1-\hat{p}) \left(\frac{1}{r_1} + \frac{1}{r_0} \right)} = \frac{n(ad-bc)^2}{r_1 r_0 k_1 k_0} = \chi_P^2$$

(see Equation 7.7). Let φ be the proportion of our sample that is exposed, so $r_1 = \varphi n$ and $r_0 = (1-\varphi)n$. As $n \rightarrow \infty$, we have $r_1 \rightarrow \infty$ and $r_0 \rightarrow \infty$. The law of large numbers (LLN) guarantees that $\hat{p}_1 \rightarrow p_1$, $\hat{p}_0 \rightarrow p_0$, and

$$\hat{p} \rightarrow p_\varphi = \varphi p_1 + (1-\varphi)p_0.$$

In large samples,

$$\chi_P^2 \approx \frac{(p_1 - p_0)^2}{p_\varphi(1-p_\varphi) \left(\frac{1}{r_1} + \frac{1}{r_0} \right)} = \frac{(p_1 - p_0)^2}{p_\varphi(1-p_\varphi) \frac{1}{\varphi(1-\varphi)n}} \quad (7.11)$$

The numerator of Equation 7.11 is fixed, but the denominator depends on r_1 , r_0 , and $\varphi = r_1/n$. By sampling according to exposure, we can choose r_1 and r_0 to increase the power of the Pearson chi-squared test for a fixed total number of participants.

7.3.2 Score test for independence in a cohort study*

We need to make sure that sampling by exposure does not change the score test of the null hypothesis that exposure and disease are independent. Using a $\text{binomial}(r_1, p_1)$ distribution for the number of individuals with disease in the exposed group and a $\text{binomial}(r_0, p_0)$ distribution for the number of individuals with disease in the unexposed group, the log likelihood is

$$\ell(p_1, p_0) = \mathcal{A} \ln p_1 + \mathcal{B} \ln(1 - p_1) + \mathcal{C} \ln p_0 + \mathcal{D} \ln(1 - p_0),$$

where we have dropped terms that do not depend on p_1 or p_0 . In order to calculate the expected information for the score test, we view the log likelihood as a random variable whose value will be determined by the realized values a, b, c , and d of the random variables $\mathcal{A}, \mathcal{B}, \mathcal{C}$, and \mathcal{D} . The score function and the information function will also be treated as random variables.

Because $\ell(p_1, p_0)$ depends on two parameters, the score function is a column vector of length two:

$$U(p_1, p_0) = \begin{pmatrix} \frac{\partial}{\partial p_1} \ell(p_1, p_0) \\ \frac{\partial}{\partial p_0} \ell(p_1, p_0) \end{pmatrix} = \begin{pmatrix} \frac{\mathcal{A}}{p_1} - \frac{\mathcal{B}}{1-p_1} \\ \frac{\mathcal{C}}{p_0} - \frac{\mathcal{D}}{1-p_0} \end{pmatrix}.$$

The information $I(p_1, p_0)$ is a 2x2 matrix

$$\begin{bmatrix} \frac{\partial^2}{\partial p_1^2} \ell(p_1, p_0) & \frac{\partial^2}{\partial p_1 \partial p_0} \ell(p_1, p_0) \\ \frac{\partial^2}{\partial p_0 \partial p_1} \ell(p_1, p_0) & \frac{\partial^2}{\partial p_0^2} \ell(p_1, p_0) \end{bmatrix} = \begin{bmatrix} \frac{\mathcal{A}}{p_1^2} + \frac{\mathcal{B}}{(1-p_1)^2} & 0 \\ 0 & \frac{\mathcal{C}}{p_0^2} + \frac{\mathcal{D}}{(1-p_0)^2} \end{bmatrix}.$$

The realized value of $U(p_1, p_0)$ and the observed information $I(p_1, p_0)$ are obtained by replacing the random variables $\mathcal{A}, \mathcal{B}, \mathcal{C}$, and \mathcal{D} with their realized values a, b, c , and d .

The score statistic is calculated under the null hypothesis $H_0 : p_1 = p_0 = p$, and we use the expected information (D. A. Freedman 2007). Let $\mathbb{E}_0(Y)$ be the expected value of a random variable Y calculated under H_0 . Then $\mathbb{E}_0(\mathcal{A}) = n_1 p$, $\mathbb{E}_0(\mathcal{B}) = n_1(1 - p)$, $\mathbb{E}_0(\mathcal{C}) = n_0 p$, and $\mathbb{E}_0(\mathcal{D}) = n_0(1 - p)$, so the expected information under H_0 is

$$\mathcal{J}(p, p) = \mathbb{E}_0[I(p, p)] = \begin{bmatrix} \frac{n_1}{p} + \frac{n_1}{1-p} & 0 \\ 0 & \frac{n_0}{p} + \frac{n_0}{1-p} \end{bmatrix}.$$

Both $U(p, p)$ and $\mathcal{J}(p, p)$ depend on the unknown p , which we replace with its maximum likelihood estimate $\hat{p} = k_1/n$. This gives us the score

$$U(\hat{p}, \hat{p}) = \begin{pmatrix} \frac{a}{\hat{p}} - \frac{b}{1-\hat{p}} \\ \frac{c}{\hat{p}} - \frac{d}{1-\hat{p}} \end{pmatrix} = \begin{pmatrix} \frac{na}{k_1} - \frac{nb}{k_0} \\ \frac{nc}{k_1} - \frac{nd}{k_0} \end{pmatrix} = \begin{pmatrix} \frac{n(ad-bc)}{k_1 k_0} \\ -\frac{n(ad-bc)}{k_1 k_0} \end{pmatrix}.$$

where we used $k_1 = a + c$ and $k_0 = b + d$. The expected information at $p = \hat{p}$ is

$$\mathcal{J}(\hat{p}, \hat{p}) = \begin{bmatrix} \frac{r_1 n^2}{k_1 k_0} & 0 \\ 0 & \frac{r_0 n^2}{k_1 k_0} \end{bmatrix} \Rightarrow \mathcal{J}^{-1}(\hat{p}, \hat{p}) = \begin{bmatrix} \frac{k_1 k_0}{r_1 n^2} & 0 \\ 0 & \frac{k_1 k_0}{r_0 n^2} \end{bmatrix}$$

where we used $n_1 = r_1$ and $n_0 = r_0$. The score statistic is

$$U(\hat{p}, \hat{p})^\top J(\hat{p}, \hat{p})^{-1} U(\hat{p}, \hat{p}) = \frac{n(ad - bc)^2}{r_1 r_0 k_1 k_0} = \chi_P^2,$$

from Equation 7.7. Because H_0 reduces the degrees of freedom from two (p_1 and p_0) to one ($p_1 = p_0 = p$), χ_P^2 has an asymptotic χ^2 distribution with $2 - 1 = 1$ degree of freedom under the null. Therefore, Pearson's chi-squared test is the score test of independence of exposure and disease in a cohort study. The row sums r_1 and r_0 are fixed by design, and we condition on the column sums k_1 because we use the maximum likelihood estimate $\hat{p} = k_1/n$ of the risk of disease under H_0 .

When it uses the expected information, the score test does not depend on the parameterization of the model for p_1 and p_0 (Boos and Stefanski 2013). We get the same score statistic χ_P^2 and the same χ_1^2 distribution under the null even if the model uses transformations of p_1 and p_0 (e.g., log or logit) or if it is parameterized in terms of the *risk difference* $RD = p_1 - p_0$, the *risk ratio* $RR = p_1/p_0$, or the *odds ratio* $OR = \text{odds}(p_1)/\text{odds}(p_0)$ where $\text{odds}(p) = p/(1 - p)$. All roads lead to the same score test of the null hypothesis that exposure and disease are independent, which corresponds to $RD = 0$ and $RR = OR = 1$.

7.3.3 Optimal sampling by exposure

Having established that χ_P^2 is the score statistic for testing the independence of exposure and disease in a cohort study, we can choose r_1 and r_0 to maximize the power of the test for a given number of participants $n = r_1 + r_0$. The value of the chi-squared statistic in Equation 7.11 depends on r_1 and r_0 only in the denominator, so we can maximize the statistic by minimizing its denominator. Writing the denominator of Equation 7.10 in terms of p_1 , p_0 , and $\varphi = r_1/n$ of the sample that is exposed and simplifying gives us

$$\frac{np(1-p)}{r_1 r_0} = \frac{\varphi}{1-\varphi} p_1(1-p_1) + \frac{1-\varphi}{\varphi} p_0(1-p_0) + C(p_1, p_0) \quad (7.12)$$

where $C(p_1, p_0) = p_1(1-p_0) + p_0(1-p_1)$ does not depend on φ . The derivative of this with respect to φ is

$$\frac{d}{d\varphi} \frac{np(1-p)}{r_1 r_0} = \frac{p_1(1-p_1)}{(1-\varphi)^2} - \frac{p_0(1-p_0)}{\varphi^2}, \quad (7.13)$$

which equals zero when

$$\frac{\varphi}{1-\varphi} = \sqrt{\frac{p_0(1-p_0)}{p_1(1-p_1)}}. \quad (7.14)$$

To see that this is a minimum and not a maximum, notice that the function in equation Equation 7.12 takes large values for φ near one when $p_1(1-p_1) > 0$ and for φ near zero when $p_0(1-p_0) > 0$. It also has a positive second derivative with respect to φ .

Solving for φ in Equation 7.14 shows that a proportion exposed of

$$\varphi^* = \frac{1}{1 + \sqrt{\frac{p_1(1-p_1)}{p_0(1-p_0)}}}. \quad (7.15)$$

maximizes the expected value of the Pearson chi-squared statistic χ_P^2 for a given n (Walter 1977). The expression inside the square root is the variance of a Bernoulli(p_1) random variable divided by the variance of a Bernoulli(p_0) random variable. Figure 7.1 shows how φ^* depends on this variance ratio. When $p_1 \approx p_0$, the Bernoulli variance ratio is approximately one and $\varphi^* \approx 0.5$.

Listing 7.1 `optim-phi.R`

```
## Optimal proportion exposed in a cohort study

# plot of optimal phi as a function of the Bernoulli variance ratio
logvratio <- seq(-3, 3, by = 0.01)
phi <- function(v) 1 / (1 + sqrt(v))
plot(logvratio, phi(exp(logvratio)), type = "l", xaxt = "n", ylim = c(0, 1),
     xlab = "Bernoulli variance ratio (log scale)",
     ylab = expression(paste("Optimal proportion exposed or cases (", phi, "*)")))
axis(1, at = log(c(1 / c(16, 8, 4, 2), 1, c(2, 4, 8, 16))),
     labels = c("1/16", "1/8", "1/4", "1/2", 1, 2, 4, 8, 16))
grid()
abline(h = 0.5, col = "darkgray")
```




Figure 7.1: The optimal proportion exposed φ^* in a cohort study as a function of the Bernoulli variance ratio $p_1(1 - p_1)/(p_0(1 - p_0))$. In a case-control study, φ^* represents the optimal proportion of the sample who are cases and the Bernoulli variance ratio is $\pi_1(1 - \pi_1)/(\pi_0(1 - \pi_0))$. There is a dark gray horizontal line at $\varphi = 0.5$, which represents a balanced study.

The “optimal” proportion exposed φ^* from Equation 7.15 is based on maximizing the value of χ_P^2 in large samples. For a given sample size, the power of the test is actually determined by the distribution of possible values of χ_P^2 , so the maximum power can occur at a value of φ slightly different from φ^* . Figure 7.2 shows the power achieved by Pearson’s chi-squared test at several combinations of p_1 , p_0 , and n . In all cases, the power at $\varphi = 0.5$ is close to that at φ^* . In several cases, the power at $\varphi = 0.5$ exceeds that at φ^* . If we have strong enough

prior information about p_1 and p_0 to justify an imbalanced study design, the value of testing the null hypothesis that $p_1 = p_0$ is questionable. Without such prior information, a balanced study is a safe bet to be optimal or near-optimal in terms of the power to detect an association between exposure and disease (Walter 1977).

7.4 R

7.5 Case-control studies

The Pearson chi-squared statistic χ_P^2 from Equation 7.7 can also be rewritten in terms of the prevalence of exposure among **cases** (participants who have disease or disease onset) and **controls** (participants who do not have disease or disease onset). This leads to the **case-control** study design.

7.5.1 Selection by disease

As above, let π_1 be the exposure prevalence in cases and π_0 be the exposure prevalence in controls. Their maximum likelihood estimates are $\hat{\pi}_1 = a/k_1$ and $\hat{\pi}_0 = c/k_0$, so the maximum likelihood estimate of $\pi_1 - \pi_0$ is

$$\hat{\pi}_1 - \hat{\pi}_0 = \frac{a}{a+c} - \frac{b}{b+d} = \frac{ad-bc}{(a+c)(b+d)} = \frac{ad-bc}{k_1 k_0}. \quad (7.16)$$

Section 7.2.1 showed that null hypothesis that exposure and disease are independent is equivalent to $H_0 : \pi_1 = \pi_0 = \pi$ where π is the marginal prevalence of exposure.

In large samples under the null, \mathcal{A} has a binomial(k_1, π) conditional distribution, \mathcal{B} has a binomial(k_0, π) conditional distribution, and they are conditionally independent given the column sums k_1 and k_0 . Thus, the large-sample variance of $\hat{\pi}_1 - \hat{\pi}_0$ under the null is

$$\text{Var}_0(\hat{\pi}_1 - \hat{\pi}_0) = \pi(1-\pi) \left(\frac{1}{k_1} + \frac{1}{k_0} \right) = \pi(1-\pi) \frac{n}{k_1 k_0} \quad (7.17)$$

where we used $k_1 + k_0 = n$. Replacing the unknown π with its maximum likelihood estimate $\hat{\pi} = r_1/n$, we get the estimated null variance

$$\hat{\text{Var}}_0(\hat{\pi}_1 - \hat{\pi}_0) = \hat{\pi}(1-\hat{\pi}) \frac{n}{k_1 k_0} = \frac{r_1 r_0}{k_1 k_0 n} \quad (7.18)$$

where we used $1 - \hat{\pi} = r_0/n$. Combining the results in Equation 7.16} and Equation 7.18, we get

$$\frac{(\hat{\pi}_1 - \hat{\pi}_0)^2}{\hat{\text{Var}}_0(\hat{\pi}_1 - \hat{\pi}_0)} = \frac{n(ad-bc)^2}{r_1 r_0 k_1 k_0} = \chi_P^2$$




Figure 7.2: The power of the Pearson chi-squared test from a cohort study as a function of the proportion of the sample exposed (φ) at several combinations of p_1 and p_0 for $n = 400$ (solid), $n = 200$ (dashed), and $n = 100$ (dotted). There is a dark gray solid line at $\varphi = 0.5$, representing a balanced study, and a dark gray dashed line at φ^* from Equation 7.15. The same power is achieved by a case control study where π_1 replaces p_1 , π_0 replaces p_0 , and φ is the proportion of the sample who are cases.

(see Equation 7.7). The LLN guarantees that $\hat{\pi}_1 \rightarrow \pi_1$ as $k_1 \rightarrow \infty$ and that $\hat{\pi}_0 \rightarrow \pi_0$ as $k_0 \rightarrow \infty$. In large samples,

$$\chi_P^2 \approx \frac{(\pi_1 - \pi_0)^2}{\pi(1 - \pi) \left(\frac{1}{k_1} + \frac{1}{k_0} \right)} \quad (7.19)$$

because the sample average

$$\frac{k_1 \pi_1 + k_0 \pi_0}{n} \rightarrow \pi$$

as $n \rightarrow \infty$ by the LLN. The numerator of Equation 7.19 is fixed, but the denominator depends on k_1 and k_0 . By sampling according to disease status, we can choose k_1 and k_0 to increase the power of the Pearson chi-squared test for a fixed total number of participants.

7.5.2 Score test for independence in a case-control study*

As with sampling by exposure in a cohort study, sampling by disease in a case-control study does not affect the score test of the null hypothesis that exposure and disease are independent. Using a $\text{binomial}(k_1, \pi_1)$ distribution for the number of exposed cases and a $\text{binomial}(k_0, \pi_0)$ distribution for the number of exposed controls, we get the log likelihood

$$\ell(\pi_1, \pi_0) = \mathcal{A} \ln \pi_1 + \mathcal{C} \ln(1 - \pi_1) + \mathcal{B} \ln \pi_0 + \mathcal{D} \ln(1 - \pi_0)$$

as a random variable whose value will be determined by the data. Calculating the score $U(\pi, \pi)$ and the expected information $\mathcal{J}(\pi, \pi)$ under the null hypothesis $H_0 : \pi_1 = \pi_0 = \pi$ and evaluating them at $\hat{\pi} = r_1/n$, we get

$$U(\hat{\pi}, \hat{\pi}) = \begin{pmatrix} \frac{a}{\hat{\pi}} + \frac{c}{1-\hat{\pi}} \\ \frac{b}{\hat{\pi}} + \frac{d}{1-\hat{\pi}} \end{pmatrix} = \begin{pmatrix} \frac{n(ad-bc)}{r_1 r_0} \\ -\frac{n(ad-bc)}{r_1 r_0} \end{pmatrix}$$

and

$$\mathcal{J}(\hat{\pi}, \hat{\pi}) = \begin{bmatrix} \frac{k_1 n^2}{r_1 r_0} & 0 \\ 0 & \frac{k_0 n^2}{r_1 r_0} \end{bmatrix} \Rightarrow \mathcal{J}^{-1}(\hat{\pi}, \hat{\pi}) = \begin{bmatrix} \frac{r_1 r_0}{k_1 n^2} & 0 \\ 0 & \frac{r_1 r_0}{k_0 n^2} \end{bmatrix}$$

The score statistic is

$$U(\hat{\pi}, \hat{\pi})^\top \mathcal{J}(\hat{\pi}, \hat{\pi})^{-1} U(\hat{\pi}, \hat{\pi}) = \frac{n(ad-bc)^2}{r_1 r_0 k_1 k_0} = \chi_P^2,$$

which is the Pearson chi-squared statistic from Equation 7.7. The null hypothesis reduces the degrees of freedom from two (π_1 and π_0) to one ($\pi_1 = \pi_0 = \pi$), so the score statistic has a χ_1^2 distribution under H_0 . Therefore, Pearson's chi-squared test is the score test of the null hypothesis $H_0 : \pi_0 = \pi_1$ in a case-control study. The column sums k_1 and k_0 are fixed by design, and we condition on the row sums r_1 and r_0 because we use the maximum likelihood estimate $\hat{\pi} = r_1/n$ for the prevalence of exposure under H_0 . Because of the invariance of the score test when it uses the expected information, any parameterization of the model for the exposure prevalences π_1 and π_0 leads to the same test of the null hypothesis that exposure and disease are independent.

7.5.3 Optimal sampling by disease

Having established that χ^2_P is the score statistic for testing the independence of exposure and disease in a case-control study, we can choose k_1 and k_0 to maximize the power of the test for a given number of participants $n = k_1 + k_0$. Let φ be the proportion of the sample who are cases. Then

$$\begin{aligned}k_1 &= \varphi n \\k_0 &= (1 - \varphi)n \\ \pi &= \varphi\pi_1 + (1 - \varphi)\pi_0.\end{aligned}$$

Substituting these into equation Equation 7.17 and simplifying gives us the denominator as a function of φ :

$$\frac{n\pi(1 - \pi)}{k_1 k_0} = \frac{\varphi}{1 - \varphi}\pi_1(1 - \pi_1) + \frac{1 - \varphi}{\varphi}\pi_0(1 - \pi_0) + C(\pi_1, \pi_0)$$

where $C(\pi_1, \pi_0) = \pi_1(1 - \pi_0) + \pi_0(1 - \pi_1)$ does not depend on φ . This is identical to The derivative with respect to φ is

$$\frac{d}{d\varphi} \frac{n\pi(1 - \pi)}{r_1 r_0} = \frac{\pi_1(1 - \pi_1)}{(1 - \varphi)^2} - \frac{\pi_0(1 - \pi_0)}{\varphi^2}.$$

This is identical to Equation 7.13 if we replace p_1 with π_1 and p_0 with π_0 , so the same argument used in Section 7.3.3 tells us that the Pearson chi-squared statistic χ^2_P from a case-control study is maximized when the proportion of the sample comprised of cases is

$$\varphi^* = \frac{1}{1 + \sqrt{\frac{\pi_1(1 - \pi_1)}{\pi_0(1 - \pi_0)}}}. \quad (7.20)$$

Here, the expression inside the square root is the variance of a Bernoulli(π_1) random variable divided by the variance of a Bernoulli(π_0) random variable. Figure 7.1 shows how ϕ^* depends on this variance ratio. When $\pi_1 \approx \pi_0$, the Bernoulli variance ratio is approximately one $\phi^* \approx 0.5$.

The power functions shown in Figure 7.2 apply to a case-control study if we replace p_1 with π_1 and p_0 with π_0 . The justification for recruiting equal numbers of cases and controls in a case-control study is exactly the same as that for recruiting equal numbers of exposed and unexposed in a cohort study: When testing the null hypothesis can be justified, a balanced study is almost always optimal or near-optimal in terms of its power to detect an association between exposure and disease (Walter 1977).

7.6 Choice of study design

We have shown that the power of the Pearson and hypergeometric chi-squared tests can be increased by sampling participants according to exposure (in a cohort study) or disease (in a

case-control study) instead of taking a random sample from the population. It remains to see how to choose between a cohort study and a case-control study.

7.6.1 Odds ratio

To choose between the cohort and case-control study designs, it is extremely helpful that the estimated odds ratio is the same for all three study designs. In Table 7.2, the estimated odds ratio comparing the risks of disease in the exposed (numerator) and the unexposed (denominator) is

$$\frac{\text{odds}(\hat{p}_1)}{\text{odds}(\hat{p}_0)} = \frac{a/b}{c/d} = \frac{ad}{bc}$$

where r_1 canceled out of the numerator and r_0 canceled out of the denominator in the middle expression. The estimated odds ratio comparing the prevalence exposure in cases (numerator) and controls (denominator) is

$$\frac{\text{odds}(\hat{\pi}_1)}{\text{odds}(\hat{\pi}_0)} = \frac{a/b}{c/d} = \frac{ad}{bc}$$

where k_1 canceled out of the numerator and k_0 canceled out of the denominator in the middle expression. The Pearson chi-squared statistic can be rewritten in terms of the odds ratio:

$$\chi_P^2 = \frac{n(\frac{ad}{bc} - 1)^2 b^2 c^2}{r_1 r_0 k_1 k_0} = \frac{n(\hat{\text{OR}} - 1)^2 b^2 c^2}{r_1 r_0 k_1 k_0}.$$

Let

$$\Delta_n = n(\hat{\text{OR}} - 1),$$

which does not depend on which study design we use.

A random sample from the population has

$$\chi_P^2 = \Delta_n \hat{p}_0 (1 - \hat{p}_1) \hat{\pi}_0 (1 - \hat{\pi}_1).$$

because $b = r_1(1 - \hat{p}_1) = k_0 \hat{\pi}_0$ and $c = r_0 \hat{p}_0 = k_1(1 - \hat{\pi}_1)$. Close to the null hypothesis, $\hat{p}_1 \approx \hat{p}_0 \approx \hat{p}$ and $\hat{\pi}_0 \approx \hat{\pi}_1 \approx \hat{\pi}$. In large samples close to the null hypothesis,

$$\chi_P^2 \approx \Delta_n p(1 - p)\pi(1 - \pi).$$

because $\hat{p} \rightarrow p$ and $\hat{\pi} \rightarrow \pi$ as $n \rightarrow \infty$ by the LLN. A balanced cohort study has $r_0 = r_1 = n/2$ and

$$\chi_P^2 = \frac{\Delta_n (1 - \hat{p}_1)^2 \hat{p}_0^2}{4\hat{p}(1 - \hat{p})}.$$

because $bc = n^2(1 - \hat{p}_1)\hat{p}_0/4$ and $k_1 k_0 = n^2\hat{p}(1 - \hat{p})$. In a large sample close to (but not under) the null hypothesis,

$$\chi_P^2 \approx \frac{\Delta_n p^2(1 - p)^2}{4p(1 - p)} = \frac{\Delta_n}{4} p(1 - p).$$

Following similar logic for a case-control study, we get

$$\chi_P^2 \approx \frac{\Delta_n}{4} \pi(1 - \pi)$$

in large samples near the null hypothesis. Because $v(1-v) \leq 1/4$ for $v \in [0, 1]$, the χ_P^2 statistics from the cohort and case-control studies are both upper bounds for the χ_P^2 statistic from a random sample of the population.

Close to the null, a cohort study will be more powerful than a case-control study when

$$p(1 - p) > \pi(1 - \pi)$$

and a case-control study will be more powerful than a cohort study when

$$p(1 - p) < \pi(1 - \pi).$$

The advantage of a cohort study will be greatest for a rare exposure and a risk of disease close to 1/2, and the advantage of a case-control study will be greatest for rare disease and a prevalence of exposure close to 1/2. Both study designs are always more powerful than a random sample from the population.

7.6.2 Imbalance and efficiency on a fixed budget

Even when testing the null hypothesis is defensible, an imbalanced study design can be justified when one exposure or disease group is substantially more difficult or expensive to recruit than the other. In a cohort study with a rare exposure, exposed individuals might be harder to recruit than unexposed individuals. In a case-control study with a rare disease, cases might be harder to recruit than controls. Even when the greatest power for a given number of participants is achieved with a balanced study, the greatest power for a given study's resources may occur with imbalanced groups.

Deliberately imbalanced designs are used most often in case-control studies, but the principle is the same in cohort studies. Let C be the ratio of the cost of recruiting a case to that of recruiting a control, and B be the budget of the study (expressed as the total number of controls that could be enrolled if no cases were enrolled). As in Table 7.2, k_1 is the number of cases and k_0 is the number of controls. We need to minimize the variance of $\hat{\pi}_1 - \hat{\pi}_0$ from Equation 7.17 given that

$$k_1 C + k_0 = B.$$

For simplicity, we will assume that the prevalences of exposure π_1 (in cases) and π_0 (in controls) are approximately equal, so we can ignore the fact that $\hat{\pi}$ depends on $\varphi = k_1/n$.⁵ To maximize

⁵Without this assumption, it is difficult or impossible to derive an explicit expression for the optimal ratio φ^* because the total sample size n depends on φ , which complicates the derivatives. An optimal ratio can be calculated numerically.

the value of χ_P^2 close to (but not under) the null, we need to minimize

$$\frac{1}{k_1} + \frac{1}{k_0} = \frac{1}{k_1} + \frac{1}{B - k_1 C}$$

over k_1 . The derivative with respect to k_1 is

$$\frac{d}{dk_1} \left(\frac{1}{k_1} + \frac{1}{B - k_1 C} \right) = -\frac{1}{k_1^2} + \frac{C}{(B - k_1 C)^2},$$

which equals zero when

$$k_0^2 = k_1^2 C.$$

This corresponds to $k_0 = k_1 \sqrt{C}$ or recruiting \sqrt{C} controls per case (O. S. Miettinen 1969; Nam 1973; Gail et al. 1976). The optimal proportion of the sample who are cases is

$$\varphi_C^* = \frac{1}{1 + \sqrt{C}}.$$

A nearly identical argument based on Equation 7.9 shows that this φ_C^* is also the optimal proportion exposed in a cohort study where the cost of recruiting an exposed individual is C times that of recruiting an unexposed individual. This \sqrt{C} rule is a good approximation to more accurate and complicated optimal sampling rules (Meydrecht and Kupper 1978; Pike and Casagrande 1979; Morgenstern and Winn 1983).

With a total sampling budget of B , the optimal numbers of cases is

$$k_1^* = \frac{B}{\sqrt{C} + C}$$

and the optimal number of controls is

$$k_0^* = k_1^* \sqrt{C} = \frac{B}{1 + \sqrt{C}}.$$

The minimum variance of the risk difference that we can achieve near the null is proportional to

$$V^* = \frac{1}{k_1^*} + \frac{1}{k_0^*} = \frac{(1 + \sqrt{C})^2}{B}.$$

If we use a balanced study design, $k_1 = k_0 = B/(1 + C)$ and the variance of the risk difference is proportional to

$$V^{\text{bal}} = \frac{2}{k_1} = \frac{2(1 + C)}{B}.$$

For any given budget B , the asymptotic relative efficiency of the optimal study compared to a balanced study is

$$\frac{V^{\text{bal}}}{V^*} = \frac{2(1 + C)}{(1 + \sqrt{C})^2}.$$

It is plotted as a function of C in Figure 7.3. The difference is small for moderate values of C , with relative efficiencies of approximately 1.029 for $C = 2$ and 1.146 for $C = 5$. In extreme scenarios (i.e., as $C \rightarrow 0$ or $C \rightarrow \infty$), the optimal study is twice as efficient as a balanced study with the same budget (Nam 1973).




Figure 7.3: The asymptotic relative efficiency of an optimal case-control study compared to a balanced study with the same budget when recruiting a case costs C times as much as recruiting a control. There is a dark gray line at a relative efficiency of one. The same relative efficiency applies to cohort studies when recruiting an exposed individual costs C times as much as recruiting an unexposed individual.

The relative efficiency can thought of as the ratio of the sampling budgets of a balanced study

and an optimal study that achieve the same power (Nam 1973; Gail et al. 1976). Thus, a balanced study requires at most twice the budget of an optimal study to achieve the same power. Brittain, Schlesselman, and Stadel (1981) found that sampling costs were approximately 33-66% of total costs in five case-control studies funded by the National Institute of Child Health and Human Development in the 1970s. Compared to a balanced study design, they found that optimal sampling of cases and controls would reduce total study costs by at most 8.5% for $C \leq 5$ and at most 4.5% for $C \leq 3$. As usual, balanced study designs are close to optimal.

Listing 7.2 chisq-power.R

```
## Actual power of a Pearson chi-squared test

# calculate Pearson chi-squared test power
# This can take a few minutes to run with large n.
powers <- function(p1, p0, n, level = 0.95) {
  chisq_alpha <- qchisq(level, df = 1)
  htest <- function(r1) {
    r0 <- n - r1
    joint_dbinom <- outer(0:r1, 0:r0,
                          function(a, c) dbinom(a, r1, p1) * dbinom(c, r0, p0))
    joint_include <- outer(0:r1, 0:r0,
                           function(a, c) max(a, c) > 0 & a + c < n)
    acpower <- Vectorize(function(a, c) {
      if (max(a, c) > 0 & a + c < n) {
        b <- r1 - a
        d <- r0 - c
        k1 <- a + c
        k0 <- b + d
        chisqP <- n * (a * d - b * c)^2 / (r1 * r0 * k1 * k0)
        return(chisqP > chisq_alpha)
      } else {
        return(0)
      }
    })
    joint_power <- outer(0:r1, 0:r0, acpower)
    return(sum(joint_dbinom * joint_power) / sum(joint_dbinom * joint_include))
  }
  r1s <- 1:(n - 1)
  powers <- sapply(r1s, htest)
  return(data.frame(r1 = r1s, power = powers, n = n))
}

# optimal value proportion exposed (or proportion cases)
optimphi <- function(p1, p0) 1 / (1 + sqrt(p1 * (1 - p1) / (p0 * (1 - p0))))

# Pearson chi-squared test power for p1 = 0.1 and p0 = 0.02
power_10_02_400 <- powers(0.10, 0.02, 400)
power_10_02_200 <- powers(0.10, 0.02, 200)
power_10_02_100 <- powers(0.10, 0.02, 100)

# Pearson chi-squared test power for p1 = 0.10 and p0 = 0.05
power_10_05_400 <- powers(0.10, 0.05, 400)
power_10_05_200 <- powers(0.10, 0.05, 200)
power_10_05_100 <- powers(0.10, 0.05, 100)

# Pearson chi-squared test power for p1 = 0.2 and p0 = 0.02
power_20_02_400 <- powers(0.20, 0.02, 400)
power_20_02_200 <- powers(0.20, 0.02, 200)
power_20_02_100 <- powers(0.20, 0.02, 100)

# Pearson chi-squared test power for p1 = 0.2 and p0 = 0.05
```

Listing 7.3 optimal-budget.R

```
## Relative efficiency of imbalanced study design on fixed budget

# variance ratio comparing balanced study to budget-optimal study
logC <- seq(-3, 3, by = 0.01)
releff <- function(C) 2 * (1 + C) / (1 + sqrt(C))^2
plot(logC, releff(exp(logC)), type = "l", ylim = c(0, 2), xaxt = "n",
     xlab = expression(paste("Cost ratio ", italic("C"), " (log scale)")),
     ylab = "Asymptotic relative efficiency of budget-optimal study")
axis(1, at = log(c(1 / c(20, 10, 5, 2), 1, c(2, 5, 10, 20))),
     labels = c("1/20", "1/10", "1/5", "1/2", 1, 2, 5, 10, 20))
grid()
abline(h = 1, col = "darkgray")
```

8 Internal and External Validity

Validity will be evaluated in terms of two major criteria. First, and as a basic minimum, is what can be called *internal validity*: did in fact the experimental stimulus make some significant difference in this specific instance? The second criterion is that of *external validity*, *representativeness*, or *generalizability*: to what populations, settings, and variables can this effect be generalized? Both criteria are obviously important although it turns out that they are to some extent incompatible, in that the controls required for internal validity often tend to jeopardize representativeness. (Campbell 1957)

In statistics, we make inferences about a population based on a sample. A study is said to have **internal validity** if it makes accurate measurements or inferences within the sample itself, and it is said to have **external validity** if these inferences accurately describe the population up to random sampling error (Campbell 1957). Both internal and external validity are best thought of as continuous, not binary. High internal validity is a prerequisite for high external validity, but there is often a tradeoff between them in practice. For simplicity, we focus on internal and external validity for descriptive epidemiology (i.e., for association and not necessarily causation).

So far, our discussion of 2x2 tables has assumed that the classification of exposure and disease is completely accurate and that the participants are a random sample from the population. Table 8.1 shows our 2x2 table based on true exposure and disease classifications. In reality, **misclassification** and **selection bias** threaten the validity of almost all epidemiologic studies. It is critical to understand where they come from and what they do.

Table 8.1: 2x2 table of true disease and exposure

	$D = 1$	$D = 0$	Total
$X = 1$	a	b	r_1
$X = 0$	c	d	r_0
Total	k_1	k_0	n

8.1 Misclassification

Misclassification of exposure and disease threatens both the internal and external validity of an epidemiologic study. In a cohort study, we compare the exposed and unexposed groups and we have to classify disease outcomes in each group. In a case-control study, we compare cases and controls and we have to classify exposure in each group.

Nondifferential misclassification occurs when the same classification errors affect both populations being compared. Under nondifferential misclassification, a test of the null hypothesis is still has the correct significance level but the power of the test is reduced—much like a reduction in the effective sample size (Bross 1954; T. Rubin, Rosenbaum, and Cobb 1956). Nondifferential classification almost always causes bias toward the null, making the expected value of a given measure of association closer to the null than its true value. However, a measure of association under nondifferential misclassification can be farther away from the null than its true value due to random variation (Gullen, Bearman, and Johnson 1968; Sorahan and Gilthorpe 1994; Wacholder et al. 1995; Yland et al. 2022).

Differential misclassification occurs when classification errors differ between the two populations being compared. Differential misclassification can distort both the significance level and power of a hypothesis test, and it can cause bias toward the null, away from the null, or across the null. The unpredictability of the size and direction of the bias makes differential misclassification fundamentally more dangerous than nondifferential misclassification.

8.1.1 Nondifferential misclassification of disease

In our discussion of diagnostic tests, we let D^+ indicate $D = 1$, D^- indicate $D = 0$, T^+ indicate testing positive for disease, and T^- indicate testing negative. Let D^{obs} be the measured disease outcome of individuals in a cohort study where disease is detected using a diagnostic test with sensitivity

$$\text{sens}_D = \Pr(T^+ | D^+) = \Pr(D^{\text{obs}} = 1 | D = 1)$$

and specificity

$$\text{spec}_D = \Pr(T^- | D^-) = \Pr(D^{\text{obs}} = 0 | D = 0).$$

We assume that

$$\text{sens}_D = \Pr(T^+ | D^+) > \Pr(T^+ | D^-) = 1 - \text{spec}_D,$$

so individuals with disease are more likely to test positive than individuals without disease.¹ This is equivalent to assuming that $\text{sens}_D + \text{spec}_D > 1$. We also assume that the misclassification of each participant is independent of the misclassification of all other participants.

¹These tests are in the top left half of a receiver operating characteristic (ROC) plot from Section 2.5.1, which has $1 - \text{spec}_D$ is the horizontal axis and sens_D is the vertical axis. A test with $\text{sens}_D = 1 - \text{spec}_D$ (on the diagonal of the ROC plot) is a useless test. A test with $\text{sens}_D < 1 - \text{spec}_D$ (in the bottom right half of an ROC plot) is worse than useless, but it can be redeemed by swapping the definitions of T^+ and T^- .

Table 8.2: 2x2 table with misclassified disease status

	$D^{\text{obs}} = 1$	$D^{\text{obs}} = 0$	Total
$X = 1$	a^{obs}	b^{obs}	r_1
$X = 0$	c^{obs}	d^{obs}	r_0
Total	k_1^{obs}	k_0^{obs}	n

Table 8.2 shows a 2x2 table with misclassification of disease. The row sums r_1 and r_0 are the same as in Table 8.1 because there is no misclassification of exposure.

Misclassification of disease is **nondifferential** when the sensitivity and specificity of the test are the same in all exposure groups. In other words, we have nondifferential misclassification of disease if and only if

$$\Pr(T^+ | D^+, X = x) = \Pr(T^+ | D^+) = \text{sens}_D$$

and

$$\Pr(T^- | D^-, X = x) = \Pr(T^- | D^-) = \text{spec}_D$$

for all possible values x of exposure X . It is critical that nondifferential misclassification is defined in terms of the sensitivity and specificity of the test, not its positive predictive value (PPV) or negative predictive value (NPV). When there is an association between exposure and disease, nondifferential misclassification of disease may produce different PPVs and NPVs in the exposed and unexposed because these predictive values depend on the prevalence of disease in addition to the sensitivity and specificity of the test (D. J. Newell 1962; Buell and Dunn Jr 1964).

Under nondifferential misclassification, the probability that an exposed person tests positive for disease is

$$\begin{aligned} p_1^{\text{obs}} &= p_1 \text{sens}_D + (1 - p_1)(1 - \text{spec}_D) \\ &= (1 - \text{spec}_D) + (\text{sens}_D + \text{spec}_D - 1)p_1 \end{aligned}$$

where p_1 is the true risk of disease in the exposed. Similarly, the probability that an unexposed person tests positive for disease is

$$p_0^{\text{obs}} = (1 - \text{spec}_D) + (\text{sens}_D + \text{spec}_D - 1)p_0$$

where p_0 is the true risk of disease in the unexposed. The misclassified risk difference is

$$\text{RD}^{\text{obs}} = p_1^{\text{obs}} - p_0^{\text{obs}} = (\text{sens}_D + \text{spec}_D - 1)(p_1 - p_0). \quad (8.1)$$

Given the margins of Table 8.2, the number \mathcal{A}^{obs} of exposed individuals who test positive for disease has a hypergeometric distribution with mean $r_1 p_1^{\text{obs}}$ and the number \mathcal{C}^{obs} of unexposed

people who test positive for disease has a hypergeometric distribution with mean $r_0 p_0^{\text{obs}}$. The estimated risk difference based on the misclassified data is

$$\hat{\text{RD}}^{\text{obs}} = \hat{p}_1^{\text{obs}} - \hat{p}_0^{\text{obs}},$$

where $\hat{p}_1^{\text{obs}} = a^{\text{obs}}/r_1$ and $\hat{p}_0^{\text{obs}} = c^{\text{obs}}/r_0$. It is an unbiased estimate of RD^{obs} .

When $\text{sens}_D < 1$ or $\text{spec}_D < 1$, the misclassified risk difference RD^{obs} in Equation 8.1 is closer to zero than the true risk difference (Bross 1954; T. Rubin, Rosenbaum, and Cobb 1956; D. Newell 1963). The risk ratio and odds ratio are also biased toward the null under nondifferential misclassification (Goldberg 1975; Copeland et al. 1977). This bias operates on average, not for every single estimate based on misclassified data. Even under nondifferential misclassification of disease, random variation can produce an estimate of the risk difference, risk ratio, or odds ratio that is farther from the null than the true value (Gullen, Bearman, and Johnson 1968; Sorahan and Gilthorpe 1994; Wacholder et al. 1995; Yland et al. 2022).

When $\text{sens}_D + \text{spec}_D > 1$ (as is true of any useful diagnostic or screening test), Equation 8.1 implies that the null hypothesis that $p_1^{\text{obs}} = p_0^{\text{obs}}$ is equivalent to the null hypothesis that $p_1 = p_0$. Both null hypotheses are equivalent to the null hypothesis that exposure and disease are independent (see Section 7.2.1). Therefore, a test of the null hypothesis that X and D^{obs} are independent is also a valid test of the independence of X and D (Bross 1954; T. Rubin, Rosenbaum, and Cobb 1956). The Pearson chi-squared statistic for Table 8.2 is

$$\chi_{\text{Pobs}}^2 = \frac{n(a^{\text{obs}}d^{\text{obs}} - b^{\text{obs}}c^{\text{obs}})^2}{r_1 r_0 k_1^{\text{obs}} k_0^{\text{obs}}}, \quad (8.2)$$

and it has a χ_1^2 distribution under the null hypothesis that $p_1 = p_0$. If we set the critical value at the $1 - \alpha$ quantile of the χ_1^2 distribution, the test will reject the null with probability α when $p_1 = p_0$ even under nondifferential misclassification of disease. A similar result holds for the hypergeometric chi-squared test, Fisher's exact test, and other tests of independence for 2x2 tables from Section 7.2.

Although nondifferential misclassification does not affect the significance level of a hypothesis test of the null hypothesis that $p_1 = p_0$, it reduces the power of the test away from the null (Bross 1954; T. Rubin, Rosenbaum, and Cobb 1956; Rogot 1961). The Pearson chi-squared statistic based on the misclassified data in Table 8.2 can be rewritten

$$\chi_{\text{Pobs}}^2 = \frac{(\hat{p}_1^{\text{obs}} - \hat{p}_0^{\text{obs}})^2}{\hat{p}^{\text{obs}}(1 - \hat{p}^{\text{obs}})\left(\frac{1}{r_1} + \frac{1}{r_0}\right)}.$$

where $\hat{p}^{\text{obs}} = k_1^{\text{obs}}/n$ is the misclassified estimate of the marginal risk of disease among the study participants. Let $\varphi \in (0, 1)$ be the proportion of the sample that is exposed, which we assume to be (approximately) constant as $n \rightarrow \infty$. Let

$$K_D = \text{sens}_D + \text{spec}_D - 1,$$

so $K_D \in (0, 1)$ whenever we have a useful but imperfect test for disease. When both $r_1 = \varphi n$ and $r_0 = (1 - \varphi)n$ are large, the numerator on the right-hand side of Equation 8.2 is approximately

$$\mathbb{E}(\hat{p}_1^{\text{obs}} - \hat{p}_0^{\text{obs}})^2 = K_D^2(p_1 - p_0)^2$$

by the law of large numbers (LLN) and the *continuous mapping theorem*.² Similarly, \hat{p}^{obs} is approximately

$$\begin{aligned} p^{\text{obs}} &= p \text{sens}_D + (1 - p)(1 - \text{spec}_D) \\ &= (1 - \text{spec}_D) + K_D p, \end{aligned}$$

where

$$p = \varphi p_1 + (1 - \varphi)p_0$$

is the marginal risk of disease among the study participants. Thus,

$$\hat{p}^{\text{obs}}(1 - \hat{p}^{\text{obs}}) \approx (1 - \text{spec}_D + K_D p)(1 - \text{sens}_D + K_D(1 - p)).$$

in large samples. It follows that

$$\chi_{\text{Pobs}}^2 \approx \frac{K_D^2 p(1 - p)}{(1 - \text{spec}_D + K_D p)(1 - \text{sens}_D + K_D(1 - p))} \chi_{\text{P}}^2$$

where χ_{P}^2 is the Pearson chi-squared statistic based on the correctly classified data in Table 8.1. Therefore, nondifferential misclassification of disease has approximately the same effect as multiplying the sample size n by the effective sample size ratio

$$\text{ESSR}_D = \frac{K_D^2 p(1 - p)}{(1 - \text{spec}_D + K_D p)(1 - \text{sens}_D + K_D(1 - p))} \leq 1$$

with equality if and only if $\text{sens}_D = \text{spec}_D = 1$. Thinking about nondifferential misclassification as a reduction in the effective sample size is a good way to remember both that it preserves the correct significance level under the null and that it reduces power away from the null (Bross 1954; T. Rubin, Rosenbaum, and Cobb 1956).

When the prevalence or risk of disease is low, the effective sample size depends much more on the specificity of the test than on the sensitivity of the test (T. Rubin, Rosenbaum, and Cobb 1956). Figure 8.1 shows the effective sample size ratio ESSR_D for three values of the marginal risk of disease in the sample (p) under two different scenarios: one where $\text{spec}_D = 1$ while sensitivity varies from zero to one and one where $\text{sens}_D = 1$ while specificity varies from zero to one. For all three values of p , ESSR_D is substantially lower in the scenario with varying specificity. This difference is greatest for $p = 0.02$ and smallest for $p = 0.40$. If $p = 0.5$, the two scenarios produce identical curves. If $p > 0.5$, then ESSR_D depends more on the sensitivity than the specificity of the test for disease.

²The *continuous mapping theorem* says that if a statistic $\hat{\theta}_n \rightarrow \theta$ in probability and f is a continuous function in a neighborhood of θ , then $f(\hat{\theta}_n) \rightarrow f(\theta)$ in probability. Convergence in probability can be replaced with convergence in distribution or convergence almost surely (Chung 2000). Here, the statistic is $\hat{p}_1 - \hat{p}_0$, which converges to $p_1 - p_0$, and the function is $f(v) = v^2$.




Figure 8.1: The effective sample size ratio $ESSR_D$ as a function of $sens_D$ when $spec_D = 1$ (gray lines) and as a function of $spec_D$ when $sens_D = 1$ (black lines).

8.1.2 Nondifferential misclassification of exposure

Nondifferential misclassification of exposure has effects similar to those of nondifferential misclassification of disease. Although we usually discuss sensitivity and specificity in the context of a test for disease, the same ideas can be applied to a test or measurement used to determine exposure status. For simplicity, we will focus on a binary exposure X with X^+ indicating $X = 1$ and X^- indicating $X = 0$.

Table 8.3: 2x2 table with misclassified exposure

	$D = 1$	$D = 0$	Total
$X^{\text{obs}} = 1$	a^{obs}	b^{obs}	r_1^{obs}
$X^{\text{obs}} = 0$	c^{obs}	d^{obs}	r_0^{obs}
Total	k_1	k_0	n

Let X^{obs} be the measured disease outcome of individuals in a case-control study when we classify exposure using a test T_X that has sensitivity

$$\text{sens}_X = \Pr(T_X^+ | X^+) = \Pr(X^{\text{obs}} = 1 | X = 1)$$

and specificity

$$\text{spec}_X = \Pr(T_X^- | X^-) = \Pr(X^{\text{obs}} = 0 | X = 0).$$

We assume that $\text{sens}_X > 1 - \text{spec}_X$, so exposed individuals are more likely to test positive for exposure than unexposed individuals. This is equivalent to assuming $\text{sens}_X + \text{spec}_X > 1$.³ We also assume that the misclassification of each participant is independent of the misclassification of all other participants. Table 8.3 shows a 2x2 table with exposure misclassification. The column sums k_1 and k_0 are the same in both tables because there is no misclassification of disease status.

The misclassification of exposure is nondifferential when the sensitivity and specificity of the exposure test are the same in cases and controls. In other words, we need

$$\Pr(T_X^+ | X^+, D = d) = \Pr(T_X^+ | X^+)$$

and

$$\Pr(T_X^- | X^-, D = d) = \Pr(T_X^- | X^-)$$

for all possible values d of disease status D . As with disease, it is critical that nondifferential misclassification of exposure is defined through the sensitivity and specificity of the test for exposure. When there is an association between exposure and disease, nondifferential misclassification can produce a PPV and NPV that differ between cases and controls because these predictive values depend on the prevalence of exposure in addition to the sensitivity and specificity of the test (D. J. Newell 1962; Buell and Dunn Jr 1964).

Under nondifferential misclassification, the probability that a case tests positive for exposure is

$$\pi_1^{\text{obs}} = (1 - \text{spec}_X) + (\text{sens}_X + \text{spec}_X - 1)\pi_1$$

³As with a test for disease, a test for exposure with $\text{sens}_X + \text{spec}_X = 1$ would be a useless test (on the diagonal of an ROC curve) and a test with $\text{sens}_X + \text{spec}_X < 1$ would need to have the definitions of T_X^+ and T_X^- reversed.

where π_1 is the true prevalence of exposure among cases. Similarly, the probability that a control tests positive for exposure is

$$\pi_0^{\text{obs}} = (1 - \text{spec}_X) + (\text{sens}_X + \text{spec}_X - 1)p_0$$

where π_0 is the true prevalence of exposure in controls. The misclassified difference in exposure prevalences is

$$\pi_1^{\text{obs}} - \pi_0^{\text{obs}} = (\text{sens}_X + \text{spec}_X - 1)(\pi_1 - \pi_0).$$

When $\text{sens}_X + \text{spec}_X > 1$ (as is true of any useful test for exposure), the null hypothesis that $\pi_1^{\text{obs}} = \pi_0^{\text{obs}}$ is equivalent to the null hypothesis that $\pi_1 = \pi_0$, which is equivalent to the null hypothesis that exposure and disease are independent (see Section 7.2.1). Therefore, any test of the independence of X^{obs} and D has the correct significance level under the null hypothesis that X and D are independent (Bross 1954).⁴

Like nondifferential misclassification of disease, nondifferential misclassification of exposure reduces the power of the hypothesis test that exposure and disease are independent (Bross 1954; T. Rubin, Rosenbaum, and Cobb 1956; Rogot 1961). The maximum likelihood estimates $\hat{\pi}_1^{\text{obs}} = a^{\text{obs}}/k_1$ and $\hat{\pi}_0^{\text{obs}} = b^{\text{obs}}/k_0$ are unbiased. The Pearson chi-squared statistic based on the misclassified data in Table~?? can be rewritten

$$\chi_{\text{Pobs}}^2 = \frac{(\hat{\pi}_1^{\text{obs}} - \hat{\pi}_0^{\text{obs}})^2}{\hat{\pi}^{\text{obs}}(1 - \hat{\pi}^{\text{obs}})\left(\frac{1}{k_1} + \frac{1}{k_0}\right)}. \quad (8.3)$$

where $\hat{\pi}^{\text{obs}} = k_1^{\text{obs}}/n$ is the misclassified estimate of the marginal prevalence of exposure among the study participants. Let φ_X be the proportion of the sample that consists of cases, and let $K_X = \text{sens}_X + \text{spec}_X - 1$, so $K_X \in (0, 1)$ whenever we have a useful but imperfect test for exposure. When both $k_1 = \varphi_X n$ and $k_0 = (1 - \varphi_X)n$ are large, the numerator on the right-hand side of Equation 8.3 is approximately

$$\mathbb{E}(\hat{\pi}_1^{\text{obs}} - \hat{\pi}_0^{\text{obs}})^2 = K_X^2(\pi_1 - \pi_0)^2,$$

and

$$\hat{\pi}^{\text{obs}} \approx \mathbb{E}(\hat{\pi}^{\text{obs}}) = (1 - \text{spec}_X) + K_X \pi$$

where

$$\pi = \varphi_X \pi_1 + (1 - \varphi_X) \pi_0$$

is the marginal prevalence of exposure among the study participants, In large samples,

$$\hat{\pi}^{\text{obs}}(1 - \hat{\pi}^{\text{obs}}) \approx (1 - \text{spec}_X + K_X \pi)(1 - \text{sens}_X + K_X(1 - \pi)).$$

⁴Case control studies typically use the odds ratio $\text{odds}(\pi_1)/\text{odds}(\pi_0)$, not the difference $\pi_1 - \pi_0$, to compare the exposure prevalences in cases and controls. The difference between the prevalences is being used here only to establish that a hypothesis test of the independence of X and D based on misclassified data has the correct significance level.

For hypothesis testing, nondifferential misclassification of exposure has approximately the same effect as multiplying the sample size n by the effective sample size ratio

$$\text{ESSR}_X = \frac{K_X^2 \pi(1 - \pi)}{(1 - \text{spec}_X + K_X \pi)(1 - \text{sens}_X + K_X(1 - \pi))} \leq 1$$

with equality if and only if $\text{sens}_X = \text{spec}_X = 1$. Just like nondifferential misclassification of disease, nondifferential misclassification of exposure acts like reduction in the effective sample size. It preserves the significance level under the null, but it reduces the power of the test away from the null. A similar reduction in power occurs when more complex exposures (such as dietary intakes) are measured with error, requiring larger sample sizes to achieve a given power (L. S. Freedman, Schatzkin, and Wax 1990).

The curves in Figure 8.1 are the same if we replace the marginal risk of disease p with the marginal prevalence of exposure π . The effective sample size ratio ESSR_X depends on the specificity more than the sensitivity when $\pi < 0.5$, and it depends on the sensitivity more than the specificity when $\pi > 0.5$. While diseases typically (and fortunately) have low risks, exposures can have both low and high prevalences.

When there are more than two levels of exposure, nondifferential misclassification does not always bias a measure of association toward the null for all exposure categories (Walker, Velema, and Robins 1988; Dosemeci, Wacholder, and Lubin 1990; Verkerk and Buitendijk 1992; Correa-Villaseñor et al. 1995). Misclassification causes the risks of disease in different exposure categories to get closer to each other on average. Without loss of generality, suppose that higher exposure is associated with a higher risk of disease. Misclassification of high-exposure individuals to lower-exposure categories can increase the apparent risk of disease in these categories, and misclassification of low-exposure individuals into higher-exposure categories can decrease the apparent risk of disease in these categories. The risk in the highest-exposure category can only go down on average due to misclassification, and the risk in the lowest-exposure category can only go up on average. In both cases, this results in bias toward the null—and these are the only possible cases for a binary exposure. The risk in an intermediate-exposure category can go up or down on average, so some measures of association can be biased away from the null. Despite this exception, bias toward the null remains the most likely outcome of nondifferential misclassification of exposure (Dosemeci, Wacholder, and Lubin 1990; Correa-Villaseñor et al. 1995). However, random variation can produce point estimates closer to, farther from, or across the null compared to the true value of a measure of association.

8.1.3 Simultaneous nondifferential misclassification

Although we discussed nondifferential misclassification of disease in the context of a cohort study and nondifferential misclassification of exposure in the context of a case-control study, simultaneously misclassification of X and D can occur in any epidemiologic study. Table 8.4

Table 8.4: 2x2 table for a study with misclassified exposure and disease

	$D^{\text{obs}} = 1$	$D^{\text{obs}} = 0$	Total
$X^{\text{obs}} = 1$	a^{obs}	b^{obs}	r_1^{obs}
$X^{\text{obs}} = 0$	c^{obs}	d^{obs}	r_0^{obs}
Total	k_1^{obs}	k_0^{obs}	n

shows a 2x2 table with X and D both misclassified. The row totals are affected by misclassification of X , and the column totals are affected by misclassification of D . Only the total sample size n is unaffected.

The effects of nondifferential misclassification of both X and D can be derived by imagining that we misclassify one first and then the other. Here, we will consider misclassifying X and then D . When we misclassify X , we have the equivalent null hypotheses

$$X \perp\!\!\!\perp D \iff X^{\text{obs}} \perp\!\!\!\perp D.$$

where the symbol $\perp\!\!\!\perp$ indicates independence (Dawid 1979). When we misclassify D in addition to X , we have the equivalent null hypotheses

$$X^{\text{obs}} \perp\!\!\!\perp D \iff X^{\text{obs}} \perp\!\!\!\perp D^{\text{obs}}.$$

Therefore,

$$X \perp\!\!\!\perp D \iff X^{\text{obs}} \perp\!\!\!\perp D^{\text{obs}}$$

so a test of the null hypothesis that X and D are independent based on the misclassified data in Table 8.4 has the correct significance level (as long as $\text{sens}_X + \text{spec}_X > 1$ and $\text{sens}_D + \text{spec}_D > 1$). However, the power of the test is reduced when we misclassify X and reduced again when we misclassify D . Simultaneous misclassification of X and D has approximately the same effect as multiplying the sample size by

$$\text{ESSR}_X \text{ESSR}_D \leq 1$$

with equality if and only if $\text{sens}_X = \text{spec}_X = 1$ and $\text{sens}_D = \text{spec}_D = 1$.

8.2 Selection bias

Participants in an epidemiologic study can be selected according to exposure (in a cohort study) or according to disease (in a case-control study), but they cannot be selected according to both. In a cohort study, selection must be conditionally independent of disease given exposure so that risks of disease are estimated accurately in all exposure groups. In a case-control study, selection must be conditionally independent of exposure given disease, so the prevalence

of exposure is measured accurately among both cases and controls.. Selection according to exposure and disease simultaneously leads to **selection bias**, which is a threat to the external validity of a study.⁵ A study with uncontrolled selection bias is neither generalizable nor transportable.

8.2.1 Selection bias in cohort studies

In a cohort study, selection bias leads to biased estimates of the risks of disease in exposure groups. Let S indicate selection into the study, so $S_i = 1$ if individual i is selected into the study and $S_i = 0$ otherwise. When only X and D are measured, there is no selection bias in a cohort study if and only if the conditional probability of disease given exposure in sampled individuals equals that in the population:

$$\Pr(D = 1 \mid X = x, S = 1) = \Pr(D = 1 \mid X = x) \quad (8.4)$$

for both $x = 1$ and $x = 0$. By the definition of conditional probability,

$$\Pr(D = 1 \mid X = x, S = 1) = \frac{\Pr(D = 1, S = 1 \mid X = x)}{\Pr(S = 1 \mid X = x)}.$$

Multiplying both sides of Equation 8.4 by $\Pr(S = 1 \mid X = x)$ show that there is no selection bias in a cohort study if and only if

$$\Pr(D = 1, S = 1 \mid X = x) = \Pr(D = 1 \mid X = x) \Pr(S = 1 \mid X = x), \quad (8.5)$$

which means that D and S are conditionally independent given X . This condition can be relaxed somewhat if additional covariates are measured. In that case, we only need D and S to be conditionally independent given the measured covariates.

8.2.2 Selection bias in case-control studies

In a case-control study, selection bias leads to biased estimates of exposure prevalences in cases and controls. When only X and D are measured, there is no selection bias in a case-control study if and only if the conditional probability of exposure given disease in sampled individuals equals that in the underlying population:

$$\Pr(X = 1 \mid D = d) = \Pr(X = 1 \mid D = d, S = 1) \quad (8.6)$$

for $d = 1$ and $d = 0$. By the same argument used for the cohort study, there is no selection bias in a case-control study if and only if

$$\Pr(X = 1, S = 1 \mid D = d) = \Pr(X = 1 \mid D = d) \Pr(S = 1 \mid D = d),$$

which means that X and S are conditionally independent given D . As with selection bias in a cohort study, this condition can be relaxed if additional covariates are measured.

⁵In causal inference, selection bias can threaten both the internal and external validity of a study. It can cause an apparent association between X and D within the study sample that does not represent a causal effect (M. Á. Hernán, Hernández-Díaz, and Robins 2004).

8.2.3 Prospective and retrospective studies

A **prospective study** is one in which exposure information is collected and recorded prior to disease onset. A **retrospective study** is one in which exposure information is collected after the onset of disease. Traditionally, cohort studies were called “prospective studies” and case-control studies were called “retrospective studies”. While this classification is often accurate, it is possible for either design to be prospective or retrospective (Rothman, Greenland, and Lash 2008).

Because selection into a retrospective study occurs after disease onset and relevant exposures occur prior to disease onset, retrospective studies are more susceptible to selection bias than prospective studies. Because knowledge of disease occurrence can affect recall or measurement of exposure, retrospective studies are also more susceptible to differential misclassification.

8.2.4 Generalizability and transportability

To discuss sources of bias in epidemiologic studies, we will use terminology adapted from Dahabreh and Hernán (2019) and illustrated in Figure 8.2. These terms are meant to be consistent with the Consolidated Standards of Reporting Trials (CONSORT) statement (Moher et al. 2001; Altman et al. 2001) as well as the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement (Elm et al. 2007; Vandembroucke et al. 2007). The **eligible population** is the population of individuals who meet the eligibility criteria for a study—whether or not they are invited to participate or willing to participate. Individuals within the eligible population who are invited to participate are the **invited population**, and those within the invited population who enroll in the study are the **study sample**.⁶ Members of the study sample are called **participants**. Inferences based on data from the study sample are applied to a **target population** that could be the eligible population or a population that includes individuals outside the eligible population.

A study that makes valid inferences for the eligible population has **generalizability**, and a study that makes valid inferences for a larger or different target population has **transportability** to that population. Generalizability and transportability live along a spectrum of external validity. Generalizability is typically a prerequisite for transportability, and a generalizable study can be transportable to some target populations but not to others. Qualitative insights (e.g., smoking causes lung cancer) might be generalizable or transportable even when the estimated risks of disease or prevalences of exposure are not. The best way to ensure that the results of a study are widely applicable is to make the eligible population as inclusive as possible within ethical and logistical constraints (Bibbins-Domingo and Helman 2022).

⁶We avoid use of the term “study population” because it sometimes refers to the study sample and sometimes to the eligible population.




Figure 8.2: Schematic illustration of the relationship between the study sample, the eligible population, and a target population. A target population can contain all, part, or none of the eligible population.

8.2.5 Example: Berkson’s bias

Berkson (1946) discussed a hypothetical case-control study to test whether cholecystitis (i.e., gallbladder inflammation) is associated with diabetes. The cases are patients who come to the clinic for diabetes treatment. The controls are nondiabetic patients who come to the clinic to get eyeglasses to correct refractive errors, a diagnosis considered to be independent of cholecystitis based on existing knowledge of human biology. The overall population has 10,000,000 individuals. The prevalence of diabetes is 1%, the prevalence of refractive errors is 10%, and the prevalence of cholecystitis is 3%. All three conditions are assumed to occur independently.

Table 8.5 shows the distribution of cholecystitis among individuals with diabetes and individuals with refractive errors. Eligible cases are individuals with diabetes, and eligible controls are individuals with refractive errors but no diabetes. The prevalence of cholecystitis is 3% in both groups, so $\pi_1 = \pi_0 = 0.03$. It follows that the Pearson chi-squared statistic $\chi^2_P = 0$ in the 2x2 table for the eligible population.

The study sample consists of patients who visit the clinic for diabetes or refractive errors. Each diagnosis comes with a probability of visiting the clinic in the relevant time period. In one version of the example, diabetes patients visit the clinic with probability 0.05, refractive error patients visit with probability 0.20, and cholecystitis patients visit with probability 0.15. For patients with multiple conditions, “we shall say that these selective probabilities operate independently, as though a person who had two diseases were like [conjoined] twins, each one

Table 8.5: Cholecystitis among eligible cases and controls in Berkson (1946)

	Eligible cases	Eligible controls	Total
Cholecystitis	3,000	29,700	32,700
No cholecystitis	97,000	960,300	1,057,300
Total	100,000	990,000	1,090,000

Table 8.6: Combinations of cholecystitis (C), diabetes (D), and refractive errors (R) in Berkson (1946).

Condition	Population	Selection probability	Clinic visitors
None	8,642,700	0	0
C only	267,300	0.15	40,095
D only	87,300	0.05	4,365
R only	960,300	0.20	192,060
C and D	2,700	0.1925	520
C and R	29,700	0.32	9,504
D and R	9,700	0.24	2,328
C, D, and R	300	0.354	106
Total	10,000,000	0.0249	248,978

of whom had one disease, so that the probability of the twins' coming to the hospital is the probability of either one getting there, but the presence of one disease does not affect the other in any way" (Berkson 1946). For example, a patient with both diabetes and refractive error visits the clinic with probability $1 - (1 - 0.05)(1 - 0.20) = 0.24$. Table 8.6 shows the numbers of individuals in the population and among clinic visitors at each combination of cholecystitis, diabetes, and refractive errors.

Table 8.7 shows the 2x2 table for the study sample. The cases with cholecystitis include the 520 individuals with diabetes and cholecystitis only and the 106 individuals with all three conditions. The cases without cholecystitis include the 4,365 individuals with diabetes only and the 2,328 individuals with diabetes and refractive errors only. In this table, we have

$$\chi_P^2 = \frac{208,883(626 \times 192,060 - 6,693 \times 192,060)^2}{10,130 \times 198,753 \times 7,319 \times 201,564} \approx 225.447.$$

The p-value is 5.9×10^{-51} .

If we ignored selection bias, we would conclude that there is almost certainly an association between cholecystitis and diabetes in the eligible population. The example is constructed with no such association. Because the study sample included only clinic visitors and individuals

Table 8.7: Cholecystitis among cases and controls in Berkson (1946)

	Cases	Controls	Total
Cholecystitis	$520 + 106 = 626$	9,504	10,130
No cholecystitis	$4,365 + 2,328 = 6,693$	192,060	198,753
Total	7,319	201,564	208,883

with multiple conditions (including cholecystitis) were more likely to visit the clinic, selection and exposure (cholecystitis) are not conditionally independent given disease in this example.

8.3 R

Listing 8.1 ESSratio.R

```
## Effective sample size under nondifferential misclassification

# function that returns the effective sample size ratio
ess_ratio <- function(sens, spec, p) {
  # returns the multiplier of the sample size to get the effective sample size
  # under nondifferential misclassification with marginal risk (or prevalence)
  # p in the sample
  K <- sens + spec - 1
  Kden <- (1 - spec + K * p) * (1 - sens + K * (1 - p))
  return(K^2 * p * (1 - p) / Kden)
}

# data frame for ESSR with specificity = 1 and varying sensitivity
s <- seq(0.01, 1, by = 0.005)
p <- c(0.02, 0.05, 0.1, 0.2, 0.4)
pnames <- c("p02", "p05", "p10", "p20", "p40")
essr_sens <- outer(s, p, function(s, p) ess_ratio(sens = s, spec = 1, p = p))
colnames(essr_sens) <- pnames
essr_sens <- as.data.frame(essr_sens)

# data frame for ESSR with sensitivity = 1 and varying specificity
essr_spec <- outer(s, p, function(s, p) ess_ratio(sens = 1, spec = s, p = p))
colnames(essr_spec) <- pnames
essr_spec <- as.data.frame(essr_spec)

# plot
plot(s, essr_spec$p02, type = "l", asp = 1, xlim = c(0, 1), ylim = c(0, 1),
     xlab = "Sensitivity (gray) or specificity (black)",
     ylab = "Effective sample size ratio")
lines(s, essr_spec$p10, lty = "dashed")
lines(s, essr_spec$p40, lty = "dotdash")
lines(s, essr_sens$p02, col = "darkgray")
lines(s, essr_sens$p10, col = "darkgray", lty = "dashed")
lines(s, essr_sens$p40, col = "darkgray", lty = "dotdash")
grid()
legend("topleft", bg = "white",
      lty = c("solid", "dashed", "dotdash"),
      legend = c("p = 0.02", "p = 0.10", "p = 0.40"))
text(0.48, 0.52, srt = 45, col = "darkgray",
     "Specificity = 1 with varying sensitivity")
text(0.68, 0.32, srt = 45, "Sensitivity = 1 with varying specificity")
```

Listing 8.2 Berkson.R

```
## Berkson (1946) example of selection bias

# Pearson chi-squared test for the eligible population (X and D independent)
poptab <- matrix(c(3000, 97000, 29700, 960300), nrow = 2)
chisq.test(poptab, correct = FALSE)
# Fisher's exact test (with confidence limits for odds ratio)
fisher.test(poptab)

# Pearson chi-squared test for the study sample (X and D not independent)
sampletab <- matrix(c(626, 6693, 9504, 192060), nrow = 2)
chisq.test(sampletab, correct = FALSE)
# Fisher's exact test (with confidence limits for odds ratio)
fisher.test(sampletab)
```

9 Measures of Association in Cohort Studies

The P value, which is the final common pathway for almost all statistical tests, conveys no information about the extent to which two groups differ or two variables are associated. Highly “significant” P values can accompany negligible differences (if the study is large) and unimpressive P values can accompany strong associations (if the study is small). P values, therefore, are not good measures of the strength of the relation between study variables. (Rothman 1978)

9.1 Measures of association

A **measure of association** indicates both the direction and magnitude of the difference between two groups, so a point and interval estimate of a measure of association conveys much more information than a hypothesis test (Rothman 1978). We will first consider measures of association in cohort studies, where participants are selected based on exposure and then followed up (prospectively or retrospectively) to measure disease occurrence. As before, let X be a binary treatment or exposure, and let D be a binary disease outcome. We assume that the exposure X_i of person i is fixed by his or her time origin, that our study sample consists of individuals who were at risk of the outcome, and that there was no left truncation (i.e., delayed entry) or right censoring due to loss to follow-up. Our results can be summarized in a 2x2 table as in Table 2.1.

Ideally, the groups in a cohort study are identical except for exposure so that any difference in the outcomes can be attributed to a causal effect of the difference in exposure. In a clinical trial, this similarity can be achieved by randomizing participants to different levels of exposure. If the number of study participants is large enough, the different groups will be nearly identical in both measured and unmeasured covariates. In an observational study, exposure groups can have differences other than exposure that completely or partially explain the observed differences in outcomes, which is called **confounding** (Simpson 1951; O. S. Miettinen and Cook 1981). For now, we will not worry about whether the differences between groups are causal effects of treatment or exposure, which is why we call these measures of *association*.

9.1.1 Risk difference

If the risk of disease onset in $(0, t]$ is p_1 in the exposed and p_0 in the unexposed, then the **risk difference** is

$$\text{RD} = p_1 - p_0,$$

which can take any value in $[-1, 1]$. When exposure and disease are independent, $\text{RD} = 0$ because $p_1 = p_0$ (see Section 7.2.1).

When there is no delayed entry or loss to follow-up, the risk (cumulative incidence) in any given time interval $(0, t]$ can be estimated using methods for a binomial proportion. Based on the results from Section 3.2.2, the maximum likelihood estimate (MLE) of the risk difference is

$$\hat{\text{RD}} = \hat{p}_1 - \hat{p}_0 = \frac{a}{r_1} - \frac{c}{r_0}, \quad (9.1)$$

which is defined as long as $r_1 > 0$ and $r_0 > 0$. It is an unbiased estimate of the true RD.

Because the outcomes in the two exposure groups are independent, the estimated variance of $\hat{\text{RD}}$ is

$$\widehat{\text{Var}}(\hat{\text{RD}}) = \frac{\hat{p}_1(1 - \hat{p}_1)}{r_1} + \frac{\hat{p}_0(1 - \hat{p}_0)}{r_0}. \quad (9.2)$$

The r_1 and r_0 in the denominators are sometimes replaced with $r_1 - 1$ and $r_0 - 1$ by analogy with the $n - 1$ in the denominator of the sample variance (Rothman, Greenland, and Lash 2008). The Wald test statistic for the null hypothesis $H_0 : \text{RD} = \text{RD}_0$ is

$$Z_{\text{RD}} = \frac{\hat{\text{RD}} - \text{RD}_0}{\sqrt{\widehat{\text{Var}}(\hat{\text{RD}})}}. \quad (9.3)$$

In large samples under the null, Z_{RD} has a standard normal distribution and Z_{RD}^2 has a chi-squared distribution with one degree of freedom. The corresponding $1 - \alpha$ Wald confidence limits for the RD are

$$\hat{\text{RD}} \pm z_{1-\frac{\alpha}{2}} \sqrt{\widehat{\text{Var}}(\hat{\text{RD}})}. \quad (9.4)$$

As in Section 3.6, this confidence interval includes all values of RD_0 such that the Wald test in Equation 9.3 would fail to reject the null hypothesis at significance level α . For a 95% confidence interval, $z_{1-\frac{\alpha}{2}} \approx 1.96$. When the expected numbers of events are small, this confidence interval can have limits outside $[-1, 1]$. Confidence intervals with better performance can be obtained by inverting score or likelihood ratio tests or by using Bayesian methods (Agresti and Min 2005).

9.2 R

9.2.1 Risk ratio

The **risk ratio** comparing the exposed to the unexposed is

$$\text{RR} = \frac{p_1}{p_0}$$

where p_1 is the risk in the exposed and p_0 is the risk in the unexposed. It is defined whenever $p_1 \geq 0$ and $p_0 > 0$, and it can take any value in $[0, \infty)$. When exposure and disease are independent, $\text{RR} = 1$ because $p_1 = p_0$ (see Section 7.2.1). The MLE of the risk ratio is

$$\hat{\text{RR}} = \frac{\hat{p}_1}{\hat{p}_0} = \frac{a/r_1}{c/r_0}, \quad (9.5)$$

which is defined as long as $c > 0$ (which implies $r_0 > 0$) and $r_1 > 0$.

It is difficult to estimate the variance of a ratio, so we use a log transformation to get a sum:

$$\ln \hat{\text{RR}} = \ln \hat{p}_1 - \ln \hat{p}_0.$$

Because outcomes in the two groups are independent, we have

$$\text{Var}(\ln \hat{\text{RR}}) = \text{Var}(\ln \hat{p}_0) + \text{Var}(\ln \hat{p}_1)$$

by Equation 1.24. Using the delta method from Section 3.6.1 and the fact that $\frac{d}{dx} \ln x = \frac{1}{x}$, we get the estimated variance

$$\hat{\text{Var}}(\ln \hat{p}_i) = \frac{1}{\hat{p}_i^2} \text{Var}(\hat{p}_i) = \frac{1}{\hat{p}_i^2} \times \frac{\hat{p}_i(1 - \hat{p}_i)}{n_i} = \frac{1}{m_i} - \frac{1}{r_i}$$

where $m_1 = a$ and $m_0 = c$. Therefore,

$$\hat{\text{Var}}(\ln \hat{\text{RR}}) = \frac{1}{a} - \frac{1}{r_1} + \frac{1}{c} - \frac{1}{r_0}. \quad (9.6)$$

This is nonnegative because $a \leq r_1$ and $c \leq r_0$.

The Wald test statistic for the null hypothesis $H_0 : \text{RR} = \text{RR}_0$ is calculated on the log scale:

$$Z_{\text{RR}} = \frac{\ln \hat{\text{RR}} - \ln \text{RR}_0}{\sqrt{\hat{\text{Var}}(\ln \hat{\text{RR}})}} = \frac{\ln \hat{\text{RR}} - \ln \text{RR}_0}{\sqrt{\frac{1}{a} - \frac{1}{r_1} + \frac{1}{c} - \frac{1}{r_0}}}. \quad (9.7)$$

Because $a \leq r_1$, we have $1/a \geq 1/r_1$ with equality only if $a = r_1$. Similarly, $1/c \geq 1/r_0$ with equality only if $c = r_0$. In large samples under the null, Z_{RR} has a standard normal distribution and Z_{RR}^2 has a chi-squared distribution with one degree of freedom (Katz et al. 1978).

The $1 - \alpha$ Wald confidence limits for $\ln \text{RR}$ are

$$\ln \hat{\text{RR}} \pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{1}{a} - \frac{1}{r_1} + \frac{1}{c} - \frac{1}{r_0}}. \quad (9.8)$$

The corresponding log-transformed $1 - \alpha$ Wald confidence limits for the RR are

$$\hat{\text{RR}} \exp \left(\pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{1}{a} - \frac{1}{r_1} + \frac{1}{c} - \frac{1}{r_0}} \right) \quad (9.9)$$

As in Section 3.6, this confidence interval includes all possible values RR_0 such that the Wald test in Equation 9.7 would fail to reject the null hypothesis at significance level α . The log transformation ensures that the confidence interval has appropriate bounds because $\ln \text{RR} \in (-\infty, \infty)$ if and only if $\text{RR} \in (0, \infty)$. Confidence intervals with better performance can be obtained by inverting score or likelihood ratio tests or by using Bayesian methods (Agresti and Min 2005).

9.3 R

9.3.1 Odds ratio

The **odds** corresponding to a probability p is

$$\text{odds}(p) = \frac{p}{1-p}.$$

For $p \in [0, 1)$, the odds can take any value in $[0, \infty)$. The odds function is one-to-one because

$$\frac{\text{odds}(p)}{1 + \text{odds}(p)} = p$$

for any $p \in [0, 1)$. Thus, any probability can be converted to an odds and vice versa.

The **odds ratio** comparing the exposed to the unexposed is

$$\text{OR} = \frac{\text{odds}(p_1)}{\text{odds}(p_0)} = \frac{p_1/(1-p_1)}{p_0/(1-p_0)},$$

which is defined when $p_1 \geq 0$ and $p_0 > 0$. It can take any value in $[0, \infty)$. When exposure and disease are independent, $\text{OR} = 1$ because $\text{odds}(p_1) = \text{odds}(p_0)$. The MLE of the odds ratio is

$$\hat{\text{OR}} = \frac{\text{odds}(\hat{p}_1)}{\text{odds}(\hat{p}_0)} = \frac{a/(r_1 - a)}{c/(r_0 - c)} = \frac{ad}{bc}, \quad (9.10)$$

which is defined as long as $b > 0$ (which implies $r_1 > 0$) and $c > 0$ (which implies $r_0 > 0$).

As with the risk ratio, we use a log transformation to turn the product into a sum for variance calculations:

$$\ln \hat{\text{OR}} = \text{logit}(\hat{p}_1) - \text{logit}(\hat{p}_0)$$

where

$$\text{logit}(p) = \ln \frac{p}{1-p}$$

is the **logit transformation** from Section 3.6.1. Because outcomes in the two groups are independent, we have

$$\text{Var}(\ln \hat{\text{OR}}) = \text{Var}(\text{logit}(\hat{p}_1)) + \text{Var}(\text{logit}(\hat{p}_0)) \quad (9.11)$$

by Equation 1.24. Because

$$\text{logit}'(p) = \frac{1}{p} + \frac{1}{1-p} = \frac{1}{p(1-p)},$$

the delta method gives us the estimated variance

$$\hat{\text{Var}}(\text{logit}(\hat{p}_i)) = \frac{1}{\hat{p}_i^2(1-\hat{p}_i)^2} \text{Var}(\hat{p}_i) = \frac{1}{m_i} + \frac{1}{r_i - m_i}$$

where $m_1 = a$ and $m_0 = c$. The Wald test statistic for the null hypothesis $H_0 : \text{OR} = \text{OR}_0$ is calculated on the log scale:

$$Z_{\text{OR}} = \frac{\ln \hat{\text{OR}} - \ln \text{OR}_0}{\sqrt{\hat{\text{Var}}(\ln \hat{\text{OR}})}}. \quad (9.12)$$

In large samples under the null, Z_{OR} has a standard normal distribution and Z_{OR}^2 has a chi-squared distribution with one degree of freedom (Woolf 1955).

The $1 - \alpha$ Wald confidence limits for $\ln \text{OR}$ are

$$\ln \hat{\text{OR}} \pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}}. \quad (9.13)$$

The corresponding log-transformed $1 - \alpha$ Wald confidence limits for the OR are

$$\hat{\text{OR}} \exp \left(\pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}} \right) \quad (9.14)$$

As in Section 3.6, this confidence interval includes all possible values OR_0 such that the Wald test in Equation 9.12 would fail to reject the null hypothesis at significance level α . The log transformation ensures that the confidence interval has appropriate bounds because $\ln \text{OR} \in (-\infty, \infty)$ if and only if $\text{OR} \in (0, \infty)$. Confidence intervals with better performance can be obtained by inverting score or likelihood ratio tests or by using Bayesian methods (Agresti and Min 2005).

9.4 R

9.4.1 Incidence rate ratio

If there is delayed entry or loss to follow-up, we cannot calculate a risk ratio or odds ratio directly but we can still calculate the incidence rate in each group. Recall that the incidence rate is a maximum likelihood for an exponential rate parameter λ . If times to disease onset in the each exposure groups have an exponential distribution, then the **incidence rate ratio** is

$$\text{IRR} = \frac{\lambda_1}{\lambda_0}$$

where λ_1 is the rate in the exposed and λ_0 is the rate in the unexposed. It is defined whenever $\lambda_1 \geq 0$ and $\lambda_0 > 0$, and it can take any value in $[0, \infty)$. When exposure and disease are independent, $\text{IRR} = 1$ because $\lambda_1 = \lambda_0$. The incidence rate ratio is sometimes called the *incidence density ratio* (O. Miettinen 1976), and it equals the hazard ratio when the times to events in both exposure groups have exponential distributions.

Let T_1 be the total person-time in the exposed group and T_0 be the total person-time in the unexposed group. Based on the results from Section 5.3.2, the MLE of the incidence rate ratio is

$$\widehat{\text{IRR}} = \frac{\hat{\lambda}_1}{\hat{\lambda}_0} = \frac{a/T_1}{c/T_0}. \quad (9.15)$$

As with the risk ratio and odds ratio, we use a log transformation to get a sum instead of a ratio for variance calculations:

$$\ln \widehat{\text{IRR}} = \ln \frac{a}{T_1} - \ln \frac{c}{T_0}.$$

Because outcomes in the two groups are independent,

$$\text{Var}(\ln \widehat{\text{IRR}}) = \text{Var}\left(\ln \frac{a}{T_1}\right) + \text{Var}\left(\ln \frac{c}{T_0}\right).$$

By the delta method, the estimated variance of $\ln \widehat{\text{IRR}}$ is

$$\widehat{\text{Var}}\left(\ln \frac{m_i}{T_i}\right) = \left(\frac{T_i}{m_i}\right)^2 \text{Var}\left(\frac{m_i}{T_i}\right) = \frac{T_i^2}{m_i^2} \times \frac{m_i}{T_i^2} = \frac{1}{m_i} \quad (9.16)$$

where $m_1 = a$ and $m_0 = c$. The Wald test statistic for the null hypothesis $H_0 : \text{IRR} = \text{IRR}_0$ is calculated on the log scale:

$$Z_{\text{IRR}} = \frac{\ln \widehat{\text{IRR}} - \ln \text{IRR}_0}{\sqrt{\widehat{\text{Var}}(\ln \widehat{\text{IRR}})}} = \frac{\ln \widehat{\text{IRR}} - \ln \text{IRR}_0}{\sqrt{\frac{1}{a} + \frac{1}{c}}}. \quad (9.17)$$

In large samples under the null, Z_{IRR} has a standard normal distribution and Z_{IRR}^2 has a chi-squared distribution with one degree of freedom.

The $1 - \alpha$ Wald confidence limits for the $\ln \text{IRR}$ are

$$\ln \hat{\text{IRR}} \pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{1}{a} + \frac{1}{c}}.$$

The corresponding log-transformed $1 - \alpha$ Wald confidence limits for the IRR are

$$\hat{\text{IRR}} \exp \left(\pm z_{1-\frac{\alpha}{2}} \sqrt{\frac{1}{a} + \frac{1}{c}} \right). \quad (9.18)$$

This confidence interval includes all possible values IRR_0 such that the Wald test in Equation 9.17 would fail to reject the null hypothesis at significance level α . The log transformation ensures that the confidence interval has appropriate bounds because $\ln \text{IRR} \in (-\infty, \infty)$ if and only if $\text{IRR} \in (0, \infty)$. Confidence intervals with better performance can be obtained by inverting score or likelihood ratio tests or by using Bayesian methods (Agresti 2013).

9.5 R

9.6 Generalized linear models

The foundation for all regression models is **linear regression**. Let Y denote an *outcome* and let X_1, \dots, X_k be a set of *predictors* or *covariates* that we wish to use to predict Y . Then a linear regression model has the form

$$\mathbb{E}[Y | X] = \beta_0 + \beta_1 X_1 + \dots + \beta_k X_k,$$

or equivalently

$$Y = \beta_0 + \beta_1 X_1 + \dots + \beta_k X_k + \varepsilon,$$

where ε is an error term with mean zero. The point estimates of the **coefficients** $\beta_0, \beta_1, \dots, \beta_k$ are obtained by ordinary least squares, which is equivalent to assuming a normal distribution for ε and using maximum likelihood estimation. The coefficient β_0 is usually called the **intercept**, and it represents the mean outcome when all predictors equal zero. Each β_j can be interpreted as the change in the expected value of $\mathbb{E}(Y | X)$ associated with a one-unit increase in X_j when all other predictors are held constant.

Because probabilities are means of indicator variables (see Section 1.3.1), a linear regression model with binary disease outcome D with a binary exposure or treatment X can be used to estimate risks:

$$\Pr(D = 1 | X = x) = \beta_0 + \beta_1 x.$$

The intercept β_0 is the risk of disease among the unexposed ($X = 0$), and the coefficient β_1 is the risk difference RD:

$$\text{RD} = (\beta_0 + \beta_1) - \beta_0 = \beta_1.$$

However, the likelihood of this model is not quite correct for binary outcomes. The conditional distribution of D given X is a Bernoulli (see Section 1.5.2) distribution, not a normal distribution. Although the point estimates of β_0 and β_1 are unbiased, hypothesis tests and confidence intervals based on this model are distorted.

In a **generalized linear model** (GLM), we have

$$g(\mathbb{E}[Y | X]) = \beta_0 + \beta_1 X_1 + \dots + \beta_k X_k \quad (9.19)$$

where g is called the **link function** and the likelihood is determined by the **family** of the model, which specifies the conditional distribution of Y given X (Nelder and Wedderburn 1972; McCullagh and Nelder 1989). The left-hand side of Equation 9.19 is called the **linear predictor**. Linear regression is a GLM from the *Gaussian family* with the *identity link* $g(y) = y$. In practice, the family is usually determined by the outcome type (e.g., binomial family for binary outcomes, Gaussian family for continuous outcomes, and Poisson family for count outcomes) and the link is usually determined by the measure of association that we are trying to estimate.

GLMs from the *binomial family* can be used to estimate risk differences, risk ratios, odds ratios, and incidence rate ratios using binary outcome data. For some of these measures of association, there are alternative GLMs that can be used if a binomial GLM does not converge. For simplicity, we will focus on two-sample inference, so our models will contain a single binary predictor X . The measure of association estimated by the model is determined by the link function. In models with a single binary covariate, the Wald confidence intervals for the measure of association match the traditional confidence intervals from Section 9.1 calculated using the delta method and the binomial variance. However, binomial GLMs allow the calculation of score and likelihood ratio confidence intervals, and they can be used in Bayesian inference. The resulting interval estimates often perform better than Wald confidence intervals in terms of coverage probability and width (Agresti and Min 2005; Agresti 2013).

9.6.1 Risk differences and the identity link

To estimate risk differences, a GLM from the **binomial family** with an **identity link** $g(p) = p$ can be used. In this model

$$\Pr(D = 1 | X = x) = \beta_0 + \beta_1 x,$$

and a binomial likelihood is used to estimate the coefficients. The risk of disease in the unexposed is

$$p_0 = \Pr(D = 1 | X = 0) = \beta_0,$$

and the risk of disease in the exposed is

$$p_1 = \Pr(D = 1 \mid X = 1) = \beta_0 + \beta_1.$$

The risk difference is

$$\text{RD} = p_1 - p_0 = (\beta_1 + \beta_0) - \beta_0 = \beta_1.$$

Thus, $\hat{\beta}_0$ is the estimated risk of disease in the unexposed and $\hat{\beta}_1$ is the estimated risk difference. Their $1 - \alpha$ confidence intervals can be interpreted as confidence intervals for the risk in the exposed and the risk difference, respectively. When the confidence interval for β_1 is a Wald confidence interval, it will match Equation 9.4. However, the Gaussian GLM can be used to calculate score or likelihood ratio confidence limits or calculate a Bayesian posterior distribution.

The estimated risk of disease in the exposed is $\hat{\beta}_0 + \hat{\beta}_1$, and its estimated variance is

$$\widehat{\text{Var}}(\hat{\beta}_0 + \hat{\beta}_1) = \widehat{\text{Var}}(\hat{\beta}_0) + \widehat{\text{Var}}(\hat{\beta}_1) + 2 \text{Cov}(\hat{\beta}_0, \hat{\beta}_1) \quad (9.20)$$

by equation Equation 1.24. Each of the variances and covariances on the right can be obtained from the covariance matrix for the regression coefficients. The corresponding $1 - \alpha$ Wald confidence interval is

$$(\hat{\beta}_0 + \hat{\beta}_1) \pm z_{1-\frac{\alpha}{2}} \sqrt{\widehat{\text{Var}}(\hat{\beta}_0 + \hat{\beta}_1)}, \quad (9.21)$$

which is accurate in large samples.

Because probabilities must live in the interval $[0, 1]$, the set of possible combinations of β_0 and β_1 is constrained. We need both $\beta_0 \in [0, 1]$ and $\beta_0 + \beta_1 X \in [0, 1]$ for all values of X in our data. Figure 9.1 shows the possible combinations of β_0 and β_1 in a binomial GLM with the identity link and a binary X that is an indicator variable for exposure or treatment as in Table 2.1. In this case, the model will fail to converge if $a = 0$ (which implies $\beta_0 + \beta_1 = 0$), $b = 0$ (which implies $\beta_0 + \beta_1 = 1$), $c = 0$ (which implies $\beta_0 = 0$), or $d = 0$ (which implies $\beta_1 = 1$).




Figure 9.1: The gray triangle shows possible combinations of the intercept β_0 and the slope β_1 in a binomial GLM with the identity link and a single binary predictor coded 0/1.

9.6.1.1 Gaussian GLM with robust variance for risk differences

When a linear binomial GLM fails to converge, a common workaround is to use a Gaussian GLM with an identity link and a robust (sandwich) variance estimator. A normal(p, σ^2) distribution has mean p , so the regression produces unbiased point estimates of the coefficients. However, it estimates a single variance σ^2 . The Bernoulli variance changes with p , so groups with different risks should have different variances. The σ^2 from the linear regression typically produces Wald confidence intervals that are slightly too narrow. The robust variance

estimator corrects for this, producing valid Wald confidence intervals. Score and likelihood ratio confidence intervals are not available because the likelihood is not quite correct.

9.7 R

9.7.1 Risk ratios and the log link

A binomial GLM with a **log link** $g(p) = \ln p$ is called a **log-binomial regression** model. In this model

$$\ln(\Pr(D = 1 \mid X = x)) = \beta_0 + \beta_1 x.$$

The risk of disease in the unexposed is

$$p_0 = \exp(\beta_0),$$

and the risk of diseased in the exposed is

$$p_1 = \exp(\beta_0 + \beta_1).$$

The risk ratio comparing the exposed to the unexposed is

$$\text{RR} = \frac{e^{\beta_0 + \beta_1}}{e^{\beta_0}} = e^{\beta_1}.$$

Thus, $\exp(\hat{\beta}_0)$ is the estimated risk of disease in the unexposed and $\exp(\hat{\beta}_1)$ is the estimated risk ratio comparing the exposed to the unexposed. If the $1 - \alpha$ confidence interval for β_i is (ℓ_i, u_i) , then (e^{ℓ_i}, e^{u_i}) is the corresponding confidence interval for the risk of disease in the unexposed ($i = 0$) or the risk ratio ($i = 1$). When the confidence interval for β_1 is a Wald confidence interval, it will match the confidence interval for $\ln \text{RR}$ in Equation 9.8 and the corresponding confidence interval for the RR in Equation 9.9. However, the log-binomial GLM can be used to calculate score or likelihood ratio confidence limits or a Bayesian posterior distribution.

The estimated risk of disease in the exposed is $\exp(\hat{\beta}_0 + \hat{\beta}_1)$. The estimated variance of $\hat{\beta}_0 + \hat{\beta}_1$ is given in Equation 9.20, and $1 - \alpha$ confidence limits for the sum are given in Equation 9.21. The corresponding confidence limits for the risk in the exposed are

$$e^{(\hat{\beta}_0 + \hat{\beta}_1) \pm z_{1-\frac{\alpha}{2}} \sqrt{\text{Var}(\hat{\beta}_0 + \hat{\beta}_1)}} \quad (9.22)$$

which is accurate in large samples. It is not possible to get score or likelihood ratio confidence intervals for the risk in the exposed without reparameterizing the model, but Bayesian methods can be used to calculate credible intervals.

As in the binomial GLM for risk differences, not all combinations of β_0 and β_1 produce probabilities in $[0, 1]$. the parameter space for log-binomial regression is bounded in the sense that

not all combinations of β_0 and β_1 are possible. We get a probability greater than one whenever $\beta_0 + \beta_1 X > 0$. When the maximum likelihood estimate $(\hat{\beta}_0, \hat{\beta}_1)$ is close to this boundary for some values of X in the data, the model can fail to converge. In some cases, this problem can be solved by reparameterizing the model to put the maximum farther away from the boundary of the new parameter space or by using more sophisticated numerical methods to maximize the likelihood (Williamson, Eliasziw, and Fick 2013). Figure 9.2 shows the possible combinations of β_0 and β_1 in a binomial GLM with the identity link and a binary predictor X that is an indicator variable for exposure or treatment as in Table 2.1. In this case, the model will not converge if $a = 0$ (which implies $\beta_0 + \beta_1 = -\infty$), $b = 0$ (which implies $\beta_0 + \beta_1 = 0$), $c = 0$ (which implies $\beta_0 = -\infty$) or $d = 0$ (which implies $\beta_0 = 0$).




Figure 9.2: The gray area shows the possible combinations of the intercept β_0 and the slope β_1 in a binomial GLM with the log link and a single binary predictor coded 0/1.

9.7.1.1 Poisson GLM with robust variance for risk ratios

When a log-binomial GLM fails to converge, a common workaround is to use a Poisson GLM with a log link and a robust (sandwich) variance (Zou 2004; Naimi and Whitcomb 2020). The Poisson GLM with a log link has no constraints on β_0 and β_1 because a Poisson mean can be any positive number. Because the mean of both the Poisson(p) and Bernoulli(p) distributions equal p , the Poisson GLM produces unbiased point estimates of the coefficients. However, the variance of a Poisson(p) distribution is p , which is larger than the Bernoulli(p) variance

of $p(1 - p)$. Zou (2004) showed that, in a Poisson GLM with a log link and a single binary covariate, the robust (sandwich) variance equals the delta method variance of $\ln \text{RR}$. Point estimates and Wald confidence limits for the coefficients, the risk in the unexposed and the exposed, and the risk ratio can be obtained in the same way as for the log-binomial model.

9.8 R

9.8.1 Odds ratios and the logit link

A binomial GLM with a **logit link** $g(p) = \text{logit}(p)$ is called a **logistic regression** model, which was originally developed by Berkson (1944) and later refined by Cox (1958). In this model,

$$\text{logit}(\Pr(D = 1 | X = x)) = \beta_0 + \beta_1 x. \quad (9.23)$$

The odds of disease in the unexposed is

$$\text{odds}(p_0) = e^{\beta_0},$$

and the odds of diseased in the exposed is

$$\text{odds}(p_1) = e^{\beta_0 + \beta_1}.$$

The odds ratio comparing the exposed to the unexposed is

$$\text{OR} = \frac{e^{\beta_0 + \beta_1}}{e^{\beta_0}} = e^{\beta_1}.$$

Thus, $\exp(\hat{\beta}_0)$ is the estimated odds of disease in the unexposed and $\exp(\hat{\beta}_1)$ is the estimated odds ratio comparing the exposed to the unexposed. If the $1 - \alpha$ confidence interval for β_i is (ℓ_i, u_i) , then (e^{ℓ_i}, e^{u_i}) is the corresponding confidence interval for the odds of disease in the unexposed ($i = 0$) or the odds ratio ($i = 1$). When the confidence interval for β_1 is a Wald confidence interval, it will match the confidence interval for $\ln \text{OR}$ in Equation 9.13 and the corresponding confidence interval for the OR in Equation 9.14. However, the logistic GLM can be used to calculate score or likelihood ratio confidence limits or a Bayesian posterior distribution.

The estimated odds of disease in the exposed is $\exp(\hat{\beta}_0 + \hat{\beta}_1)$. The estimated variance of $\hat{\beta}_0 + \hat{\beta}_1$ is given in Equation 9.20, and $1 - \alpha$ confidence limits for the sum are given in Equation 9.21. The corresponding confidence limits for the odds ratio in the exposed are given in Equation 9.22, which is accurate in large samples. It is not possible to get score or likelihood ratio confidence intervals for the odds in the exposed without reparameterizing the model, but Bayesian methods can be used to calculate credible intervals.

Unlike the GLMs for the risk difference and risk ratio, there are no restrictions on β_0 and β_1 in a logistic regression model. Thus, it is the most numerically stable of the three regression models. However, with a single predictor X that is an indicator of treatment or exposure as in Table 2.1, it will fail to converge if $a = 0$ (which implies $\beta_0 + \beta_1 = -\infty$), $b = 0$ (which implies $\beta_0 + \beta_1 = \infty$), $c = 0$ (which implies $\beta_0 = \infty$), or $d = 0$ (which implies $\beta_0 = -\infty$).

Any estimate of the odds of disease can be used to obtain an estimate of the risk of disease using the inverse function for the logit transformation, which is the *expit* or *logistic* function from Equation 3.19. The name *logistic regression* comes from the fact that the logistic function is used to get a probability from the corresponding odds (Berkson 1944). In the model from Equation 9.23, the risk of disease in the unexposed is

$$\text{expit}(e^{\beta_0}) = \frac{1}{1 + e^{-(e^{\beta_0})}},$$

and the risk of disease in the exposed is

$$\text{expit}(e^{\beta_0 + \beta_1}) = \frac{1}{1 + e^{-(e^{\beta_0 + \beta_1})}}.$$

Point estimates of these risks can be obtained by replacing the unknown β_0 and β_1 with their maximum likelihood estimates $\hat{\beta}_0$ and $\hat{\beta}_1$, and these estimated risks can be used to obtain point estimates of the risk ratio and risk difference. Confidence limits for the risks in the exposed and unexposed can be obtained by applying the logistic function to the confidence limits for the corresponding odds. Because the same odds ratio can occur with many different values of the risk difference or risk ratio, confidence limits for the RD or RR cannot be obtained directly from the confidence limits for the OR.

Because the risks of disease in the exposed and unexposed can be calculated using the logistic regression model, we can also get point estimates of the risk difference and risk ratio. Logit-transformed Wald confidence limits for the risk difference or risk ratio can be obtained using a multivariable version of the delta method from Section 3.6.1 and the covariance matrix from the fitted logistic regression model. Similarly, the binomial GLM for the risk difference in Section 9.6.1 could be used to obtain point and interval estimates of the risk ratio or odds ratio, and the log-binomial for the risk ratio in Section 9.7.1 could be used to obtain point and interval estimates of the risk difference or odds ratio. Although it is more convenient to use a regression model that expresses your preferred measure of association in terms of a single coefficient, the measure of association does not dictate the choice of regression model or vice versa.

9.9 R

9.9.1 Cumulative hazard ratio and the complementary log-log link*

If $H_1(t)$ is the cumulative hazard function in the exposed and $H_0(t)$ is the cumulative hazard function in the unexposed (see Section 5.2.3), then

$$H_1(t) = -\ln(1 - p_1)$$

and

$$H_0(t) = -\ln(1 - p_0).$$

The **cumulative hazard ratio** is

$$\text{cHR}(t) = \frac{H_1(t)}{H_0(t)} = \frac{-\ln(1 - p_1)}{-\ln(1 - p_0)}. \quad (9.24)$$

If the instantaneous hazard ratio $h_1(t)/h_0(t)$ is constant in time, then this is equal to the cumulative hazard ratio. If the unexposed have exponential times to events, then $h_0(t) = \lambda_0$ and the cumulative hazard ratio equals

$$\frac{H_1(t)}{H_0(t)} = \frac{\int_0^t h_1(u) du}{\lambda_0 t} = \frac{1}{t} \int_0^t \frac{h_1(u)}{\lambda_0} du,$$

which is the average instantaneous hazard ratio over $(0, t]$.

If we take logarithms on both sides of Equation 9.24, we get

$$\ln(-\ln(1 - p_1)) = \ln(\text{cHR}(t)) + \ln(-\ln(1 - p_0)).$$

The function of p_1 and p_0 in this equation is the **complementary log-log** function

$$\text{cloglog}(p) = \ln(-\ln(1 - p)),$$

which has the inverse function

$$\text{cloglog}^{-1}(v) = 1 - e^{-(e^v)}.$$

If we have data with no delayed entry or loss to follow-up, the complementary log-log link function allows us to estimate the cumulative hazard ratio using a binomial GLM.

In a binomial GLM with the complementary log-log link,

$$\text{cloglog}(\Pr(D = 1 \mid X = x)) = \beta_0 + \beta_1 x. \quad (9.25)$$

The cumulative hazard of disease in the unexposed ($x = 0$) is e^{β_0} , so their risk of disease is

$$\text{cloglog}^{-1}(\beta_0) = 1 - e^{-(e^{\beta_0})}.$$

The cumulative hazard in the exposed ($x = 1$) is $e^{\beta_0 + \beta_1}$, so their risk of disease is

$$\text{cloglog}^{-1}(\beta_0 + \beta_1) = 1 - e^{-(e^{\beta_0 + \beta_1})}.$$

The cumulative hazard ratio comparing the exposed to the unexposed is

$$\frac{e^{\beta_0 + \beta_1}}{e^{\beta_0}} = e^{\beta_1}$$

Point estimates of these quantities can be obtained by replacing the unknown β_0 and β_1 with their maximum likelihood estimates $\hat{\beta}_0$ and $\hat{\beta}_1$. The $1 - \alpha$ confidence limits for the cumulative hazard in the unexposed can be obtained by exponentiating the confidence limits for β_0 , and confidence limits for their risk of disease can be obtained by applying cloglog^{-1} to the confidence limits for β_0 . Confidence limits for the cumulative hazard ratio can be obtained by applying cloglog^{-1} to the $1 - \alpha$ confidence limits for β_1 .

Because risks can be estimated for both exposure groups, we can also calculate point estimates of the risk difference, risk ratio, and odds ratio. Complementary log-log-transformed Wald confidence limits for each of these measures of association can be calculated using the multivariable version of the delta method from Section 3.6.1 and the covariance matrix from the fitted model.

The binomial GLM for the cumulative hazard ratio in Equation 9.25 assumes complete follow-up of all participants in the interval $(0, t]$ over which the risks p_1 and p_0 are defined, so it cannot be used if there is delayed entry or loss to follow-up. When there is delayed entry or loss to follow-up, methods from survival analysis are needed to estimate the hazard ratio.

9.10 R

9.10.1 Poisson GLMs for incidence rate ratios

When times to events have an $\text{exponential}(\lambda)$ distribution, then the number of events in a total person-time of T has a $\text{Poisson}(\lambda T)$ distribution (see Section 5.5). In a Poisson GLM with a log link for incidence data, we have

$$\ln(\mathbb{E}[\text{count} \mid X, T_X]) = \ln \lambda(X) + \ln T_X$$

where T_X is the total person time in the group with exposure X . Let $\mu(x) = \lambda(x)T_x$ be expected count in the group with $X = x$. The Poisson GLM is

$$\ln \mu(x) = \ln \lambda(x) + \ln T_x = \beta_0 + \beta_1 x + \ln T_x.$$

The term $\ln T_x$ is an **offset** because it has a fixed coefficient, which equals one in this case. Thus,

$$\ln \lambda(x) = \beta_0 + \beta_1 x.$$

The incidence rate in the unexposed is

$$\lambda_0 = e^{\beta_0},$$

the incidence rate in the exposed is

$$\lambda_1 = e^{\beta_0 + \beta_1},$$

and the incidence rate ratio is

$$\text{IRR} = \frac{e^{\beta_0 + \beta_1}}{e^{\beta_0}} = e^{\beta_1}.$$

The point estimates and $1 - \alpha$ confidence limits for β_0 and β_1 , for the incidence rate in the unexposed and the IRR, and for the risk in the exposed can be obtained in the same way as in a log-binomial GLM. Because the sum of Poisson random variables is also a Poisson random variable, this models can be fit with either individual or grouped person-time data. This model does not directly assume rare events, and a robust variance is not necessary. However, if an event can occur only once per participant, the rare event assumption ensures that the count of events has a low probability of being limited by the numbers of exposed and unexposed participants in the study.

9.11 R

9.11.1 Poisson GLMs for risks

For rare events (i.e., events with probabilities close to zero), the Poisson likelihood is almost the same as the binomial likelihood. If $X \sim \text{Poisson}(p)$ and p is close to zero, then

$$\begin{aligned}\Pr(X = 0) &= e^{-p} \approx 1 - p, \\ \Pr(X = 1) &= pe^{-p} \approx p(1 - p) \approx p.\end{aligned}$$

Because $(1 + p)(1 - p) = 1 - p^2$, we have

$$\Pr(X > 1) = 1 - (1 + p)e^{-p} \approx 1 - (1 + p)(1 - p) = p^2,$$

which is much smaller than both p and $1 - p$. Because $1 - p \approx 1$, the Poisson variance p and the Bernoulli variance $p(1 - p)$ are nearly identical for rare events.

A Poisson GLM with a log link can also be used to estimate risk ratios using counts of rare events in populations with known sizes. The expected count in each exposure group $X = x$ is

$$\ln(\mathbb{E}[\text{count} \mid X = x, N_x]) = \ln p(x) + \ln N_x$$

where $p(x)$ is the risk of the event and N_X is the total population with exposure X . Let $\mu(x) = p(x)N_x$ be the expected count in the group with $X = x$. The Poisson GLM for the risk is

$$\ln \mu(x) = \ln p(x) + \ln N_x = \beta_0 + \beta_1 x + \ln N_x.$$

The term $\ln N_x$ on the right-hand side is an offset because it has a fixed coefficient equal to one. Thus,

$$\ln p(x) = \beta_0 + \beta_1 x.$$

The risk in the unexposed is

$$p_0 = e^{\beta_0},$$

the risk in the exposed is

$$p_1 = e^{\beta_0 + \beta_1},$$

and the risk ratio is

$$\text{RR} = \frac{e^{\beta_0 + \beta_1}}{e^{\beta_0}} = e^{\beta_1}.$$

The point estimates and $1 - \alpha$ confidence limits for β_0 and β_1 , the risk in the unexposed, the risk ratio, and the risk in the exposed can be obtained in the same way as in a log-binomial GLM. When the event is not rare, a robust variance should be used. However, this adjustment will underestimate the variance when the number of groups is small.

The primary drawback of using Poisson GLMs to estimate risks and risk ratios is that the likelihood is not quite correct—especially for events that are not rare. This limits their use in Bayesian methods and forces the use of Wald instead of score or likelihood ratio confidence intervals. However, a Poisson GLM with a log link and a robust variance is an alternative to a log-binomial GLM when the latter fails to converge.

9.12 Rothman diagrams

The unit square is the set of all ordered pairs $(x, y) \in \mathbb{R}^2$ where both x and y are in the interval $[0, 1]$. To represent a point (x, y) in the unit square, we can plot x on a horizontal axis (the x-axis) and y on a vertical axis (the y-axis). Rothman (1975) introduced a very useful geometric perspective where we let x represent the risk of disease in the unexposed or untreated and y represent the risk of disease in the exposed or treated. We call these **Rothman diagrams** (Richardson, Robins, and Wang 2017; Kenah 2024), and they are similar to the *L'Abbé plots* used in meta-analysis (L'Abbé, Detsky, and O'Rourke 1987).

9.12.1 Contour lines

On a Rothman diagram, every point in the unit square represents a risk in the exposed and a risk in the unexposed. We can use these risks to calculate measures of association such as the

risk difference, risk ratio, odds ratio, or (cumulative) hazard ratio. For a function $f(x, y)$, the set of points with $f(x, y) = m$ for any given m is called a **contour line** or *contour* of f . If we think of the risk difference as a function

$$\text{RD}(p_0, p_1) = p_1 - p_0,$$

then the contour lines of RD link the points (p_0, p_1) in the unit square that have the same risk difference. Similarly, we can consider the contour lines of the risk ratio

$$\text{RR}(p_0, p_1) = \frac{p_1}{p_0},$$

the odds ratio

$$\text{OR}(p_0, p_1) = \frac{\text{odds}(p_1)}{\text{odds}(p_0)},$$

and the (cumulative) hazard ratio

$$\text{HR}(p_0, p_1) = \frac{-\ln(1 - p_1)}{-\ln(1 - p_0)}.$$

Figure 9.3 shows the contour lines for the risk difference, risk ratio, odds ratio, and hazard ratio. The null line $p_1 = p_0$ is a contour line for all four measures of association. All other contours of the risk difference and risk ratio are straight, and all other contours of the odds ratio and hazard ratio are curved.




Figure 9.3: Contour lines for the odds ratio, risk ratio, risk difference, and hazard ratio. The null line is solid. All other contours lines are dashed. Each contour line is labeled with the corresponding value of the measure of association.

9.12.2 Relationships among the RR, OR, and HR

The odds ratio is always farther from the null than the risk ratio because

$$OR = RR \frac{1-p_0}{1-p_1} \implies \begin{cases} OR > RR & \text{if } p_1 > p_0, \\ OR = RR & \text{if } p_1 = p_0, \\ OR < RR & \text{if } p_1 < p_0. \end{cases}$$

Because $\text{Var}(\ln \hat{OR}) > \text{Var}(\ln \hat{RR})$, this does not imply that a hypothesis test based on the odds ratio is more powerful than a test based on the risk ratio.

9.12.3 Relationships between changes in the RD, RR, and OR*

It is surprising but true that the odds ratio, risk ratio, and risk difference can change in different directions relative to their null values when the risks of disease in the exposed or the unexposed change. Even if we accept this possibility, it can seem pathological and the algebra can be complicated (Brumback and Berg 2008). The problem becomes simpler if we focus on local changes where we start at a point on a Rothman diagram and keep track of the changes in the risk difference, risk ratio, and odds ratio as we move away from it.

There are no surprises if we start on the null line where $p_1 = p_0$, so $RD = 0$, $RR = 1$, and $OR = 1$. If we move along the null line, all measures stay the same. If we move to a point where $p_1 > p_0$, then all three measures increase so $RD > 0$, $RR > 1$, and $OR > 1$. If we move to a point where $p_1 < p_0$, then all three measures decrease so $RD < 0$, $RR < 1$, and $OR < 1$. Thus, all three measures agree about which direction we are moving relative to the null.

If we start at any point off the null line, these measures of association can change in different directions—some toward the null and others away from the null. If we allow the risk difference, risk ratio, and odds ratio to move independently toward or away from their null values, there are $2^3 = 8$ possible combinations. It turns out that six of these combinations are possible around any point off the null line. This is hard to see algebraically, but it is easy to see on a Rothman diagram. Figure 9.4 shows the contours of the risk difference, risk ratio, and odds ratio passing through two points: (0.2, 0.6) above the null line and (0.8, 0.4) below the null line. Figure 9.5 shows the gray square around (0.2, 0.6), where the contour line for the OR is between the contours for the RD and RR. If the RD and RR both move in the same direction, the OR must follow them—precluding two of the eight possible combinations of changes toward and away from the null. Figure 9.6 shows the gray square around (0.8, 0.4), where the contour line for the RD is between the contours for the RR and OR. If the RR and OR both move in the same direction, the RD must follow them—which prevents two of the eight possible combinations of changes toward and away from the null. At both points, six of the eight possible combinations of movements toward or away from the null are possible, one in each of the six angles defined by the contour lines through the point. However, the regions

where all three measures of association agree about whether we are moving toward or away from the null occupy much larger angles than the regions where they disagree.




Figure 9.4: Rothman diagram showing the contour lines for the odds ratio (solid), risk ratio (dashed), and risk difference (dotted) that pass through the point (0.2, 0.6) above the null line and the point (0.8, 0.4) below the null line. The gray squares are the areas shown in Figure 9.5 and Figure 9.6.




Figure 9.5: The odds ratio, risk ratio, and risk difference near the point (0.2, 0.6). The contour line for the odds ratio (solid) is between the contours for the risk difference (dotted) and risk ratio (dashed). Six combinations of changes toward and away from the null are possible when starting from this point, but the odds ratio must follow the risk difference and risk ratio if they move in the same direction.




Figure 9.6: The odds ratio, risk ratio, and risk difference near the point (0.8,0.4). The contour line for the risk difference (dotted) is between the contours for the risk ratio (dashed) and the odds ratio (solid). Six combinations of changes toward and away from the null are possible in any neighborhood of the point, but the risk difference must follow the risk ratio and odds ratio if they move in the same direction.

Listing 9.1 riskdiff.R

```
## Risk difference point and interval estimates

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)
?rats          # type q to exit
dim(rats)
names(rats)

# numbers of events and row sums
# Because follow-up of the rats was complete, risk calculations are valid.
a <- sum(rats$status[rats$rx == 1])
r1 <- sum(rats$rx == 1)
c <- with(subset(rats, rx == 0), sum(status))
r0 <- sum(rats$rx == 0)

# estimated risks of tumor onset in 104 weeks
p1hat <- a / r1
p0hat <- c / r0

# estimated risk difference and its variance
RDhat <- p1hat - p0hat
RDvar <- p1hat * (1 - p1hat) / r1 + p0hat * (1 - p0hat) / r0

# Wald hypothesis test that RD = 0 in normal and chi-squared versions
RDz <- RDhat / sqrt(RDvar)
RDz
2 * pnorm(-abs(RDz))
RDchisq <- RDz^2
RDchisq
1 - pchisq(RDchisq, df = 1)

# point estimate and 95% confidence interval for the risk difference
RDhat
RDhat + c(-1, 1) * qnorm(0.975) * sqrt(RDvar)
```

Listing 9.2 riskratio.R

```
## Risk ratio point and interval estimates

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)
?rats          # type q to exit
dim(rats)
names(rats)

# numbers of events and row sums
# Because follow-up of the rats was complete, risk calculations are valid.
a <- sum(rats$status[rats$rx == 1])
r1 <- sum(rats$rx == 1)
c <- with(subset(rats, rx == 0), sum(status))
r0 <- sum(rats$rx == 0)

# estimated risks of tumor onset in 104 weeks
p1hat <- a / r1
p0hat <- c / r0

# estimated risk ratio, log risk ratio, and variance of ln(RRhat)
RRhat <- p1hat / p0hat
lnRRhat <- log(RRhat)
lnRRvar <- 1 / a - 1 / r1 + 1 / c - 1 / r0

# Wald hypothesis test that ln(RR) = 0 in normal and chi-squared versions
lnRRz <- lnRRhat / sqrt(lnRRvar)
lnRRz
2 * pnorm(-abs(lnRRz))
lnRRchisq <- lnRRz^2
lnRRchisq
1 - pchisq(lnRRchisq, df = 1)

# point estimate and 95% confidence interval for log risk ratio
lnRRci <- lnRRhat + c(-1, 1) * qnorm(0.975) * sqrt(lnRRvar)
lnRRhat
lnRRci

# point estimate and 95% confidence interval for risk ratio
RRhat
exp(lnRRci)
```

Listing 9.3 oddsratio.R

```
## Odds ratio point and interval estimates

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)
?rats          # type q to exit
dim(rats)
names(rats)

# numbers of events and row sums
# Because follow-up of the rats was complete, risk calculations are valid.
a <- sum(rats$status[rats$rx == 1])
r1 <- sum(rats$rx == 1)
c <- with(subset(rats, rx == 0), sum(status))
r0 <- sum(rats$rx == 0)

# estimated risks of tumor onset in 104 weeks
p1hat <- a / r1
p0hat <- c / r0

# estimated odds ratio, log odds ratio, and variance of ln(ORhat)
b <- r1 - a
d <- r0 - c
odds <- function(p) p / (1 - p)
ORhat <- odds(p1hat) / odds(p0hat)
lnORhat <- log(ORhat)
lnORvar <- 1 / a + 1 / b + 1 / c + 1 / d

# Wald hypothesis test that ln(OR) = 0 in normal and chi-squared versions
lnORz <- lnORhat / sqrt(lnORvar)
lnORz
2 * pnorm(-abs(lnORz))    # two-tailed test
lnORchisq <- lnORz^2
lnORchisq
1 - pchisq(lnORchisq, df = 1)

# 95% confidence interval for log odds ratio
lnORci <- lnORhat + c(-1, 1) * qnorm(0.975) * sqrt(lnORvar)
lnORhat
lnORci

# point estimate and 95% confidence interval for the odds ratio
ORhat
exp(lnORci)
```

Listing 9.4 irratio.R

```
## Incidence rate ratio point and interval estimates

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)
?rats          # type q to exit
dim(rats)
names(rats)

# numbers of events and total rat-weeks
# The subset() function can be used as an alternative to vector indexing.
a <- sum(rats$status[rats$rx == 1])
T1 <- sum(rats$time[rats$rx == 1])
c <- with(subset(rats, rx == 0), sum(status))
T0 <- with(subset(rats, rx == 0), sum(time))

# estimated incidence rates
# The units are tumor onsets per rat-week.
ir1hat <- a / T1
ir0hat <- c / T0

# estimated incidence rate ratio, log IRR, and variance of ln(IRRhat)
IRRhat <- ir1hat / ir0hat
lnIRRhat <- log(IRRhat)
lnIRRvar <- 1 / a + 1 / c

# Wald hypothesis test that ln(IRR) = 0 in normal and chi-squared versions
lnIRRz <- lnIRRhat / sqrt(lnIRRvar)
lnIRRz
2 * pnorm(-abs(lnIRRz))    # two-tailed test
lnIRRchisq <- lnIRRz^2
lnIRRchisq
1 - pchisq(lnIRRchisq, df = 1)

# 95% confidence interval for log incidence rate ratio
lnIRRci <- lnIRRhat + c(-1, 1) * qnorm(0.975) * sqrt(lnIRRvar)
lnIRRhat
lnIRRci

# point estimate and 95% confidence interval for the incidence rate ratio
IRRhat
exp(lnIRRci)
```

Listing 9.5 glm-RD-bounds.R

```
## Bounds on beta0 and beta1 in a binomial GLM for the risk difference
# This uses the identity link. We assume a single binary covariate coded 0/1.

# plot
plot(c(0, 0, 1, 1), c(0, 1, 0, -1), type = "n",
     xlim = c(-0.75, 1.75), ylim = c(-1.25, 1.25),
     xlab = expression(paste("Intercept ", (beta[0]))),
     ylab = expression(paste("Slope ", (beta[1]))))
grid()
polygon(c(0, 0, 1, 1), c(0, 1, 0, -1), border = "darkgray", col = "gray")
grid()
abline(h = 0) # x-axis (y = 0)
abline(v = 0) # y-axis (x = 0)

# labels
text(-0.1, 0.5, expression(beta[0] == 0), srt = 90)
text(1.1, -0.5, expression(beta[0] == 1), srt = 90)
text(0.4, -0.5, expression(beta[0] + beta[1] == 0), srt = -45)
text(0.6, 0.5, expression(beta[0] + beta[1] == 1), srt = -45)
```

Listing 9.6 riskdiff-GLM.R

```
## Risk difference estimation with GLMs

# to get help on GLMs in R (type q to exit)
?glm
?family

# load packages
# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)      # rats data
library(sandwich)      # sandwich() for robust variance
library(lmtest)        # coefci() for Wald confidence intervals

# traditional RD point estimate and Wald 95% confidence interval
# Because follow-up of the rats was complete, risk calculations are valid.
r1 <- sum(rats$rx == 1)
a <- with(rats, sum(status[rx == 1]))
r0 <- sum(rats$rx == 0)
c <- with(rats, sum(status[rx == 0]))
risk1 <- a / r1
risk0 <- c / r0
RDhat <- risk1 - risk0
RDvar <- risk1 * (1 - risk1) / r1 + risk0 * (1 - risk0) / r0

# point and interval estimates of the RD
RDhat
RDhat + c(-1, 1) * qnorm(0.975) * sqrt(RDvar)

# Binomial GLM with identity link for the RD
# Default binomial link = "logit", so we must specify link = "identity".
RDglm <- glm(status ~ rx, family = binomial(link = "identity"), data = rats)
summary(RDglm)          # point estimates, p-values, CIs, global tests
names(RDglm)            # parts of the fitted model
coef(RDglm)             # estimated risk (x = 0) and RD
confint(RDglm)          # likelihood ratio CIs (better)
coefci(RDglm)           # Wald CI for RD matches calculation above

# Gaussian (normal) GLM with identity link and robust variance for the RD
RDglm2 <- glm(status ~ rx, data = rats)
coef(RDglm2)            # point estimates match binomial GLM above
confint(RDglm2)         # likelihood ratio CI too narrow
coefci(RDglm2)          # Wald CI also too narrow
coefci(RDglm2, vcov = sandwich) # robust Wald CIs match binomial GLM above

# point and interval estimates for risk238 in the exposed
# The vector c(1, 1) represents 1 * beta0 + 1 * beta1,
# and as.numeric() is used to return a number instead of a matrix.
p1hat <- sum(coef(RDglm))
p1var <- as.numeric(c(1, 1) %*% vcov(RDglm) %*% c(1, 1))
p1hat
p1hat + c(-1, 1) * qnorm(0.975) * sqrt(p1var)
```

Listing 9.7 glm-RR-bounds.R

```
## Bounds on beta0 and beta1 in a binomial GLM for the risk ratio
# This uses the log link, and we assume a single binary covariate coded 0/1.

# plot
plot(c(0, 0, -2, -2), c(0, -2, -2, 2), type = "n",
     xlim = c(-1.5, 1), ylim = c(-1.5, 1),
     xlab = expression(paste("Intercept ", (beta[0]))),
     ylab = expression(paste("Slope ", (beta[1]))))
grid()
polygon(c(0, 0, -2, -2), c(0, -2, -2, 2),
        border = "darkgray", col = "gray")
grid()
abline(h = 0) # x-axis (y = 0)
abline(v = 0) # y-axis (x = 0)

# labels
text(0.1, -0.75, expression(beta[0] == 0), srt = 90)
text(-0.5, 0.6, expression(beta[0] + beta[1] == 0), srt = -45)
arrows(-1.2, 0.2, -1.5, 0.2, code = 2, length = 0.1)
text(-0.95, 0.2, expression(beta[0] %>% -infinity))
arrows(-1.3, -1.3, -1.5, -1.5, code = 2, length = 0.1)
text(-1.1, -1.2, expression(beta[0] + beta[1] %>% -infinity))
arrows(-0.2, -1.2, -0.2, -1.5, code = 2, length = 0.1)
text(-0.2, -1.1, expression(beta[1] %>% -infinity))
```

Listing 9.8 riskratio-GLM.R

```
## Risk ratio estimation with GLMs

# to get help on GLMs in R (type q to exit)
?glm
?family

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)      # rats data
library(sandwich)      # sandwich() for robust variance
library(lmtest)        # coefci() for Wald confidence intervals

# traditional RR point estimate and Wald 95% confidence interval
# Because follow-up of the rats was complete, risk calculations are valid.
r1 <- sum(rats$rx == 1)
a <- with(rats, sum(status[rx == 1]))
r0 <- sum(rats$rx == 0)
c <- with(rats, sum(status[rx == 0]))
risk1 <- a / r1
risk0 <- c / r0
RRhat <- (a / r1) / (c / r0)
lnRRvar <- 1 / a - 1 / r1 + 1 / c - 1 / r0
lnRRci <- log(RRhat) + c(-1, 1) * qnorm(.975) * sqrt(lnRRvar)

# point and interval estimates of the RR
RRhat
exp(lnRRci)

# binomial GLM with log link (log-binomial model) for the RR
# Default binomial link = "logit", so we must specify link = "log".
RRglm <- glm(status ~ rx, family = binomial(link = "log"), data = rats)
summary(RRglm)          # point estimates, p-values, CIs, global tests
names(RRglm)            # parts of the fitted model
exp(coef(RRglm))         # estimated risk (x = 0) and RR
exp(confint(RRglm))      # likelihood ratio CIs (better)
exp(coefci(RRglm))       # log-transformed Wald CI for RD matches above

# Poisson GLM with log link and sandwich variance for the RR
# The log link is the default for the Poisson family.
RRglm2 <- glm(status ~ rx, family = poisson(link = "log"), data = rats)
exp(coef(RRglm2))        # point estimates match binomial GLM above
exp(confint(RRglm2))     # likelihood ratio CI too wide
exp(coefci(RRglm2))      # Wald CI also too wide
exp(coefci(RRglm2, vcov = sandwich)) # robust Wald CI matches log binomial
240

# point and interval estimates for risk in the exposed
# The vector c(1, 1) represents 1 * beta0 + 1 * beta1,
# and as.numeric() is used to return a number instead of a matrix.
p1hat <- exp(sum(coef(RRglm)))
lnp1var <- as.numeric(c(1, 1) %*% vcov(RRglm) %*% c(1, 1))
p1hat
```

Listing 9.9 oddsratio-GLM.R

```
## Odds ratio estimation with GLMs

# to get help on GLMs in R (type q to exit)
?glm
?family

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)      # rats data
library(sandwich)      # sandwich() for robust variance
library(lmtest)        # coefci() for Wald confidence intervals

# traditional OR point estimate and Wald 95% confidence interval
# Because follow-up of the rats was complete, risk calculations are valid.
r1 <- sum(rats$rx == 1)
a <- with(rats, sum(status[rx == 1]))
b <- r1 - a
r0 <- sum(rats$rx == 0)
c <- with(rats, sum(status[rx == 0]))
d <- r0 - c
odds1 <- a / b
odds0 <- c / d
ORhat <- odds1 / odds0
lnORvar <- 1 / a + 1 / b + 1 / c + 1 / d
lnORci <- log(ORhat) + c(-1, 1) * qnorm(.975) * sqrt(lnORvar)

# point and interval estimates of the OR
ORhat
exp(lnORci)

# binomial GLM with logit link for the OR
# Default binomial link is "logit", so it does not need to be specified.
ORglm <- glm(status ~ rx, family = binomial(), data = rats)
summary(ORglm)          # point estimates, p-values, CIs, global tests
names(ORglm)           # parts of the fitted model
exp(coef(ORglm))        # estimated odds (x = 0) and OR
exp(confint(ORglm))     # likelihood ratio CIs (better)
exp(coefci(ORglm))      # log-transformed Wald CI matches above

# point and interval estimates for risk in the exposed
# The vector c(1, 1) represents 1 * beta0 + 1 * beta1,
# and as.numeric() is used to return a number instead of a matrix.
odds1hat <- exp(sum(coef(ORglm)))
lnodds1var <- as.numeric(c(1, 1) %*% vcov(ORglm) %*% c(1, 1))
odds1hat
odds1hat * exp(c(-1, 1) * qnorm(0.975) * sqrt(lnodds1var))

# estimates of risks, risk difference, and risk ratio based on odds
expit <- function(v) 1 / (1 + exp(-v))    # logistic function
beta0 <- coef(ORglm)["(Intercept)"]
beta1 <- coef(ORglm)["rx"]
```

Listing 9.10 cumhazratio-GLM.R

```
## Cumulative hazard ratio estimation with a GLM

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)      # rats data
library(lmtest)        # coefci() for Wald confidence intervals

# numbers of events and total rat-weeks
# The subset() function can be used as an alternative to vector indexing.
a <- sum(rats$status[rats$rx == 1])
T1 <- sum(rats$time[rats$rx == 1])
c <- with(subset(rats, rx == 0), sum(status))
T0 <- with(subset(rats, rx == 0), sum(time))
ir1hat <- a / T1
ir0hat <- c / T0
IRRhat <- ir1hat / ir0hat
lnIRRvar <- 1 / a + 1 / c
lnIRRci <- log(IRRhat) + c(-1, 1) * qnorm(0.975) * sqrt(lnIRRvar)

# point and interval estimate of the IRR
IRRhat
exp(lnIRRci)

# binomial GLM with complementary log-log link
# The cumulative hazard ratio equals the hazard ratio if the HR is constant.
HRglm <- glm(status ~ rx, family = binomial(link = "cloglog"), data = rats)
summary(HRglm)          # point estimates, p-values, CIs, global tests
names(HRglm)            # parts of the fitted model
exp(coef(HRglm))        # cumulative hazard (x = 0) and HR
exp(confint(HRglm))     # likelihood ratio CIs (better)
exp(coefci(HRglm))      # log-transformed Wald CI for RD matches above

# estimates of risks, RR, and RD based on log cumulative hazard
invcloglog <- function(v) 1 - exp(-exp(v)) # inverse of complementary log-log
beta0 <- coef(HRglm)["(Intercept)"]
beta1 <- coef(HRglm)["rx"]
# risk in exposed
risk1 <- a / sum(rats$rx == 1)
risk1
invcloglog(beta0 + beta1)
# risk in unexposed
risk0 <- c / sum(rats$rx == 0)
risk0
invcloglog(beta0)
# risk difference
risk1 - risk0
invcloglog(beta0 + beta1) - invcloglog(beta0)
# risk ratio
risk1 / risk0
invcloglog(beta0 + beta1) / invcloglog(beta0)
# odds ratio
```

Listing 9.11 irratio-GLM.R

```
## Incidence rate ratio estimation with a Poisson GLM

# to get help on GLMs in R (type q to exit)
?glm
?family

# rats data is in the survival package
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)      # rats data
library(lmtest)        # coefci() for Wald confidence intervals

# numbers of events and total rat-weeks
# The subset() function can be used as an alternative to vector indexing.
a <- sum(rats$status[rats$rx == 1])
T1 <- sum(rats$time[rats$rx == 1])
c <- with(subset(rats, rx == 0), sum(status))
T0 <- with(subset(rats, rx == 0), sum(time))
ir1hat <- a / T1
ir0hat <- c / T0
IRRhat <- ir1hat / ir0hat
lnIRRvar <- 1 / a + 1 / c
lnIRRci <- log(IRRhat) + c(-1, 1) * qnorm(0.975) * sqrt(lnIRRvar)

# point and interval estimate of the IRR
IRRhat
exp(lnIRRci)

# Poisson GLM with log(rat-weeks) offset to get incidence rate ratio
# The default link = "log".
IRRglm <- glm(status ~ rx + offset(log(time)), family = poisson(), data = rats)
summary(IRRglm)          # point estimates, p-values, CIs, global tests
names(IRRglm)            # parts of the fitted model
exp(coef(IRRglm))        # estimated incidence rate (x = 0) and IRR
exp(confint(IRRglm))     # likelihood ratio CIs (better)
exp(coefci(IRRglm))      # log-transformed Wald CI for IRR matches above

# point and interval estimates for incidence rate in the exposed
# The vector c(1, 1) represents 1 * beta0 + 1 * beta1,
# and as.numeric() is used to return a number instead of a matrix.
rate1hat <- exp(sum(coef(IRRglm)))
lnrate1var <- as.numeric(c(1, 1) %*% vcov(IRRglm) %*% c(1, 1))
rate1hat
rate1hat * exp(c(-1, 1) * qnorm(0.975) * sqrt(lnrate1var))

# Poisson regression using counts in each exposure group
# Make data frame with counts and total rat-time in each treatment group.
countdat <- data.frame(rx = c(0, 1),
                      count = as.vector(by(rats$status, rats$rx, sum)),
                      time = as.vector(by(rats$time, rats$rx, sum)))
IRRcount <- glm(count ~ rx + offset(log(time)),
               family = poisson(), data = countdat)
```

Listing 9.12 contours.R

```
## Contour lines for measures of association
require(plotrix, quietly = TRUE)

# odds, logistic, and cumulative hazard functions
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)
cumhaz <- function(p) -log(1 - p)

# risk difference contours
riskdiff_contours <- function() {
  plot(x, x, type = "l", main = "Risk difference contours",
       xlab = "", ylab = "Risk in the exposed")
  grid()
  boxed.labels(.5, .5, "0", xpad = 1.5, ypad = 1.5, border = FALSE)
  for (riskdiff in c(-0.5, -0.2, 0, 0.2, 0.5)) {
    y <- x + riskdiff
    yrange <- y >= 0 & y <= 1
    lines(x[yrange], y[yrange], lty = "dashed")
    boxed.labels(0.5 - riskdiff / 2, 0.5 + riskdiff / 2,
                 as.character(riskdiff),
                 xpad = 1.5, ypad = 1.5, border = FALSE)
  }
}

# risk ratio contours
riskratio_contours <- function() {
  plot(x, x, type = "l", main = "Risk ratio contours",
       xlab = "", ylab = "")
  grid()
  boxed.labels(.5, .5, "1", xpad = 1.5, ypad = 1.5, border = FALSE)
  for (riskratio in c(0.2, 0.5, 2, 5)) {
    y <- riskratio * x
    yrange <- (y <= 1)
    lines(x[yrange], y[yrange], lty = "dashed")
    boxed.labels(1 / (riskratio + 1), riskratio / (riskratio + 1),
                 as.character(riskratio),
                 xpad = 1.5, ypad = 1.5, border = FALSE)
  }
}

# odds ratio contours
oddsratio_contours <- function() {
  plot(x, x, type = "l", main = "Odds ratio contours",
       xlab = "Risk in the unexposed",
       ylab = "Risk in the exposed")
  grid()
  boxed.labels(.5, .5, "1", xpad = 1.5, ypad = 1.5, border = FALSE)
  for (oddsratio in c(0.2, 0.5, 2, 5)) {
    lines(x, invodds(oddsratio * odds(x)), lty = "dashed")
    boxed.labels((sqrt(oddsratio) - 1) / (oddsratio - 1),
                 (oddsratio - sqrt(oddsratio)) / (oddsratio - 1),
```

Listing 9.13 changes.R

```
## Contours for the RD, RR, and OR at (0.2, 0.6) and (0.8, 0.4)

# required packages
require(ggplot2, quietly = TRUE)
require(geomtextpath, quietly = TRUE)

# odds and logistic functions
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)

# Point A at (0.2, 0.6) with OR = 6, RR = 3, and RD = 0.4
# and point B at (0.6, 0.2) with OR = 1/6, RR = 1/3, and RD = -0.4
x <- seq(0.001, 0.999, by = 0.001)
dat <- data.frame(x = x, yORa = invodds(6 * odds(x)),
                  yRRa = 3 * x, yRDa = x + 0.4,
                  yORb = invodds(odds(x) / 6), yRRb = x / 2,
                  yRDb = x - 0.4)

# with points 1A and 1B
(ggplot(dat, aes(x, yORa))
 + theme_bw()
 + scale_x_continuous(limits = c(0, 1), expand = expansion(mult = 0.02),
                      breaks = seq(0, 1, by = 0.2))
 + scale_y_continuous(limits = c(0, 1), expand = expansion(mult = 0.02),
                      breaks = seq(0, 1, by = 0.2))
 + xlab("Risk in the unexposed")
 + ylab("Risk in the exposed")
 # point A
 + annotate("point", x = 0.2, y = 0.6, size = 3)
 + annotate("text", x = 0.2, y = 0.58, hjust = 0, vjust = 1,
           label = "(0.2, 0.6)")
 + geom_textline(label = "OR = 6", hjust = 0.8)
 + geom_textline(aes(x, yRRa), label = "RR = 3", hjust = 0.9,
                 linetype = "dashed")
 + geom_textline(aes(x, yRDa), label = "RD = 0.4", hjust = 0.9,
                 linetype = "dotted")
 + geom_textline(aes(x, x), col = "darkgray", label = "Null line")
 + annotate("rect", xmin = 0.09, xmax = 0.31, ymin = 0.49, ymax = 0.71,
           alpha = 0.2)
 + annotate("text", x = 0.11, y = 0.69, hjust = 0, vjust = 1,
           label = "Fig. 9.5")
 # point B
 + annotate("point", x = 0.8, y = 0.4, size = 3)
 + annotate("text", x = 0.8, y = 0.38, hjust = 0, vjust = 1,
           label = "(0.8, 0.4)")
 + geom_textline(aes(x, yORb), hjust = 0.8, label = "OR = 1/6")
 + geom_textline(aes(x, yRRb), hjust = 0.5, linetype = "dashed",
                 label = "RR = 1/2")
 + geom_textline(aes(x, yRDb), hjust = 0.05, linetype = "dotted",
                 label = "RD = -0.4")
 + annotate("rect", xmin = 0.69, xmax = 0.91, ymin = 0.29, ymax = 0.51,
```

Listing 9.14 changesA.R

```
## Local changes in the RD, RR, and OR near (0.2, 0.6)

# required packages
require(ggplot2, quietly = TRUE)
require(geomtextpath, quietly = TRUE)

# odds and logistic functions, conversion from degrees to radians
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)
degtorad <- function(degrees) pi * (degrees / 180)

# Point A at (0.2, 0.6) with OR = 6, RR = 3, and RD = 0.4
# and point B at (0.6, 0.2) with OR = 1/6, RR = 1/3, and RD = -0.4
x <- seq(0.001, 0.999, by = 0.001)
dataA <- data.frame(x = x, yORa = invodds(6 * odds(x)),
                    yRRa = 3 * x, yRDa = x + 0.4)

# plot of contours near point A
(ggplot(dataA, aes(x, yORa))
 + coord_cartesian(xlim = c(0.1, 0.3), ylim = c(0.5, 0.7))
 + xlab("Risk in the unexposed")
 + ylab("Risk in the exposed")
 + annotate("point", x = 0.2, y = 0.6, size = 3)
 + annotate("text", 0.202, 0.598, hjust = 0, vjust = 1, label = "(0.2, 0.6)")
 + geom_textline(label = "OR = 6", hjust = 0.385)
 + geom_textline(aes(x, yRDa), label = "RD = 0.40", hjust = 0.22,
                  linetype = "dotted")
 + geom_textline(aes(x, yRRa), label = "RR = 3", hjust = 0.208,
                  linetype = "dashed")
 + annotate("text", 0.25, 0.55,
            label = "All toward the null\n OR < 6, RR < 3, RD < 0.4")
 + annotate("text", 0.15, 0.65,
            label = "All away from the null\n OR > 6, RR > 3, RD > 0.4")
 + annotate("text", angle = 49,
            x = 0.2 + 0.09 * cos(degtorad(49)),
            y = 0.6 + 0.09 * sin(degtorad(49)),
            label = "OR < 6, RR < 3, RD > 0.4")
 + annotate("text", angle = 63,
            x = 0.2 + 0.09 * cos(degtorad(63)),
            y = 0.6 + 0.09 * sin(degtorad(63)),
            label = "OR > 6, RR < 3, RD > 0.4")
 + annotate("text", angle = 52,
            x = 0.2 + 0.09 * cos(degtorad(180 + 52)),
            y = 0.6 + 0.09 * sin(degtorad(180 + 52)),
            label = "OR > 6, RR > 3, RD < 0.4")
 + annotate("text", angle = 66,
            x = 0.2 + 0.087 * cos(degtorad(180 + 66)),
            y = 0.6 + 0.087 * sin(degtorad(180 + 66)),
            label = "OR < 6, RR > 3, RD < 0.4")
)
```

Listing 9.15 changesB.R

```
## Local changes in the RD, RR, and OR near (0.8, 0.4)

# required packages
require(ggplot2, quietly = TRUE)
require(geomtextpath, quietly = TRUE)

# odds and logistic functions, conversion from degrees to radians
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)
degtorad <- function(degrees) pi * (degrees / 180)

# Point A at (0.2, 0.6) with OR = 6, RR = 3, and RD = 0.4
# and point B at (0.6, 0.2) with OR = 1/6, RR = 1/3, and RD = -0.4
x <- seq(0.001, 0.999, by = 0.001)
datB <- data.frame(x = x, yORb = invodds(odds(x) / 6), yRRb = x / 2,
                  yRDb = x - 0.4)

(ggplot(datB, aes(x, yORb))
 + coord_cartesian(xlim = c(0.7, 0.9), ylim = c(0.3, 0.5))
 + xlab("Risk in the unexposed")
 + ylab("Risk in the exposed")
 + annotate("point", x = 0.8, y = 0.4, size = 3)
 + annotate("text", 0.802, 0.398, hjust = 0, vjust = 1, label = "(0.8, 0.4)")
 + geom_textline(label = "OR = 1/6", hjust = 0.615)
 + geom_textline(aes(x, yRDb), label = "RD = -0.4", hjust = 0.78,
                 linetype = "dotted")
 + geom_textline(aes(x, yRRb), label = "RR = 1/2", hjust = 0.84,
                 linetype = "dashed")
 + annotate("text", 0.75, 0.45,
           label = "All toward the null\n OR > 1/6, RR > 1/2, RD > -0.4")
 + annotate("text", 0.85, 0.35,
           label = "All away from the null\n OR < 1/6, RR < 1/2, RD < -0.4")
 + annotate("text", angle = 36,
           x = 0.8 + 0.09 * cos(degtorad(36)),
           y = 0.4 + 0.09 * sin(degtorad(36)),
           label = "OR < 1/6, RR > 1/2, RD < -0.4")
 + annotate("text", angle = 52,
           x = 0.8 + 0.09 * cos(degtorad(52)),
           y = 0.4 + 0.09 * sin(degtorad(52)),
           label = "OR < 1/6, RR > 1/2, RD > -0.4")
 + annotate("text", angle = 36,
           x = 0.8 + 0.09 * cos(degtorad(180 + 36)),
           y = 0.4 + 0.09 * sin(degtorad(180 + 36)),
           label = "OR > 1/6, RR < 1/2, RD > -0.4")
 + annotate("text", angle = 47,
           x = 0.8 + 0.095 * cos(degtorad(180 + 49)),
           y = 0.4 + 0.095 * sin(degtorad(180 + 49)),
           label = "OR > 1/6, RR < 1/2, RD < -0.4")
)
```

10 Two-Sample Survival Analysis and the Cox Model

Survival-time patterns should be compared properly in their entirety rather than at isolated points only. (Mantel 1966)

Simple measures of association such as the risk ratio or odds ratio require the calculation of risks of disease over a specified time interval. Often, it is more efficient to compare times to events throughout an interval rather than at a single time point. Under the assumption of exponential times to events, the incidence rate allows us to calculate a rate that applies throughout the observed time period. This is a step in the right direction, but calculations of incidence rates assume exponential times to events.

For one-sample inference, survival analysis allowed us to make more relaxed parametric assumptions (e.g., Weibull or log-logistic times to events) or to avoid any parametric assumption at all (e.g., the Kaplan-Meier and Nelson-Aalen estimators). Survival analysis plays a similar role in two-sample inference, allowing us to relax assumptions and compare survival time distributions in their entirety. The resulting hypothesis tests and measures of association can be more powerful and accurate than comparisons based on risks or incidence rates. All of the measures of association we discussed in Chapter 9 can be calculated using survival analysis. We focus on a single binary exposure as before, and we assume independent left truncation (i.e., delayed entry) and right censoring as described in Section 5.1.

10.1 Measures of association in survival analysis

Let λ_1 be the rate parameter for the exposed and λ_0 be the rate parameter for the unexposed, and assume (where needed) that both groups have the same shape parameter α . The **rate ratio** is just λ_1/λ_0 . The **hazard ratio** at time t is

$$\text{HR}(t) = \frac{h(t, \alpha, \lambda_1)}{h(t, \alpha, \lambda_0)}.$$

The risk of disease onset in any interval $(0, t]$ can be calculated using the survival, cumulative hazard, or hazard functions. This allows us to calculate risk differences, risk ratios, or odds ratios similar to those in Chapter 9. In many cases, these measures of association depend on t .

10.1.1 Rate ratios and hazard ratios

Suppose times to events have a Weibull(α, λ_1) distribution in the exposed and a Weibull(α, λ_0) in the unexposed. The rate ratio is λ_1/λ_0 at all times. However, the hazard ratio at time t is

$$\text{HR}_W = \frac{\alpha \lambda_1^\alpha t^{\alpha-1}}{\alpha \lambda_0^\alpha t^{\alpha-1}} = \left(\frac{\lambda_1}{\lambda_0} \right)^\alpha.$$

Therefore, the hazard ratio is constant and equal to $(\text{rate ratio})^\alpha$. Because the exponential distribution is a special case of the Weibull distribution with $\gamma = 1$, the hazard ratio equals the rate ratio when both groups have exponential times to events.

If times to events have a log-logistic(α, λ_1) distribution in the exposed and a log-logistic(α, λ_0) in the unexposed, the rate ratio is still λ_1/λ_0 at all times. However, the hazard ratio is

$$\text{HR}_{LL} = \frac{\alpha \lambda_1^\alpha t^{\alpha-1}}{\alpha \lambda_0^\alpha t^{\alpha-1}} \times \frac{1 + (\lambda_0 t)^\alpha}{1 + (\lambda_1 t)^\alpha} = \left(\frac{\lambda_1}{\lambda_0} \right)^\alpha \frac{1 + (\lambda_0 t)^\alpha}{1 + (\lambda_1 t)^\alpha}, \quad (10.1)$$

which is not constant in time for any shape parameter $\alpha > 0$. The hazard ratio is approximately $(\lambda_1/\lambda_0)^\alpha$ just after $t = 0$, and it approaches one as $t \rightarrow \infty$. Figure 10.1 shows an example of this with shape $\alpha = 2$ and rates $\lambda_1 = 2$ and $\lambda_0 = 1$.




Figure 10.1: Hazards (top) and hazard ratio (bottom) for log-logistic distributions with shape $\alpha = 2$ and rates $\lambda_1 = 2$ in the exposed and $\lambda_0 = 1$ in the unexposed.

10.1.2 Risk differences, risk ratios, and odds ratios

All of the measures of association from Chapter 9 can be calculating using survival analysis because the estimated survival function can be used to calculate risks. For example: If the times to events have Weibull distributions in both groups, the risk of disease onset in $(0, t]$

given $X = x$ is

$$1 - S(t, \alpha, \lambda_x) = 1 - e^{-(\lambda_x t)^\alpha}$$

where $x = 1$ for the exposed and $x = 0$ for the unexposed. Using these risks, we can calculate the risk difference, risk ratio, and odds ratio comparing the exposed to the unexposed over any time interval $(0, t]$. The odds of disease onset in $(0, t]$ given $X = x$ is

$$\frac{1 - e^{-(\lambda_x t)^\alpha}}{e^{-(\lambda_x t)^\alpha}} = e^{(\lambda_x t)^\alpha} - 1,$$

so the odds ratio comparing the exposed to the unexposed at time t is

$$\text{OR}(t) = \frac{e^{(\lambda_1 t)^\alpha} - 1}{e^{(\lambda_0 t)^\alpha} - 1}.$$

When $\lambda_1 = \lambda_0$, this equals one at all t . When $\lambda_1 \neq \lambda_0$, it varies with t . Figure 10.2 shows an example of this with shape $\alpha = 2$ and rates $\lambda_1 = 2$ and $\lambda_1 = 1$. Similarly, the risk difference equals zero and the risk ratio equals one when $\lambda_1 = \lambda_0$ but both vary with t otherwise.




Figure 10.2: Odds (top) and odds ratio (bottom) for Weibull distributions with shape $\alpha = 2$ and rates $\lambda_1 = 2$ in the exposed and $\lambda_0 = 1$ in the unexposed.

If the failure time distributions are log-logistic with the same shape parameter α , the risk of disease onset in $(0, t]$ given $X = x$ is

$$1 - S(t, \alpha, \lambda_x) = 1 - \frac{1}{1 + (\lambda_1 t)^\alpha} = \frac{(\lambda_1 t)^\alpha}{1 + (\lambda_1 t)^\alpha},$$

and the corresponding odds of disease is

$$\frac{(\lambda_x t)^\alpha}{x + (\lambda_x t)^\alpha} \times \frac{x + (\lambda t)^\alpha}{1} = (\lambda_x t)^\alpha.$$

When $\lambda_1 \neq \lambda_0$, the risk difference and risk ratio are not constant in time. However, the odds ratio is

$$\frac{(\lambda_1 t)^\alpha}{(\lambda_0 t)^\alpha} = \left(\frac{\lambda_1}{\lambda_0} \right)^\alpha,$$

which is constant in time and equal to $(\text{rate ratio})^\alpha$. Thus, the odds ratio for log-logistic times to events has the same form as the hazard ratio for Weibull times to events. The risk difference and risk ratio both vary with t when $\lambda_1 \neq \lambda_0$.

10.2 Accelerated failure time models

Parametric regression models in survival analysis are based on **rate parameters**, which measure how quickly time passes relative to a baseline time-to-event distribution. In an **accelerated failure time** (AFT) regression model, predictors act multiplicatively on the random time to event T :

$$T = e^{\beta_0 + \beta_1 x_1 + \dots + \beta_k x_k} \times \tau,$$

where τ is a random sample from the baseline survival time distribution, which defines $\lambda = 1$. The multiplier of τ is the **scale parameter**

$$\sigma(\beta, x) = e^{\beta_0 + \beta_1 x_1 + \dots + \beta_k x_k},$$

which measures how much the baseline failure time distribution is compressed ($\sigma < 1$) or stretched out ($\sigma > 1$). A one-unit increase in x_j with all other covariates held constant is associated with a survival time that is multiplied by $\exp(\beta_j)$, which is called the *acceleration factor*. The rate parameter is

$$\lambda(\beta, x) = e^{-(\beta_0 + \beta_1 x_1 + \dots + \beta_k x_k)}, \quad (10.2)$$

which measures how quickly time passes relative to the baseline failure-time distribution. A one-unit increase in x_j with all other covariates held constant is associated with a **rate ratio** of $\exp(-\beta_j)$. The null hypothesis of no association with X_j corresponds to $\beta_j = 0$.

We will discuss AFT models that use exponential, Weibull, and log-logistic distributions with rate $\lambda = 1$ has their baseline distributions. The gamma and log-normal distributions are also widely used, but they do not have simple closed forms for the hazard, cumulative hazard, or survival functions. All of these models can be fit using data with left truncation and right censoring, and the construction of the likelihood is the same. AFT models are a useful alternative to analyses based on incidence rates when the times to events are not exponential.

For simplicity, we will focus on AFT models with a single binary predictor X . In these models, the rate parameter is

$$\lambda(x, \beta) = e^{-(\beta_0 + \beta_1 x)} = \begin{cases} e^{-\beta_0} & \text{in the unexposed,} \\ e^{-(\beta_0 + \beta_1)} & \text{in the exposed.} \end{cases} \quad (10.3)$$

The rate ratio is

$$\frac{\lambda_1}{\lambda_0} = \frac{e^{-(\beta_0 + \beta_1)}}{e^{-\beta_0}} = e^{-\beta_1}.$$

The relationship between this rate ratio and other measures of association depends on the underlying failure time distribution.

10.2.1 Exponential AFT model

An exponential distribution has a rate parameter but no shape parameter, so an exponential AFT model only has to estimate the coefficient vector β from Equation 10.3. In an exponential AFT model, the hazard function is

$$h(t, x, \beta) = \lambda(x, \beta),$$

which is the exponential hazard function with $\lambda = \lambda(x, \beta)$ from Equation 10.3. The corresponding cumulative hazard is

$$H(t, x, \beta) = \lambda(X, \beta)t.$$

With left-truncated and right-censored data

$$(t_i^{\text{entry}}, t_i^{\text{exit}}, \delta_i, x_i) \text{ for } i = 1, \dots, n, \quad (10.4)$$

the log likelihood for β is

$$\ell(\beta) = \sum_{i=1}^n \left(\delta_i \ln h(t_i^{\text{exit}}, x_i, \beta) - H(t_i^{\text{exit}}, x_i, \beta) + H(t_i^{\text{entry}}, x_i, \beta) \right).$$

Point and interval estimates of β can be obtained using maximum likelihood estimation (see Chapter 3) or Bayesian methods (see Chapter 12).

10.3 R

10.3.1 Weibull AFT model

The Weibull AFT model generalizes the exponential model in the same way that the Weibull distribution generalizes the exponential distribution. As in the exponential AFT model, the rate parameter is determined by x and β as in Equation 10.3. The hazard function in a Weibull AFT model is

$$h(t, \alpha, \beta, x) = \alpha \lambda(\beta, x)^\alpha t^{\alpha-1},$$

which is the hazard function of the Weibull(α, λ) distribution where $\lambda = \lambda(\beta, X)$. The corresponding cumulative hazard function is

$$H(t, \alpha, \beta, x) = (\lambda(\beta, x)t)^\alpha.$$

With left-truncated and right-censored data as in Equation 10.4, the log likelihood for α and β is

$$\ell(\alpha, \beta) = \sum_{i=1}^n \left(\delta_i \ln h(t_i^{\text{exit}}, x_i, \alpha, \beta) - H(t_i, x_i, \alpha, \beta) + H(t_i^{\text{entry}}, x_i, \alpha, \beta) \right). \quad (10.5)$$

Point and interval estimates of α and β can be obtained using maximum likelihood estimation or Bayesian methods.

10.4 R

10.4.1 Log-logistic AFT model

The log-logistic AFT model has the same likelihood as the Weibull AFT model except that we replace the Weibull hazard and cumulative hazard functions with the log-logistic hazard and cumulative hazard functions. As in the exponential and Weibull AFT models, the rate parameter is determined by x and β as in Equation 10.3. The log-logistic hazard function is

$$h(t, x, \alpha, \beta) = \frac{\alpha \lambda(x, \beta)^\alpha t^{\alpha-1}}{1 + (\lambda(x, \beta)t)^\alpha},$$

and the cumulative hazard function is

$$H(t, X, \beta, \alpha) = \ln \left(1 + t^\alpha e^{-\alpha(\beta_0 + \beta_1 X)} \right).$$

With left-truncated and right-censored data as in Equation 10.4, the likelihood is given by Equation 10.5. Point and interval estimates of α and β can be obtained using maximum likelihood estimation or Bayesian methods.

10.5 R

10.6 Log-rank test

The log rank test (Mantel 1966) is a nonparametric score test for the null hypothesis that two groups have the same failure time distribution. Let $t_1 < t_2 < \dots < t_m$ be the distinct times where failures occur. Let d_i denote the number of failures at time t_i , and let n_i denote the number of people in the risk set \mathcal{R}_i (i.e., the set of people at risk of failure at time t_i). Let X be a binary covariate. Let n_{1i} denote the number of people in R_i with $X = 1$, and let d_{1i} denote the number of of these that fail at time t_i . For now, we assume no tied failure times, so $d_{1i} = 0$ or $d_{1i} = 1$ for each i .

10.6.1 Observed and expected failures among the exposed

The log-rank test is a score test, so it uses a test statistic calculated assuming the null hypothesis is true. Here, the null hypothesis is that the survival time distribution is the same among the exposed ($X = 1$) and the unexposed ($X = 0$). Under the null hypothesis, the d_i failures at time t_i occur in individuals randomly chosen from n_i individuals in the risk set $\mathcal{R}(t_i)$. The number of exposed individuals D_{1i} among the randomly chosen d_i individuals has a hypergeometric distribution (see Section 7.1.1) with mean

$$\mathbb{E}(D_{1i}) = d_i p_{1i}$$

where

$$p_{1i} = \frac{n_{1i}}{n_i}$$

is the proportion of the risk set that is exposed. Its variance is

$$\text{Var}(D_{1i}) = p_{1i}(1 - p_{1i}) \frac{d_i(n_i - d_i)}{n_i - 1}.$$

In the special case where $d_i = 1$, this hypergeometric distribution is a Bernoulli(p_{1i}) distribution with mean p_{1i} and variance $p_{1i}(1 - p_{1i})$.

10.6.2 Chi-squared statistic

The numerator of the log-rank chi-squared statistic is total number of observed failures among the exposed minus the total number of expected failures among the exposed under the null hypothesis:

$$U = \sum_{i=1}^m (d_{1i} - d_i p_{1i}). \quad (10.6)$$

The denominator is the variance of U_{logrank} , which is

$$\text{Var}(U) = \sum_{i=1}^m p_{1i}(1 - p_{1i}) \frac{d_i(n_i - d_i)}{n_i - 1}$$

because the D_{1i} are independent. The log-rank test statistic is

$$\chi_{\text{log-rank}}^2 = \frac{U^2}{\text{Var}(U)}. \quad (10.7)$$

When the number of observed failures is large, this has a chi-squared distribution with one degree of freedom under the null. We reject the null hypothesis for large values of χ_{logrank}^2 . We get exactly the same chi-squared statistic and p-value if we use the observed and expected number of failures among the unexposed.

10.6.3 Weighted log-rank tests

Many nonparametric tests of differences between survival curves are weighted versions of the log-rank test. The weighted sum of the differences between the observed and expected numbers of events among the exposed is

$$U = \sum_{i=1}^m w_i(d_{1i} - d_i p_{1i}),$$

and the corresponding variance is

$$V = \sum_{i=1}^m w_i^2 \left(p_{1i}(1 - p_{1i}) \frac{d_i(n_i - d_i)}{n_i - 1} \right).$$

Table 10.1 shows the weights used by various tests. In the weights, $\hat{S}(t)$ is the Kaplan-Meier estimate of the survival function, $\hat{S}_0(t)$ is the Kaplan-Meier estimate among the unexposed, and $\hat{S}_1(t)$ is the Kaplan-Meier estimate among the exposed. The Harrington-Fleming test is equivalent to the log-rank test when $\rho = 0$, and it approximates the Peto-Prentice test when $\rho = 1$. The weighted tests often give larger weights to earlier survival times, where there is usually more data.

10.7 R

Table 10.1: Weighted log-rank tests (Aalen, Borgan, and Gjessing 2008).

Test	Weight (proportional to w_i)	Reference
Log-rank	1	?
Gehan-Breslow	n_i	?, ?
Tarone-Ware	$\sqrt{n_i}$?
Harrington-Fleming	$\hat{S}(t_{i-1})^\rho$?
Efron	$\hat{S}_0(t_{i-1})\hat{S}_1(t_{i-1})$?
Peto-Prentice	$\prod_{i:t_i < t} \left(1 - \frac{d_i}{n_i+1}\right)$?, ?

10.8 Cox model

The **Cox proportional hazards model** [Cox (1972)] is a regression model that can estimate hazard ratios without making any other assumption about the underlying failure time distributions.¹ It is a **semiparametric** model, which means that it has a parametric component and a nonparametric component. In the Cox model, the hazard function is

$$h(t, x, \beta) = e^{\beta_1 x_1 + \dots + \beta_k x_k} h_0(t), \quad (10.8)$$

where the first term on the right-hand side is the **relative hazard function** and $h_0(t)$ is an unspecified **baseline hazard function**. The parametric component of the model is the relative hazard, where each predictor has a multiplicative effect on the hazard function. The nonparametric component of the model is the unspecified baseline hazard. There is no intercept because $h_0(t)$ represents the hazard for an individual with all predictors equal to zero.

For simplicity, we will focus on Cox models with a single binary predictor X . In these models, the relative hazard is

$$e^{\beta_1 x} = \begin{cases} 1 & \text{in the unexposed,} \\ e^{\beta_1} & \text{in the exposed.} \end{cases}$$

Thus, the hazard ratio comparing the exposed to the unexposed is e^{β_1} . The Cox model gives us a way of estimating the hazard ratio without making any assumption about the distributions of times to events in the exposed and unexposed except for proportional hazards. In a Cox model with a single binary covariate, the log-rank test from Section 10.6 is a score test of the null hypothesis that $\beta = 0$.

¹Sir David Roxbee Cox (1924–2022) is a British statistician who helped develop logistic regression (Cox 1958) and proportional hazards regression. He worked at Imperial College London and Oxford University. As of 6 February 2025, Cox (1972) has 63,224 citations on Google Scholar.

10.8.1 Proportional hazards assumption

The proportional hazards assumption is much weaker than any assumption that the times to events in the exposed and unexposed come from a specific family, such as exponential, Weibull, or log-logistic distributions. However, it is still an assumption. The exponential and Weibull AFT models are special cases of the Cox model because the hazard ratio comparing the exposed to the unexposed is always $(\lambda_1/\lambda_0)^\alpha$ where λ_1 is the rate parameter for the exposed, λ_0 is the rate parameter for the unexposed, and α is the shape parameter. When the underlying failure times are truly exponential or Weibull, the corresponding AFT models will have slightly more power than the Cox model. The log-logistic AFT model is not a proportional hazards model because the hazard ratio changes over time, as shown in Equation 10.1.

10.8.2 Partial likelihood

The Cox model is fit using a **partial likelihood**, which leaves out parts of the full likelihood but behaves like a likelihood for the purposes of maximum likelihood estimation. The Cox partial likelihood retains critical information about the hazard ratios without placing constraints on the baseline hazard. To do this, it relies on a fundamental relationship between conditional probabilities and hazard functions.

Suppose T_1 and T_2 are independent failure times with survival functions $S_1(t)$ and $S_2(t)$, respectively. Let $T = \min(T_1, T_2)$. Then the survival function of T is

$$S(t) = S_1(t)S_2(t)$$

because $T > t$ if and only if $T_1 > t$ and $T_2 > t$. The cumulative hazard function of T is

$$H(t) = -\ln S(t) = -\ln S_1(t) - \ln S_2(t) = H_1(t) + H_2(t),$$

where $H_1(t)$ and $H_2(t)$ are the cumulative hazard functions of T_1 and T_2 . Taking derivatives, we get the hazard function

$$h(t) = H'(t) = H'_1(t) + H'_2(t) = h_1(t) + h_2(t),$$

where $h_1(t)$ and $h_2(t)$ are the hazard functions of T_1 and T_2 .

This logic extends to the minimum of any finite set of survival times T_1, \dots, T_n . The survival function of $T = \min(T_1, \dots, T_n)$ is

$$S(t) = \prod_{i=1}^n S_i(t), \tag{10.9}$$

and the hazard function is

$$h(t) = \sum_{i=1}^n h_i(t), \tag{10.10}$$

where $S_i(t)$ is the survival function and $h_i(t)$ is the hazard function of T_i .

The probability density function is the product of the hazard in Equation 10.10 and the survival in Equation 10.9. The probability density for a failure in any individual at time t is

$$(h_1(t) + \dots + h_n(t)) \prod_{i=1}^n S_i(t). \quad (10.11)$$

If the first failure occurred in person k , then the likelihood contribution would be

$$h_k(t) \prod_{i=1}^n S_i(t). \quad (10.12)$$

because the person who has an event contributes a hazard term and everyone (including the person who failed) contributes a survival term. To calculate the conditional probability that the failure occurred in person k given that there was a failure at time t , we divide the likelihood in Equation 10.12 by the likelihood in Equation 10.11:

$$\frac{h_k(t) \prod_{i=1}^n S_i(t)}{(h_1(t) + \dots + h_n(t)) \prod_{i=1}^n S_i(t)} = \frac{h_k(t)}{h_1(t) + \dots + h_n(t)}.$$

The survival functions cancel out, leaving only the hazards. Given that there is a failure at time t , the probability that it occurred in person k is proportional to their hazard $h_k(t)$.

The same logic applies to failures other than the first. As before, let $\mathcal{R}(t)$ denote the risk set (i.e., the set of individuals at risk of an observed event) at time t . Given that a failure occurs at time t , the probability that it occurred in person k is

$$\frac{h_k(t)}{\sum_{j \in \mathcal{R}(t)} h_j(t)}.$$

At any failure time t , these probabilities add up to one. If we substitute the hazard function for the Cox model from Equation 10.8, we get

$$\frac{e^{\beta x_k} h_0(t)}{\sum_{j \in \mathcal{R}(t)} e^{\beta x_j} h_0(t)} = \frac{e^{\beta x_k}}{\sum_{j \in \mathcal{R}(t)} e^{\beta x_j}}.$$

because the baseline hazard $h_0(t)$ cancels out. When there are no tied failure times, let i be the index of the individual who has an event at time t_i . Then the Cox partial likelihood is

$$L_{\text{Cox}}(\beta) = \prod_{i=1}^m \frac{e^{\beta x_i}}{\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j}}.$$

The risk sets are determined in exactly the same way as the Kaplan-Meier and Nelson-Aalen estimators in Chapter 6, so the Cox model can handle left truncation (i.e., delayed entry) and right censoring. It uses the same data from Equation 10.4 as the AFT models. For estimation of β , the partial likelihood can be used just like a normal likelihood. This is a consequence of the fact that it can be derived as a *profile likelihood* where the likelihood for β is the full likelihood maximized over all possible baseline hazard functions (Johansen 1983).

10.8.3 Correction for ties*

There are three common methods for dealing with ties in a Cox model (in order of complexity): Breslow, Efron, and exact. The Breslow approximation (Peto 1972; Norman Breslow 1974) is the simplest but least accurate. The exact method is accurate but computationally complex (Kalbfleisch and Prentice 2011). The Efron approximation (Efron 1977) is both accurate and computationally efficient. All of these methods assume that failures happen in continuous time and that ties are caused by rounding off of survival times (i.e., times measured to the day or week rather than hour, minute, and second).

10.8.3.1 Exact method

If there are tied survival times at time t_i , then the exact method calculates the mean partial likelihood contribution at time t_i over all $d_i!$ possible ways of breaking ties among the people who failed at time t_i (Kalbfleisch and Prentice 2011). These calculations get complex quickly—there are $5! = 120$ ways to break ties among 5 events, $10! = 3,628,800$ ways among 10 events, $15! \approx 1.3$ trillion ways among 15 events, and so on. For simplicity, we illustrate the calculation for two events.

Let A and B denote the indices of the individuals who fail at time t_i , with $d_i = 2$. Let x_A and x_B denote their covariates. There are two ways to break the tie: A fails first or B fails first. If A fails first, then the partial likelihood contribution from the two failures is

$$\frac{e^{\beta x_A}}{\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j}} \times \frac{e^{\beta x_B}}{\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right) - e^{\beta x_A}},$$

where the denominator in the second term accounts for the fact that A is no longer in the risk set when B fails. If B fails first, the likelihood contribution from the two failures is

$$\frac{e^{\beta x_B}}{\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j}} \times \frac{e^{\beta x_A}}{\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right) - e^{\beta x_B}},$$

where the denominator in the second term accounts for the fact that B is no longer in the risk set when A fails. In both cases, the numerator is $e^{\beta x_A + \beta x_B}$, but the denominator is slightly different. If both possibilities are equally likely (which is true if $\beta = 0$ or $x_A = x_B$), the average likelihood contribution is

$$\begin{aligned} & \frac{1}{2} \frac{e^{\beta(x_A + x_B)}}{\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right) \left[\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right) - e^{\beta x_A} \right]} \\ & + \frac{1}{2} \frac{e^{\beta(x_A + x_B)}}{\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right) \left[\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right) - e^{\beta x_B} \right]} \end{aligned} \quad (10.13)$$

Extending this to larger numbers of ties is straightforward but tedious. When there are failure times with a large number of ties, this approach becomes computationally intractable.

10.8.3.2 Efron approximation

Let $\mathcal{D}(t_i)$ denote the set of individuals who fail at time t_i . The Efron approximation (Efron 1977) approximates the denominator of the exact estimate using the mean relative hazard among the d_i individuals in $\mathcal{D}(t_i)$, which is

$$\frac{1}{d_i} \sum_{j \in \mathcal{D}(t_i)} e^{\beta x_j}.$$

This is also the average amount taken out of the sum in the denominator for each of the first $d_i - 1$ failures at time t_i . The Efron approximation to the exact mean likelihood contribution is

$$\frac{\prod_{j \in \mathcal{D}(t_i)} e^{\beta x_j}}{\prod_{k=1}^{d_i} \left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} - \frac{k-1}{d_i} \sum_{j \in \mathcal{D}(t_i)} e^{\beta x_j} \right)}$$

This is easy to calculate and is a good approximation to the exact mean likelihood contribution even when there are many ties.

In our example with two tied failures, the Efron approximation to the likelihood contribution in equation~(??) is

$$\frac{e^{\beta(x_A + x_B)}}{\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right) \left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} - \frac{1}{2} (e^{\beta x_A} + e^{\beta x_B}) \right)}. \quad (10.14)$$

In the second term in the denominator, we have taken out the average of individuals A and B .

10.8.3.3 Breslow approximation

The Breslow approximation (Peto 1972; N. E. Breslow 1972) simply ignores the fact that failures are removed from the risk set, giving the following approximation to the exact likelihood contribution:

$$\frac{\prod_{j \in D_i} e^{\beta X_j}}{\left(\sum_{j \in R_i} e^{\beta X_j} \right)^{d_i}}.$$

In our example with tied failure times in y and z , the Breslow approximation to the likelihood contribution in Equation 10.13 is

$$\frac{e^{\beta(x_A + x_B)}}{\left(\sum_{j \in \mathcal{R}(t_i)} e^{\beta x_j} \right)^2}.$$

This leaves the first person to fail (A or B) in the risk set when the second person fails. When the size of the risk set is large compared to the number of failures, this is not a terrible approximation. However, the Efron approximation stays accurate when ties become more severe.

10.8.4 Estimation of baseline survival and cumulative hazard*

Given an estimate of $\hat{\beta}$ of β_{true} , we can estimate the baseline cumulative hazard

$$H_0(t) = \int_0^t h(u) \, du$$

and the baseline survival

$$S_0(t) = e^{-H_0(t)}.$$

This allows us to estimate the cumulative hazard or survival for any given combination of covariates x : We can also estimate the cumulative hazard function for any given covariate x :

$$\hat{H}(t, x) = e^{\hat{\beta}x} \hat{H}_0(t)$$

and

$$\hat{S}(t, x) = e^{-\hat{H}(t, x)}.$$

Thus, a Cox model can be used to estimate risks, odds, and measures of association such as the risk difference, risk ratio, or odds ratio. As in Section 10.1, these measures of association will often depend on t .

One way to estimate the baseline cumulative hazard is to calculate a Nelson-Aalen estimate in the subset with $X = 0$. However, it is much more efficient to use all of the data. Here, we look at three methods that do this. Two of them are generalizations of the Nelson-Aalen estimator, and one is a generalization of the Kaplan-Meier estimator. Variance estimation for these baseline hazard estimators accounts for two sources of uncertainty: the uncertainty in our estimate of β_{true} and the uncertainty that we would have in the baseline cumulative hazard or survival even if we knew β_{true} (similar to the variance of the Nelson-Aalen estimator in Section 6.4 or Kaplan-Meier estimator in Section 6.2). For simplicity, we will focus only on the point estimates.

10.8.4.1 Breslow estimate of the baseline cumulative hazard

The Breslow estimator of $H_0(t)$ is

$$\hat{H}_0(t) = \sum_{i: t_i \leq t} \frac{d_i}{\sum_{j \in \mathcal{R}(t_i)} e^{\hat{\beta}x_j}},$$

where $\hat{\beta}$ is the maximum partial likelihood estimate of β (N. E. Breslow 1972). When $\hat{\beta} = 0$, this reduces to the Nelson-Aalen estimator from Section 6.4.

10.8.4.2 Efron estimate of the baseline cumulative hazard

The Efron estimate of $H_0(t)$ handles ties in the same way as the Efron approximation for the partial likelihood. Whenever there are $d_i > 1$ failures at time t_i in risk set R_i , the contribution to the cumulative hazard estimate is

$$\sum_{k=1}^{d_i} \frac{1}{\sum_{j \in \mathcal{R}(t_i)} e^{\hat{\beta}x_j} - \frac{k-1}{d_i} \sum_{j \in \mathcal{D}(t_i)} e^{\hat{\beta}x_j}},$$

where $\mathcal{D}(t_i)$ represents the set of d_i individuals who failed. The Efron estimate of $H_0(t)$ is

$$\hat{H}_0(t) = \sum_{i: t_i \leq t} \sum_{k=1}^{d_i} \frac{1}{\sum_{j \in \mathcal{R}(t_i)} e^{\hat{\beta}x_j} - \frac{k-1}{d_i} \sum_{j \in \mathcal{D}(t_i)} e^{\hat{\beta}x_j}}.$$

When $\hat{\beta} = 0$, this reduces to the Nelson-Aalen estimator with the Fleming-Harrington correction for ties from Section 6.4.1.

10.8.4.3 Kalbfleisch-Prentice estimate of the baseline survival

The Kalbfleisch-Prentice estimate of the survival function is based on treating the observed failure times as discrete time points where the probability of failure at time t_i is $1 - s_i$ when $X = 0$. Let $\mathbf{s} = (s_1, \dots, s_m)$. Then the likelihood for the data is

$$L(\mathbf{s}) = \prod_{i=1}^m \left(\prod_{j \in \mathcal{D}(t_i)} \left(1 - s_i^{\exp(\hat{\beta}x_j)} \right) \prod_{j \in \mathcal{R}(t_i) \setminus \mathcal{D}(t_i)} s_i^{\exp(\hat{\beta}x_j)} \right),$$

where $\mathcal{R}(t_i) \setminus \mathcal{D}(t_i)$ is the set of people in the risk set at time t_i who did not fail. The corresponding log likelihood is

$$\ell(\mathbf{s}) = \sum_{i=1}^m \left(\sum_{j \in \mathcal{D}(t_i)} \ln \left(1 - s_i^{\exp(\hat{\beta}x_j)} \right) + \sum_{j \in \mathcal{R}(t_i) \setminus \mathcal{D}(t_i)} e^{\hat{\beta}x_j} \ln s_i \right).$$

Differentiating $\ell(\mathbf{s})$ with respect to s_i and rearranging, we find that s_i solves the equation

$$\sum_{j \in \mathcal{D}(t_i)} \frac{e^{\hat{\beta}x_j}}{1 - s_i^{\exp(\hat{\beta}x_j)}} = \sum_{j \in \mathcal{R}(t_i) \setminus \mathcal{D}(t_i)} e^{\hat{\beta}x_j}. \quad (10.15)$$

When $d_i = 1$ and person i fails at time t_i , this is solved by

$$\hat{s}_i = \left(1 - \frac{e^{\hat{\beta}x_i}}{\sum_{j \in \mathcal{R}(t_i)} e^{\hat{\beta}x_j}} \right)^{\exp(-\hat{\beta}x_i)}.$$

When $d_i > 1$, Equation 10.15 must be solved numerically. The Kalbfleisch-Prentice estimate of the survival function is

$$\hat{S}_0(t) = \prod_{i: t_i \leq t} \hat{s}_i.$$

When $\hat{\beta} = 0$, this reduces to the Kaplan-Meier survival estimate from Section 6.2.

10.9 R

Listing 10.1 loglogistic-HR.R

```
## Rate ratios and hazard ratios for the log-logistic distribution

# log-logistic hazard function
hllog <- function(t, shape=1, rate=1) {
  shape * rate^shape * t^(shape - 1) / (1 + (rate * t)^shape)
}

# save old graphics parameters to restore them
mfrow_old <- par("mfrow")
mar_old <- par("mar")

# set two rows and one column and adjust margins between plots
par(mar = c(4, 4, 1, 1), mfrow = c(2, 1))

# hazards with shape = 2 and rates = 2 and 1
t <- seq(0.01, 3, by = 0.01)
plot(t, hllog(t, shape = 2, rate = 2), type = "l", lty = "dashed",
      xlab = "", ylab = "Hazard")
lines(t, hllog(t, shape = 2, rate = 1))
grid()
text(2.5, 1.75, labels = "both shape = 2")
text(1.0, 0.75, labels = "rate = 1")
text(1.25, 1.75, labels = "rate = 2")

# hazard ratio
plot(t, hllog(t, 2, 2) / hllog(t, 2, 1), type = "l", ylim = c(0, 4),
      xlab = "Time", ylab = "Hazard ratio")
grid()
text(2.5, 3.5, labels = "rate ratio = 2")

# restore old graphics parameters
par(mar = mar_old, mfrow = mfrow_old)
```

Listing 10.2 Weibull-OR.R

```
## Rate ratios and odds ratios for the Weibull distribution

# log-logistic odds function
odds_weib <- function(t, shape=1, rate=1) {
  p <- 1 - exp(-(rate * t)^shape)
  p / (1 - p)
}

# save old graphics parameters to restore them
mfrow_old <- par("mfrow")
mar_old <- par("mar")

# set two rows and one column and adjust margins between plots
par(mar = c(4, 4, 1, 1), mfrow = c(2, 1))

# odds with shape = 2 and rates = 1 and 2
t <- seq(0.01, 0.6, by = 0.01)
plot(t, odds_weib(t, shape = 2, rate = 2), type = "l", lty = "dashed",
      xlab = "", ylab = "Odds")
lines(t, odds_weib(t, shape = 2, rate = 1))
grid()
text(0.1, 2.75, labels = "both shape = 2")
text(0.4, 0.4, labels = "rate = 1")
text(0.4, 1.3, labels = "rate = 2")

# odds ratio
plot(t, odds_weib(t, 2, 2) / odds_weib(t, 2, 1), type = "l", ylim = c(0, 8),
      xlab = "Time", ylab = "Odds ratio")
grid()
text(0.1, 7, labels = "rate ratio = 2")

# restore old graphics parameters
par(mar = mar_old, mfrow = mfrow_old)
```

Listing 10.3 AFT-exponential.R

```
## Exponential accelerated failure time (AFT) model

# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)          # rats data and survreg()
library(lmtest)            # coefci() for Wald confidence intervals

# exponential AFT model
# Default distribution is Weibull, so we must specify dist = "exponential".
# Coefficients are log scale parameters = -log rate parameters.
aft_exp <- survreg(Surv(time, status) ~ rx, data = rats, dist = "exponential")
exp(-coef(aft_exp))        # estimated rate (x = 0) and rate ratio
exp(-confint(aft_exp))     # log-transformed 95% Wald confidence intervals

# estimated rate in the exposed
lnrate1hat <- -sum(coef(aft_exp))
lnrate1var <- as.numeric(c(1, 1) %*% vcov(aft_exp) %*% c(1, 1))
lnrate1ci <- lnrate1hat + c(-1, 1) * qnorm(0.975) * sqrt(lnrate1var)
exp(lnrate1hat)            # point estimate
exp(lnrate1ci)            # log-transformed 95% Wald confidence interval

# exponential AFT results match Poisson GLM with log(rat-weeks) offset
IRRglm <- glm(status ~ rx + offset(log(time)), family = poisson(), data = rats)
exp(coef(IRRglm))          # estimated incidence rate (x = 0) and IRR
exp(coefci(IRRglm))        # log-transformed Wald CIs matches above

# compare with nonparametric estimates
# Nelson-Aalen estimates (with Fleming-Harrington correction for ties)
# Formula ~ rx produces a separate estimate for each treatment group.
# Arguments stype = 2 and ctype = 2 produces NA estimate with FH correction.
ratsNA <- survfit(Surv(time, status) ~ rx, data = rats,
                  stype = 2, ctype = 2, conf.type = "log-log")

# plot of Nelson-Aalen cumulative hazard curves in treated and untreated rats
plot(ratsNA, fun = "cumhaz", col = c("darkgray", "black"),
     xlab = "Weeks after treatment", ylab = "Cumulative hazard")
grid()
legend("topleft", bg = "white", lty = rep(c("solid", "dashed"), times = 2),
     col = rep(c("black", "darkgray"), each = 2),
     legend = c("Control (Nelson-Aalen)", "Control (Exponential AFT model)",
                "Treated (Nelson-Aalen)", "Treated (Exponential AFT model)"))

# estimated cumulative hazards from exponential AFT model
aft_exp <- survreg(Surv(time, status) ~ rx, data = rats, dist = "exponential")
rate1_exp <- as.numeric(exp(-c(1, 1) %*% coef(aft_exp)))
rate0_exp <- exp(-coef(aft_exp)["(Intercept)"])
H_exp <- function(t, rate) rate * t

# add lines to plot
t <- seq(0, max(ratsNA$time), by = 0.1)
lines(t, H_exp(t, rate1_exp), lty = "dashed", col = "black")
```

Listing 10.4 AFT-Weibull.R

```
## Weibull accelerated failure time (AFT) model

# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)          # rats data and survreg()

# Weibull accelerated failure time model
# The Weibull distribution is the default for survival::survreg().
# Coefficients are log scale parameters = -log rate parameters.
aft_weib <- survreg(Surv(time, status) ~ rx, data = rats)
exp(-coef(aft_weib)["rx"])    # estimated rate (x = 0) and rate ratio
exp(-confint(aft_weib)["rx", ]) # log-transformed 95% Wald confidence intervals
shapehat <- 1 / aft_weib$scale # shape parameter point estimate
shapehat

# shape parameter Z-score and p-value
# The null hypothesis shape = 0 corresponds to an exponential distribution.
lnshapevar <- vcov(aft_weib)["Log(scale)", "Log(scale)"]
shapeZ <- log(shapehat) / sqrt(lnshapevar)
shapeZ
2 * pnorm(-abs(shapeZ))

# shape parameter 95% CI
exp(-log(aft_weib$scale) + c(-1, 1) * qnorm(.975) *
    sqrt(vcov(aft_weib)["Log(scale)", "Log(scale)"])))

# estimated rate in the exposed
lnrate1hat <- -sum(coef(aft_weib))
lnrate1var <- as.numeric(c(1, 1, 0) %*% vcov(aft_weib) %*% c(1, 1, 0))
lnrate1ci <- lnrate1hat + c(-1, 1) * qnorm(0.975) * sqrt(lnrate1var)
exp(lnrate1hat)          # point estimate
exp(lnrate1ci)           # log-transformed 95% Wald confidence interval

# compare with nonparametric estimates
# Nelson-Aalen estimates (with Fleming-Harrington correction for ties)
# Formula ~ rx produces a separate estimate for each treatment group.
# Arguments stype = 2 and ctype = 2 produces NA estimate with FH correction.
ratsNA <- survfit(Surv(time, status) ~ rx, data = rats,
    stype = 2, ctype = 2, conf.type = "log-log")

# plot of Nelson-Aalen cumulative hazard curves in treated and untreated rats
plot(ratsNA, fun = "cumhaz", col = c("darkgray", "black"),
    xlab = "Weeks after treatment", ylab = "Cumulative hazard")
grid()
legend("topleft", bg = "white", lty = 269, bty = "n",
    col = rep(c("black", "darkgray"), each = 2),
    legend = c("Control (Nelson-Aalen)", "Control (Weibull AFT model)",
        "Treated (Nelson-Aalen)", "Treated (Weibull AFT model)"))

# estimated cumulative hazards from Weibull AFT model
aft_weib <- survreg(Surv(time, status) ~ rx, data = rats)
```

Listing 10.5 AFT-loglogistic.R

```
## Log-logistic accelerated failure time (AFT) model

# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)          # rats data and survreg()

# Log-logistic accelerated failure time model
# Default distribution is Weibull, so we must specify dist = "loglogistic".
# Coefficients are log scale parameters = -log rate parameters.
aft_llog <- survreg(Surv(time, status) ~ rx, data = rats, dist = "loglogistic")
exp(-coef(aft_llog)["rx"])    # estimated rate (x = 0) and rate ratio
exp(-confint(aft_llog)["rx", ]) # log-transformed 95% Wald confidence intervals
1 / aft_llog$scale           # shape parameter point estimate

# shape parameter 95% CI
exp(-log(aft_llog$scale) + c(-1, 1) * qnorm(.975) *
    sqrt(vcov(aft_llog)["Log(scale)", "Log(scale)"])))

# estimated rate in the exposed
lnrate1hat <- -sum(coef(aft_llog))
lnrate1var <- as.numeric(c(1, 1, 0) %*% vcov(aft_llog) %*% c(1, 1, 0))
lnrate1ci <- lnrate1hat + c(-1, 1) * qnorm(0.975) * sqrt(lnrate1var)
exp(lnrate1hat)           # point estimate
exp(lnrate1ci)            # log-transformed 95% Wald confidence interval

# compare with nonparametric estimates
# Nelson-Aalen estimates (with Fleming-Harrington correction for ties)
# Formula ~ rx produces a separate estimate for each treatment group.
# Arguments stype = 2 and ctype = 2 produces NA estimate with FH correction.
ratsNA <- survfit(Surv(time, status) ~ rx, data = rats,
    stype = 2, ctype = 2, conf.type = "log-log")

# plot of Nelson-Aalen cumulative hazard curves in treated and untreated rats
plot(ratsNA, fun = "cumhaz", col = c("darkgray", "black"),
    xlab = "Weeks after treatment", ylab = "Cumulative hazard")
grid()
legend("topleft", bg = "white", lty = rep(c("solid", "dashed"), times = 2),
    col = rep(c("black", "darkgray"), each = 2),
    legend = c("Control (Nelson-Aalen)", "Control (Log-logistic AFT model)",
        "Treated (Nelson-Aalen)", "Treated (Log-logistic AFT model)"))

# estimated cumulative hazards from log-logistic AFT model
aft_llog <- survreg(Surv(time, status) ~ rx, data = rats, dist = "loglogistic")
rate1_llog <- as.numeric(exp(-c(1, 1) %*% coef(aft_llog)))
rate0_llog <- exp(-coef(aft_llog)["(Intercept)"])
shape_llog <- 1 / aft_llog$scale
H_llog <- function(t, shape, rate) log(1 + (rate * t)^shape)

# add lines to plot
t <- seq(0, max(ratsNA$time), by = 0.1)
lines(t, H_llog(t, shape_llog, rate1_llog), lty = "dashed")
```

Listing 10.6 logrank.R

```
## Log-rank test

# The log-rank test is done using survdiff() is in the survival package.
# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)          # rats data and survdiff
library(lmtest)            # coeftest() for Wald test of coefficients

# log-rank test (rho = 0 by default)
# More tumor incidence observed than expected under the null in treated rats.
survdiff(Surv(time, status) ~ rx, data = rats)

# Peto-Prentice test (rho = 1)
# More tumor incidence observed than expected under the null in treated rats.
survdiff(Surv(time, status) ~ rx, data = rats, rho = 1)

# comparison with parametric AFT models
# exponential
aft_exp <- survreg(Surv(time, status) ~ rx, data = rats, dist = "exponential")
coeftest(aft_exp)["rx", "Pr(>|z|)"]
# Weibull
aft_weib <- survreg(Surv(time, status) ~ rx, data = rats, dist = "weibull")
coeftest(aft_weib)["rx", "Pr(>|z|)"]
# log-logistic
aft_llog <- survreg(Surv(time, status) ~ rx, data = rats, dist = "loglogistic")
coeftest(aft_llog)["rx", "Pr(>|z|)"]
```

Listing 10.7 Cox-model.R

```
## Cox proportional hazards regression model

# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)          # rats data and survreg()

# Cox model with Efron correction for ties (the default)
# With a single binary predictor, the global score test is the log-rank test.
cox_efron <- coxph(Surv(time, status) ~ rx, data = rats)
names(cox_efron)
summary(cox_efron)

# coefficient point estimates, confidence intervals, and covariance matrix
coef(cox_efron)
confint(cox_efron)
vcov(cox_efron)

# hazard ratio and confidence intervals
exp(coef(cox_efron))
exp(confint(cox_efron))

# Breslow correction for ties
table(rats$time[rats$status == 1]) # table of number of tumor onsets
cox_breslow <- coxph(Surv(time, status) ~ rx, data = rats,
                    ties = "breslow")
summary(cox_breslow)
cox_breslow$method

# exact correction for ties
cox_exact <- coxph(Surv(time, status) ~ rx, data = rats,
                  ties = "exact")
summary(cox_exact)
cox_exact$method

# predicted survival in both treatment groups
# Method for estimating survival mirrors method used to correct for ties.
S_pred <- survfit(cox_efron, newdata = data.frame(rx = c(0, 1)),
                 conf.type = "log-log")
S_summary <- summary(S_pred, times = c(20, 40, 60, 80))
S_summary
names(S_summary)
S_summary$newdata      # order of predicted survival probabilities, etc.
S_summary$conf.int     # confidence level
S_summary$lower        # lower 95% confidence limits
S_summary$upper        # upper 95% confidence limits

# predicted cumulative hazard and confidence limits
# The lower bound for H(t) comes from the upper bound for S(t) and vice versa.
S_summary$cumhaz
-log(S_summary$surv)
-log(S_summary$upper)
```


11 Design and Analysis of Case-Control and Case-Cohort studies

An investigation that involves selecting representative groups of those having and not having a characteristic is expensive and time consuming, however, and is rarely if ever used. Actual practice in the field is to take two groups presumed to be representative of persons who do and do not have the disease and determine the percentage in each group who have the characteristic. Thus rather than determine the percentage of smokers and nonsmokers who have cancer of the lung, one determines the percentage of persons with and without cancer of the lung who are smokers. (Cornfield 1951)

In a cohort study, we select participants based on exposure X and follow them over time to ascertain the occurrence of disease D . When the disease is rare or when the time to disease onset is long, estimating a measure of association might take a large cohort or a long follow-up period. Because we have selected based on exposure, the study is powered to estimate the association between X and any disease outcome. However, it may not be better than a random sample from the population for looking the association between a different exposure X' and disease outcomes. When there is no clear hypothesis about the cause of a disease, it can be difficult to select a useful cohort based on exposure.

The case-control study was one of the great innovations in epidemiology in the 20th century (Nigel Paneth, Susser, and Susser 2002; Nigl Paneth, Susser, and Susser 2002). In a case-control study, we select participants based on disease outcome D and then measure their exposure X . This study design is powered to estimate the association between D and any exposure, which makes it useful for rare diseases and common exposures or for a disease for which there is no clear hypothesis about its causes. It was the study design that was used to establish that smoking causes lung cancer (Doll and Hill 1950), aspirin causes Reyes syndrome (Hurwitz et al. 1987), and that prenatal exposure to diethylstilbestrol causes vaginal clear-cell adenocarcinoma (Herbst, Ulfelder, and Poskanzer 1971). In each case, there was a rare or slowly-developing disease and no clear hypothesis about its causes.

While case control studies are more efficient than cohort studies with the same total number of participants for rare diseases and common exposures (see Section 7.6), they have less flexibility in the choice of a measure of association. The odds ratio in a case-control study approximates the risk ratio or hazard ratio from a hypothetical cohort study in the same population (Pearce 1993) However, data from a case-control study can be used to estimate absolute risks or rates

if there is additional information such as the sampling fraction of cases, the total size of the population giving rise to the cases and controls, or the overall incidence of disease (O. Miettinen 1976). Case-control studies are often retrospective, and retrospective studies can be more susceptible to differential misclassification (e.g., recall bias) and selection bias than prospective studies (see Section 8.2.3).

11.1 Case-control studies for rare diseases

In case-control studies, the odds ratio for exposure comparing cases to controls approximates the risk ratio or the incidence rate ratio that would be calculated from a large cohort study in the population from which the cases and control are sampled.

11.1.1 Cumulative case-control studies and the odds ratio

In a **cumulative case-control study**, controls are sampled from the people in the population who do not have disease. Using the notation from Table 2.1, the risk ratio comparing the exposed to the unexposed is

$$RR = \frac{a/r_1}{c/r_0} = \frac{a/c}{r_1/r_0}. \quad (11.1)$$

The final expression is an odds ratio because the numerator is the odds of exposure among the cases and the denominator is the odds of exposure in the entire cohort. This use of the odds ratio to approximate the risk ratio was first proposed by Cornfield (1951).¹ When the disease is rare in both exposure groups in a cohort study, $a \ll r_1$ and $c \ll r_0$ so

$$\frac{r_1}{r_0} \approx \frac{r_1 - a}{r_0 - c} = \frac{b}{d}.$$

Therefore,

$$RR = \frac{a/r_1}{c/r_0} \approx \frac{a/c}{b/d} = OR_X$$

so the odds ratio for exposure comparing those with $D = 1$ (cases) to those with $D = 0$ (controls) approximates the risk ratio for disease comparing the exposed to the unexposed.

¹Jerome Cornfield (1912–1979) was an American statistician who spent most of his career at the National Cancer Institute. He joined the US Bureau of Labor Statistics during the Great Depression and took math and statistics courses at the US Department of Agriculture. He combined the case control data of Doll and Hill (1950) and National Institutes of Health data to calculate the risk of lung cancer among smokers, and he showed that this strong association could not plausibly be explained by any known source of bias. He also helped design the [Framingham Heart Study](#), a large cohort study of risk factors for heart disease that began in 1948.

The odds ratio comparing cases to controls can be calculated in a case-control study, where we select participants based on disease status. From Section 9.2.1, the variance of the log risk ratio is

$$\text{Var}(\ln \text{RR}) = \frac{1}{a} - \frac{1}{r_1} + \frac{1}{c} - \frac{1}{r_0} \approx \frac{1}{a} + \frac{1}{c} \quad (11.2)$$

when the risks of disease p_1 and p_0 are both small. Thus, the precision of the risk ratio estimate in a large cohort study with a rare disease is determined almost entirely by the number of cases in each exposure group. Instead of recruiting a large population and waiting for cases to occur, it is more efficient to recruit cases directly, measure their exposure, and compare their exposure odds to those of a sample of controls.

The variance of the log odds ratio is

$$\text{Var}(\ln \text{OR}) = \frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}. \quad (11.3)$$

If we recruit k controls per case, then

$$\text{Var}(\ln \text{OR}) = \frac{1}{a} + \frac{1}{ka} + \frac{1}{c} + \frac{1}{kc} = \left(1 + \frac{1}{k}\right) \left(\frac{1}{a} + \frac{1}{c}\right). \quad (11.4)$$

Let σ_{cc} be the standard error the $\ln \text{RR}$ estimated via the $\ln \text{OR}$ from a case-control study with k controls per case, and let σ_{cohort} be the standard error of the estimated $\ln \text{RR}$ from a large cohort study with a rare disease. Comparing Equation 11.2 and Equation 11.4, we get

$$\sigma_{\text{cc}} \approx \sigma_{\text{cohort}} \sqrt{1 + \frac{1}{k}}. \quad (11.5)$$

Figure 11.1 plots this function. A case-control study with $k = 5$ has about 10% higher standard error than a full cohort study, and a case-control study with $k = 10$ has about 5% higher standard error. In practice, most case-control studies recruit 3–5 controls per case.

Listing 11.1 casecontrol-SE.R

```
## Ratio of case-control and cohort standard errors

# plot
cpc <- 1:10      # controls per case
plot(cpc, sqrt(1 + 1 / cpc), ylim = c(0, 2),
     xlab = "Controls per case",
     ylab = expression(sigma[plain(cc)] / sigma[plain(cohort)]))
grid()
abline(h = 1, col = "darkgray")
```




Figure 11.1: The standard error of the estimated $\ln RR$ from a cumulative case-control study or the estimated $\ln IRR$ from a density case-control study divided by the standard error of corresponding estimator from a large cohort study with the same number of cases.

11.2 R

11.2.1 Density case-control studies and risk-set sampling

The cumulative case-control design implicitly assumes complete follow-up (so that it is possible to sample from the entire non-diseased population at the end of follow-up). In a **density case-control study**, the odds ratio for exposure is meant to approximate the incidence rate ratio IRR. The name comes from the use of *incidence density* to refer to an incidence rate. If we have a cases from T_1 units of person-time among the exposed and c cases from T_0 units of person-time among the unexposed, the incidence rate ratio is

$$\text{IRR} = \frac{a/T_1}{c/T_0} = \frac{a/c}{T_1/T_0}. \quad (11.6)$$

The numerator is the odds ratio for exposure among the cases, and the denominator is the odds ratio for exposure among units of person-time.

In **risk set sampling** (sometimes called *incidence density sampling*), controls are sampled from the risk set at each failure time. As described in Section 6.2.1, the risk set $\mathcal{R}(t)$ consists of all participants at risk of an observed event at time t . This produces a set of controls with an exposure odds b/d approximately equal to T_1/T_0 when each group has exponential times to events (as assumed by the use of incidence rates—see Section 5.3.2) and the prevalence of exposure does not change over time (O. Miettinen 1976). When these assumptions are approximately correct,

$$\text{IRR} \approx \frac{a/c}{b/d} = \text{OR}_X$$

so the odds ratio for exposure comparing cases to controls approximates the incidence rate ratio for disease comparing the exposed to the unexposed. From Section 9.4.1,

$$\text{Var}(\ln \text{IRR}) = \frac{1}{a} + \frac{1}{c}.$$

In a density case-control study, the same control can be selected for multiple cases, and a person who is selected as a control can later become a case. If the disease is rare, there will be little or no overlap between cases and controls, so the variance of the estimated $\ln \text{OR}$ when we recruit k controls per case is given by Equation 11.4. Then relationship in Equation 11.5 and Figure 11.1 holds if σ_{cc} is the standard error the estimated $\ln \text{IRR}$ from a density case-control study and σ_{cohort} is the standard error of the estimated $\ln \text{RR}$ from a large cohort study.

In a closed cohort, the prevalence of exposure will stay approximately constant only under the null hypothesis of no exposure-disease association or when the risk of disease over the follow-up period is small in both exposure groups. For rare diseases with exponential times to events,

$$\text{RR} = \frac{1 - e^{-\lambda_1 t}}{1 - e^{-\lambda_0 t}} \approx \frac{\lambda_1}{\lambda_0} = \text{IRR}$$

where λ_1 is the incidence rate in the exposed and λ_0 is the incidence rate in the unexposed. Thus, the incidence rate ratio estimated by a density case-control study of a rare disease is

also an approximation to the risk ratio from a large cohort study. The approximation to the risk ratio from a density case-control study is generally more accurate than that of a cumulative case-control study (Greenland and Thomas 1982). The reason for this can be seen in Figure 11.2, where the contours for the incidence rate ratio (which is a special case of the hazard ratio) are closer to the risk ratio contours than the odds ratio contours are. These are the same contour lines shown in Figure 9.3, but they are plotted together and we have zoomed in to the bottom left corner.




Figure 11.2: Rothman diagram (Rothman 1975; Kenah 2024) with contour lines for the risk ratio, incidence rate ratio, and odds ratio for rare diseases. Each group of contours is labeled with their common value.

Table 11.1: “2x2 table” of exposure, cases, noncases, subcohort, and study sample in a case-cohort study.

	Cases	Noncases	Subcohort	Study Sample
$X = 1$	$a = a_x + a_s$	b	$r_{1s} = a_s + b$	$r_1 = a + b$
$X = 0$	$c = c_x + c_s$	d	$r_{0s} = c_s + d$	$r_0 = c + d$
Total	$k_1 = k_{1x} + k_{1s}$	k_0	n_s	n

11.3 R

11.4 Case-cohort studies

From Equation 11.1, the risk ratio for disease comparing the exposed to the unexposed is equal to the odds ratio for exposure comparing the cases to the entire cohort. In a **case-cohort study**, the odds ratio for exposure in the cohort is approximated using the odds ratio for exposure in a random sample of the cohort (Kupper, McMichael, and Spirtas 1975). This random sample is called the **subcohort**. Members of the subcohort are allowed to become cases, but all cases must come from within the original cohort.

Let a_s denote the number of exposed cases that come from the subcohort, and let a_x denote the number of exposed cases that come from outside the subcohort. Similarly define c_s and c_x be the number of unexposed cases from inside and outside the subcohort, respectively. Then $a = a_s + a_x$ is the total number of exposed cases and $c = c_s + c_x$ is the total number of unexposed cases. The total number of cases from the subcohort is

$$k_{1s} = a_s + c_s,$$

and the total number of cases outside the subcohort is

$$k_{1x} = a_x + c_x.$$

The total number of cases is

$$k_1 = a + c = k_{1s} + k_{1x}.$$

The b exposed controls and d unexposed controls are all within the subcohort, and the total number of controls is still $k_0 = b + d$. Table 11.1 shows a 2x2 table adapted to the case-cohort design.

In the notation of Table 11.1,

$$\text{RR}_D \approx \frac{a/c}{r_{1s}/r_{0s}} \quad (11.7)$$

where the last expression is the odds ratio for exposure comparing the cases to the entire subcohort. The variance calculation for the ln OR from a case-cohort study must account for overlap between the cases and the subcohort. When there is no overlap, $r_{1s} = b$ and $r_{0s} = d$ so the variance of the ln OR in Equation 11.3 is correct.

11.4.1 Rare diseases with rare exposures

Section 7.6 showed that a cohort study is the most powerful design for detecting a lack of independence between a rare exposure and a common disease, where $\pi(1 - \pi) < p(1 - p)$ where π is the marginal prevalence of exposure and p is the marginal prevalence of disease. For a common exposure and a rare disease, where $\pi(1 - \pi) > p(1 - p)$, a case-control study is the most powerful design for detecting a lack of independence. The case-cohort design can be efficient when you have a rare exposure and a rare disease: You can sample a cohort by exposure to ensure adequate sample sizes in both exposure groups, and you can sample by disease within the cohort to ensure there are enough cases without following the entire cohort. Sampling by both exposure and disease seems to invite selection bias, but this is prevented by taking cases only within the cohort and by using the odds ratio to approximate the risk ratio as in Equation 11.7.

11.4.2 Estimation without the rare disease assumption*

When there is overlap between the cases and the subcohort, it is possible to get a more efficient estimator of the risk ratio than the estimator in Equation 11.7. To avoid selection bias, the selection of cases within the cohort must be independent of exposure status, so

$$\Pr(\text{in subcohort} \mid \text{case}, X = x) = \Pr(\text{in subcohort} \mid \text{case}).$$

The maximum likelihood estimate of the common probability of being in the subcohort given becoming a case is

$$\hat{\Pr}(\text{in subcohort} \mid \text{case}) = \frac{a_s + c_s}{a + c}.$$

Using this common probability gives us

$$\tilde{a}_s = a \times \hat{\Pr}(\text{in subcohort} \mid \text{case}) = \frac{a(a_s + c_s)}{a + c}$$

expected exposed cases in the subcohort and

$$\tilde{a}_x = a \times \hat{\Pr}(\text{outside subcohort} \mid \text{case}) = \frac{a(a_x + c_x)}{a + c}$$

expected exposed cases outside the subcohort. The total number of exposed cases inside and outside of the subcohort is unchanged because

$$\tilde{a}_s + \tilde{a}_x = \frac{a((a_s + c_s) + (a_x + c_x))}{a + c} = a,$$

Table 11.2: Adjusted “2x2 table” of exposure, noncases, subcohort, and study sample in a case-cohort study.

	Cases	Noncases	Subcohort	Study Sample
$X = 1$	$a = \tilde{a}_x + \tilde{a}_s$	b	$\tilde{r}_{1s} = \tilde{a}_s + b$	$r_1 = a + b$
$X = 0$	$c = \tilde{c}_x + \tilde{c}_s$	d	$\tilde{r}_{0s} = \tilde{c}_s + d$	$r_0 = c + d$
Total	$k_1 = \tilde{k}_{1x} + \tilde{k}_{1s}$	k_0	\tilde{n}_s	n

but the corresponding number of exposed controls is

$$\tilde{r}_1 = \tilde{a}_s + b.$$

The expected number of unexposed cases inside and outside the subcohort is calculated in the same way, leaving the total number of unexposed cases unchanged but altering the number of unexposed members of the subcohort. Table 11.2 shows the adjusted case-cohort 2x2 table.

The estimated risk ratio comparing the exposed to the unexposed is approximated by the odds ratio for exposure comparing cases to the adjusted subcohort:

$$\hat{RR}_{\text{Sato}} = \frac{a/c}{\tilde{r}_{1s}/\tilde{r}_{0s}}. \quad (11.8)$$

The variance for Wald hypothesis tests and confidence intervals is calculated on the log scale:

$$\text{Var}(\ln \hat{RR}_{\text{Sato}}) = \frac{1}{a} + \frac{1}{c} + \frac{k_{1x} - k_{1s}}{k_1} \left(\frac{1}{\tilde{r}_{1s}} + \frac{1}{\tilde{r}_{0s}} \right) - \frac{n^2 k_{1x} k_{1s} a c}{k_1^3 \tilde{r}_{1s}^2 \tilde{r}_{0s}^2} \quad (11.9)$$

This analysis of a case-cohort study spans the range from a cumulative case-control study (when all cases occur outside the subcohort) to a cohort study (when the subcohort is the entire cohort).

11.4.2.1 All cases outside the subcohort: cumulative case-control study

When the disease is sufficiently rare that all cases occur outside the subcohort, we have $k_{1s} = 0$ and $k_{1x} = k_1$. Thus, $\tilde{a}_s = \tilde{c}_s = 0$. Plugging these into Equation 11.8, we get the estimated risk ratio

$$\hat{RR}_{\text{Sato}} = \frac{a/c}{\tilde{r}_{1s}/\tilde{r}_{0s}} = \frac{a/c}{b/d},$$

which is the odds ratio from a cumulative case-control study. Plugging these into Equation 11.9, we get

$$\text{Var}(\ln \hat{RR}_{\text{Sato}}) = \frac{1}{a} + \frac{1}{c} + \frac{1}{\tilde{r}_{1s}} + \frac{1}{\tilde{r}_{0s}} = \frac{1}{a} + \frac{1}{c} + \frac{1}{b} + \frac{1}{d},$$

which the large-sample variance of the log odds ratio from Equation 11.3. Thus, the case-cohort point and interval estimates of the risk ratio match those of the cumulative case-control study in Section 11.1.1.

11.4.2.2 All cases in the subcohort: cohort study

When the subcohort includes the entire cohort, we have $k_{1x} = 0$ and $k_{1s} = k_1$, so $\tilde{a}_s = a$ and $\tilde{c}_s = c$. It follows that $\tilde{r}_{1s} = r_1$ and $\tilde{r}_{0s} = r_0$. Plugging these into Equation 11.8, we get the estimated risk ratio

$$\hat{RR}_{\text{Sato}} = \frac{a/c}{\tilde{r}_{1s}/\tilde{r}_{0s}} = \frac{a/r_1}{c/r_0},$$

which is the estimated risk ratio from a cohort study. Plugging these into Equation 11.9, we get

$$\text{Var}(\ln \hat{RR}_{\text{Sato}}) = \frac{1}{a} + \frac{1}{c} - \frac{1}{\tilde{r}_{1s}} - \frac{1}{\tilde{r}_{0s}} = \frac{1}{a} - \frac{1}{r_1} + \frac{1}{c} - \frac{1}{r_0},$$

which the large-sample variance of the log risk ratio from Section 9.2.1. Thus, the case-cohort point and interval estimates of the risk ratio match those of a cohort study.

11.5 Nested case-control studies

The nested case-control study is a generalization of the density case-control study that relaxes the assumption of constant hazards of failure. It was first used to study lung cancer among asbestos miners in Quebec (Liddell, McDonald, and Thomas 1977; Thomas 1977). Let X_j denote the exposure status of person j . The Cox partial likelihood for the log hazard ratio β is

$$L(\beta) = \prod_{i=1}^m \frac{e^{\beta X_i}}{\sum_{j \in \mathcal{R}(t_i)} e^{\beta X_j}},$$

where $t_1 < t_2 < \dots < t_m$ are the distinct failure times, person i is the person who fails at time t_i , and $\mathcal{R}(t)$ is the risk set at time t as in Section 10.8. In a nested case-control study, each risk set $\mathcal{R}(t_i)$ is replaced by a sample $R^*(t_i)$ that includes the individual who had an event and a random sample of other members of $R(t_i)$. The Cox partial likelihood becomes

$$L(\beta) = \prod_{i=1}^m \frac{e^{\beta x_i}}{\sum_{j \in R^*(t_i)} e^{\beta x_j}}. \quad (11.10)$$

By the same logic that led to the Cox partial likelihood for a cohort study, the likelihood contribution at each event time t_i is the conditional probability that an event occurred in individual i given that an event occurred in the matched case-control set $R^*(t_i)$ (Oakes 1981). Maximum likelihood estimation yields consistent and asymptotically normal point and interval estimates for $\hat{\beta}$ without any rare disease assumption (Borgan, Goldstein, and Langholz 1995).

Let $\hat{\beta}_{\text{cc}}$ be the maximum partial likelihood estimate from a nested case-control study and $\hat{\beta}_{\text{cohort}}$ be the maximum partial likelihood estimate from the full cohort. When $\beta = 0$ and there are k controls sampled per case,

$$\text{Var}(\hat{\beta}_{\text{cc}}) \approx \left(1 + \frac{1}{k}\right) \text{Var}(\hat{\beta}_{\text{cohort}})$$

which is the same relationship that held for the cumulative case-control study versus a full cohort study in Figure 11.1. When $\beta \neq 0$, the relative efficiency of a nested case-control study can be somewhat lower than this. However, this efficiency can be improved using more sophisticated strategies of sampling from the risk sets.

11.5.1 Conditional logistic regression

A nested case-control study can be analyzed using **conditional logistic regression**, which produces the partial likelihood in Equation 11.10 using the matched case-control sets (NE Breslow et al. 1978). To see the connection with the logistic regression model (i.e., a binomial generalized linear model with a logit link), consider a matched set with one case and k controls and let p_j the risk of disease in person j . Then the probability that there is one failure and no other failures is

$$\sum_{i=1}^{k+1} \left(p_i \prod_{j \neq i} (1 - p_j) \right) = \sum_{i=1}^{k+1} \frac{p_i}{1 - p_i} \prod_{j=1}^{k+1} (1 - p_j).$$

Without loss of generality, we can number the group members so that person one is the case. The probability that person one is the case given that there is one failure in the group is

$$\frac{\frac{p_1}{1-p_1} \prod_{j=1}^{k+1} (1 - p_j)}{\sum_{i=1}^k \frac{p_i}{1-p_i} \prod_{j=1}^{k+1} (1 - p_j)} = \frac{\text{odds}(p_1)}{\sum_{i=1}^{k+1} \text{odds}(p_j)} \quad (11.11)$$

where $\text{odds}(p_j) = p_j/(1 - p_j)$ is the odds corresponding to p_j . Let $\text{odds}(p_{ij})$ be the odds of disease for person j in the matched case-control set \mathcal{R}_i^* where person i is the case. Then the conditional logistic regression model assumes

$$\text{logit}(p_{ij}) = \ln \text{odds}(p_{ij}) = \beta_{0i} + \beta x_j,$$

where β_{i0} is an intercept specific to \mathcal{R}_i^* and x_j is the covariate for person j . When there are m distinct event times, the likelihood for β in the conditional logistic regression model is

$$L(\beta) = \prod_{i=1}^m \frac{e^{\beta_{0i} + \beta x_i}}{\sum_{j \in \mathcal{R}^*(t_i)} e^{\beta_{0i} + \beta x_j}} = \prod_{i=1}^m \frac{e^{\beta x_i}}{\sum_{j \in \mathcal{R}^*(t_i)} e^{\beta x_j}}, \quad (11.12)$$

which is exactly the same as the Cox partial likelihood for the nested case-control study in Equation 11.10. The intercept cancels out just like the unspecified baseline hazard. Point and interval estimates of β_{true} can be calculated using maximum likelihood estimation or Bayesian methods. The estimated hazard ratio comparing the exposed to the unexposed is $e^{\hat{\beta}}$, and confidence limits or credible limits for the hazard ratio can be obtained by exponentiating the confidence limits or credible limits for β_{true} .

11.6 R

Listing 11.2 casecontrol-cumulative.R

```
## Cumulative case-control study

# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival)          # rats data

# estimate risk ratio from cohort study with log-binomial regression
# Risk calculations are valid because follow-up is complete over 104 weeks.
cohort_RR <- glm(status ~ rx, data = rats, family = binomial(link = "log"))
exp(coef(cohort_RR))      # estimated risk ratio = 2
exp(confint(cohort_RR))   # 95% confidence interval (1.14, 3.51)

# sample controls from rats who did not have incidence tumors
# We will use 4 controls per case and sample without replacement.
ncase <- sum(rats$status)
rat_id <- 1:nrow(rats)
controls <- sample(rat_id[rats$status == 0], 4 * ncase)

# combine case and control data
casedat <- subset(rats, status == 1)
controldat <- rats[controls, ]
ccrats <- rbind(casedat, controldat)

# logistic regression model for exposure in cases and controls
# The exposure odds ratio comparing cases and controls approximates the RR.
# In the case-controls data, status = 1 for cases and status = 0 for controls.
ccx <- glm(rx ~ status, data = ccrats, family = binomial())
exp(coef(ccx))
exp(confint(ccx))

# logistic regression model for case/control status in exposed and unexposed
# By symmetry of the odds ratio, we can switch exposure and outcome.
# The estimated odds ratio is the same, but the intercepts are different.
ccd <- glm(status ~ rx, data = ccrats, family = binomial())
exp(coef(ccd))
exp(confint(ccd))

# case-control / cohort coefficient standard error ratio
# With 4 controls per case, it is approximately sqrt(1 + 1 / 4) = 1.12.
sqrt(vcov(cohort_RR)[2, 2]) # log risk ratio SE in cohort study
sqrt(vcov(ccd)[2, 2])      # log odds ratio SE in case-control study
sqrt(vcov(ccd)[2, 2] / vcov(cohort_RR)[2, 2])
```

Listing 11.3 RRAprox.R

```
## Approximation to the risk ratio in case-control studies

# contour labels
require(plotrix, quietly = TRUE)

# odds, logistic, and cumulative hazard functions
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)
cumhaz <- function(p) -log(1 - p)

# Rothman diagram with RR, OR, and HR contours
riskratios <- c(0.2, 0.5, 2, 5)
p0 <- seq(0.0001, 0.11, by = 0.001)
plot(p0, p0, type = "l", col = "darkgray", xlim = c(0, 0.1), ylim = c(0, 0.1),
      xlab = "Risk in the unexposed", ylab = "Risk in the exposed")
grid()
for (riskratio in riskratios) {
  p1 <- riskratio * p0

  # risk ratio contours
  lines(p0, riskratio * p0, lty = "solid")

  # odds ratio contours
  lines(p0, invodds(riskratio * odds(p0)), lty = "dashed")

  # cumulative hazard ratio contours
  lines(p0, 1 - (1 - p0)^riskratio, lty = "dotted")

  # labels
  boxed.labels(0.1 / (riskratio + 1), 0.1 * riskratio / (riskratio + 1),
               as.character(riskratio),
               xpad = 1.62, ypad = 1.62, border = FALSE)
}
legend("topright", bg = "white", lty = c("solid", "dotted", "dashed"),
      legend = c("Risk ratio", "Hazard ratio", "Odds ratio"))
```

Listing 11.4 casecontrol-density.R

```
## Density case-control study

# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival) # rats data and survreg()

# estimate incidence rate ratio from cohort study with exponential AFT model
# The estimated incidence rate ratio is exp(-beta_rx).
cohort_IRR <- survreg(Surv(time, status) ~ rx, data = rats,
                      dist = "exponential")
exp(-coef(cohort_IRR))
exp(-confint(cohort_IRR))

# function to sample controls for each case
control_sample <- function(id, k) {
  # id should be a rat who has an event
  if (rats$status[id] == 0) stop("Rat ", id, " did not have a tumor.")
  t <- rats$time[id]

  # possible controls are riskset minus individuals with events at time t
  rat_id <- 1:nrow(rats)
  controlset <- rat_id[with(rats, (time > t) | (time == t & status == 0))]

  # sample up to k controls
  if (length(controlset) > 1) {
    ksamp <- min(length(controlset), k)
    controls <- sample(controlset, ksamp)
  } else {
    controls <- NULL
  }
  controls
}
control_sample(1, 4) # no tumor
control_sample(2, 4) # returns sampled control ids

# generate case-control data for one case
cc_set <- function(id, k) {
  controls <- rats[control_sample(id, k), ]
  controls$status <- 0
  ccdat <- rbind(rats[id, ], controls)

  # use case id to identify case-control set
  ccdat$case <- id

  # return data for case-control set
  ccdat
}
cc_set(1, 4)
cc_set(2, 4)

# generate density case-control data
```

Listing 11.5 casecontrol-nested.R

```
## Nested case-control study and conditional logistic regression

# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(survival) # rats data and clogit() function

# estimate hazard ratio from cohort study using Cox model
cohort_HR <- coxph(Surv(time, status) ~ rx, data = rats)
exp(coef(cohort_HR))
exp(confint(cohort_HR))

# function to sample controls for each case
control_sample <- function(id, k) {
  # id should be a rat who has an event
  if (rats$status[id] == 0) stop("Rat ", id, " did not have a tumor.")
  t <- rats$time[id]

  # possible controls are riskset minus individuals with events at time t
  rat_id <- 1:nrow(rats)
  controlset <- rat_id[with(rats, (time > t) | (time == t & status == 0))]

  # sample up to k controls
  if (length(controlset) > 1) {
    ksamp <- min(length(controlset), k)
    controls <- sample(controlset, ksamp)
  } else {
    controls <- NULL
  }
  controls
}
control_sample(1, 4) # no tumor
control_sample(2, 4) # returns sampled control ids

# generate case-control data for one case
cc_set <- function(id, k) {
  controls <- rats[control_sample(id, k), ]
  controls$status <- 0
  ccdat <- rbind(rats[id, ], controls)

  # use case id to identify case-control set
  ccdat$case <- id

  # return data for case-control set
  ccdat
}
cc_set(1, 4)
cc_set(2, 4)

# generate nested case-control data
# We are recruiting k = 4 controls per case.
cases <- rat_id[rats$status == 1] # rats with incident tumors
```

12 Bayesian analysis of cohort and case-control studies

Probability logic also provides a basis for recognizing prior distributions as an integral component of statistical analysis, rather than the current misleading practice of pretending that statistics applied to observational data are objective. This basis is important, because the use of realistic priors in a statistical analysis can yield more stringent tests of hypotheses and more accurate estimates than conventional procedures. (Greenland 1998)

When we considered the Bayesian estimation of risks and rates in Chapter 4, we used the beta conjugate distribution for binomial models for risks and the gamma conjugate distribution for exponential or Poisson models for rates. When we are comparing two samples in a cohort or case-control study, there are no simple conjugate distributions for parameters. Instead, there are algorithms for sampling from the posterior distribution, and inferences are based on these samples.

12.1 Prior distributions

A noninformative prior is meant to “let the data speak for itself”, but this generally comes at the price of ignoring existing knowledge about the exposure, the outcome, and the population. With a large sample, Bayesian analysis with noninformative priors produces results similar to maximum likelihood. However, Bayesian methods do not rely on the central limit theorem, so they adapt more easily to small sample sizes.

Although prior distributions are often viewed with suspicion, they are an important advantage of the Bayesian approach to statistical inference. The flat priors implicit in frequentist methods do not imply objectivity. Using a prior distribution that incorporates background knowledge will produce more precise and accurate parameter estimates and predictions than an analysis using noninformative priors.

12.2 Posterior distributions

Without conjugate distributions, deriving the joint posterior distribution for model parameters can be much more difficult. The most common approach is to take samples from the posterior distribution and use these samples to get point and interval estimates of parameters or functions of parameters. Sampling from the posterior is complicated by the fact that we only know the posterior up to a constant of proportionality. If $\pi(\theta)$ is the prior distribution and $L(\theta)$ is the likelihood for our data, then

$$\pi(\theta | \text{data}) = \frac{L(\theta)\pi(\theta)}{\pi(\text{data})} \propto L(\theta)\pi(\theta) \quad (12.1)$$

where $\pi(\text{data})$ is the marginal probability of the data, which is generally difficult or impossible to calculate.

12.2.1 Markov chain Monte Carlo

In **Markov chain Monte Carlo** (MCMC), we generate a random walk across the set of possible θ so that the distribution of points we visit converges to the posterior distribution (Gelman et al. 2014). We choose a starting point θ_0 . At each θ_k , we propose a θ^* from a *proposal distribution* or *jumping distribution* $J(\theta^* | \theta_k)$. In the **Metropolis algorithm** (Metropolis et al. 1953), the proposal distribution is symmetric in the sense that

$$J(\theta^* | \theta_k) = J(\theta_k | \theta^*)$$

for any θ^* and θ_k . We then choose whether to stay at the same place (i.e., $\theta_{k+1} = \theta_k$) or to jump to θ^* (i.e., $\theta_{k+1} = \theta^*$). The distribution of points we visit will converge the posterior distribution of θ if

$$\pi(\theta_k | \text{data}) \Pr(\text{jump from } \theta_k \text{ to } \theta^*) = \pi(\theta^* | \text{data}) \Pr(\text{jump from } \theta^* \text{ to } \theta_k)$$

so that jumps from θ_k to θ^* happen as often as the reverse jumps from θ^* to θ_k . This is called the *detailed balance condition*, and the jump probabilities can be replaced with probability densities when the space of possible θ is continuous.

Rearranging the detailed balance condition, we get

$$\Pr(\text{jump from } \theta_k \text{ to } \theta^*) = \frac{\pi(\theta^* | \text{data})}{\pi(\theta_k | \text{data})} \Pr(\text{jump from } \theta^* \text{ to } \theta_k).$$

If we always jump from θ^* to θ_k when $\pi(\theta^* | \text{data}) < \pi(\theta_k | \text{data})$, then the probability of jumping from θ_k to θ^* must be

$$r = \frac{\pi(\theta^* | \text{data})}{\pi(\theta_k | \text{data})} = \frac{L(\theta^*)\pi(\theta^*)}{L(\theta_k)\pi(\theta_k)},$$

where the unknown $\pi(\text{data})$ from Equation 12.1 has canceled out. Therefore, we will meet the detailed balance condition if

$$\theta_{k+1} = \begin{cases} \theta^* & \text{with probability } \min(r, 1), \\ \theta_k & \text{otherwise.} \end{cases}$$

This is not the only rule that will lead to the detailed balance condition, but it is the one used by the Metropolis algorithm.

The **Metropolis-Hastings algorithm** (Hastings 1970) allows the proposal distribution to be asymmetric. In that case, the procedure is the same except that

$$r = \frac{\pi(\theta^* | \text{data})/J(\theta^* | \theta_k)}{\pi(\theta_k | \text{data})/J(\theta_k | \theta^*)}.$$

This allows much greater flexibility in proposal distributions. A good proposal distribution should be easy to sample from, make it easy to calculate r , propose jumps that are not too big and not too small (Gelman et al. 2014). If the proposed jumps are too small, the space of possible θ will not be explored effectively by the MCMC random walk even if we accept most jumps. If the proposed jumps are too large, the proposed θ^* will be rejected too often and the MCMC random walk will get stuck.

The initial samples in an MCMC have a distribution that has not yet converged to the posterior distribution of θ . This period is called **burn-in** or **warm-up**, and early samples are generally discarded. Even after burn-in, the samples produced by an MCMC can be highly correlated, so the effective sample size is much less than the actual number of samples. This correlation can be reduced by **thinning** the chain by keeping, for example, every 10th sample. To monitor convergence, it is common to start several chains in different places and calculate the variation within chains and between chains for each component of θ . When convergence is reached, the variation within chains is similar to the variation between chains.

12.2.2 Hamiltonian Monte Carlo

Hamiltonian Monte Carlo (HMC) adapts methods from physics to tune the proposed jumps in an MCMC (Duane et al. 1987; Neal 1996), allowing the random walk to explore the posterior distribution more efficiently. HMC treats θ as a position and adds a momentum variable ϕ that has the same dimension (i.e., number of components) as θ . Starting from (θ_k, ϕ_k) , both θ and ϕ are updated multiple times in *leapfrog steps* to generate a proposal (θ^*, ϕ^*) . At the end of the leapfrog steps, a Metropolis-Hastings step decides whether to stay at (θ_k, ϕ_k) or jump to (θ^*, ϕ^*) . Usually, these steps are rejected with much lower probability than the proposed jumps in an MCMC.

The momentum is used to nudge θ toward values of θ with higher posterior density. If θ takes a path with decreasing posterior density, its momentum ϕ starts to decrease and eventually point in the opposite direction, pulling θ back toward a region with higher posterior density. If

θ takes a path with increasing posterior density, its momentum ϕ will increase in that direction until it crosses a peak and the posterior density starts to decrease again (Gelman et al. 2014). The size of the jumps acts like kinetic energy, and $-\ln \pi(\theta | \text{data})$ acts like the potential energy. The random walk is attracted to regions of low potential energy (i.e., high posterior density) like a marble rolling around a bowl, but the conservation of energy ensures that the marble does not get stuck at the bottom.

12.2.3 Laplace approximation

12.2.4 Inference with samples from the posterior

12.3 Cohort studies

12.3.1 Risk ratios

Main messages:

- Specifying an informative prior based on background knowledge can improve precision.
- Samples from the posterior can be used for inference about parameters and functions of parameters.

12.4 R

12.4.1 Odds ratios

Main messages:

- The regression model does not dictate the measure of association. Here, we get risks and risk ratios out of a logistic regression model, which is specified in terms of odds and odds ratios.
- Using samples from the posterior distribution is easier and more accurate than using the delta method.

12.5 R

12.5.1 Accelerated failure time models

12.5.2 Proportional hazards models

12.6 Case-control studies

12.6.1 Conditional logistic regression

Listing 12.1 riskratio-Bayes.R

```
## Bayesian estimation of risk ratios

# load packages
# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(rstanarm)          # Bayesian regression models
library(survival)          # rats data

# GLMs in rstanarm are "stanreg" objects
? stan_glm
? coef.stanreg

# binomial GLM with log link (log-binomial model) for the RR
RRglm <- glm(status ~ rx, family = binomial(link = "log"), data = rats)
exp(coef(RRglm))           # estimated risk (x = 0) and RR
exp(confint(RRglm))        # likelihood ratio CIs

# Bayesian GLM with log link fit using a flat prior for coefficients
# Use "prior = NULL" to specify a flat prior.
# Samples four chains with 2000 iterations each by default.
# In each chain, the first 1000 samples are warmup and the last 1000 are kept.
RRbayes_non <- stan_glm(status ~ rx, data = rats,
                        family = binomial(link = "log"), prior = NULL)
prior_summary(RRbayes_non) # summary of prior distributions
summary(RRbayes_non)       # summary of model fit (look for Rhat = 1)
coef(RRbayes_non)          # posterior medians (linear predictor scale)
posterior_interval(RRbayes_non) # 90% credible intervals (default)
posterior_interval(RRbayes_non, prob = 0.95) # 95% credible intervals
exp(coef(RRbayes_non))     # posterior medians for risk (rx = 0) and RR
exp(posterior_interval(RRbayes_non, prob = 0.95)) # 95% credible intervals

# data frame of samples from the posterior distribution
# This allows you to calculate posterior means and functions of coefficients.
# Use double quotes for variable names with non-letters, like (Intercept).
post_non <- as.data.frame(RRbayes_non)
median(post_non$(Intercept)) # equals intercept from coef()
median(post_non$rx)          # equals rx coefficient from coef()
mean(post_non$rx)            # posterior mean log RR
quantile(post_non$rx, 0.025) # lower 95% credible interval for log RR
quantile(post_non$rx, 0.975) # upper 95% credible interval for log RR
quantile(post_non$rx, c(0.025, 0.975))

# point estimates and credible intervals for risk in the treated
post_non$lnrisk1 <- post_non$(Intercept) + post_non$rx
post_non$risk1 <- exp(post_non$lnrisk1)
median(post_non$lnrisk1)     # posterior median log risk in treated rats
median(post_non$risk1)       # posterior median risk in treated rats
quantile(post_non$risk1, c(0.025, 0.975)) # 95% credible interval for risk

# histogram of samples from posterior distribution of log(risk0)
# Use freq = FALSE to get probability densities instead of counts
```

Listing 12.2 oddsratio-Bayes.R

```
## Bayesian estimation of odds ratios

# load packages
# The rats data is from:
# Mantel, Bohidar, and Ciminera (1977). Cancer Research 37: 3863-3868.
library(rstanarm)          # Bayesian regression models
library(survival)          # rats data

# GLMs in rstanarm are "stanreg" objects
? stan_glm
? coef.stanreg

# binomial GLM with log link (log-binomial model) for the RR
ORglm <- glm(status ~ rx, family = binomial(link = "log"), data = rats)
exp(coef(ORglm))           # estimated odds (x = 0) and OR
exp(confint(ORglm))        # likelihood ratio CIs

# Bayesian GLM with identity link fit using a flat prior for coefficients
# Use "prior = NULL" to specify a flat prior.
# Samples four chains with 2000 iterations each by default.
# In each chain, the first 1000 samples are warmup and the last 1000 are kept.
ORbayes_non <- stan_glm(status ~ rx, data = rats,
                        family = binomial(link = "logit"), prior = NULL)
prior_summary(ORbayes_non) # summary of prior distributions
summary(ORbayes_non)      # summary of model fit (look for Rhat = 1)
coef(ORbayes_non)         # posterior medians (linear predictor scale)
posterior_interval(ORbayes_non) # 90% credible intervals (default)
posterior_interval(ORbayes_non, prob = 0.95) # 95% credible intervals
exp(coef(ORbayes_non))    # posterior medians for odds (rx = 0) and OR
exp(posterior_interval(ORbayes_non, prob = 0.95)) # 95% credible intervals

# data frame of samples from the posterior distribution
# This allows you to calculate posterior means and functions of coefficients.
post_non <- as.data.frame(ORbayes_non)

# point estimates and credible intervals for pdds in the treated
post_non$lnodds1 <- post_non$(Intercept) + post_non$rx
post_non$odds1 <- exp(post_non$lnodds1)
median(post_non$lnodds1) # posterior median log odds in treated rats
median(post_non$odds1)   # posterior median odds in treated rats
quantile(post_non$odds1, c(0.025, 0.975)) # 95% credible interval for odds

# point estimates and credible intervals for risks and risk ratios
expit <- function(v) 1 / (1 + exp(-v))
post_non$risk0 <- expit(post_non$(Intercept))
post_non$risk1 <- expit(post_non$lnodds1)
post_non$oddsratio <- exp(post_non$rx)
post_non$riskratio <- post_non$risk1 / post_non$risk0
median(post_non$riskratio)
quantile(post_non$riskratio, c(0.025, 0.975))
```

Part III

Principles of Causal Inference

13 Causality in Public Health

Since the statistician can seldom or never make experiments for himself, he has to accept the data of daily experience, and discuss as best he can the relations of a whole group of changes; he cannot, like the physicist, narrow down the issue to the effect of one variation at a time. The problems of statistics are in this sense far more complex than the problems of physics. (Yule 1897)

13.1 Koch's postulates

The earliest explicit theory of causality in public health was developed by the German physician Jakob Henle (1809–1885) and his student Robert Koch, who were early proponents of the germ theory of disease.¹ In a book published in 1840, Henle proposed criteria for considering a microorganism to be a cause of disease. These were developed by his student Koch, who presented revised criteria in a series of lectures between 1884 and 1890 (Evans 1976). These criteria are:

1. The microorganism is present in every case of disease under circumstances that can account for the pathological changes and clinical course of the disease.
2. It is not found in non-cases of the disease.
3. After being isolated and grown in pure culture, it can induce the disease in a healthy host.

The first criterion requires that the alleged pathogen is a **necessary cause** of the disease, so the disease occurs only if it is present. The second and third criteria require that the alleged pathogen is a **sufficient cause** of the disease, so the disease occurs whenever it is present. In other words, the disease occurs in the host if and only if the pathogen is present.

¹Robert Koch (1843–1910) was a German physician who discovered the bacteria that cause anthrax and tuberculosis. In 1884, he proved that the bacterium *Vibrio cholerae* causes cholera. These results helped establish the germ theory of disease, and Koch is considered one of the founders of modern bacteriology.

13.1.1 Lack of sufficiency: cholera

These criteria were never meant to be used as a rigid definition of causation. Even in the late 19th century, it was clear that necessary and sufficient causes would not be found for many diseases. In 1855, Max von Pettenkofer tried to replicate John Snow's observations from the 1854 cholera epidemic in London by analyzing the spread of cholera in an 1854 outbreak in Munich.² His map of cases and his analysis of areas supplied by two water companies did not show a correlation between drinking water source and the risk of cholera. To explain these results, he argued that cholera was not caused by a pathogen alone. He believed that four conditions were necessary to have an epidemic: a specific pathogen, the right local conditions, the right seasonal conditions, and the right individual conditions. In the case of cholera, he believed that soil played a key role in facilitating transmission of the then-unidentified pathogen: the cholera pathogen could not cause disease before it acquired virulence in moist, porous soil that contained decaying organic matter (Evans 1973).

He retained this belief long after the German Cholera Commission headed by Koch identified the bacteria *Vibrio cholerae* as the cause of cholera in Egypt and India in 1884 (Howard-Jones 1973). On 7 October 1892, the 74-year-old Pettenkofer experimented on himself to prove his point. He neutralized his stomach acid with baking soda and swallowed a milliliter of fresh broth culture from a dying cholera patient. He wrote later: "Even if I had deceived myself and the experiment endangered my life, I would have looked Death quietly in the eye for mine would have been no foolish or cowardly suicide; I would have died in the service of science like a soldier on the field of honor."

It turned out that he developed only a light diarrhea (which contained profuse *Vibrio cholerae*). Pettenkofer had probably had cholera in an 1830 epidemic, so he may have been partially protected by lingering immunity. Several of his students developed severe diarrhea trying the same experiment, but fortunately none died (Evans 1973; Howard-Jones 1973).

Pettenkofer considered his experiment a success because he did not develop the classic symptoms of cholera, but a more nuanced interpretation is that infection with *Vibrio cholerae* has a wide range of clinical manifestations, ranging from no clinical illness to severe dehydration and death. Koch discovered asymptomatic carriers of cholera in 1893 [Evans (1976)]. In the 1960s, epidemiologic investigations of cholera outbreaks in Hong Kong (Van de Linde and Forbes 1965) and Dhaka, Bangladesh (McCormack, Islam, and Fahimuddin 1969) suggested that the ratio of cholera infections to clinical cases could be as high as 100 to 1. This finding was confirmed by a mathematical modeling study of historical cholera data from Bengal (King et al. 2008). Unless we allow for this range of clinical manifestations in our definition of cases and non-cases, infection with *Vibrio cholerae* is not a sufficient cause of cholera.

²Max Joseph von Pettenkofer (1818–1901) was a medically-trained Bavarian chemist who made important contributions to hygiene, environmental health, and epidemiology. He established the first chairs in hygiene in medical schools in Bavaria, convinced the city of Munich to establish a clean water supply from the mountains, and did an early calculation of the money saved by improving public health. His interests included air, drinking and groundwater, soil, sewage disposal, and air exchange and heating in houses.

Table 13.1: Causes of the common cold (Wat 2004)

Virus	Proportion of cases (%)
Rhinovirus	30–50
Coronavirus	10–15
Influenza virus	5–15
Respiratory syncytial virus (RSV)	5
Parainfluenza virus	5
Adenovirus	< 5
Metapneumovirus	≈ 2
Unknown virus	20–30

Once the relationship between a pathogen and a disease is established (e.g., tuberculosis and *Mycobacterium tuberculosis*), the presence of the pathogen can become part of the definition of the disease. This can be a useful way of identifying a group of clinical illnesses that have a common method of treatment or control. However, it is logically circular from the point of view of Koch’s postulates:

For example, in tuberculosis, is the tubercle bacillus found in 100 per cent of the patients who have clinical manifestations of tuberculosis? Of course not! Perhaps, it is found in about 90 per cent of the cases. This does not prevent us from stating that the tubercle bacillus is a cause of tuberculosis. Actually, what one does is try to look for another causative agent in these 10 per cent of the cases in which tubercle bacilli have not been found. In fact, there is a danger of going through a certain amount of circular reasoning since an investigator may well say that the disease is not tuberculosis unless the tubercle bacillus is isolated, resulting in a one-to-one correspondence between the isolation of the tubercle bacillus and tuberculosis. (Lilienfeld 1959)

13.1.2 Lack of necessity: the common cold

By around 1960, it was clear that a number of common clinical syndromes could be caused by different pathogens, and that the predominant pathogen for a given syndrome could vary by population, geographic location, and year (Evans 1976). The common cold (stuffy nose, sneezing, sore throat, and cough) is the most common infectious syndrome in humans. Table 13.1 shows the viruses known to cause the common cold. Clearly, none of them is a necessary cause of the disease.

13.2 Chronic diseases

In the mid-20th century, interest in the causes of chronic diseases came to the forefront with the debate on smoking and lung cancer. Yerushalmy and Palmer (1959) tried to adapt Koch's postulates to chronic diseases, outlining three principles:³

1. The suspected characteristic must be found more frequently in persons with the disease in question than in persons without the disease.
2. Persons possessing the characteristic must develop the disease more frequently than do persons not possessing the characteristic.
3. The given characteristic is found to be associated with one, or at most a few, diseases (specificity).

The first principle was addressed primarily through case-control studies, and the second principle was addressed primarily through cohort studies. They argued that the first two principles were related to Koch's first postulate, replacing the requirement that the pathogen be a necessary cause of disease:

Because the characteristics currently under study are neither necessary nor sufficient, investigations of etiologic factors in many chronic diseases lack the advantage of a one-to-one correspondence between cause and effect, in either direction. The importance of any characteristic as a possible cause or cause-carrying vector for a given disease can then be revealed not by its presence in every case, but only by an increase in the relative frequency of its occurrence among persons with the disease. Consequently, the statistical method must play an important role in investigations of causative factors in chronic diseases. (Yerushalmy and Palmer 1959)

13.2.1 Specificity

Yerushalmy and Palmer (1959) argued that their principle of specificity was related to Koch's second and third postulates, where the causal agent should not be found in non-cases and should cause the same disease in a health host. In particular, they argued that the lack of specificity was a possible reason to doubt that the observed association between smoking and lung cancer had a causal interpretation:

To return to the smoking–lung cancer illustration, if smoking were shown to be related to lung cancer only or restricted to lung cancer and several related and

³We encountered Jacob Yerushalmy (1904–1973) earlier as the person who first proposed the concepts of sensitivity and specificity for diagnostic and screening tests (Yerushalmy 1947). He was a statistician at the US Public Health Service and at the University of California, Berkeley.

physiologically explainable diseases, the association would have specificity and significance in suggesting a causal relationship. If, on the other hand, similar relationships can be shown with a variety of diseases, some of which cannot reasonably be thought to be influenced by smoking per se, then the association with cancer of the lung lacks specificity. The support which the statistical association provides for a causal relationship between smoking and lung cancer is correspondingly reduced. (Yerushalmy and Palmer 1959)

In their view, requiring specificity of the association was analogous to the requirement that the alleged pathogen induce the same disease in a healthy host, which would separate it from microorganisms that just happened to flourish in individuals with the disease or individuals at high risk of disease.

In a commentary on Yerushalmy and Palmer (1959), Sartwell (1960) gave several counterexamples against specificity as a criterion for causal relationships: “For example, streptococci are associated with sore throats, scarlet fever, otitis media, erysipelas, puerperal sepsis, osteomyelitis, and numerous less common conditions.” Other examples included alcohol causing both acute gastritis and liver cirrhosis and multiple health effects of air pollution.

Although specificity is not generally accepted as an argument against causation, Weiss (2002) gave several examples where specificity of outcome or specificity of exposure could help clarify an argument for or against a causal interpretation of an observed association. For specificity of outcomes, one example was that screening sigmoidoscopy was associated with a reduction in mortality from tumors in areas of the colon reachable by the sigmoidoscope but not tumors further up strengthens the case that the reduction in mortality is caused by the colon cancer screening (Selby et al. 1992; Newcomb et al. 1992). For specificity of exposure, one example was the fact that long-acting hypnotic or anxiolytic drugs were associated with an increased risk of hip fracture in elderly people but short-acting drugs were not (Ray et al. 1987; Ray, Griffin, and Downey 1989).

13.2.2 Strength of association

In another commentary on Yerushalmy (1947), Lilienfeld (1959) pointed out that the strength of an association should be considered when evaluating specificity, presenting the standardized mortality ratios in Table 13.2 comparing smokers to nonsmokers for multiple diseases. A standardized mortality ratio (SMR) is a ratio of the observed number of deaths from a given cause in a given group to the number expected based on using age- and sex-specific mortality rates for the same cause in the general population. The SMR for lung cancer is far larger than the others, so the association could be seen as specific if the strength of the association is taken into account.

One reason that a strong association is more likely to be causal is that it is more difficult (but never impossible) to explain as a result of bias. Cornfield et al. (1959) showed that the strong association between smoking and lung cancer could only be explained by an unmeasured

Table 13.2: Standardized mortality ratios (SMRs) from Lilienfeld (1959).

Cause of death	SMR (smokers vs. nonsmokers)
Lung cancer	9.35
Respiratory disease	2.76
Coronary heart disease	1.58
Hypertensive cardiovascular disease	1.56
Other cardiovascular diseases	1.40
Cancer except lung	1.29

factor that had an even stronger association with lung cancer. The large volume of research on smoking and lung cancer in the 1950s had not identified anything like what was needed.

13.2.3 Biological plausibility

Lilienfeld (1959) argued that biological plausibility should be taken into account when considering whether an association might be causal:

To illustrate the need for considering biologic plausibility, let us assume that we have found an association between cigarette smoking and ingrown toenails. Obviously, one would not interpret this as a causative relationship because it does not seem plausible on the basis of current biologic knowledge. It is needless to point out that our interpretation of any relationship is limited by our biologic knowledge, and it may well be that an association which at present does not appear to be biologically plausible will turn out to be so when our knowledge has been extended. ... On the other hand, the association with lung cancer appears entirely plausible in light of the present knowledge of carcinogenesis, since it is not unreasonable to visualize the inhalation and deposition of a chemical carcinogen from cigarette smoke which initiates a neoplastic process.

Sartwell (1960) gives a remarkable example of changing biological plausibility. Cheever (1861) used the association of typhus with “vermin with which the bodies of the sick might be infested” as an example of a “nonsense correlation”. In 1916, the bacteria that causes typhus was discovered by the Brazilian physician Henrique da Rocha Lima (1879–1956), who named it *Rickettsia prowazeki* after Czech and American colleagues who had died of typhus.⁴ It is

⁴Henrique da Rocha Lima (1879–1956) was a Brazilian physician, pathologists, and microbiologist who was one of the founders of the Oswaldo Cruz Institute and the University of São Paulo. He and his colleague Stanislaus von Prowazek (1875–1915), a Czech biologist and parasitologist, were both infected with typhus while working in a World War I prisoner-of-war camp hospital in Cottbus, Germany in 1915. Prowazek died, but Lima survived and identified the bacterium in 1916. Lima named the genus *Rickettsia* after Howard Taylor Ricketts (1871–1910), an American pathologist who discovered that Rocky Mountain spotted fever is carried by ticks and died of typhus in Mexico City while studying the disease.

spread by body lice.

13.2.4 Multiple causation

The assumption that there was, ultimately, a single cause for each disease had a long twilight even after it was known to be unrealistic for infectious diseases. By analogy to insect-borne pathogens, Yerushalmy and Palmer (1959) tried to draw a distinction between causes of a disease and “vectors” of the causative agent:

In many of the important chronic diseases we are not yet at the stage of attempting to identify a definite, final, and single entity as a causal agent. Rather we are concerned with the investigation of conditions, often environmental, which may be involved in the causation of a given disease. These conditions, however, may, at best, be looked upon only as vectors or vehicles which may contain the specific causative agent.

They suggested that smoking might, at worst, be a vector for the true cause of lung cancer. Lilienfeld (1959) pushed back against this distinction using the examples of typhoid and diphtheria:

From a molecular viewpoint, the typhoid bacillus can also be considered a vector of a specific chemical agent which is the “real” cause of the disease. With respect to diphtheria there are differences between virulent and avirulent strains of the organism, each of which can be transformed into the other. Obviously, according to the criteria set forth by Yerushalmy and Palmer, one cannot state that the diphtheria bacillus is the cause of diphtheria. Do they feel that it is necessary to know the actual biochemical agents involved in the causation of disease before one can make an inference about a cause of a disease?

He also argued that the distinction between a “vector” and a “cause” was not necessary for successful public health intervention:

At this point it is rather pertinent to indicate that even if we had complete knowledge of causative agents at a molecular level, it would still be necessary, in many instances, to have information concerning vectors in order to institute effectively the measures required for the prevention and control of the disease. For developing methods of control one needs to know that polluted water is a cause of typhoid fever; knowledge that protein X in the typhoid bacillus is the specific causative agent does not necessarily lead to methods of control.

For example, improved access to clean water had already led to dramatic reductions in deaths from cholera in London before *Vibrio cholerae* was shown to cause cholera by Robert Koch in 1884. Similarly, the Cuban doctor and epidemiologist Carlos Finlay (1833–1915) set the stage for the control of yellow fever throughout the Americas by discovering that the disease was

transmitted by mosquitoes.⁵ At the time, yellow fever was widely believed to be transmitted by fomites. The actual yellow fever virus was not isolated until 1927.

13.3 Hill Criteria

To the strength and biological plausibility of the association, Sartwell (1960) added replication of the association by different investigators in different populations and a dose-response relationship, where the dose could be measured in the duration of exposure, the intensity of exposure, or a combination of both. The Surgeon General's Advisory Committee on Smoking and Health report *Smoking and Health* (United States Surgeon General's Advisory Committee on Smoking 1964) used the following criteria to evaluate the causal effects of smoking: consistency of the association (similar to replication), strength of the association, specificity of the association, the temporal relationship implied by the association (i.e., causes must occur before effects), and the coherence of the association (similar to biological plausibility).

These criteria were expanded by Hill (1965) into the nine “viewpoints” that, while useful, cannot constitute “hard-and-fast rules of evidence that must be obeyed before we accept cause and effect.” These became known as **Hill's criteria**.

1. **Strength:** He uses the example of Percival Pott's investigation of scrotum cancer among chimney sweeps. As late as the 1920s, mortality from scrotal cancer among chimney sweeps was 200 times that of workers not exposed to tar or mineral oils. He also argues for evaluating strength using risk ratios rather than risk differences.
2. **Consistency:** This is fulfilled if the association has been “repeatedly observed by different persons, in different places, circumstances and times’”. However, he cautions that replication is not always possible, giving an example of deaths from lung and nasal sinus cancer among workers at a nickel refinery in Wales. Between 1929 and 1938, the workers had 16 deaths from lung cancer and 10 death from sinus cancer where only one lung cancer death and less than one sinus cancer death would be expected based on age-specific death rates in England and Wales. A similar pattern was observed between 1948 and 1956. A change to the refinery was made in 1923, and the men who started work after that time had no excess deaths from cancer at either site.
3. **Specificity:** Among the nickel refinery workers, the argument for causality was strengthened by the fact that there was no apparent excess cancer mortality other than the lung

⁵Carlos Finlay (1833–1915) was a Cuban doctor and epidemiologist. In 1881 and 1882, he proposed that yellow fever was spread by mosquitoes and identified the mosquito as the genus *Aedes*. This was finally proven in 1900 through a series of dangerous experiments on volunteers by a team of Cuban and American physicians in the US Army Yellow Fever Commission led by Walter Reed (1851–1902). These experiments killed an American physician named Jesse William Lazear (1866–1900), who had allowed an infected mosquito to bite him. Reed drafted one of the earliest informed consent forms for these experiments, which were in both English and Spanish. See https://en.wikipedia.org/wiki/Yellow_fever.

and the nose. However, he also notes that tainted milk was known to cause diphtheria, tuberculosis, undulating fever, sore throats, dysentery, and typhoid.

4. **Temporality:** Causes must always precede effects, but he notes that establishing the temporal order is not necessarily straightforward with diseases that develop slowly.
5. **Biological gradient:** “For instance, the fact that the death rate from lung cancer rises linearly with the number of cigarettes smoked daily, adds a very great deal to the simpler evidence that cigarette smokers have a higher death rate than non-smokers.”
6. **Plausibility:** The plausibility of an association based on current biological knowledge is helpful but cannot be required. He uses the examples of typhus and rubella to show that a true causal relationship may appear implausible at first due to a lack of biological knowledge.
7. **Coherence:** A causal interpretation of the association should not conflict with “generally known facts about the natural history and biology of the disease”. This is a sort of converse to plausibility. As a counterexample, he points out that arsenic is known to cause skin cancer in humans but not in any other animal.
8. **Experiment:** This encompasses both controlled experiments and “natural” experiments. For example, the fact that lung and sinus cancer mortality was no longer elevated in nickel refinery workers after the change in 1923 strongly suggests that the change reduced exposure to one or more causes of these cancers.
9. **Analogy:** He uses the examples of thalidomide and rubella causing birth defects to argue that “we would surely be ready to accept slighter but similar evidence with another drug or another viral disease in pregnancy.”

13.3.1 Statistics in causal inference

Hill (1965) notes that statistical tests of significance have only a marginal role to play in establishing causal relationships: “Such tests can, and should, remind us of the effects that the play of chance can create, and they will instruct us in the likely magnitude of those effects. Beyond that they contribute nothing to the ‘proof’ of our hypothesis.” Commenting on the increased use of statistics in public health research between World War I (1914–1918) and World War II (1939–1945), he says:

Perhaps too often generalities were based upon two men and a laboratory dog while the treatment of choice was deduced from a difference between two bedfuls of patients and might easily have no true meaning. It was therefore a useful corrective for statisticians to stress, and to teach the need for, tests of significance merely to serve as guides to caution before drawing a conclusion, before inflating the particular to the general.

This respectful skepticism about significance testing is healthy. It is now widely accepted that, while statistical inference is crucial for understanding the role of random variation, causal inference must also rely on concepts from outside probability and statistics.

13.4 Observation versus experiments

Opponents of the idea that smoking causes lung cancer often pointed to the fact that studies linking smoking and lung cancer were observational, not randomized experiments. This leaves open the possibility that there is an unmeasured difference between the smokers and nonsmokers that explains the different risks or rates of lung cancer onset. For example, Ronald Fisher suggested that there could be an underlying genetic predisposition that caused both smoking and lung cancer (Stolley 1991). For retrospective studies (where exposure is measured after the onset of disease), Yerushalmy and Palmer (1959) pointed out the possibility of systematically different recall of exposure: “As an example, knowledge of the presence of a congenital malformation in a newborn infant may lead to more thorough questioning of the mother and to her recalling certain infections during pregnancy which might well have gone unnoticed had the birth been normal.” Establishing a fundamental distinction between observation and experiment is convenient for the defense of a possibly harmful exposure.

Cornfield (1954) outlined several arguments against seeing a fundamental distinction between causal evidence from observational studies and experiments. He used the example of Snow’s studies of cholera to argue that “there are cases in which uncontrolled observations can be so analyzed as to eliminate the possibility that extraneous variables account for the observed association.” He also argued that “there is no automatic guarantee in any particular instance that extraneous variables have been controlled by direct experimentation.” He illustrated this using the example of an experiment designed to remove the thyroid gland on blood sugar levels:

We may randomize animals among a control and thyroidectomized group and thus eliminate the possibility that any large difference between the two treatments arose from the different characteristics of the animals treated. But we have not eliminated the possible effect of other extraneous variables in which the experimenter is equally interested such as the operation removing the thyroid, or the non-specific effect of thyroidectomy on weight loss. ...

We must indicate the specific variables we wish to control and must devise specific experimental procedures to control them.

Finally, he points out that many widely accepted therapies and interventions were undertaken on the basis of observational data alone, including flouridation of water and smallpox vaccination. He concludes that:

The truth of the matter appears to be that medical knowledge (and, one suspects, many other kinds as well) has always advanced by a combination of many different

kinds of observation, some controlled, and some uncontrolled, some directly, and some only tangentially related to the problems at hand. Although some methods of observation are clearly to be preferred to others when a choice is possible, there are no magical methods that invariably lead to the right answer.

13.4.1 Intervention

It is not possible to learn everything we need to know in public health without careful observational studies in addition to clinical trials and laboratory studies. The ultimate judge of causality in public health is successful interventions to help people lead healthier and happier lives. The level of evidence we require before acting on a causal hypothesis should depend on consequences of intervening or failing to intervene. As Hill (1965) put it:

All scientific work is incomplete—whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time.

14 Potential Outcomes and Attributable Risk

Epidemiology is often defined in terms of study of the determinants of the distribution of the disease; but we should not forget that the more widespread is a particular cause, the less it explains the distribution of cases. The hardest cause to identify is the one that is universally present, for then it has no influence on the distribution of disease. (Rose 1985)

14.1 Potential outcomes

Association is not causation. But why not? To understand the distinction, it is crucial to consider the difference between observation and intervention. Let X be an indicator of a binary exposure, with $X = 1$ in the exposed and $X = 0$ in the unexposed. Suppose we define a time scale and time interval $(0, t]$ during which we measure the occurrence of disease. Each study participant would have two **potential outcomes** (D. B. Rubin 1974): The potential outcome D^1 is their outcome under exposure ($X = 1$) and the potential outcome D^0 is their outcome under no exposure ($X = 0$). These potential outcomes are random variables $D^1(\omega)$ and $D^0(\omega)$ defined for each individual ω in our population Ω . Table 14.1 shows the four possible combinations of potential outcomes for an individual ω , which are often called **causal types**

If we could see both D^0 and D^1 for a single individual, we would know whether treatment was harmful, neutral, or beneficial for them. However, we can usually see at most one of these outcomes. If ω is exposed, we see $D^1(\omega)$ but not $D^0(\omega)$. If ω is unexposed, we see $D^0(\omega)$ but not $D^1(\omega)$. A perfect epidemiological study would require a time machine: We would first measure the risk of disease in the study population when everyone is exposed. Then we would go back in time, prevent exposure for them all, and measure the risk of disease over the same time interval. Any measure of the difference in disease occurrence between these two parallel timelines would represent a causal effect of exposure.

Table 14.1: Causal types from Greenland and Robins (1986).

	$D^1 = 1$	$D^1 = 0$
$D^0 = 1$	No effect (doomed)	Exposure preventive
$D^0 = 0$	Exposure causative	No effect (immune)

14.1.1 Measures of causal effect

The **counterfactual risk** under exposure in the population Ω is

$$\Pr(D^1 = 1),$$

and the counterfactual risk under no exposure is

$$\Pr(D^0 = 1).$$

Using these counterfactual risks, we can express a causal effect in terms of any of our measures of association from Chapter 9. The causal risk difference is

$$RD = \Pr(D^1 = 1) - \Pr(D^0 = 1),$$

the causal risk ratio is

$$RR = \frac{\Pr(D^1 = 1)}{\Pr(D^0 = 1)},$$

and the causal odds ratio is

$$OR = \frac{\text{odds}(\Pr(D^1 = 1))}{\text{odds}(\Pr(D^0 = 1))},$$

where $\text{odds}(p) = p/(1-p)$. When an exposure X is not binary, these measures can be calculated for any two distinct levels of X .

14.1.2 Confounding and exchangeability

When we cannot see our population under both exposure and no exposure, we cannot calculate $\Pr(D^1 = 1)$ or $\Pr(D^0 = 1)$ directly. If our population contains both exposed and unexposed individuals, we can estimate

$$\Pr(D = 1 \mid X = 1)$$

and

$$\Pr(D = 1 \mid X = 0).$$

We have **confounding** when

$$\Pr(D = 1 \mid X = x) \neq \Pr(D^x = 1)$$

for $x = 1$ or $x = 0$. When we have confounding, we cannot use the conditional risks of disease given exposure to calculate the measures of causal effect from Section 14.1.1. Confounding can occur when there is an unobserved common cause of X and D , which results in an association between X and D in the population that differs from the causal effect of X on D (Pearl 1993, 1995).

To avoid confounding, we need **exchangeability** of the potential disease outcomes given exposure, which means that

$$D^x \perp\!\!\!\perp X$$

for all possible values x of X (Rosenbaum and Rubin 1983). In other words, the *potential outcomes* are independent of the *realized exposure*. If exposure causes disease, the realized disease outcomes will not be independent of exposure. To see why, imagine that $D^1(\omega) = 1$ and $D^0(\omega) = 0$ for all individuals ω in our population Ω . Then the realized disease outcome $D = X$, but we have exchangeability because all $\omega \in \Omega$ have the same potential outcomes.

Under exchangeability, we get

$$\begin{aligned} \Pr(D^x = 1) &= \Pr(D^x = 1 \mid X = x) \quad \text{by exchangeability} \\ &= \Pr(D = 1 \mid X = x) \quad \text{by consistency.} \end{aligned}$$

Therefore, we can estimate the counterfactual risks by calculating the conditional risks of disease given X . We can then use these to estimate the measures of causal effect from Section 14.1.1.

When exchangeability fails, we might still have **conditional exchangeability** given a set of covariates C that are not causally affected by X . This can be written

$$D^x \perp\!\!\!\perp X \mid C.$$

If we measure C , then

$$\begin{aligned} \Pr(D^x = 1 \mid C) &= \Pr(D^x = 1 \mid C, X = x) \quad \text{by conditional exchangeability} \\ &= \Pr(D = 1 \mid C, X = x) \quad \text{by consistency.} \end{aligned}$$

Thus, we can estimate conditional counterfactual risks given C by calculating conditional risks of disease given X and C . These can be used to calculate conditional measures of causal effect given C , or we can calculate marginal measures of causal effect through standardization to any given distribution of C (as long as the distribution of C contains only values present in our population).

14.1.3 Selection bias and the analytic cohort condition

Under exchangeability, we have $\Pr(D^x = 1) = \Pr(D = 1 \mid X = x)$ in our population. However, we typically do not observe the entire population. Instead, we observe a sample of the population. This could be a random sample of the population or a sample selected by exposure (in a cohort study) or by disease (in a case-control study). Let S indicate selection into the study, so $S = 1$ for members of our study sample and $S = 0$ for everyone else. **Selection bias** occurs when selection into the study distorts the true association between X and D in the population eligible for the study (Berkson 1946; M. Á. Hernán, Hernández-Díaz, and Robins

2004). Confounding is specific to causal inference, but selection bias can affect both causal inference and prediction (i.e., both analytic and descriptive epidemiology).

Using the data from our study, we cannot calculate $\Pr(D = 1 \mid X = x)$ directly. Instead, we can calculate

$$\Pr(D = 1 \mid X = x, S = 1).$$

We would like to have

$$\Pr(D^x = 1) = \Pr(D = 1 \mid X = x) = \Pr(D = 1 \mid X = x, S = 1).$$

However, exchangeability in the population implies only the first equality. To guarantee the second equality, we need to have the **analytic cohort condition** (Kenah 2023) where

$$S^x \perp\!\!\!\perp D^x \mid X.$$

In other words, if we intervene to set $X = x$, the potential disease outcome D^x and potential selection S^x are independent of each other. To estimate a risk of disease accurately, selection into the study must be independent of disease outcome.

With both exchangeability and the analytic cohort condition, we get

$$\begin{aligned} \Pr(D^x = 1) &= \Pr(D^x = 1 \mid X = x) && \text{by exchangeability} \\ &= \Pr(D^x = 1 \mid X = x, S^x = 1) && \text{by the analytic cohort condition} \\ &= \Pr(D = 1 \mid X = x, S = 1) && \text{by consistency.} \end{aligned}$$

Therefore, we can estimate causal measures of the effect of X using data from our cohort study.

When the analytic cohort condition fails, we might still have a conditional analytic cohort condition (Kenah 2023) where

$$S^x \perp\!\!\!\perp D^x \mid (X, C)$$

for a set C of measured covariates that are not causally affected by X . If the analytic cohort condition holds given C , then

$$\begin{aligned} \Pr(D^x = 1 \mid C) &= \Pr(D^x = 1 \mid C, X = x) && \text{by exchangeability} \\ &= \Pr(D^x = 1 \mid C, X = x, S^x = 1) && \text{by the analytic cohort condition} \\ &= \Pr(D = 1 \mid C, X = x, S = 1) && \text{by consistency.} \end{aligned}$$

Therefore, we can estimate conditional counterfactual risks given C by calculating conditional risks of disease given X and C in our cohort study. These can be used to calculate conditional measures of causal effect given C , or we can calculate marginal measures of causal effect through standardization to any given distribution of C (as long as the distribution of C contains only values present in our study sample).

14.2 Attributable risk

Measures of attributable risk attempt to measure the proportion of a given disease that could be prevented by preventing a given exposure, either among the exposed or in the entire population. These measures implicitly assume that the observed difference in the occurrence of disease between the exposed and the unexposed represents a causal effect. In other words, they assume that the disease occurrence among the unexposed represents what would have happened among the exposed if exposure had been prevented.

14.2.1 Sufficient-component cause model (causal pies)

Rothman (1976) proposed a model of causation now known as the **sufficient-component cause model**. A **sufficient cause** of disease is one that will inevitably lead to the disease, possibly after a period of time called the *induction period* (Rothman, Greenland, and Lash 2008). Each sufficient cause is called a **causal pie**, and it is made up of one or more component causes. The loss of any one of these component causes will destroy the sufficient cause. A given disease can have more than one sufficient cause, so the removal of one sufficient cause may not prevent the disease. However, the removal of a sufficient cause can delay the onset of disease if the disarmed sufficient cause would have been the one that first caused disease (after being completed and going through its induction period).

A component cause is a **necessary cause** of a disease if it is a component of all possible sufficient causes of the disease. A component cause is a **sufficient cause** of a disease if it constitutes a sufficient cause all by itself. Removing a necessary cause will prevent all cases of a disease (e.g., smallpox eradication), but removing a sufficient cause leaves open the possibility that some other sufficient cause will induce the disease. However, most exposures of interest in public health are neither necessary nor sufficient to produce a given disease:

Most causes that are of interest in the health field are components of sufficient causes, but are not sufficient in themselves. Drinking contaminated water is not sufficient to produce cholera, and smoking is not sufficient to produce lung cancer, but both of these are components of sufficient causes. Identification of all the components of a given sufficient cause is unnecessary for prevention, in that blocking the causal role of but one component renders the joint action of the other causes insufficient, and prevents the effect. (Rothman 1976).

The apparent strength of a risk factor for is determined by the context in which it occurs as well as the biology of the disease. The relative risk (e.g., the risk difference, risk ratio, odds ratio, or hazard ratio) associated with an exposure X will depend on the prevalence of the other components of the sufficient causes in which it is a component. If the other components of those sufficient causes have low prevalence, few people will develop disease upon exposure to X (because the addition of X does not complete any sufficient cause) and the relative risk associated with exposure to X will be small. If the other components have high prevalence,

many people will develop disease upon exposure to X (because exposure to X completes at least one sufficient cause) and the relative risk associated with X will be large. Rothman (1976) gives the example of phenylketonuria (PKU), a genetic disorder that results in decreased metabolism of the amino acid phenylalanine:

... in a society where most people eat high phenylalanine diets, the inheritance of the (rare) gene for PKU would appear to be a “strong” risk factor for phenylketonuric [intellectual disability], and phenylalanine in the diet would appear to be a weak risk factor. In another society, however, in which the gene for PKU is very common and few people eat high phenylalanine diets, inheritance of the gene would be a weak risk factor and phenylalanine in the diet would be a strong risk factor.

14.2.2 Attributable risk among the exposed

The **attributable risk among the exposed** is the proportion of risk among the exposed that is due to exposure. For simplicity, we assume that exposure is defined so that the exposed have higher or equal risk of disease. Let p_1 denote the cumulative incidence (risk) among the exposed in a given time interval, and let p_0 denote the cumulative incidence among the unexposed in the same interval. Then

$$\text{AR} = \frac{p_1 - p_0}{p_1} = \frac{\text{RR} - 1}{\text{RR}} \quad (14.1)$$

where $\text{RR} = p_1/p_0$ is the risk ratio (Levin 1953; Cole and MacMahon 1971). The second equality holds only when $p_0 > 0$, but the first equality holds even when $p_0 = 0$. This is meant to measure the decrease in the risk among the exposed that would occur if exposure could be prevented.

14.2.3 Population attributable risk

The **population attributable risk** is the proportion of risk in the population that is due to exposure. If the prevalence of exposure is π , then the total risk in the population is

$$(1 - \pi)p_0 + \pi p_1 = p_0 + \pi(p_1 - p_0).$$

The excess risk in the population due to exposure is $\pi(r_1 - r_0)$, so the population attributable risk (Levin 1953; Cole and MacMahon 1971) is

$$\text{PAR} = \frac{\pi(p_1 - p_0)}{p_0 + \pi(p_1 - p_0)} = \frac{\pi(\text{RR} - 1)}{1 + \pi(\text{RR} - 1)}.$$

When $\pi = 1$, this is equal to the attributable risk among the exposed. This is meant to measure the decrease in risk in the population that would occur if exposure could be prevented.

When the odds ratio from a case control study approximates the risk ratio (as in a cumulative case-control study with a rare disease or a case-cohort study), the AR can be estimated using case-control data and the PAR can be estimated using case-control data and the prevalence of exposure. These measures can be adjusted for confounding and effect measure modification, and they can be redefined to estimate the proportion of cases prevented by an exposure or treatment associated with reduced risk (O. S. Miettinen 1974).

14.2.4 Dependence on time interval

Both measures of attributable risk depend on the time interval considered. For example, suppose individuals in our population have exponential($\lambda = 1$) lifetimes when unexposed and exponential($\lambda = 2$) lifetimes when exposed. In the time interval $(0, t]$, the attributable risk among the exposed is

$$\text{AR}(t) = \frac{(1 - e^{-2t}) - (1 - e^{-t})}{1 - e^{-2t}} = \frac{e^{-t} - e^{-2t}}{1 - e^{-2t}}.$$

As t approaches zero from above (i.e., $t \downarrow 0$), $\text{AR}(t) \rightarrow 1/2$ (which can be shown using l'Hôpital's rule). As $t \rightarrow \infty$, $\text{AR}(t) \rightarrow 0$.

14.2.5 Adding up attributable risks

If we have several different causes of disease, the attributable risk among the exposed for all of them can add up to more than one. For example, imagine that disease can only occur if a person has both exposure X and exposure Y . The attributable risk among the exposed for X would be

$$\text{AR}_X = \frac{p_1 - 0}{p_1} = 1,$$

where p_1 is the risk among individuals who have $X = 1$. Similarly, the attributable risk among the exposed for Y would be $\text{AR}_Y = 1$. Thus, we would have $\text{AR}_X + \text{AR}_Y = 2$. The sufficient-component cause model is useful for understanding why attributable risks for all possible causes could add up to more than one.

14.3 Excess and etiologic cases

While measures of attributable risk are straightforward to calculate, their interpretation is more difficult than it seems at first. Greenland and Robins (1988) pointed out two different meanings of the concept “attributable to exposure” that are often used interchangeably:

- Cases for which exposure played a causal role, which they called **etiologic cases**.

- Cases that would not have occurred if exposure had not occurred, which they called **excess cases**.

All excess cases are etiologic cases, but not all etiologic cases are excess cases. This becomes easier to see if we explicitly consider the potential times to onset of disease with and without exposure. Assume that we are following study participants over an interval $(0, t]$. Let T_j^0 be the time to disease onset in person j under no exposure and T_j^1 be the corresponding time to disease onset under exposure. Because we assume exposure does not prevent disease, we have $T_j^1 \leq T_j^0$.

- If $T_j^1 = T_j^0$, then exposure has no effect on disease in person j and j is not an etiologic case.
- If $T_j^1 < T_j^0$, then exposure has an effect on disease in person j and j is an etiologic case.

For j to be an excess case, we must have $T_j^1 \leq t$ (so that j becomes a case when exposed) and $t < T_j^0$ (so that j is not a case when not exposed). In other words, we need $T_j^1 \leq t < T_j^0$. This is possible only when $T_j^1 < T_j^0$, so j can be an excess case only if they are also an etiologic case. An etiologic case becomes an excess case only if exposure reduces the time to onset enough that they become a case during the follow-up period.

14.3.1 Excess and etiologic fractions

Because an individual can be an excess case only if they are also an etiologic case, there are three types of cases that we detect. Suppose we have the following numbers of cases:

- A_0 cases whose onsets time is not affected by exposure (non-etiological cases).
- A_1 etiologic cases who are not excess cases (i.e., they are cases with or without exposure).
- A_2 etiologic cases who are also excess cases (i.e., they are cases only with exposure).

Let $M = A_0 + A_1 + A_2$ be the total number of cases. The **etiologic fraction** is the proportion of cases that are etiologic cases:

$$\text{etiologic fraction} = \frac{A_1 + A_2}{M}.$$

The **excess fraction** is the proportion of cases that are excess cases:

$$\text{excess fraction} = \frac{A_2}{M}.$$

The excess fraction is always less than or equal to the etiologic fraction.

If we observed a total of N exposed individuals and detected M cases, then the risk of disease over the time interval $(0, t]$ is

$$p_1 = \frac{M}{N} = \frac{A_0 + A_1 + A_2}{N}.$$

Without exposure, we would have detected $A_0 + A_1$ cases and the risk of disease would have been

$$p_0 = \frac{A_0 + A_1}{N}.$$

The attributable risk among the exposed would be

$$\frac{p_1 - p_0}{p_1} = \frac{(A_0 + A_1 + A_2) - (A_0 + A_1)}{A_0 + A_1 + A_2} = \frac{A_2}{M},$$

which is the excess fraction. Similarly, the population attributable risk is

$$\frac{\pi(p_1 - p_0)}{p_0 + \pi(p_1 - p_0)} = \frac{\pi A_2}{A_0 + A_1 + p A_2}$$

when the prevalence of exposure is p . The A_1 etiologic cases who are not excess cases have disease onset earlier because of exposure, so they are cases caused by exposure who are not captured in either measure of attributable risk. Because we cannot see both T^1 and T^0 for any individual, there is no way to estimate the proportion of cases who are of this type without strong assumptions (Greenland and Robins 1988).

To estimate the etiologic fraction, we need to make assumptions about the joint distribution of the potential disease onset times T^0 and T^1 that are difficult to justify or refute. Even if we can accurately estimate the distribution of times to disease onset in the exposed and the unexposed, the marginal distributions of T_0 and T_1 do not tell us what their joint distribution is. Under some models for T_0 and T_1 , the etiologic fraction can be estimated by replacing the risk ratio in Equation 14.1 with a hazard ratio. Under slightly weaker assumptions, this will give us a lower bound for the etiologic fraction (J. M. Robins and Greenland 1989).

14.3.2 Limitations of the etiologic fraction

The etiologic fraction, if it could be calculated, would usually be a more complete measure of the proportion of cases caused by a given exposure than the excess fraction. However, Greenland and Robins (1988) give a cautionary example:

Unfortunately, even if we know exactly what the etiologic fraction is, it is not necessarily a useful measure of the effect of exposure on disease occurrence. To see this, compare the impact of the genetic conditions that produce Tay-Sachs disease and Huntington's chorea. Both conditions lead to premature death, and both may be considered to have etiologic fractions for death (among the exposed)

that approach one. Nevertheless, persons who develop Tay-Sachs disease die in early childhood, whereas persons who develop Huntington's chorea usually survive well into adulthood and can lead rich, if shortened, lives. The etiologic fraction is not sensitive to this distinction.

They continue the example to illustrate how survival analysis can clarify the relationship between exposure and disease:

Interestingly, in the preceding example, the excess fraction at age 20 years would clearly distinguish the two conditions (since it would be near one for Tay-Sachs and near zero for Huntington's chorea), as would the incidence density [hazard] fraction in early childhood. More generally, we would suggest turning attention to direct measures of exposure effect on incidence time whenever the latter is important.

14.4 Sensitivity analysis

14.4.1 Cornfield's inequality

Cornfield et al. (1959) was a vigorous and lucid defense of the idea that smoking causes lung cancer. One of the arguments against this was the “constitutional hypothesis” that there was an underlying difference between smokers and nonsmokers that explained the difference in lung cancer risks. Using statistics alone, there is almost no way to prove that this is not true. However, the result now known as **Cornfield's inequality** does show that any such underlying difference would have to be implausibly large.

Suppose there is a true causal exposure or characteristic X such that the risk of lung cancer over a given age interval $(a, b]$ is p_1 among those with $X = 1$ and p_0 for those with $X = 0$. Now suppose the prevalence of X is π_1 among smokers and π_0 among nonsmokers. We assume that $p_1 > p_0$ (so X is a risk factor for lung cancer) and $\pi_1 > \pi_0$ (so X is positively associated with smoking), and we assume that smoking has no effect on lung cancer other than its association with X . Over the age interval $(a, b]$, the risk of lung cancer among smokers is

$$p_{\text{smk}} = \pi_1 p_1 + (1 - \pi_1) p_0,$$

and the risk of lung cancer among nonsmokers is

$$p_{\text{non}} = \pi_0 p_1 + (1 - \pi_0) p_0.$$

The risk ratio for lung cancer associated with smoking is

$$\frac{p_{\text{smk}}}{p_{\text{non}}} = \frac{\pi_1 p_1 + (1 - \pi_1) p_0}{\pi_0 p_1 + (1 - \pi_0) p_0} = \frac{\pi_1 \frac{p_1}{p_0} + (1 - \pi_1)}{\pi_0 \frac{p_1}{p_0} + (1 - \pi_0)}. \quad (14.2)$$

The derivative of the function

$$f(x) = \frac{\pi_1 x + (1 - \pi_1)}{\pi_0 x + (1 - \pi_0)}$$

is strictly positive for all x when $\pi_1 > \pi_0$, so $f(x)$ always increases as x increases. As $x \rightarrow \infty$, we have $f(x) \rightarrow \pi_1/\pi_0$. Therefore,

$$\frac{p_{\text{smk}}}{p_{\text{non}}} = f\left(\frac{r_1}{r_0}\right) < \frac{\pi_1}{\pi_0}.$$

Thus the risk ratio associated with smoking has to be less than the ratio of the prevalence of X among smokers to the prevalence of X among nonsmokers.

Cornfield et al. (1959) cite a result from a study of holders of US government life insurance that was available only to veterans who served in the US Armed Forces between 1917 and 1949 (Dorn 1959). In this group, there were 187 deaths from lung cancer among cigarette smokers between July, 1954 and December, 1956. Based on age-specific rates of death from lung cancer among never-smokers and occasional smokers, the expected number of deaths was 20. This implies a risk ratio of $187/20 = 9.35$. To explain this using an unobserved cause X of death from lung cancer that was associated with cigarette smoking, we would need

$$\frac{p_1}{p_0} \geq 9.35.$$

The prevalence of X among nonsmokers could be at most $1/9.35 \approx 0.107$.

Even more, we can have $\pi_1/\pi_0 = 9.35$ only if the risk ratio $p_1/p_0 = \infty$, which would happen only if X was a necessary cause of death from lung cancer. We can rearrange Equation 14.2 to get

$$\pi_0 \leq \frac{\frac{p_1}{p_0} - \frac{p_{\text{smk}}}{p_{\text{non}}}}{\frac{p_{\text{smk}}}{p_{\text{non}}} \left(\frac{p_1}{p_0} - 1 \right)}$$

This shows that we must have

$$\frac{p_1}{p_0} > \frac{p_{\text{smk}}}{p_{\text{non}}}.$$

If we have $p_1/p_0 = 100$, we have $p_0 \leq 0.098$ and $\pi_1/\pi_0 > 10.2$. If $p_1/p_0 = 10$, we have $\pi_0 \leq 0.0077$ and $\pi_1/\pi_0 > 129.46$. The constitutional hypothesis is workable only if there is an undiscovered gene, hormone, or other covariate that is an extraordinarily strong predictor of both cigarette smoking and death from lung cancer.

With a relative risk of 9.35, the attributable risk of death from lung cancer among cigarette smokers is

$$\frac{9.35 - 1}{9.35} = 0.89,$$

which is equal to the excess fraction. The etiologic fraction of death from lung cancer due to smoking is at least this large and almost certainly larger.

14.4.2 E-values

15 Confounding and Selection Bias on DAGs

A recent study in Buffalo, for example, indicates that smokers differ significantly from nonsmokers in a number of characteristics: they are more neurotic, are more frequently hospitalized, and they change jobs and spouses more often than nonsmokers. Had the two groups been compared for other characteristics, it is quite possible that they would have been found to differ in these also. It is conceivable that some of these other characteristics, rather than smoking, are responsible in whole or in part for the increase in lung cancer among smokers. (Yerushalmy and Palmer 1959)

15.1 Simpson's paradox

The modern discussion of confounding began with Simpson (1951).¹ Table 15.1 shows the example from this paper. Among males and females, treatment is protective. The odds ratio for death comparing the treated and untreated is

$$\begin{aligned}\frac{5/8}{3/4} &= \frac{20}{24} = \frac{5}{6} \approx 0.83 \text{ among men,} \\ \frac{15/12}{3/2} &= \frac{30}{36} = \frac{5}{6} \approx 0.83 \text{ among women.}\end{aligned}$$

If we ignore biological sex and calculate the crude odds ratio, we get

$$\frac{20/20}{6/6} = 1.$$

This apparent contradiction has come to be known as **Simpson's paradox**. Simpson concluded: "The treatment can hardly be rejected as valueless to the race when it is beneficial to males and females."

This paradox can be resolved using **causal directed acyclic graphs** (causal DAGs), where nodes represent variables and directed paths from one variable to another represent causal

¹Edward H. Simpson (1922–2019) was a British civil servant who grew up in Northern Ireland and became interested in statistics while working as a codebreaker at Bletchley Park in World War II. He went on to earn a PhD in mathematical statistics at the University of Cambridge in 1946 before joining the UK Ministry of Education.

Table 15.1: Epidemiologic data stratified by sex (left) and unstratified (right) from Simpson (1951)

	Male		Female		Crude	
	Dead	Alive	Dead	Alive	Dead	Alive
Treated	5	8	15	12	20	20
Untreated	3	4	3	2	6	6

effects. A causal DAG can be used to represent our knowledge or hypotheses about causal relationships among variables (Pearl 1995; Greenland, Pearl, and Robins 1999a). In epidemiology, causal DAGs give us useful new insights about how confounding and selection bias occur and how to control them. They also allow us to clearly express the causal assumptions underlying the design and analysis of an epidemiologic study.

15.2 Directed acyclic graphs

In a causal DAG, a series of arrows pointing from a variable X to a variable Y is used to show that changing a variable X (e.g., flipping a switch) will cause a change in Y (e.g., whether the light is on). A simple example is shown in Figure 15.1. The direction of the arrows captures the asymmetry of causal relationships across time: The past affects the future but the future does not affect the past. In this example, the flipping the light switch can turn on the light but unscrewing the light bulb will not flip the switch. It is good practice to write a DAG so that all arrows point in a consistent direction (e.g., left to right) that represents the passage of time.




Figure 15.1: Directed acyclic graph (DAG) showing the causal effect of a light switch on a light.

Listing 15.1 dag-lightswitch.R

```
## Directed acyclic graph for a light switch

# dagitty can be installed from github.com/jtextor/dagitty
# ggdag and ggplot2 can be installed using install.packages()
library(dagitty)
library(ggdag, warn.conflicts = FALSE)
library(ggplot2)

# define the DAG
light <- dagitty('dag{
  "Light switch" -> "Light on"
}')
coordinates(light) <- list(x = c("Light switch" = 0, "Light on" = 1),
                           y = c("Light switch" = 0, "Light on" = 0))

# plot the DAG
(ggdag_classic(light)
 + theme_dag_gray_grid()
 + xlim(-0.5, 1.5)
 + ylim(-0.5, 0.5)
)
```

15.2.1 Adding variables and arrows

When building a causal DAG, we cannot arbitrarily choose which variables to include. Let X be an exposure or treatment, D be a disease outcome. To make a causal DAG that represents the causal effect of X on D , we start with X and D . Given a set of variables on the DAG, we must add any variable that has a causal effect on two or more of these variables. We continue doing so until there is no common cause of any two variables on the DAG (or, in reality, until any remaining causal relationships are negligible).

The presence or absence of arrows between variables on a DAG are defined in terms of the effects of interventions. Let A and B be variables on a DAG and let $V = (V_1, \dots, V_k)$ denote all of the other variables on the DAG. Let

$$B^{(a,v)}(\omega)$$

be the potential outcome for B in person ω in our population Ω when we intervene to set $A(\omega) = a$ and $V(\omega) = v = (v_1, \dots, v_k)$. There is an arrow from A to B if and only if there are two values a_0 and a_1 and a vector of values v such that

$$B^{(a_1,v)}(\omega) \neq B^{(a_0,v)}(\omega)$$

for at least one $\omega \in \Omega$. Intuitively, this means that changing A alters the value of B for at least one $\omega \in \Omega$ even when we intervene to hold all other variables fixed.

The arrow from A to B tells us that, for at least one individual, A has a causal effect on B that is not mediated through any other variable in the DAG. However, the arrow is either there or not there. It does not tell us anything about how large this effect is, how much of the population experiences it, or anything else quantitative. Some arrows might represent large causal effects for a large proportion of the population while others represent a small causal effect for a small proportion of the population. Still others could represent a large causal effect for a small proportion of the population or a small effect for a large proportion. The DAG abstracts away all of these differences, leaving only what we need to think clearly about the structure of the causal relationships.

15.2.2 Paths and causal paths

The arrows between variables on a DAG are often called **edges**, which can help us distinguish between situations where we must pay attention to the direction of the arrow and situations where we can safely ignore it. The *endpoints* of an edge are the head and tail of the arrow. Two edges are **adjacent** when they have endpoints at the same node.

On a DAG, a **path** from A to B is any sequence of distinct adjacent edges that lead from A to B where we can ignore the direction of the arrows. The length of the path is the number of edges it contains. A path might consist of only one arrow. A path from A to B where we follow the direction of the arrows is called a **directed path** or a **causal path**. The DAG in Figure 15.2 includes the following paths:

- The path $B \rightarrow D$ is causal but the path $D \leftarrow B$ is noncausal.
- There are two paths from A to C : $A \rightarrow C$ and $A \rightarrow B \rightarrow C$. Both paths are causal.
- There are two paths from B to C : $B \rightarrow C$ and $B \leftarrow A \rightarrow C$. Only the first path is causal.
- There are two paths from C to D : $C \leftarrow A \rightarrow B \rightarrow D$ and $C \leftarrow B \rightarrow D$. Neither path is causal.




Figure 15.2: Directed acyclic graph (DAG) showing ancestors, parents, children, and descendants.

15.3 R

15.3.1 Ancestors and descendants

If we can reach node B along a directed path starting at node A , then A is an **ancestor** of B and B is a **descendant** of A . If there is an arrow from A to B , then A is a **parent** of B and B is a **child** of A . Parents are ancestors, and children are descendants.² These relationships are labelled in Figure 15.2. If we intervene to set the value of the variable A , this affects descendants of A on the DAG. The ancestors of A are unaffected.

15.4 R

A **cycle** is a directed path from a variable A back to itself. A DAG is *acyclic* because a cycle would require at least one arrow representing a causal effect that moves backward in time. Thus, a variable on a DAG cannot be its own ancestor or descendant. To show a feedback loop between variables A and B on a DAG, we represent each variable at multiple time points. Figure 15.3 shows a feedback loop between A and B over two time points. The links from A_1 to A_2 and B_1 to B_2 show the causal effect of each variable's value at $t = 1$ on its value at $t = 2$. Unfortunately, time in the world of DAGs is stubbornly discrete.

²Sometimes the ancestors and descendants of a variable V are defined to include V itself. The *proper ancestors* and *proper descendants* of V do not include V .




Figure 15.3: Directed acyclic graph (DAG) showing a feedback loop between A and B .

15.4.1 Joint distributions consistent with a DAG*

The joint probability density (or mass) function of the variables on a causal DAG can be factored using the conditional distribution of each variable given its parents. If V_1, \dots, V_n are variables on a DAG (where the subscript does not necessarily represent time), then the joint probability density is

$$\Pr(V_1 = v_1, \dots, V_n = v_n) = \prod_{i=1}^n \Pr(V_i = v_i \mid \text{pa}_i)$$

where pa_i represents the values of the parents of V_i and we let $\Pr()$ represent probability density functions or probability mass functions as needed. A joint distribution of V_1, \dots, V_n is consistent with the DAG if and only if it can be factored in this way. A given DAG is consistent with many possible joint distributions, but the conditional independence relations on it hold for all of them. Some of these distributions may have additional conditional independencies that are not implied by the DAG.³

15.4.2 Open paths and associations

A path from a variable A to a variable B can be **open** or **closed**. Each variable along the path (except A and B) acts like a valve, and the path is open only if all of these valves are open. A variable's state depends on the path: A variable can be open for some paths and closed for other paths. If all paths between A and B are closed, then A and B are independent. If there is at least one open path from A to B , then are distributions consistent with the DAG where A and B are not independent.

³Generating an independence between two variables that is not implied by the DAG requires us to find combinations of parameters that solve a system of equations. When the set of solutions has Lebesgue measure zero in the space of possible parameters, the dependencies implied by the DAG occur in almost all joint distributions consistent with the DAG.

Whether a variable C is open or closed along a given path is determined by the rules of **d-separation** (or *directional separation*). The first two of these are:

- A variable C on the path is a **collider** if both arrows adjacent to it along the path point toward C . A collider is closed.
- Any variable that is not a collider is open. A variable V can be a collider on one path and a non-collider on another path.

Two variables on a DAG are **d-separated** when all paths between them are closed. When there is at least one open path between them, they are **d-connected**. Thus, two variables that are d-separated are independent. If two variables are d-connected, they are dependent in most (but not necessarily all) joint distributions consistent with the DAG. The DAG in Figure 15.4 has the following open and closed paths:

- The path $A \rightarrow C \leftarrow B$ is closed by the collider at C . There are no other paths between A and B , so A and B are d-separated and $A \perp\!\!\!\perp B$ (i.e., A is independent of B).
- The path $B \rightarrow C \rightarrow D$ is open, so B and D are d-connected and it is possible that $B \not\perp\!\!\!\perp D$ (i.e., B is not independent of D). On this path, C is not a collider.




Figure 15.4: Directed acyclic graph (DAG) to illustrate open and closed paths.

15.5 R

15.5.1 Conditional associations

A DAG can also be used to evaluate conditional associations. Conditioning on a variable V means that we look at the joint distribution of the other variables in the subset of our population Ω with $V(\omega) = v$ for some possible value v . In a DAG, conditioning on a variable is represented by putting a square around it. The effects of conditioning on a variable are determined by two more rules of d-separation:

- Conditioning on a collider or a descendant of a collider opens the path through the collider. Conditioning on an ancestor of a collider does not open the path.
- Conditioning on a non-collider closes the path through it. Conditioning on an ancestor or descendant of a non-collider does not close the path.

Conditioning on a variable switches its state along any path that goes through it. If the variable was open, it becomes closed. If the variable was closed, it becomes open. Conditioning on a descendant of a collider is the only way that conditioning on a variable not on a path can change whether the path is open or closed. The DAG in Figure 15.5 has the following open and closed paths:

- The path $A \rightarrow C \leftarrow B$ is opened by conditioning on the collider at C . Because A and B are d-connected given C , it is possible that $A \not\perp\!\!\!\perp B | C$ (i.e., A is not conditionally independent of B given C) in a joint distribution consistent with the DAG.
- Because D is a descendant of the collider C on the path from A to B , conditioning on it opens the path. Thus, A and B are d-connected given D and it is possible that $A \not\perp\!\!\!\perp B | D$.
- The path $B \rightarrow C \rightarrow D$ is closed by conditioning on the non-collider at C , and there are no other paths from B to D . Because B and D are d-separated given C , the DAG implies that $B \perp\!\!\!\perp D | C$ (i.e., B is conditionally independent of D given C).




Figure 15.5: Directed acyclic graph (DAG) to illustrate conditionally open and closed paths. The box around the variable C indicates conditioning on C .

15.6 R

The same rules apply if we condition on multiple variables simultaneously. Conditioning on V_1, \dots, V_k means that we look at the joint distribution of the other variables in the subset of our population Ω with $V_1(\omega) = v_1, \dots, V_k(\omega) = v_k$. Variables that are d-separated when we condition on a variable or set of variables V are conditionally independent given V .

15.7 Confounding and selection bias

The fact that association does not imply causation can be explained very simply using DAGs. An association between variables A and B (where we assume that A comes before B) means that there is at least open path between them on any causal DAG that includes both variables. If all of the open paths from A to B are causal, then this association represents a causal effect of A on B in the population where the association was observed. If some of these open paths are noncausal, the association does not accurately represent a causal effect in the population.

In the design and analysis of an epidemiologic study, our goal is to close all non-causal pathways from exposure X to disease outcome D while keeping all causal pathways open. This almost always require measuring variables other than X and D .

15.7.1 Confounding and open backdoor paths

15.7.2 Selection bias and colliders

15.7.3 Simpson's paradox revisited




Figure 15.6: Directed acyclic graph (DAG) for the example from Simpson (1951).

15.7.4 Berkson's bias

Listing 15.2 dag-family.R

```
## Paths, ancestors, and descendants on a DAG

# load packages
# I set "warn.conflicts = FALSE" to suppress an unnecessary error message.
library(dagitty)
library(ggdag, warn.conflicts = FALSE)
library(ggplot2)

# define the DAG
fam <- dagitty('dag{
  A -> B -> C
  A -> C
  B -> D
}')

# plot the DAG
# Uncomment coord_equal() to get a better-looking DAG in an R plot window.
coordinates(fam) <- list(x = c(A = 0, B = 1, C = 2, D = 2),
                        y = c(A = 0, B = 0, C = 0.5, D = -0.5))

(ggdag_classic(fam)
 + theme_dag_gray_grid()
 + xlim(-0.2, 2.2)
 # + coord_equal()
 # node A
 + annotate("text", x = 0, y = -0.1, label = "Parent of B and C")
 + annotate("text", x = 0, y = -0.2, label = "Ancestor of B, C, and D")
 # node B
 + annotate("text", x = 1, y = -0.1, label = "Child of A")
 + annotate("text", x = 1, y = -0.2, label = "Parent of C and D")
 + annotate("text", x = 1, y = -0.3, label = "Ancestor of C and D")
 # node C
 + annotate("text", x = 2, y = 0.35, label = "Child of A and B")
 + annotate("text", x = 2, y = 0.25, label = "Descendant of A and B")
 # node D
 + annotate("text", x = 2, y = -0.25, label = "Descendant of A and B")
 + annotate("text", x = 2, y = -0.35, label = "Child of B")
)
```

Listing 15.3 dag-family-paths.R

```
## Paths and causal (directed) paths on a DAG

# load packages
library(dagitty)

# define the DAG
fam <- dagitty('dag{
  A -> B -> C
  A -> C
  B -> D
}')

# paths from B to D
# Setting "directed = TRUE" returns causal paths.
paths(fam, "B", "D")
paths(fam, "B", "D", directed = TRUE)
paths(fam, "D", "B")
paths(fam, "D", "B", directed = TRUE)

# paths from A to C
paths(fam, "A", "C")
paths(fam, "A", "C", directed = TRUE)

# paths from B to C
paths(fam, "B", "C")
paths(fam, "B", "C", directed = TRUE)

# paths from C to D
paths(fam, "C", "D")
paths(fam, "C", "D", directed = TRUE)
```

Listing 15.4 dag-family-apcd.R

```
## Ancestors, parents, children, and descendants on a DAG

# load packages
library(dagitty)

# define the DAG
fam <- dagitty('dag{
  A -> B -> C
  A -> C
  B -> D
}')

# node A
# Proper ancestors and descendants do not include the node itself.
ancestors(fam, "A")
ancestors(fam, "A", proper = TRUE)
parents(fam, "A")
children(fam, "A")
descendants(fam, "A")
descendants(fam, "A", proper = TRUE)

# node B
ancestors(fam, "B", proper = TRUE)
parents(fam, "B")
children(fam, "B")
descendants(fam, "B", proper = TRUE)

# node C
ancestors(fam, "C", proper = TRUE)
parents(fam, "C")
children(fam, "C")
descendants(fam, "C", proper = TRUE)

# node D
ancestors(fam, "D", proper = TRUE)
parents(fam, "D")
children(fam, "D")
descendants(fam, "D", proper = TRUE)
```

Listing 15.5 dag-feedback.R

```
# Feedback loop on a DAG

library(dagitty)
library(ggdag)
library(ggplot2)

# define the DAG
loop <- dagitty('dag{
  A1 -> B1 -> A2 -> B2
  A1 -> A2
  B1 -> B2
}')

# generate DAG data for plot
coordinates(loop) <- list(x = c(A1 = 0, B1 = 1, A2 = 2, B2 = 3),
                          y = c(A1 = 0, B1 = 0, A2 = 0, B2 = 0))
loop_dat <- tidy_dagitty(loop)

# plot DAG using ggplot() to allow curved arrows
# Uncomment coord_equal() to get a better-looking DAG in an R plot window.
(ggplot(loop_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 # + coord_equal()
 + geom_dag_text(color = "black", size = 8, parse = TRUE,
                 label = c(expression(A[1]), expression(A[2]),
                             expression(B[1]), expression(B[2])))
 + geom_dag_edges_arc(curvature = c(0.5, 0, 0, 0, -0.5))
)
```

Listing 15.6 dag-valves.R

```
## Open and closed paths on a DAG

# load R packages
library(dagitty)
library(ggdag)
library(ggplot2)

# define DAG
valves <- dagitty('dag{
  A -> C
  B -> C -> D
}')

# plot DAG using ggplot() directly to allow for curved arrows
# Uncomment coord_equal() to get a better-looking DAG in an R plot window.
coordinates(valves) <- list(x = c(A = 0, B = 1, C = 2, D = 3),
                           y = c(A = 0, B = 0, C = 0, D = 0))
valves_dat <- tidy_dagitty(valves)
(ggplot(valves_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 + coord_equal()
 + ylim(-0.1, 0.6)
 + geom_dag_text(color = "black", size = 8, parse = TRUE)
 + geom_dag_edges_arc(curvature = c(0.4, 0, 0))
)
```

Listing 15.7 dag-valves-paths.R

```
## Open and closed paths on a DAG

# load R packages
library(dagitty)
library(ggdag)

# define DAG
valves <- dagitty('dag{
  A -> C
  B -> C -> D
}')

# path from A to B is blocked by the collider at C
paths(valves, "A", "B")
dconnected(valves, "A", "B")
dseparated(valves, "A", "B")
isCollider(valves, "A", "C", "B")

# path from B to D is open because C is not a collider on it
paths(valves, "B", "D")
dconnected(valves, "B", "D")
dseparated(valves, "B", "D")
isCollider(valves, "B", "C", "D")

# conditional independence relations implied by the DAG
impliedConditionalIndependencies(valves)
```

Listing 15.8 dag-cvalves.R

```
## Open and closed paths on a DAG

# load R packages
library(dagitty)
library(ggdag)
library(ggplot2)

# define DAG
valves <- dagitty('dag{
  A -> C
  B -> C -> D
}')

# generate data for plotting DAG using ggplot()
# Use geom_dag_label() for adjusted variables to get a box around them.
coordinates(valves) <- list(x = c(A = 0, B = 1, C = 2, D = 3),
                           y = c(A = 0, B = 0, C = 0, D = 0))
cvalves_dat <- control_for(valves, "C", activate_colliders = FALSE)
cvalves_adj <- filter(cvalves_dat, adjusted == "adjusted")
cvalves_unadj <- filter(cvalves_dat, adjusted == "unadjusted")

# plot DAG with ggplot() to allow for boxes and curved arrows
# Uncomment coord_equal() to get a better-looking DAG in an R plot window.
(ggplot(cvalves_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 # + coord_equal()
 + ylim(-0.1, 0.6)
 + geom_dag_label(data = cvalves_adj, parse = TRUE, size = 8, fill = NA,
                  label.padding = unit(0.15, "lines"))
 + geom_dag_text(data = cvalves_unadj, parse = TRUE,
                 color = "black", size = 8)
 + geom_dag_edges_arc(curvature = c(0.4, 0, 0))
)
```

Listing 15.9 dag-cvalves-paths.R

```
## Conditionally open and closed paths on a DAG

# load R packages
library(dagitty)
library(ggdag)

# define DAG
valves <- dagitty('dag{
  A -> C
  B -> C -> D
}')

# path from A to B opened by conditioning on the collider at C
# The third argument Z is a variable or vector of variables to condition on.
isCollider(valves, "A", "C", "B")
paths(valves, "A", "B", Z = "C")
dconnected(valves, "A", "B", "C")
dseparated(valves, "A", "B", "C")

# path from A to B opened by conditioning on D (descendant of collider C)
isCollider(valves, "A", "C", "D")
paths(valves, "A", "B", "D")
dconnected(valves, "A", "B", "D")
dseparated(valves, "A", "B", "D")

# path from B to D closed by conditioning on non-collider at C
isCollider(valves, "B", "D", "C")
paths(valves, "B", "D", "C")
dconnected(valves, "B", "D", "C")
dseparated(valves, "B", "D", "C")

# conditional independence relations implied by the DAG
impliedConditionalIndependencies(valves)
```

Listing 15.10 simpson-dag.R

```
## DAG for Simpson's paradox (Simpson, JRSSB, 1951)

# load R packages
library(dagitty)
library(ggdag)
library(ggplot2)
library(ggraph) # for label_rect()

# define the DAG
simpson <- dagitty('dag{
  "Sex" -> "Death"
  "Sex" -> "Selection"
  "Sex" -> "Treatment"
  "Treatment" -> "Death"
}')

# generate tidy DAG data
coordinates(simpson) <- list(
  x = c("Sex" = 0, "Selection" = 1, "Treatment" = 1, "Death" = 2),
  y = c("Sex" = 0, "Selection" = -0.5, "Treatment" = 0, "Death" = 0))
# simpson_dat <- tidy_dagitty(simpson)
simpson_dat <- control_for(simpson, "Selection", activate_colliders = FALSE)
simpson_adj <- filter(simpson_dat, adjusted == "adjusted")
simpson_unadj <- filter(simpson_dat, adjusted == "unadjusted")

# plot the DAG using ggplot() to allow curved arrows
# Uncomment "+ coord_equal()" to get a better-looking plot in an R window.
# The start_cap and end_cap arguments keep the arrows from covering the text.
# The size for label_rect should be 3.57 * the text font size.
(ggplot(simpson_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 + coord_cartesian(ylim = c(-0.6, 0.6))
 + geom_text(aes(label = name), data = simpson_unadj, parse = TRUE,
               size = 8, col = "black")
 + geom_dag_label(data = simpson_adj, parse = TRUE, size = 8, fill = NA,
                  label.padding = unit(0.1, "lines"))
 + geom_dag_edges_arc(aes(start_cap = label_rect(name, fontsize = 8 * 3.57),
                           end_cap = label_rect(to, fontsize = 8 * 3.57)),
                       curvature = c(0.5, 0, 0, 0), inherit = TRUE)
)
```

16 Confounding and Selection Bias on SWIGs

As discussed in numerous textbooks, the common consequence of selection bias is that the association between exposure and outcome among those selected for analysis differs from the association among those eligible. (M. Á. Hernán, Hernández-Díaz, and Robins 2004)

17 Causal Effects and Standardization

Your father's lightsaber. This is the weapon of a Jedi knight. Not as clumsy and random as a blaster. An elegant weapon for a more civilized age. (Obi-Wan Kenobi, *Star Wars*, 1977)¹

Potential outcomes, directed acyclic graphs (DAGs), and single-world intervention graphs (SWIGs) have greatly clarified thinking about causal inference in epidemiology as well as other social and natural sciences. The causal effect of a binary exposure X on a disease outcome D is the change in the risk of D caused by intervening to change exposure from $X = 0$ to $X = 1$. This definition matches the effect estimated in a randomized trial, which estimates the effect of a change in exposure on the risk of disease in the population eligible for the trial. In a large randomized study, the treatment and control groups are both representative of the eligible population.

When there is confounding and selection bias, it is possible that neither exposure group is representative of the eligible population. If we can identify a set C of covariates that can be used to control confounding and selection bias, we can calculate causal effects within strata defined by C . However, we can combine these conditional causal effects into marginal causal effects through an elegant process called standardization, which is the lightsaber of causal inference (where regression models are blasters).

17.1 Measures of association in a cohort study with bias

The key idea in causal inference is that there is a fundamental difference between observation and intervention. Let X be a binary exposure, D be a binary disease outcome, C be a discrete confounder, and S denote selection into the study. For simplicity, we assume that X does not change over time. The occurrence of D is measured over a time interval $(0, t]$. Using these data, we can calculate crude measures of association or measures of association conditional on C .

¹[Star Wars](#) is a space opera film written and directed by George Lucas, produced by Gary Kurtz, and distributed by 20th Century Fox. It was released on May 25, 1977. [Obi-Wan Kenobi](#) was played by Alec Guinness. The events depicted took place a long time ago in a galaxy far, far away ...

17.1.1 Confounding and selection bias

Figure 17.1 shows a simple DAG for a cohort study with confounding, selection bias, and a causal effect of X on D . There is confounding because of the open backdoor path $X \leftarrow C \rightarrow D$. There is selection bias because the noncausal path $X \rightarrow S \leftarrow X \rightarrow D$ is opened by conditioning on the collider at S . The analytic case-control condition fails because of the path $X \rightarrow S$, and there is no way to close this. The confounding and selection bias occur whether or not there is a causal effect of X on D , which is represented by the path $X \rightarrow D$.




Figure 17.1: Directed acyclic graph (DAG) showing a cohort study with confounding, selection bias, and a causal effect of X on D .

If we condition on C in Figure 17.1, this closes both the backdoor path from X to D as well as the noncausal path from X to D that was opened by conditioning on S . Figure 17.2 shows the single-world intervention graph (SWIG) corresponding to an intervention that sets $X = x$, which has a box around C to represent conditioning on it. There is also a box around little x to show that the path $S^x \leftarrow x \rightarrow D^x$ is closed because x represents a fixed hypothetical value of X . However, x is not a variable that we can measure and condition on when we analyze the data. The SWIG shows that measuring C and conditioning on it is sufficient to control both:

- We have exchangeability $D^x \perp\!\!\!\perp X \mid C$ because D^x and big X (which represents the actual or realized exposure status) are d-separated given C , which is a non-descendant of X .
- We have the analytic cohort condition $S^x \perp\!\!\!\perp D^x \mid (X, C)$ because S^x and D^x are d-separated given big X and C , which is a nondescendant of X . The paths through little x are closed, but we do not include x in the conditional independence statements.




Figure 17.2: Single-world intervention graph (SWIG) for setting $X = x$ in the DAG from Figure 17.1. The box around C indicates conditioning on C , and the box around little x shows that paths through it are closed.

17.1.2 Crude measures

A **crude measure of association** is a comparison of the risks of disease in the exposed and unexposed in the study sample. The crude risk difference is

$$\text{RD}_{\text{crude}} = \Pr(D = 1 \mid X = 1, S = 1) - \Pr(D = 1 \mid X = 0, S = 1), \quad (17.1)$$

the crude risk ratio is

$$\text{RR}_{\text{crude}} = \frac{\Pr(D = 1 \mid X = 1, S = 1)}{\Pr(D = 1 \mid X = 0, S = 1)}, \quad (17.2)$$

the crude odds ratio is

$$\text{OR}_{\text{crude}} = \frac{\text{odds}(\Pr(D = 1 \mid X = 1, S = 1))}{\text{odds}(\Pr(D = 0 \mid X = 0, S = 1))}, \quad (17.3)$$

and the crude cumulative hazard ratio is

$$\text{CHR}_{\text{crude}} = \frac{-\ln(1 - \Pr(D = 1 \mid X = 1, S = 1))}{-\ln(1 - \Pr(D = 1 \mid X = 0, S = 1))}.$$

These are measures of association, which do not necessarily represent causal effects.

17.1.3 Marginal causal effects

When we have no confounding and no selection bias,

$$\begin{aligned} \Pr(D^x = 1) &= \Pr(D^x = 1 \mid X = x) && \text{by exchangeability} \\ &= \Pr(D^x = 1 \mid X = x, S^x = 1) && \text{by the analytic cohort condition} \\ &= \Pr(D = 1 \mid X = x, S = 1) && \text{by consistency.} \end{aligned} \quad (17.4)$$

Thus, the estimated risk in each exposure group is an unbiased estimate of the **marginal causal risk** under the same exposure in the eligible population. Therefore, each crude measure of association is a consistent estimator of a **marginal causal effect**, which is a measure of association that compares $\Pr(D^1 = 1)$ to $\Pr(D^0 = 1)$. In terms of a hypothetical experiment, this is the causal effect we would see if we compared the entire eligible population under an intervention that set $X = 1$ to itself under an intervention that set $X = 0$.

In a study represented by the DAG in Figure 17.1, the first equality in Equation 17.4 fails because of confounding and the second equality fails because of selection bias. If there is confounding or selection bias, the crude measures of association do not represent marginal causal effects.

When there is confounding, part of the difference in risk captured by the crude measures of association is due to different distributions of C in the exposed and unexposed. In the DAG in Figure 17.1, the open path between C and X means that we can have

$$\Pr(C = c | X = 1) \neq \Pr(C = c | X = 0),$$

so the distribution of C is different in the exposed and unexposed groups. Because of the open path between C and D , the risk of disease can depend on C . Thus, the different distributions of C would cause a difference in risk even if X had no causal effect on D . When we add selection bias, the situation deteriorates further.

17.1.4 Stratum-specific measures

A **stratum-specific measure of association** is a comparison of the risks of disease in the exposed and unexposed in the subset of the study with the same value of covariates $C = c$. A stratum can also be defined by multiple covariates at the same time, in which case we let C represent the set of covariates and c a vector of values of these covariates (e.g., $C_1 = c_1, \dots, C_k = c_k$). In both cases, the stratum-specific risk difference given $C = c$ is

$$RD_{C=c} = \Pr(D = 1 | C = c, X = 1, S = 1) - \Pr(D = 1 | C = c, X = 0, S = 1), \quad (17.5)$$

the crude risk ratio is

$$RR_{C=c} = \frac{\Pr(D = 1 | C = c, X = 1, S = 1)}{\Pr(D = 1 | C = c, X = 0, S = 1)}, \quad (17.6)$$

the crude odds ratio is

$$OR_{C=c} = \frac{\text{odds}(\Pr(D = 1 | C = c, X = 1, S = 1))}{\text{odds}(\Pr(D = 0 | C = c, X = 0, S = 1))}, \quad (17.7)$$

and the crude cumulative hazard ratio is

$$CHR_{C=c} = \frac{-\ln(1 - \Pr(D = 1 | C = c, X = 1, S = 1))}{-\ln(1 - \Pr(D = 1 | C = c, X = 0, S = 1))}.$$

As with crude measures of association, these do not necessarily represent causal effects.

17.1.5 Conditional causal effects

When we have no confounding and no selection bias given C , as in a study represented by the DAG in Figure 17.1, then

$$\begin{aligned}\Pr(D^x = 1 \mid C = c) &= \Pr(D^x = 1 \mid C = c, X = x) && \text{by exchangeability given } C \\ &= \Pr(D^x = 1 \mid C = c, X = x, S^x = 1) && \text{by the analytic cohort condition} \\ &= \Pr(D = 1 \mid C = c, X = x, S = 1) && \text{by consistency.}\end{aligned}\tag{17.8}$$

Thus, the estimated conditional risk given $C = c$ in each exposure group is an unbiased estimate of the causal conditional risk given $C = c$ in the eligible subpopulation if we intervene to set the same exposure. Therefore, each conditional measure of association is a consistent estimator of a **conditional causal effect**, which is a measure of association that compares $\Pr(D^1 = 1 \mid C = c)$ to $\Pr(D^0 = 1 \mid C = c)$. In terms of a hypothetical experiment, this is the causal effect we would see if we compared the entire eligible subpopulation with $C = c$ under an intervention that set $X = 1$ to itself under an intervention that set $X = 0$.

In a study represented by the DAG in Figure 17.1, both equalities in Equation 17.8 hold because conditioning on C controls confounding and selection bias. If there is residual confounding or selection bias after conditioning on C , at least one of the stratum-specific measures of association does not represent a conditional causal effect. This could happen, for example, if there are common causes of two or more variables on the DAG that are not included. In practice, there is always residual confounding and selection bias. Our goal in study design and analysis is to reduce these to the point that the remaining bias is small compared to the causal effect of X on D that we are looking for.

17.2 Standardization

The basic idea behind **standardization** is to calculate the risk of disease in hypothetical exposed and unexposed population with the same distribution of C . If conditioning on C controls confounding and selection bias, then a measure of association that compares these standardized risks can be interpreted as a measure of a marginal causal effect. The distribution of C used to calculate $\Pr(D^x = 1)$ is less important than the fact that the same distribution is used for both exposure groups.

17.2.1 Reconstructing marginal causal risks

Imagine that we intervene to set $X = x$ for the entire population. Then the risk of disease would be

$$\Pr(D^x = 1) = \sum_c \Pr(D^x \mid C = c) \Pr(C = c),\tag{17.9}$$

where the sum is over all possible values c of C in the population. When conditioning on C controls confounding and selection bias as in Equation 17.8, then

$$\Pr(D^x = 1) = \sum_c \Pr(D = 1 | C = c, X = x, S = 1) \Pr(C = c).$$

Thus, the we can estimate the marginal causal risks $\Pr(D^1 = 1)$ and $\Pr(D^0 = 1)$ using data from our study sample and the distribution of C in the population.

Unfortunately, the distribution of C in the population often cannot be recovered from our study sample. In the study represented by the DAG in Figure 17.1, the open paths $C \rightarrow X \rightarrow S$ and $C \rightarrow S$ mean that

$$\Pr(C = c | S = 1) \neq \Pr(C = c),$$

so we cannot get $\Pr(C = c)$ without data external to the study. This is not selection bias because it does not prevent us from getting an unbiased estimate of $\Pr(D^x = 1 | C = c)$.

17.2.2 Standardized risks and measures of association

To standarize, we choose a distribution of C calculate what the marginal risks in the exposed and unexposed would be if they both had this distribution of C . Let the probability that $C = c$ in our **standard population** be

$$\Pr_{\text{std}}(C = c).$$

The corresponding **standardized risk** given $X = x$ based on data from our study sample is

$$\Pr_{\text{std}}(D = 1 | X = x, S = 1) = \sum_c p_{xc} \Pr_{\text{std}}(C = c),$$

where

$$p_{xc} = \Pr(D = 1 | C = c, X = x, S = 1).$$

To calculate a standardized estimate, we need each possible value of C in the standard population to be represented in the study sample.

Because the same distribution of C is used for both exposure groups and there is no causal effect of X on C , any measure of association that compares $\Pr_{\text{std}}(D = 1 | X = 1, S = 1)$ and $\Pr_{\text{std}}(D = 1 | X = 0, S = 1)$ represents a marginal causal effect in our standard population. The standardized risk difference is

$$\text{RD}_{\text{std}} = \Pr_{\text{std}}(D = 1 | X = 1, S = 1) - \Pr_{\text{std}}(D = 1 | X = 0, S = 1), \quad (17.10)$$

the standardized risk ratio is

$$\text{RR}_{\text{std}} = \frac{\Pr_{\text{std}}(D = 1 | X = 1, S = 1)}{\Pr_{\text{std}}(D = 1 | X = 0, S = 1)}, \quad (17.11)$$

the standardized odds ratio is

$$\text{OR}_{\text{std}} = \frac{\text{odds}(\text{Pr}_{\text{std}}(D = 1 | X = 1, S = 1))}{\text{odds}(\text{Pr}_{\text{std}}(D = 0 | X = 0, S = 1))}, \quad (17.12)$$

and the standardized cumulative hazard ratio is

$$\text{CHR}_{\text{std}} = \frac{-\ln(1 - \text{Pr}_{\text{std}}(D = 1 | X = 1, S = 1))}{-\ln(1 - \text{Pr}_{\text{std}}(D = 1 | X = 0, S = 1))}. \quad (17.13)$$

When conditioning on C controls confounding and selection bias, these represent marginal causal effects in the standard population. For some distribution of C , they would represent marginal causal effects in the eligible population. However, we may or may not be able to estimate this distribution of C using our study sample.

17.2.3 Treatment effects

Using only data from the study sample, we have three standard choices for a standard population: the entire study sample, the exposed or treated, and the unexposed or controls. When there is no confounding or selection bias, we can use our study sample to estimate the marginal distribution of C and the conditional distributions of C given $X = 1$ and given $X = 0$ in the eligible population.

When there is confounding but no selection bias, we can use our study sample to estimate the distributions of C in the exposed and the unexposed in the eligible population but not the marginal distribution of C

- If S is independent of C , then the distribution of C in our study sample is a random sample from the distribution of C in the eligible population. In a cohort study where selection depends on exposure X and C is a confounder, there will almost always be an open path from C to S in a causal DAG representing the study. In Figure 17.1, we have the open path $C \rightarrow X \rightarrow S$ even if we remove the path $C \rightarrow S$ that causes selection bias.
- If S is independent of C given X , then the distribution of C given $X = x$ in the study sample is a random sample from the distribution of C in the eligible subpopulation with $X = x$. In a cohort study where selection depends on X and there is selection bias through C , then there will almost always be an open path from C to S even when we condition on X . In Figure 17.1, we have the open path $C \rightarrow S$.

When our study sample is a random sample from the eligible population, we can use our study sample to estimate the distribution of C or the conditional distribution of C given X in the eligible population. This is rarely the case. In a cohort study where selection is determined by X , we can get the marginal distribution of C when there is no association between C and S and we can get the conditional distribution of C given X when there is no association between C and S given X .

- When there is confounding by C , the marginal distribution of C differs systematically between the study sample and the eligible population because of an open path from C to S through X . When there is no selection bias, C and S are d-separated by conditioning on X , we can use the study sample to estimate the conditional distribution of C given X in the eligible population. You can see this by removing the path $C \rightarrow S$ from the DAG in Figure 17.1.
- When there is selection bias by C , both the marginal distribution of C and the conditional distribution of C given X differs systematically between the study sample and the eligible population because there is open path from C to S that is not closed by conditioning on X .

For the risk difference, calculating standardized risks and then taking the difference is the same as taking the same weighted average of the stratum-specific risk differences. The standardized risk difference RR_{std} equals

$$\sum_c p_{1c} \Pr_{\text{std}}(C = c) - \sum_c p_{0c} \Pr_{\text{std}}(C = c) = \sum_c (p_{1c} - p_{0c}) \Pr_{\text{std}}(C = c).$$

The standardized risk difference using the entire population is called the **average treatment effect** (ATE). This can be estimated using data from a cohort study if there is no confounding or selection bias by C . The **average treatment effect among the treated** (ATET) is the standardized risk difference using the distribution of C in the exposed or treated population, and the **average treatment effect among controls** (ATEC) is the standardized risk difference using the distribution of C unexposed or control population. These can be estimated when there is no selection bias through C . For measures other than the risk difference, we can talk about the marginal treatment effect, the treatment effect among the treated, or the treatment effect among controls.

17.2.4 Confidence limits

When the standard distribution of C is fixed and the stratum-specific risks are estimated independently (i.e., the estimated risks are independent), the variance of a standardized risk can be estimated using Equation 1.24:

$$\hat{\text{Var}}(\hat{\Pr}_{\text{std}}(D = 1 | X = x, S = 1)) = \sum_c \hat{\text{Var}}(\hat{p}_{xc}) \Pr_{\text{std}}(C = c)^2$$

The variance of a standardized measure of association can then be obtained using the delta method from Section 3.6.1. For the risk difference, no transformation is needed. For the risk ratio, we use a log transformation. For the odds ratio, we use a logit transformation. For the cumulative hazard ratio, we use a complementary log-log transformation.

When the estimated risks in different strata of C are not independent (e.g., they are estimated using C as a predictor in a regression model), then we must account for the covariances of the

estimated risks in different strata. When the distribution of C is estimated (e.g., we are using the distribution of C in the study sample), then we must account for the uncertainty in the distribution of C . Bootstrapping can account for all of these sources of variation.

17.3 Simpson's paradox standardized

The DAG in Figure 15.6 shows the causal structure underlying the example given by Simpson (1951) that is reproduced in Table 15.1. Using DAGs and SWIGs, we could show that conditioning on biological sex would remove all confounding and selection bias, so the conditional odds ratio is a better estimate of the effect of treatment than the crude odds ratio. The example is constructed so that the conditional odds ratio is exactly the same for males and females, but this is too much to hope for in reality. Standardization gives us a less fragile point of view.

17.3.1 Crude risks and measures of association

In this example, the crude risk of death under treatment is

$$\Pr(D = 1 \mid X = 1, S = 1) = \frac{20}{20 + 20} = 0.5$$

and the crude risk of death under control is

$$\Pr(D = 1 \mid X = 0, S = 1) = \frac{6}{6 + 6} = 0.5.$$

The corresponding crude measures of association are

$$\text{RD}_{\text{crude}} = 0$$

and

$$\text{RR}_{\text{crude}} = \text{OR}_{\text{crude}} = \text{CHR}_{\text{crude}} = 1.$$

Thus, all crude measures of association show no apparent effect of treatment on the risk of death.

Because there is confounding by biological sex, the crude risks are not unbiased estimates the causal risks that would occur if we intervened to make the entire eligible population treated or untreated. The sex distribution differs between the treated and control groups, and sex is a predictor of mortality in the example. There are $5 + 8 = 13$ treated males and $15 + 12 = 27$ treated females, so

$$\Pr(\text{male} \mid X = 1, S = 1) = \frac{13}{13 + 27} = 0.325.$$

There are $3 + 4 = 7$ untreated males and $3 + 2 = 5$ untreated females, so

$$\Pr(\text{male} \mid X = 0, S = 1) = \frac{7}{7 + 5} \approx 0.583.$$

The crude risks do not have a causal interpretation in terms of a hypothetical experiment, and the crude measures of association do not represent marginal causal effects.

17.4 R

17.4.1 Conditional risks and measures of association

According to the DAG in Figure 15.6, conditioning on biological sex removes all confounding and selection bias. Among females, the risk of death in the treated is

$$\Pr(D = 1 \mid \text{female}, X = 1, S = 1) = \frac{15}{15 + 12} \approx 0.56$$

and the risk of death in the untreated is

$$\Pr(D = 1 \mid \text{female}, X = 0, S = 1) = \frac{3}{3 + 2} = 0.6.$$

Assuming the DAG in Figure 15.6 is correct, these can be interpreted as conditional causal risks given female sex. The causal risk of death under treatment is less than the causal risk of death under no treatment, suggesting that treatment reduces mortality in females. Given female sex, the conditional risk difference is

$$\text{RD}_{\text{female}} = \frac{15}{27} - \frac{3}{5} \approx -0.044,$$

the conditional risk ratio is

$$\text{RR}_{\text{female}} = \frac{15/27}{3/5} \approx 0.926,$$

the conditional odds ratio is

$$\text{OR}_{\text{female}} = \frac{\text{odds}(15/27)}{\text{odds}(3/5)} \approx 0.833,$$

and the conditional cumulative hazard ratio is

$$\text{CHR}_{\text{female}} = \frac{-\ln(1 - 15/27)}{-\ln(1 - 3/5)} \approx 0.885.$$

The risk difference is below zero and the ratio measures are all below one. Because they are based on conditional causal risks, these estimate the conditional causal effect of treatment given female sex.

Among males, the risk of death in the treated is

$$\Pr(D = 1 \mid \text{male}, X = 1, S = 1) = \frac{5}{5 + 8} \approx 0.385$$

and the risk of death among among the untreated is

$$\Pr(D = 1 \mid \text{male}, X = 0, S = 1) = \frac{3}{3 + 4} \approx 0.429.$$

Assuming the DAG in Figure 15.6 is correct, these can be interpreted as conditional causal risks given male sex. As in females, the causal risk of death under treatment is less than the causal risk of death under no treatment, suggesting that treatment reduces mortality among males. Given male sex, the conditional risk difference is

$$\text{RD}_{\text{male}} = \frac{5}{13} - \frac{3}{7} \approx -0.044,$$

the conditional risk ratio is

$$\text{RR}_{\text{male}} = \frac{5/13}{3/7} \approx 0.897,$$

the conditional odds ratio is

$$\text{OR}_{\text{male}} = \frac{\text{odds}(5/13)}{\text{odds}(3/7)} \approx 0.833,$$

and the conditional cumulative hazard ratio is

$$\text{CHR}_{\text{male}} = \frac{-\ln(1 - 5/13)}{-\ln(1 - 3/7)} \approx 0.868.$$

Because they are based on conditional causal risks, these estimate the conditional causal effect of treatment given male sex. These are similar to the causal effect estimates for females, but only the odds ratios are identical (both equal to 5/6). There is effect measure modification on all other scales.

17.5 R

17.5.1 Standardized risks and measures of association

Assuming the DAG in Figure 15.6 is correct, we can calculate marginal causal risks by standardizing to the same distribution of biological sex under treatment and no treatment. In a population that is half female and half male, the causal risk of death under treatment is

$$\begin{aligned} \Pr_{\text{std}}(D = 1 \mid X = 1, S = 1) \\ &= \frac{1}{2} \Pr(D = 1 \mid \text{female}, X = 1, S = 1) + \frac{1}{2} \Pr(D = 1 \mid \text{male}, X = 1, S = 1) \\ &\approx 0.470 \end{aligned}$$

and the causal risk of death under no treatment is

$$\begin{aligned}\Pr_{\text{std}}(D = 1 \mid X = 1, S = 1) \\ &= \frac{1}{2} \Pr(D = 1 \mid \text{female}, X = 0, S = 1) + \frac{1}{2} \Pr(D = 1 \mid \text{male}, X = 0, S = 1) \\ &\approx 0.514.\end{aligned}$$

The causal risk of death under treatment is lower, suggesting that treatment would reduce mortality in this population. These estimated causal risks can be used to calculate standardized measures of association. From Equation 17.10, the standardized risk difference is

$$\text{RD}_{\text{std}} \approx -0.044.$$

From Equation 17.11, the standardized risk ratio is

$$\text{RR}_{\text{std}} \approx 0.914.$$

From Equation 17.12, the standardized odds ratio is

$$\text{OR}_{\text{std}} \approx 0.873.$$

From Equation 17.13, the standardized cumulative hazard ratio is

$$\text{CHR}_{\text{std}} \approx 0.879.$$

As with crude and conditional measures, the standardized cumulative hazard ratio is between the standardized risk ratio and odds ratio.

If there is no effect measure modification on a scale that is collapsible, the standardized measure will equal the conditional measures of association in all standard populations. If there is effect measure modification or noncollapsibility, the standardized measure will depend on the standard population used. In this example, there is effect measure modification on the risk difference and risk ratio scales. There is no effect measure modification on the odds ratio scale, but the odds ratio is noncollapsible. There is both effect measure modification and noncollapsibility on the cumulative hazard ratio scale. Therefore, all four standardized measures of association depend on the standard population used.

17.6 R

Listing 17.1 dag-cxsd.R

```
# DAG for cohort study with confounding and selection bias

# load R packages
library(dagitty)
library(ggdag, warn.conflicts = FALSE)
library(ggplot2)

# define the DAG
cohort <- dagitty('dag{
  C -> D
  C -> S
  C -> X
  X -> D
  X -> S
}')

# generate data for plotting DAG using ggplot()
# Use geom_dag_label() for adjusted variables to get a box around them.
coordinates(cohort) <- list(x = c(C = 0, X = 1, S = 1.5, D = 2),
                             y = c(C = 0, X = 0, S = -0.3, D = 0))
cohort_dat <- control_for(cohort, "S", activate_colliders = FALSE)
cohort_adj <- filter(cohort_dat, adjusted == "adjusted")
cohort_unadj <- filter(cohort_dat, adjusted == "unadjusted")

# plot DAG with ggplot() to allow for boxes and curved arrows
(ggplot(cohort_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 + coord_equal()
 + ylim(-0.4, 0.3)
 + geom_dag_label(data = cohort_adj,
                  parse = TRUE, size = 8, fill = NA,
                  label.padding = unit(0.15, "lines"))
 + geom_dag_text(data = cohort_unadj, parse = TRUE,
                 color = "black", size = 8)
 + geom_dag_edges_arc(curvature = c(0.2, -0.13, 0, 0, 0))
)
```

Listing 17.2 swig-cxsd.R

```
# DAG for cohort study with confounding and selection bias

# load R packages
library(dagitty)
library(ggdag, warn.conflicts = FALSE)
library(ggplot2)

# define the DAG
cohort <- dagitty('dag{
  C -> D
  C -> S
  C -> X
  x -> D
  x -> S
}')

# generate data for plotting DAG using ggplot()
# Use geom_dag_label() for adjusted variables to get a box around them.
coordinates(cohort) <- list(x = c(C = 0, X = 0.9, x = 1.1, S = 2, D = 3),
                           y = c(C = 0, X = 0, x = 0, S = -0.5, D = 0))
cohort_dat <- control_for(cohort, c("C", "x"), activate_colliders = FALSE)
label(cohort_dat) <- c("C" = "C", "X" = "X", "x" = "x",
                      "D" = "Dx", "S" = "Sx")
cohort_adj <- filter(cohort_dat, adjusted == "adjusted")
cohort_unadj <- filter(cohort_dat, adjusted == "unadjusted")

# plot DAG with ggplot() to allow for boxes and curved arrows
(ggplot(cohort_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 + coord_equal()
 + geom_dag_label(data = cohort_adj, parse = TRUE, size = 8, fill = NA,
                  label.padding = unit(0.15, "lines"))
 + geom_dag_text(aes(label = label), data = cohort_unadj, parse = TRUE,
                  color = "black", size = 8)
 + geom_dag_edges_arc(curvature = c(0.25, -0.15, 0, 0, 0))
 + annotate("text", x = 1, y = 0.01, size = 8, label = "|")
)
```

Listing 17.3 simpson-crude.R

```
# Crude measures of association in Simpson's paradox (JRSSB, 1951)

# data frame
simpson <- data.frame(male = rep(c(0, 1), each = 4),
                      treated = rep(c(0, 1, 0, 1), each = 2),
                      dead = rep(c(0, 1), times = 4),
                      count = c(2, 3, 12, 15, 4, 3, 8, 5))

# function to calculate risk
risk <- function(rows) {
  # rows is a vector of TRUE/FALSE that selects rows
  count <- simpson$count[rows]
  dead <- simpson$dead[rows]
  sum(count * dead) / sum(count)
}

# odds and cumulative hazard
odds <- function(p) p / (1 - p)
chaz <- function(p) -log(1 - p)

# crude risks and measures of association
p1 <- risk(simpson$treated == 1)
p0 <- risk(simpson$treated == 0)
RD <- p1 - p0
RR <- p1 / p0
OR <- odds(p1) / odds(p0)
CHR <- chaz(p1) / chaz(p0)
```

Listing 17.4 simpson-cond.R

```
# Conditional measures of association in Simpson's paradox (JRSSB, 1951)

# data frame
simpson <- data.frame(male = rep(c(0, 1), each = 4),
                      treated = rep(c(0, 1, 0, 1), each = 2),
                      dead = rep(c(0, 1), times = 4),
                      count = c(2, 3, 12, 15, 4, 3, 8, 5))

# function to calculate risk
risk <- function(rows) {
  # rows is a vector of TRUE/FALSE that selects rows
  count <- simpson$count[rows]
  dead <- simpson$dead[rows]
  sum(count * dead) / sum(count)
}

# odds and cumulative hazard
odds <- function(p) p / (1 - p)
chaz <- function(p) -log(1 - p)

# conditional risks and measures of association among females
p1f <- risk(with(simpson, treated == 1 & male == 0))
p0f <- risk(with(simpson, treated == 0 & male == 0))
RDf <- p1f - p0f
RRf <- p1f / p0f
ORf <- odds(p1f) / odds(p0f)
CHRF <- chaz(p1f) / chaz(p0f)

# conditional risks and measures of association among males
p1m <- risk(with(simpson, treated == 1 & male == 1))
p0m <- risk(with(simpson, treated == 0 & male == 1))
RDm <- p1m - p0m
RRm <- p1m / p0m
ORm <- odds(p1m) / odds(p0m)
CHRM <- chaz(p1m) / chaz(p0m)
```

Listing 17.5 simpson-std.R

```
# Standardized measures of association in Simpson's paradox (JRSSB, 1951)

# data frame
simpson <- data.frame(male = rep(c(0, 1), each = 4),
                      treated = rep(c(0, 1, 0, 1), each = 2),
                      dead = rep(c(0, 1), times = 4),
                      count = c(2, 3, 12, 15, 4, 3, 8, 5))

# function to calculate risk
risk <- function(rows) {
  # rows is a vector of TRUE/FALSE that selects rows
  count <- simpson$count[rows]
  dead <- simpson$dead[rows]
  sum(count * dead) / sum(count)
}

# odds and cumulative hazard
odds <- function(p) p / (1 - p)
chaz <- function(p) -log(1 - p)

# conditional risks among females
p1f <- risk(with(simpson, treated == 1 & male == 0))
p0f <- risk(with(simpson, treated == 0 & male == 0))

# conditional risks among males
p1m <- risk(with(simpson, treated == 1 & male == 1))
p0m <- risk(with(simpson, treated == 0 & male == 1))

# standardized risks (standard population half female and half male)
pf <- 0.5
pm <- 1 - pf
p1std <- pf * p1f + pm * p1m
p0std <- pf * p0f + pm * p0m

# standardized measures of association
RDstd <- p1std - p0std
RRstd <- p1std / p0std
ORstd <- odds(p1std) / odds(p0std)
CHRstd <- chaz(p1std) / chaz(p0std)
```

18 Geometry of Causal Inference

Let no one ignorant of geometry enter here.

(inscription above the entrance to [Plato's Academy](#), circa 387 BC)

While algebra is useful and often definitive, a geometric perspective can be a more useful guide to intuition. A geometrical perspective on causal inference first proposed in Rothman (1975) clarifies the relationships between confounding, effect measure modification, and collapsibility (Kenah 2024). Through the lens of regression models, these concepts blend together almost inextricably. Through the lens of standardization and geometry, the distinctions between them are clear.

18.1 Rothman diagrams

The **unit square** is the set of all ordered pairs $(x, y) \in \mathbb{R}^2$ where both x and y are in the interval $[0, 1]$ (i.e., the interval including zero, one, and all real numbers in between). To represent the point (x, y) , we can plot x on a horizontal axis (the x-axis) and y on a vertical axis (the y-axis). Rothman (1975) introduced a geometric perspective on causal inference where x represents the risk of disease in the unexposed or untreated and y represents the risk of disease in the exposed or treated. A similar plot was introduced by L'Abbé, Detsky, and O'Rourke (1987) for meta-analysis, and these *L'Abbé plots* were used by Richardson, Robins, and Wang (2017) to discuss the estimation of risk differences and risk ratios.

18.1.1 Example: smoking and 20-year mortality

As an illustration, we will use an example of confounding given by Appleton, French, and Vanderpump (1996). It occurred in a cohort of women who participated in a study of thyroid and heart disease in Newcastle upon Tyne, United Kingdom in 1972-1974 (Tunbridge et al. 1977). Their smoking status was measured in the original study, and their 20-year survival status was measured in a follow-up study (Vanderpump et al. 1995). Table 18.1 shows the crude 2x2 table for smoking and 20-year mortality.

Table 18.2 shows the corresponding crude measures of association estimated using binomial generalized linear models (GLMs). Binomial GLMs used the logit link for the odds ratio, the log link for the risk ratio, the identity link for the risk difference, and the complementary log-log link for the cumulative hazard ratio. Smokers had lower 20-year mortality than nonsmokers,

Table 18.1: Crude 2x2 table for smoking status in the original study and 20-year mortality.

	Dead	Alive	Total
Smoker	139	443	582
Nonsmoker	230	502	732
Total	369	945	1,314

Table 18.2: Crude measures of association for smoking and 20-year mortality with likelihood ratio confidence limits and p-value (which does not depend on the measure of association).

	Estimate	95% confidence interval	p-value
Odds ratio	0.685	(0.535, 0.875)	0.0024
Risk ratio	0.760	(0.633, 0.908)	0.0024
Risk difference	-0.075	(-0.123, -0.027)	0.0024
Cumulative hazard ratio	0.724	(0.584, 0.892)	0.0024

and this difference was statistically significant. The binomial GLMs produced a likelihood ratio p-value of 0.0024. A Pearson chi-squared test (which is the score test) produces a p-value of 0.0025, and a Fisher's exact test produces a p-value of 0.0029 with 95% confidence limits of (0.531, 0.882) for the odds ratio.

Table 18.3 shows 2x2 tables stratified by age at the time of the original survey adapted from Appleton, French, and Vanderpump (1996). Older participants were less likely to smoke but more likely to die within 20 years than younger participants. Among those aged 18-64 years, the prevalence of smoking was $533/1,072 \approx 0.497$ and the risk of death was $162/1,072 \approx 0.151$. Among those aged ≥ 65 years, the prevalence of smoking was $49/242 \approx 0.202$ and the risk of death was $207/242 \approx 0.855$. The difference in survival between smokers and nonsmokers was due in part to different age distributions, so the causal effect of smoking on 20-year mortality was confounded by age.

Table 18.3: Age-stratified 2x2 tables for smoking and 20-year mortality.

18-64 years	Dead	Alive	Total	65+ years	Dead	Alive	Total
Smoker	97	436	533	Smoker	42	7	49
Nonsmoker	65	474	539	Nonsmoker	165	28	193
Total	162	910	1,072	Total	207	35	242

18.2 R

18.2.1 Causal points

Let X be a binary exposure or treatment, D be a binary disease outcome, and C be a binary covariate that is not causally affected by X . Let D^x be the potential disease outcome when we intervene to set $X = x$ (D. B. Rubin 1974). The exposure, outcome, and covariate of individual i are X_i , D_i , and C_i , respectively. The potential outcome of i under an intervention that sets $X_i = x$ is D_i^x . If $X_i = x$, then $D_i = D_i^x$ by consistency of potential outcomes (Pearl 2009).

In our example, X is smoking status at the time of the original survey, D is death within 20 years, and C is age. The potential outcome D^1 is death within 20 years as a smoker, and D^0 is death within 20 years as a nonsmoker. By consistency, $D = D^1$ for smokers and $D = D^0$ for nonsmokers. We see only one of the two potential outcomes for each individual.

Probabilities are defined by proportions of the underlying population. For example, $\Pr(X = x, C = c)$ is the proportion of the population with $X = x$ and $C = c$. Conditional probabilities are defined by proportions of subpopulations. For example, $\Pr(X = x | C = c)$ is the proportion of the subpopulation with $C = c$ that has $X = x$. Probabilities and conditional probabilities can be estimated using a sample of n individuals from the population, with uncertainty due to sampling variation summarized in terms of frequentist confidence intervals or Bayesian credible intervals. In our example, the study participants can be seen as a sample of size $n = 1,314$ from the population of women in the United Kingdom between 1972 and 1974. For simplicity, we will assume no selection bias and ignore sampling variation whenever possible.

The causal risk of disease when we intervene to set $X = 1$ is $\Pr(D^1 = 1)$, and the causal risk of disease when we set $X = 0$ in the entire population is $\Pr(D^0 = 1)$. The point

$$p_{\text{marg}} = \left(\Pr(D^0 = 1), \Pr(D^1 = 1) \right) \quad (18.1)$$

on the Rothman diagram is the **marginal causal point** for the population. It is causal because it is based on causal risks of disease under intervention, and it is marginal because it ignores the covariate C .

In the subpopulation with $C = c$, the causal risk of disease when we set $X = x$ is:

$$\Pr(D^x = 1 | C = c) = \frac{\Pr(D^x = 1, C = c)}{\Pr(C = c)}$$

The point

$$p_c = \left(\Pr(D^0 = 1 | C = c), \Pr(D^1 = 1 | C = c) \right)$$

on the Rothman diagram is the **stratum-specific causal point** for the subpopulation with $C = c$.

In practice, we are almost always missing the data needed to plot causal points on a Rothman diagram. To draw marginal or stratum-specific causal points, we need both potential outcomes D_i^1 and D_i^0 for each individual i in our sample. In our example, we would need to know whether the smokers would have survived for 20 years had they been nonsmokers and whether the nonsmokers would have survived for 20 years had they been smokers.

18.2.2 Association points

Unlike causal points, we can plot **association points** using data on the eligible population. The risk of disease among the unexposed is $\Pr(D = 1 \mid X = 0)$, and the risk of disease among the exposed is $\Pr(D = 1 \mid X = 1)$. The point

$$p_{\text{crude}}^* = \left(\Pr(D = 1 \mid X = 0), \Pr(D = 1 \mid X = 1) \right)$$

on the Rothman diagram is the **crude association point** for the population, which is approximated by the crude association point for the study sample. Figure 18.1 shows the crude point for the data from Table 18.1. Its x-coordinate is the risk of death among nonsmokers, which is $230/702 \approx 0.314$. Its y-coordinate is the risk of death among smokers, which is $139/582 \approx 0.239$. The **null line** is the set of all points where the risks of death in the unexposed and the exposed are equal. It is a diagonal line from the point $(0, 0)$ to the point $(1, 1)$.

The conditional risk of disease given $X = x$ and $C = c$ in the eligible population is

$$\Pr(D = 1 \mid X = x, C = c) = \frac{\Pr(D = 1, X = x, C = c)}{\Pr(X = x, C = c)}.$$

The point

$$p_c^* = \left(\Pr(D = 1 \mid X = 0, C = c), \Pr(D = 1 \mid X = 1, C = c) \right)$$

is the **stratum-specific association point** for the subpopulation with $C = c$. There is one stratum-specific association point for each value of C . Figure 18.1 shows the stratum-specific association points for the age groups in Table 18.3. For both smokers and nonsmokers, the risks of death were much higher in the older age stratum, and these differences in mortality due to age were much larger than the differences due to smoking.

When conditioning on C controls confounding of the causal effect of X on D , exchangeability given C and consistency guarantee that

$$\begin{aligned} \Pr(D^x = 1 \mid C = c) &= \Pr(D^x = 1 \mid X = x, C = c) \\ &= \Pr(D = 1 \mid X = x, C = c) \end{aligned} \tag{18.2}$$

for $x = 0$ and $x = 1$ (Pearl 2009; M. A. Hernán and Robins 2023). Thus, the causal and association points are the same (up to random variation) within each stratum of C . In our

example, the stratum-specific association points represent stratum-specific causal points if stratifying into the 18-64 and 65+ year age groups removes all confounding of the association between smoking and 20-year survival. In reality, there is likely to be residual confounding by age within these groups. Better control of confounding could be achieved with a larger number of age groups or a well-chosen regression model.

Pretending that we can plot association points for the eligible population has allowed us to ignore selection bias. When we have data only from a sample of this population, we need

$$\Pr(D = 1 \mid C = c, X = x, S = 1) = \Pr(D = 1 \mid C = c, X = x).$$

If the analytic cohort condition holds, both sides are equal to $\Pr(D^x = 1 \mid C = c)$ by equations Equation 17.8 (for the left-hand side) and Equation 18.2 (for the right-hand side). Under the analytic cohort condition, the association points for the study sample match the association points for the eligible population up to sampling variation, which is accounted for in both Bayesian and frequentist inference. Focusing on association points in the eligible population helps us isolate confounding from selection bias.

18.2.3 Standardization and line segments

If we have two points $p_0 = (x_0, y_0)$ and $p_1 = (x_1, y_1)$ in \mathbb{R}^2 , we can multiply them by scalars and add them like vectors to get another point in \mathbb{R}^2 :

$$a_0 p_0 + a_1 p_1 = (a_0 x_0 + a_1 x_1, a_0 y_0 + a_1 y_1).$$

As time t goes from zero to one, the point

$$p(t) = (1 - t)p_0 + tp_1$$

traces the line segment from p_0 to p_1 . This line segment is the set

$$\{(x, y) \in \mathbb{R}^2 : (x, y) = (1 - t)p_0 + tp_1 \text{ for some } t \in [0, 1]\}, \quad (18.3)$$

which is the set of all points $p(t)$ that we cross while going from p_0 to p_1 in a straight line.

Because C is not causally affected by X , $\Pr(C = 0)$ and $\Pr(C = 1)$ remain the same no matter how we intervene to set X . For any possible value x of X ,

$$\begin{aligned} \Pr(D^x = 1) &= \Pr(D^x = 1 \mid C = 0) \Pr(C = 0) \\ &\quad + \Pr(D^x = 1 \mid C = 1) \Pr(C = 1) \end{aligned} \quad (18.4)$$

by the law of total probability. If p_0 and p_1 are the stratum-specific causal points for $C = 0$ and $C = 1$, then

$$p_{\text{marg}} = p_0 \Pr(C = 0) + p_1 \Pr(C = 1).$$

Because $\Pr(C = 0) + \Pr(C = 1) = 1$, the marginal causal point is on the line segment connecting the stratum-specific causal points. Other points on this line segment are marginal causal points for populations with the same stratum-specific causal points but different distributions of C . For example, the point $0.5p_0 + 0.5p_1$ halfway between p_0 and p_1 is the marginal causal point for a population where $\Pr(C = 1) = 0.5$.

With association points, line segments correspond to standardized risks of disease Kenah (2024). The standardized risk of disease given $X = x$ is the marginal risk of disease in a hypothetical *standard population* where the prevalence of $C = 1$ equals $\Pr_{\text{std}}(C = 1)$. The standardized risk of disease under $X = x$ is

$$\begin{aligned} \Pr_{\text{std}}(D = 1 | X = x) &= \Pr(D = 1 | X = x, C = 0) \Pr_{\text{std}}(C = 0) \\ &\quad + \Pr(D = 1 | X = x, C = 1) \Pr_{\text{std}}(C = 1). \end{aligned} \quad (18.5)$$

Standardization allows us to calculate marginal risks of disease using the same distribution of C for both exposure groups, which removes confounding by C . The corresponding *standardized association point*

$$\begin{aligned} p_{\text{std}}^* &= (\Pr_{\text{std}}(D = 1 | X = 0), \Pr_{\text{std}}(D = 1 | X = 1)) \\ &= p_0^* \Pr_{\text{std}}(C = 0) + p_1^* \Pr_{\text{std}}(C = 1) \end{aligned}$$

is on the line segment connecting the stratum-specific points p_0^* and p_1^* . Each point on this **standardized segment** represents a standardized association point for some standard population. For example, the point $0.5p_0^* + 0.5p_1^*$ corresponds to a standard population with $\Pr_{\text{std}}(C = 1) = 0.5$.

If there is no unmeasured confounding of the causal effect of X on D within strata of C and $\Pr_{\text{std}}(C = 1) = \Pr(C = 1)$, then

$$p_{\text{std}}^* = p_0 \Pr(C = 0) + p_1 \Pr(C = 1) = p_{\text{marg}}.$$

so the standardized point equals the marginal causal point (up to sampling variation). If we standardize to any other distribution of C , we get the marginal causal point for the corresponding standard population.

In our example, there are 1,072 women aged 18-64 years and 242 women aged 65+ years at the time of the original survey. Using this age distribution, the standardized risk of death among smokers is

$$\left(\frac{1,072}{1,314} \times \frac{97}{533} \right) + \left(\frac{242}{1,314} \times \frac{42}{49} \right) \approx 0.306$$

and the standardized risk of death among nonsmokers is

$$\left(\frac{1,072}{1,314} \times \frac{65}{539} \right) + \left(\frac{242}{1,314} \times \frac{165}{193} \right) \approx 0.256.$$

This standardized point is plotted in Figure 18.1 with the label “All ages”. If stratifying by age has controlled confounding of the causal effect of smoking on 20-year mortality, the x-coordinate of this point is the causal risk of death in the study sample if we had intervened

to make all participants nonsmokers, and its y-coordinate is the causal risk of death if we had intervened (unethically) to make all participants smokers.

Among the 582 smokers in the study sample, there are 533 women aged 18-64 years and 49 women aged 65+ years. Using this age distribution, the standardized risk of death among smokers is

$$\left(\frac{533}{582} \times \frac{97}{533}\right) + \left(\frac{49}{582} \times \frac{42}{49}\right) = \frac{97 + 42}{582} \approx 0.239,$$

which is just the marginal risk of death among smokers in the sample. The corresponding standardized risk of death among nonsmokers is

$$\left(\frac{533}{582} \times \frac{65}{539}\right) + \left(\frac{49}{582} \times \frac{165}{193}\right) \approx 0.182.$$

This point is plotted in Figure 18.1. It has the same y-coordinate as the crude point because of consistency: Because we see D^1 for smokers, their actual risk of death equals their risk of death under an intervention that makes them smokers. If stratifying by age has controlled confounding, the x-coordinate of this point is the counterfactual risk of death among smokers had we intervened to make them nonsmokers. Compared to the standardized point for the study sample, the point for smokers is closer to the stratum-specific point for the 18-64 year age group because smokers were younger on average.

Among the 732 nonsmokers, there are 539 women aged 18-64 years and 193 women aged ≥ 65 years. Figure 18.1 shows the standardized point for this age distribution, which has the same x-coordinate as the crude point because of consistency (i.e., we see D^0 for nonsmokers). If stratifying by age has controlled confounding, then the y-coordinate of this point is the counterfactual risk of death among nonsmokers had we intervened to make them smokers. Compared to the standardized points for smokers and for the study sample, the point for nonsmokers is closer to the stratum-specific point for the 65+ year age group because nonsmokers were older on average.




Figure 18.1: A Rothman diagram with the crude association point (open circle), the age-stratified association points (solid circles), the standardized segment (black line), and three standardized points (open circles). Each point is labeled with the proportion of the standard population that is aged > 65 years.

18.3 Confounding

The set in Equation 18.3 is a line segment connecting p_0 and p_1 because we use the same t for both axes. If we allow different values of t for the two axes, we get the set

$$\begin{aligned} \{(x, y) \in \mathbb{R}^2 : x = (1 - t_x)x_0 + t_x x_1 \text{ and } y = (1 - t_y)y_0 + t_y y_1 \\ \text{for some } t_x, t_y \in [0, 1]\}, \end{aligned} \quad (18.6)$$

which is a rectangle with sides parallel to the axes and corners at p_0 and p_1 . It is called the *circumscribing rectangle* because it is the smallest rectangle with sides parallel to the axes that contains these points. The line segment in Equation 18.3 is a diagonal of this rectangle.

18.3.1 Confounding rectangle

The crude association point p_{crude}^* has the same x-coordinate as the standardized point for the unexposed

$$p_0^* \Pr(C = 0 \mid X = 0) + p_1^* \Pr(C = 1 \mid X = 0),$$

and it has the same y-coordinate as the standardized point for the exposed

$$p_0^* \Pr(C = 1 \mid X = 0) + p_1^* \Pr(C = 1 \mid X = 1).$$

If the distribution of C is different in the unexposed and the exposed, then p_{crude}^* will be off the standardized segment connecting p_0^* and p_1^* (unless they share an x-coordinate or a y-coordinate). However, it must be in the circumscribing rectangle with corners at p_0^* and p_1^* and sides parallel to the axes Kenah (2024). This is the **confounding rectangle**, and the standardized segment is one of its diagonals. In the limit of a large sample, the crude association point p_{crude}^* is on the standardized segment connecting p_0^* and p_1^* if and only if the causal effect of X on D is not confounded by C . Due to sampling variation, this equivalence is only approximate in practice.

Figure 18.2 shows a Rothman diagram with the confounding rectangle for the data in Table 18.3. The crude point is off the standardized segment because the age distributions for smokers and nonsmokers are different. The stratum-specific points define two corners of the rectangle. The other two corners represent the most extreme confounding possible given the stratum-specific risks of death in the exposed and unexposed. The large difference in the risk of death between the two age strata creates a large confounding rectangle that contains points far above and far below the null line. Thus, unmeasured confounding could create an association that exaggerates or reverses the causal effect of smoking on 20-year mortality.




Figure 18.2: A Rothman diagram with the standardized segment (solid) and the confounding rectangle (dashed).

18.3.2 Confounders with more than two levels*

The generalization of the line segment in Equation 18.3 for $k \geq 1$ points p_1, \dots, p_k is the *convex hull*

$$\{(x, y) \in \mathbb{R}^2 : (x, y) = w_1 p_1 + \dots + w_k p_k \text{ for } w_1, \dots, w_k \geq 0 \text{ such that } w_1 + \dots + w_k = 1\}. \quad (18.7)$$

The convex hull is the set of all weighted sums of the points p_1, \dots, p_k where the weights are nonnegative and add up to one. Geometrically, it is the shape you would get if you stretched

a rubber band around all the points. It is *convex* because it contains the line segment joining any two of its points. If $k = 1$, the convex hull is the point p_1 . If $k = 2$, the convex hull is the line segment connecting p_1 and p_2 .

Now suppose that C has $k \geq 1$ possible values c_1, \dots, c_k . Then we have k stratum-specific association points p_1^*, \dots, p_k^* . The standardized segment is the convex hull for $k = 2$ strata. For $k > 2$ strata, we will call the convex hull of the stratum-specific points the **standardized hull**. Stratum-specific points can be in its interior or on its perimeter.

Figure 18.3 shows the standardized hull for the six age strata adapted from Appleton, French, and Vanderpump (1996). The point for the 45-54 year age group is in its interior, but all other stratum-specific points are on its perimeter. Almost all of the standardized hull is above the null line, where the risk of death for smokers is higher than the risk of death for nonsmokers.

For any $k \geq 1$, we get a confounding rectangle. Using different sets of weights for the exposed and unexposed to calculate a possible crude point, we can get any point in the circumscribing rectangle for p_1^*, \dots, p_k^* . It has sides parallel to x-axis with y-coordinates at the smallest and largest stratum-specific risks in the exposed, and it has sides parallel to the y-axis with x-coordinates equal to the smallest and largest stratum-specific risks in the unexposed. It contains the entire standardized hull. Unlike the $k = 2$ case, the confounding rectangle for $k > 2$ does not necessarily have stratum-specific points at any of its corners. Figure 18.3 shows the confounding rectangle for the six age strata.

When there is no confounding of the causal effect of X on D by C , the crude point will always be inside the standardized hull. Each point in the standardized hull is a marginal causal point for some standard population. For $k > 2$, it is possible to get a crude point inside the standardized hull even when there is confounding, in which case the marginal causal point we calculate is not actually the marginal causal point for our standard population. In the limit of a large sample, there must be confounding if the crude point is outside the standardized hull.




Figure 18.3: The standardized hull (solid) and the confounding rectangle (dashed) for six age strata adapted from Appleton, French, and Vanderpump (1996). Only the top right corner of the confounding rectangle is a stratum-specific point.

18.4 Effect measure modification

Effect measure modification occurs when a given stratum-specific measures of association differs across strata. Unlike confounding, effect measure modification depends on the scale or measure of association we use. The relationship between confounding and effect measure modification has often been a source of confusion and mythology in epidemiology, but there is

really no relationship at all.

18.4.1 Contour lines

On a Rothman diagram, every point in the unit square represents a risk in the exposed and a risk in the unexposed. We can use these risks to calculate measures of association such as the odds ratio, risk ratio, or risk difference. If we think of the odds ratio as a function

$$\text{OR}(x, y) = \frac{y/(1-y)}{x/(1-x)},$$

then the set of points with $\text{OR}(x, y) = m$ for any given m is called a *contour line* or *contour* of the odds ratio. Contours can be straight lines or curves, and each possible m corresponds to a different contour line.

We can also find contour lines for the risk ratio $\text{RR}(x, y) = y/x$, the risk difference $\text{RD}(x, y) = y - x$, and the hazard ratio. To estimate the hazard ratio from binary data, we need to assume that there is a constant hazard ratio for the exposed compared to the unexposed during the time interval over which risk is defined. If so, this hazard ratio is

$$\text{CHR}(x, y) = \frac{\log(1-y)}{\log(1-x)}.$$

The incidence rate ratio is a special case of the hazard ratio where we assume an exponential distribution of times to disease onset in each exposure group.

Figure 18.4 shows contour lines for the odds ratio, risk ratio, risk difference, and hazard ratio Richardson, Robins, and Wang (2017). The null line is a contour line for all measures of association, corresponding to $\text{RD}(x, y) = 0$ and $\text{OR}(x, y) = \text{RR}(x, y) = \text{CHR}(x, y) = 1$. On a Rothman diagram, C is an effect modifier for a measure of association M when the stratum-specific points are on different contour lines of M . If we randomly choose two points in the unit square, it would be an astonishing coincidence if both were on the same contour line for a given measure of association. Thus, effect measure modification should be seen as normal, not pathological or unusual.




Figure 18.4: Contour lines for the odds ratio, risk ratio, risk difference, and hazard ratio. The null line is solid. All other contours lines are dashed. Each contour line is labeled with the corresponding value of the measure of association.

18.4.2 Interaction

In a regression model, an **interaction term** is used to allow a measure of association between exposure and disease to differ between groups defined by third covariate. If X is treatment and

Table 18.4: Link functions and effect measure modification (for the conditional association of X and D given C)

Link function	Function	Measure (given C)	$X = 0$	$X = 1$
Identity	$g(y) = y$	Risk difference	β_1	$\beta_1 + \beta_3$
Log	$g(y) = \ln y$	Risk ratio	e^{β_1}	$e^{\beta_1 + \beta_3}$
Logit	$g(y) = \ln(\text{odds}(y))$	Odds ratio	e^{β_1}	$e^{\beta_1 + \beta_3}$
Complementary log-log	$g(y) = \ln(-\ln(1 - y))$	Cumulative hazard ratio	e^{β_1}	$e^{\beta_1 + \beta_3}$

Table 18.5: Stratum-specific measures of association for smoking and 20-year mortality with likelihood ratio p-values for the interaction term and unstratified estimates with likelihood ratio 95% confidence intervals.

	Stratum-specific estimates			Unstratified estimate	
	18-64 years	65+ years	p-value	Estimate	95% confidence interval
Risk difference	0.061	0.002	0.300	0.052	(0.013, 0.091)
Risk ratio	1.509	1.003	0.010	1.062	(0.952, 1.166)
Odds ratio	1.622	1.018	0.353	1.537	(1.119, 2.125)
Cumulative hazard ratio	1.563	1.008	0.085	1.316	(1.034, 1.676)

C is a stratification variable (possibly but not necessarily to control confounding and selection bias), then a GLM with an interaction term is

$$g(\Pr(D = 1 | C = c, X = x, S = 1)) = \beta_0 + \beta_1 x + \beta_2 c + \beta_3 xc.$$

The change in $g(\Pr(D = 1 | C = c, X = x, S = 1))$ associated with a one-unit change in X given a fixed value $C = c$ is

$$g(\Pr(D = 1 | C = c, X = x + 1, S = 1)) - g(\Pr(D = 1 | C = c, X = x, S = 1)) = \beta_1 + \beta_3 c.$$

Table 18.4 shows how the scale on which the interaction term estimates effect measure modification depends on the link function $g()$.

Table 18.5 shows stratum-specific measures of association estimated using binomial GLMs that include an interaction between smoking and age group with likelihood-ratio p-values for the null hypothesis that the coefficient on the interaction term equals zero. It also shows the unstratified measure of association estimated using the same binomial GLMs without an interaction. According to the point estimates alone, there is effect measure modification on all four scales—with a harmful effect of smoking in the 18-64 year age group and a near-null effect of smoking in the 65+ year age group. However, there is little evidence of effect measure modification on the odds ratio or the risk difference scales. There is weak evidence of effect measure modification on the hazard ratio scale and strong evidence on the risk ratio scale.

18.5 R

The Rothman diagrams in Figure 18.5 show the contour lines for the stratum-specific measures of association and for the common measure of association on the odds ratio, risk ratio, risk difference, and hazard ratio scales. For each measure of association, the points for the 18-64 year age group and the 65+ year age group are on different contour lines, so there is effect measure modification by age group. On the odds ratio and risk difference scales, the contour line for the common estimate passes close to both stratum-specific points. On the risk ratio and hazard ratio scales, the stratum-specific points are farther from the contour line for the common estimate, which partly explains the lower p-values for the interaction term on these scales.




Figure 18.5: Contour lines containing the stratum-specific points (dashed) and the contour line corresponding to the common measure of association (solid) for the risk difference, risk ratio, odds ratio, and cumulative hazard ratio.

We can evaluate effect measure modification whether or not the “effects” are causal. There is effect modification on a given scale when the stratum-specific measures of association are on different contour lines for the measure of association, which can occur whether or not the crude point is on the standardized segment. There is confounding when the crude point is off the standardized segment (or outside the standardized hull), which can occur whether or not

the stratum-specific points are on different contour lines for a given measure of association. Confounding and effect modification are logically independent. However, we must control confounding if we want to determine whether a causal effect differs between strata.

18.6 Collapsibility

If C is a risk factor for disease but not a confounder, a measure of association M is said to be **collapsible** if $M = m$ in the marginal 2x2 table whenever $M = m$ in all 2x2 tables defined by strata C (Whittemore 1978; Greenland, Pearl, and Robins 1999b). Thus, the marginal and stratum-specific values of a collapsible measure M are equal whenever there is no confounding by C and no effect modification of M by C . A measure that is not collapsible is **noncollapsible**. The risk ratio and risk difference are collapsible but the odds ratio and cumulative hazard ratio are not (Samuels 1981; O. S. Miettinen and Cook 1981; Greenland 1996).

18.6.1 Definition in terms of standardized measures

An equivalent but simpler definition is that M is collapsible if the standardized $M = m$ whenever $M = m$ in each stratum of C . Because standardization removes any confounding by C , this is equivalent to the definition that assumes no confounding by C .

Leaving confounding out of the definition of collapsibility avoids a common source of confusion in epidemiology and biostatistics, where students are often taught to detect confounding by looking for a change in an estimated measure of association upon adjustment for a covariate. This *change-in-estimates* method can spuriously detect confounding when it is based on a noncollapsible measure of association (O. S. Miettinen and Cook 1981; Greenland, Pearl, and Robins 1999b).

18.6.2 Straight contour lines

A measure M is collapsible if and only if all of its contour lines are straight. In Figure 18.4, the collapsible risk ratio and risk difference have straight contours but the noncollapsible odds ratio and hazard ratio have curved contours. Because the null line is a contour for all measures of association and it is straight, all measures of association are collapsible under the null hypothesis.

If all contours of M are straight and there is no effect measure modification of M by C , then all stratum-specific points for M given C lie on the contour of M corresponding to the common $M = m$. Because the stratum-specific points given C are all contained in a line segment, this is also the standardized segment (or standardized hull if C has more than two levels). Any standardized point must be on the same contour of M , so the standardized $M = m$ for any

standard population. Therefore, M is collapsible if all of its contour lines are straight. This situation is illustrated in Figure 18.6, where all standardized risk differences equal the common stratum-specific risk difference of 0.052.




Figure 18.6: Collapsibility along a straight contour line. The entire standardized segment is contained on the common risk difference contour. The estimated risks are based on a binomial GLM with an identity link and no interaction.

Suppose M has curved contour lines but there is no effect measure modification of M by C . Then all stratum-specific points for M lie on the same curved contour corresponding to the common measure $M = m$. If we pick any two stratum-specific points and connect them with a straight line segment, then this segment is not contained in the same contour of M . Thus, we

can find a standard population where the standardized $M \neq m$. Therefore, M is collapsible only if its contour lines are straight. This situation is illustrated in Figure 18.7, where the stratum-specific odds ratio is 1.537 but the standardized segment has a minimum odds ratio of 1.229, which occurs in a standard population that is approximately 48.4% aged 18-64 years and 51.6% aged ≥ 65 years.




Figure 18.7: Noncollapsibility along a curved contour line. Except for its endpoints at the stratum-specific points, the entire standardized segment is between the null line and the contour for the common odds ratio. The estimated risks are based on a logistic regression model with no interaction.

18.6.3 Noncollapsibility and changes upon adjustment

A change in an estimated measure of association upon covariate adjustment is caused by a combination of confounding, selection bias, effect measure modification, and noncollapsibility. Generating a large difference between adjusted and unadjusted measures through noncollapsibility alone requires a common stratum-specific estimate far from the null (so the contour has high curvature) and large differences in risk between strata. For the odds ratio and cumulative hazard ratio, noncollapsibility generates bias toward the null but never across the null. Thus, the changes caused by noncollapsibility alone have a predictable direction and are usually small.

Confounding, selection bias, and effect measure modification can generate large changes much more easily than noncollapsibility, and these changes can occur in any direction—including across the null. These sources of bias affect all measures of association, whether collapsible or not.

Noncollapsibility reflects a genuine difference between marginal and conditional measures of association, not bias. Collapsible measures such as the risk difference or risk ratio allow us to ignore this difference under ideal conditions with no confounding, no selection bias, and no effect measure modification by C . Noncollapsibility is not a reason to avoid using measures of association such as the odds ratio or cumulative hazard ratio.

Listing 18.1 rothman-glm.R

```
## Binomial GLM analysis of smoking and 20-year mortality

# load R packages
library(dplyr)      # for case_when()
library(lmtest)     # for lrtest()

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                      "65-74", "75+"),
                    ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                    death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                    age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
               times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                           103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                           AFVdat$age >= "65-74" ~ "65+")

# crude 2x2 table and hypothesis tests
twobytwo <- function(covariate = NULL, dat = AFVdat) {
  # generate crude or stratified 2x2 tables
  # covariate should be a string naming a variable in dat
  formla <- "~ smoking + death"
  # update formula if there is a covariate specified
  if (!is.null(covariate)) formla <- paste(formla, "+", covariate)
  tab22 <- xtabs(formla, data = dat, drop.unused.levels = TRUE)
  # format stratified 2x2 tables into a list
  if (length(dim(tab22)) > 2) {
    tab22 <- unlist(apply(tab22, 3, list), recursive = FALSE)
  } else {
    tab22 <- list(tab22)
  }
  # reorder rows and columns and add margins to 2x2 table(s)
  lapply(tab22, function(x) addmargins(x[c(2, 1), ], c(2, 1))))
}

# crude 2x2 table and hypothesis tests
crude22 <- twobytwo()[[1]]
crude22_nomarg <- crude22[-3, -3] # remove margins
chisq.test(crude22_nomarg, correct = FALSE) # Pearson chi-squared test
fisher.test(crude22_nomarg) # Fisher's exact test

# crude measures of association
mest <- function(model, pval = TRUE, ...) {
  # extract point and interval estimates from GLM
  meas <- coef(model)["smoking"]
  ci <- confint(model, ...)[["smoking", ]]
  # get risk/odds ratio point and interval estimates from their logarithms
```

Listing 18.2 rothman-std.R

```
## Rothman diagram for smoking and 20-year mortality

# load R packages
library(dplyr) # for case_when()
library(lmtest) # for lrtest()

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                     "65-74", "75+"),
                   ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                   death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                   age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
              times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                        103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                          AFVdat$age >= "65-74" ~ "65+")

# 2x2 tables
twobytwo <- function(covariate = NULL, dat = AFVdat) {
  # generate crude or stratified 2x2 tables
  # covariate should be a string naming a variable in dat
  formla <- "~ smoking + death"
  # update formula if there is a covariate specified
  if (!is.null(covariate)) formla <- paste(formla, "+", covariate)
  tab22 <- xtabs(formla, data = dat, drop.unused.levels = TRUE)
  # format stratified 2x2 tables into a list
  if (length(dim(tab22)) > 2) {
    tab22 <- unlist(apply(tab22, 3, list), recursive = FALSE)
  } else {
    tab22 <- list(tab22)
  }
  # reorder rows and columns and add margins to 2x2 table(s)
  lapply(tab22, function(x) addmargins(x[c(2, 1), ][, c(2, 1)]))
}
strat2 <- twobytwo("binage")

# risk calculations
condrisk <- function(covariate = NULL, dat = AFVdat) {
  # function to calculate crude or stratified risks in smokers and nonsmokers
  # covariate should be a string naming a variable in dat
  strat2 <- twobytwo(covariate, dat) 376
  risk <- function(v) v[, 1] / v[, 3] # v = (alive, dead)
  risks <- do.call(rbind, lapply(strat2, risk))
  colnames(risks) <- c("smokers", "nonsmokers", "marginal")
  as.data.frame(risks)
}
margrisk <- condrisk()
```

Listing 18.3 rothman-conf.R

```
## Rothman diagram for smoking and 20-year mortality

# load R packages
library(dplyr)      # for case_when()
library(plotrix)

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                      "65-74", "75+"),
                    ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                    death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                    age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
               times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                           103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                          AFVdat$age >= "65-74" ~ "65+")

# 2x2 tables
twobytwo <- function(covariate = NULL, dat = AFVdat) {
  # generate crude or stratified 2x2 tables
  # covariate should be a string naming a variable in dat
  formla <- "~ smoking + death"
  # update formula if there is a covariate specified
  if (!is.null(covariate)) formla <- paste(formla, "+", covariate)
  tab22 <- xtabs(formla, data = dat, drop.unused.levels = TRUE)
  # format stratified 2x2 tables into a list
  if (length(dim(tab22)) > 2) {
    tab22 <- unlist(apply(tab22, 3, list), recursive = FALSE)
  } else {
    tab22 <- list(tab22)
  }
  # reorder rows and columns and add margins to 2x2 table(s)
  lapply(tab22, function(x) addmargins(x[c(2, 1), ], c(2, 1))))
}
strat2 <- twobytwo("binage")

# risk calculations
condrisk <- function(covariate = NULL, dat = AFVdat) {
  # function to calculate crude or stratified risks in smokers and nonsmokers
  # covariate should be a string naming a variable in dat
  strat2 <- twobytwo(covariate, dat) 377
  risk <- function(v) v[, 1] / v[, 3] # v = (alive, dead)
  risks <- do.call(rbind, lapply(strat2, risk))
  colnames(risks) <- c("smokers", "nonsmokers", "marginal")
  as.data.frame(risks)
}
margrisk <- condrisk()
```

Listing 18.4 rothman-conf7.R

```
## Rothman diagram for smoking and 20-year mortality

# load R packages
library(dplyr)
library(plotrix)

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                      "65-74", "75+"),
                    ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                    death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                    age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
               times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                          103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                           AFVdat$age >= "65-74" ~ "65+")

# 2x2 tables
twobytwo <- function(covariate = NULL, dat = AFVdat) {
  # generate crude or stratified 2x2 tables
  # covariate should be a string naming a variable in dat
  formla <- "~ smoking + death"
  # update formula if there is a covariate specified
  if (!is.null(covariate)) formla <- paste(formla, "+", covariate)
  tab22 <- xtabs(formla, data = dat, drop.unused.levels = TRUE)
  # format stratified 2x2 tables into a list
  if (length(dim(tab22)) > 2) {
    tab22 <- unlist(apply(tab22, 3, list), recursive = FALSE)
  } else {
    tab22 <- list(tab22)
  }
  # reorder rows and columns and add margins to 2x2 table(s)
  lapply(tab22, function(x) addmargins(x[c(2, 1), ][, c(2, 1)]))
}
strat7 <- twobytwo("age")

# risk calculations
condrisk <- function(covariate = NULL, dat = AFVdat) {
  # function to calculate crude or stratified risks in smokers and nonsmokers
  # covariate should be a string naming a variable in dat
  strat2 <- twobytwo(covariate, dat) 378
  risk <- function(v) v[, 1] / v[, 3] # v = (alive, dead)
  risks <- do.call(rbind, lapply(strat2, risk))
  colnames(risks) <- c("smokers", "nonsmokers", "marginal")
  as.data.frame(risks)
}
margrisk <- condrisk()
```

Listing 18.5 rothman-contours.R

```
## Contour lines for measures of association

# load R packages
require(plotrix)      # for boxed.labels()

# odds ratio, cumulative hazard ratio, and inverses
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)
chaz <- function(p) -log(1 - p)
invchaz <- function(chaz) 1 - exp(-chaz)

# contour lines plot functions
# risk differences
riskdiff_contours <- function() {
  plot(x, x, type = "l", main = "Risk difference contours",
       xlab = "", ylab = "Risk in the exposed")
  grid()
  boxed.labels(.5, .5, "0", xpad = 1.5, ypad = 1.5, border = FALSE)
  for (riskdiff in c(-0.5, -0.2, 0, 0.2, 0.5)) {
    y <- x + riskdiff
    yrange <- y >= 0 & y <= 1
    lines(x[yrange], y[yrange], lty = "dashed")
    boxed.labels(0.5 - riskdiff / 2, 0.5 + riskdiff / 2,
                 as.character(riskdiff),
                 xpad = 1.5, ypad = 1.5, border = FALSE)
  }
}

# risk ratios
riskratio_contours <- function() {
  plot(x, x, type = "l", main = "Risk ratio contours",
       xlab = "", ylab = "")
  grid()
  boxed.labels(.5, .5, "1", xpad = 1.5, ypad = 1.5, border = FALSE)
  for (riskratio in c(0.2, 0.5, 2, 5)) {
    y <- riskratio * x
    yrange <- y <= 1
    lines(x[yrange], y[yrange], lty = "dashed")
    boxed.labels(1 / (riskratio + 1), riskratio / (riskratio + 1),
                 as.character(riskratio),
                 xpad = 1.5, ypad = 1.5, border = FALSE)
  }
}

# odds ratios
oddsratio_contours <- function() {
  plot(x, x, type = "l", main = "Odds ratio contours",
       xlab = "Risk in the unexposed",
       ylab = "Risk in the exposed")
  grid()
  boxed.labels(.5, .5, "1", xpad = 1.5, ypad = 1.5, border = FALSE)
  for (oddsratio in c(0.2, 0.5, 2, 5)) {
    lines(x, invodds(oddsratio * odds(x)), lty = "dashed")
  }
}
```

Listing 18.6 rothman-glm2.R

```
## Binomial GLM analysis of smoking and 20-year mortality with interactions

# load R packages
library(dplyr)      # for case_when()
library(lmtest)     # for lrtest()

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                      "65-74", "75+"),
                    ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                    death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                    age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
               times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                           103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                          AFVdat$age >= "65-74" ~ "65+")

# binomial GLMs with identity link for risk difference
# Model without interaction requires a starting point for numerical stability.
# We get a starting point from a linear regression model.
intx_idbinom <- glm(death ~ smoking * binage, data = AFVdat,
                   family = binomial(link = "identity"))
nointx_lm <- lm(death ~ smoking + binage, data = AFVdat)
nointx_idbinom <- glm(death ~ smoking + binage, data = AFVdat,
                    family = binomial(link = "identity"),
                    start = coef(nointx_lm))

# log-binomial regression for risk ratio
# Both models require a starting point due to numerical instability.
# We get these from Poisson GLMs with a log link.
intx_poisson <- glm(death ~ smoking * binage, data = AFVdat,
                   family = poisson())
intx_logbinom <- glm(death ~ smoking * binage, data = AFVdat,
                   family = binomial(link = "log"),
                   start = coef(intx_poisson))
nointx_poisson <- glm(death ~ smoking + binage, data = AFVdat,
                   family = poisson())
nointx_logbinom <- glm(death ~ smoking + binage, data = AFVdat,
                   family = binomial(link = "log"),
                   start = coef(nointx_poisson) - 0.1)
```

Listing 18.7 rothman-intx.R

```
## Contour lines and interaction

# load R packages
library(dplyr)      # for case_when()
library(lmtest)     # for lrtest()

# odds ratio, cumulative hazard ratio, and inverses
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)
chaz <- function(p) -log(1 - p)
invchaz <- function(chaz) 1 - exp(-chaz)

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                      "65-74", "75+"),
                    ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                    death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                    age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
               times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                           103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                          AFVdat$age >= "65-74" ~ "65+")

# 2x2 tables
twobytwo <- function(covariate = NULL, dat = AFVdat) {
  # generate crude or stratified 2x2 tables
  # covariate should be a string naming a variable in dat
  formla <- "~ smoking + death"
  # update formula if there is a covariate specified
  if (!is.null(covariate)) formla <- paste(formla, "+", covariate)
  tab22 <- xtabs(formla, data = dat, drop.unused.levels = TRUE)
  # format stratified 2x2 tables into a list
  if (length(dim(tab22)) > 2) {
    tab22 <- unlist(apply(tab22, 3, list), recursive = FALSE)
  } else {
    tab22 <- list(tab22)
  }
  # reorder rows and columns and add margins to 2x2 table(s)
  lapply(tab22, function(x) addmargins(x[c(2, 1), ], c(2, 1))))
}

# risk calculations
condrisk <- function(covariate = NULL, dat = AFVdat) {
  # function to calculate crude or stratified risks in smokers and nonsmokers
  # covariate should be a string naming a variable in dat
  strat2 <- twobytwo(covariate, dat)
  risk <- function(v) v[, 1] / v[, 3] # v = (alive, dead)
```

Listing 18.8 rothman-collaps.R

```
## Collapsibility and straight contour lines (risk difference)

# load R packages
library(dplyr)          # for case_when()

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                      "65-74", "75+"),
                    ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                    death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                    age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
               times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                           103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                          AFVdat$age >= "65-74" ~ "65+")

# binomial GLM with identity link for risk difference
# Model without interaction requires a starting point for numerical stability.
# We get a starting point from a linear regression model.
nointx_lm <- lm(death ~ smoking + binage, data = AFVdat)
nointx_idbinom <- glm(death ~ smoking + binage, data = AFVdat,
                     family = binomial(link = "identity"),
                     start = coef(nointx_lm))

# risk difference collapsibility plot
pred_newdata <- data.frame(binage = rep(c("18-64", "65+"), each = 2),
                          smoking = rep(c(0, 1), times = 2))
predformat <- function(predrisk) {
  data.frame(matrix(predrisk, ncol = 2, byrow = TRUE,
                    dimnames = list(c("18-64", "65+"),
                                    c("nonsmokers", "smokers"))))
}
predrisk_idbinom <- predformat(predict(nointx_idbinom, type = "response",
                                     newdata = pred_newdata))
plot(predrisk_idbinom$nonsmokers, predrisk_idbinom$smokers, pch = 19,
     xlim = c(0, 1), ylim = c(0, 1), asp = 1,
     xlab = "Risk in the unexposed (nonsmokers)",
     ylab = "Risk in the exposed (smokers)")
x <- seq(0, 1, by = 0.01)
y <- x + coef(nointx_idbinom)["smoking"]
yrange <- y >= 0 & y <= 1
lines(x[yrange], y[yrange], lty = "dashed")
segments(0, 0, 1, 1, col = "darkgray")
segments(predrisk_idbinom["18-64", "nonsmokers"],
          predrisk_idbinom["18-64", "smokers"],
          predrisk_idbinom["65+", "nonsmokers"],
          predrisk_idbinom["65+", "smokers"])
```

Listing 18.9 rothman-noncollaps.R

```
## Noncollapsibility and curved contour lines (odds ratio)

# load R packages
library(dplyr)      # for case_when()
library(plotrix)    # for boxed.labels()

# odds ratio and inverse
odds <- function(p) p / (1 - p)
invodds <- function(odds) odds / (1 + odds)

# data from Appleton et al. (The American Statistician, 1996)
# Using an ordered factor allows the use of <, =, and > for comparison.
agegroups <- factor(c("18-24", "25-34", "35-44", "45-54", "55-64",
                     "65-74", "75+"),
                   ordered = TRUE)
AFVdat <- data.frame(smoking = rep(c(0, 0, 1, 1), times = length(agegroups)),
                   death = rep(c(0, 1, 0, 1), times = length(agegroups)),
                   age = rep(agegroups, each = 4))
AFVrows <- rep(seq_len(nrow(AFVdat)),
              times = c(61, 1, 53, 2, 152, 5, 121, 3, 114, 7, 95, 14, 66, 12,
                        103, 27, 81, 40, 64, 51, 28, 101, 7, 29, 0, 64, 0, 13))
AFVdat <- AFVdat[AFVrows, ]
AFVdat$binage <- case_when(AFVdat$age < "65-74" ~ "18-64",
                          AFVdat$age >= "65-74" ~ "65+")

# logistic regression (binomial GLM with logit link) for odds ratio
nointx_logistic <- glm(death ~ smoking + binage, data = AFVdat,
                      family = binomial(link = "logit"))

# noncollapsibility of the odds ratio
pred_newdata <- data.frame(binage = rep(c("18-64", "65+"), each = 2),
                          smoking = rep(c(0, 1), times = 2))
predformat <- function(predrisk) {
  data.frame(matrix(predrisk, ncol = 2, byrow = TRUE,
                    dimnames = list(c("18-64", "65+"),
                                    c("nonsmokers", "smokers"))))
}
predrisk_logistic <- predformat(predict(nointx_logistic, type = "response",
                                       newdata = pred_newdata))

# find minimum odds ratio
std_odds <- function(t) {
  xcoord <- with(predrisk_logistic,
                (1 - t) * nonsmokers[1] + t * nonsmokers[2])
  ycoord <- with(predrisk_logistic, (1 - t) * smokers[1] + t * smokers[2])
  odds(ycoord) / odds(xcoord)
}
minodds <- optimize(std_odds, c(0, 1))
tmin <- minodds$minimum
xmin <- with(predrisk_logistic,
            (1 - tmin) * nonsmokers[1] + tmin * nonsmokers[2])
ymin <- with(predrisk_logistic, (1 - tmin) * smokers[1] + tmin * smokers[2])
```

Part IV

Epidemiologic and Statistical Methods for Causal Inference

19 Stratified Analysis

To interpret a measure of association as a causal effect, there must be no confounding or selection bias. We have discussed how stratification can help us control bias in causal inference. Suppose that we have a variable C with k different levels such that stratification on C is sufficient to prevent confounding and selection bias. Also suppose that we have chosen a measure of association appropriate for the scientific or public health question we are trying to answer. The next steps are:

1. Decide whether there is effect modification. To test whether there is effect measure modification (which is often referred to as testing *homogeneity*), it is often necessary to calculate a pooled measure of association.
2. If there is effect modification, report stratum-specific measures of association or standardize to a distribution of C . In a case-control study, we may only be able to estimate the conditional odds ratios (which might estimate risk ratios or incidence rate ratios). In a cohort study, we can calculate stratum-specific risks and standardized measures of association.
3. If there is no effect modification, report the pooled measure of association. If the measure is collapsible (or nearly collapsible), this will approximate the population-level measure of association.

Unless we standardize, this approach estimates conditional measures of the association between X and D given C . If conditioning on C controls confounding and selection bias, then these conditional measures of association can be interpreted in terms of conditional causal effects. We will assume that each stratum has the stratum-specific 2x2 table shown in Table 19.1 and that we ignore tables with $n_i = 0$.

Table 19.1: Stratum-specific 2x2 table

	$D = 1$	$D = 0$	Total
$X = 1$	a_i	b_i	r_{1i}
$X = 0$	c_i	d_i	r_{0i}
Total	k_{1i}	k_{0i}	n_i

19.1 Pooled measures of association

Estimators of a common measure of association have two goals that are not always compatible. First, minimize variance. Second, try to perform well in sparse strata. If you stratify by several variables, you will often end up with the data spread across many 2x2 tables that can have small numbers of individuals, including cells with zero individuals. Cells with zero individuals are often called **zero cells**, and data with a large number of cells with small numbers of individuals are called **sparse data**. There are three general methods of estimating common measures of association conditional on a set of covariates C :

- Woolf estimators (Woolf 1955): These minimize variance but rely on having large samples in each stratum.
- Mantel-Haenszel estimators (Mantel and Haenszel 1959): These come close to minimizing variance but perform much better with sparse strata.
- Regression models: These can handle continuous covariates as well as categorical covariates. They have low variance and are almost (but not always) as tolerant of sparse strata as Mantel-Haenszel estimators. The regression models that can be used for this purpose include generalized linear models (GLMs), conditional logistic regression, and regression models from survival analysis. Because of their flexibility and performance, regression models are the most widely used of these methods.

The Woolf and Mantel-Haenszel estimators are weighted averages of the stratum-specific measures of association:

$$\frac{\sum_{i=1}^m w_i \hat{M}_i}{\sum_{i=1}^k w_i}. \quad (19.1)$$

where \hat{M}_i is the estimated stratum-specific measure of association, w_i is the weight given to stratum i , and m is the number of strata. This weighted average is different from the weighted average that we use in standardization because it is an average of the stratum-specific measures of association rather than an average of stratum-specific risks (which are then compared using a measure of association).

19.1.1 Woolf estimators

The variance of the weighted average in Equation 19.1 is minimized by letting

$$w_i = \frac{1}{\text{Var}(\hat{M}_i)}.$$

These are the weights used by Woolf estimators (Woolf 1955). For ratio measures, Woolf estimators are calculated on the log scale and then transformed back to the odds ratio, risk

ratio, or incidence rate ratio scale. For the odds ratio, the Woolf estimator is

$$\ln \hat{OR}_W = \frac{\sum_{i=1}^m w_i \ln \hat{OR}_i}{\sum_{i=1}^k w_i}$$

where

$$w_i = \left(\frac{1}{a_i} + \frac{1}{b_i} + \frac{1}{c_i} + \frac{1}{d_i} \right)^{-1}.$$

If there is any stratum with a zero cell, this estimator is undefined. One correction that is sometimes used is to add 0.5 to all cells before calculating the stratum-specific log odds ratios and variances (Jewell 2003), which is a small-sample correction for the log odds ratio.

19.1.2 Mantel-Haenszel estimators

Mantel-Haenszel estimators, which are sometimes called Cochran-Mantel-Haenszel estimators (Cochran 1954; Mantel and Haenszel 1959), use weights that approximate inverse variance weights under the null hypothesis but do not blow up in sparse strata. Variance calculation for Mantel-Haenszel estimators can be complicated (J. Robins 1986).

Odds ratio

From Table 19.1, the odds ratio in stratum i is

$$\hat{OR}_i = \frac{a_i d_i}{b_i c_i}$$

The Mantel-Haenszel odds ratio is

$$\hat{OR}_{MH} = \frac{\sum_{i=1}^m a_i d_i / n_i}{\sum_{i=1}^k b_i c_i / n_i},$$

which we get from Equation 19.1 using

$$w_i = \frac{b_i c_i}{n_i}.$$

These weights can be seen in the denominator of \hat{OR}_{MH} . Strata with $b_i c_i = 0$ will be ignored, but the estimator is defined whenever at least one stratum has $b_i c_i \neq 0$. Because they can be used for case-control studies, the Mantel-Haenszel odds ratio is the most widely used of all Mantel-Haenszel pooled measures of association.

The Mantel-Haenszel weights for the odds ratio approximate inverse-variance weights under the null hypothesis that the common stratum-specific OR = 1. If $\hat{OR}_i = 1$, then $a_i d_i = b_i c_i$. We can rearrange $\text{Var}(\ln \hat{OR}_i)$ from Equation 9.11 to get

$$\frac{1}{a_i} + \frac{1}{b_i} + \frac{1}{c_i} + \frac{1}{d_i} = \frac{a_i + d_i}{a_i d_i} + \frac{b_i + c_i}{b_i c_i} = \frac{a_i + b_i + c_i + d_i}{b_i c_i} = \frac{n}{b_i c_i}.$$

Using the delta method, we get

$$\text{Var}(\hat{OR}_i) = \text{Var}\left(e^{\ln \hat{OR}_i}\right) \approx \left(e^{\ln \hat{OR}_i}\right)^2 \text{Var}(\ln \hat{OR}_i) = \text{Var}(\ln \hat{OR}_i). \quad (19.2)$$

when $\hat{OR}_i \approx 1$ in stratum i . Therefore, the inverse variance weight of \hat{OR}_i under the null hypothesis is approximately $b_i c_i / n_i$.

Risk ratio

From Table 19.1, the risk ratio in stratum i is

$$\hat{RR}_i = \frac{a_i / r_{1i}}{c_i / r_{0i}} = \frac{a_i r_{0i}}{c_i r_{1i}}.$$

The Mantel-Haenszel risk ratio is

$$\hat{RR}_{MH} = \frac{\sum_{i=1}^m a_i r_{0i} / n_i}{\sum_{i=1}^k c_i r_{1i} / n_i}$$

which we get from Equation 19.1 using the weights

$$w_i = \frac{c_i r_{1i}}{n_i}$$

that can be seen in the denominator. Strata with $c_i r_{1i} = 0$ will be ignored, but the estimator is defined whenever at least one stratum has $c_i r_{1i} \neq 0$.

The Mantel-Haenszel weights for the risk ratio can be derived by assuming both the null hypothesis that $RR_i = 1$ in each stratum i and that the risk of disease is small in each stratum. If $\hat{RR}_i = 1$, then $a_i r_{0i} = C_i r_{1i}$. We can rearrange $\text{Var}(\ln \hat{RR}_i)$ from Equation 9.6 to get

$$\frac{1}{a_i} - \frac{1}{r_{1i}} + \frac{1}{c_i} - \frac{1}{r_{0i}} = \frac{r_{0i} - a_i}{a_i r_{1i}} + \frac{r_{1i} - c_i}{c_i r_{1i}} = \frac{n_i - k_{1i}}{c_i r_{0i}} \approx \frac{n_i}{c_i r_{0i}}$$

where the final approximation comes from the fact that $k_{1i} \ll n_i$ if the disease is rare in each stratum. By replacing \hat{OR}_i with \hat{RR}_i in Equation 19.2, we get

$$\text{Var}(\hat{RR}_i) \approx \text{Var}(\ln \hat{RR}_i)$$

when $\hat{RR}_i \approx 1$ in stratum i . Therefore, the inverse variance weight of \hat{RR}_i for a rare disease under the null hypothesis is approximately $b_i c_i / n_i$.

Incidence rate ratio

In stratum i , let T_{1i} be the total exposed person-time, T_{0i} be the total unexposed person-time, and $T_i = T_{0i} + T_{1i}$ be the total person-time. The incidence ratio ratio in stratum i is

$$\widehat{\text{IRR}}_i = \frac{a_i/T_{1i}}{c_i/T_{0i}} = \frac{a_i T_{0i}}{c_i T_{1i}}.$$

The Mantel-Haenszel risk ratio is

$$\widehat{\text{IRR}}_{\text{MH}} = \frac{\sum_{i=1}^k a_i T_{0i}/T_i}{\sum_{i=1}^k c_i T_{1i}/T_i}$$

which we get from Equation 19.1 using the weights

$$w_i = \frac{c_i T_{1i}}{T_i}$$

that can be seen in the denominator. Strata with $c_i T_{1i} = 0$ will be ignored, but the estimator is defined whenever at least one stratum has $c_i T_{1i} \neq 0$.

The Mantel-Haenszel weights for the risk ratio can be derived by assuming both the null hypothesis that $\text{IRR}_i = 1$ in each stratum i . It does not require any rare-disease assumption. If $\widehat{\text{IRR}}_i = 1$, then $a_i T_{0i} = c_i T_{1i}$ so

$$\frac{1}{a_i} = \frac{T_{0i}}{c_i T_{1i}}.$$

We can rearrange $\text{Var}(\ln \widehat{\text{RR}}_i)$ from Equation 9.16 to get

$$\frac{1}{a_i} + \frac{1}{c_i} = \frac{T_{0i}}{c_i T_{1i}} + \frac{1}{c_i} = \frac{T_{0i} + T_{1i}}{c_i T_{1i}} = \frac{T_i}{c_i T_{1i}}$$

By replacing $\widehat{\text{OR}}_i$ with $\widehat{\text{IRR}}_i$ in Equation 19.2, we get

$$\text{Var}(\widehat{\text{IRR}}_i) \approx \text{Var}(\ln \widehat{\text{IRR}}_i)$$

when $\widehat{\text{IRR}}_i \approx 1$ in stratum i . Therefore, the inverse variance weight of $\widehat{\text{IRR}}_i$ under the null hypothesis is approximately $c_i T_{1i}/T_i$.

19.2 Testing homogeneity

Tests of homogeneity typically have low power and require large samples within each stratum. With that caveat, the basic idea is to see whether assuming a constant measure of association is a reasonable approximation. A test of homogeneity can be done using a Wald χ^2 test or by testing interaction terms in a regression model.

19.2.1 Wald χ^2 tests

Suppose we have k strata, let M_i be the stratum-specific measure of association, and M be an estimate of a common measure of association. A Wald test of homogeneity uses the test statistic

$$\sum_{i=1}^m \frac{(\hat{M}_i - \hat{M})^2}{\text{Var}(\hat{M}_i)},$$

which has a χ^2_{k-1} distribution under the null hypothesis that all $M_i = M$.

For ratio measures such as the risk ratio or odds ratio, M_i and M should be the logarithm of the ratio. For the Mantel-Haenszel odds ratio, the Wald χ^2 statistic is

$$\chi^2_{\text{MH}} = \sum_{i=1}^m \frac{(\ln \hat{\text{OR}}_i - \ln \hat{\text{OR}}_{\text{MH}})^2}{\text{Var}(\ln \hat{\text{OR}}_i)},$$

where

$$\text{Var}(\ln \hat{\text{OR}}_i) = \frac{1}{a_i} + \frac{1}{b_i} + \frac{1}{c_i} + \frac{1}{d_i}.$$

Under the null hypothesis that $M_i = M$ in each stratum i , the test statistic χ^2_{MH} has a χ^2_{k-1} distribution. It is important not to confuse this test of homogeneity with the test of the null hypothesis that the Mantel-Haenszel odds ratio equals one.

19.2.2 Interaction terms

As explained in Section 18.4.2, it is possible to test for homogeneity of an odds ratio, risk ratio, or incidence rate ratio by fitting an appropriate generalized linear model (GLM) or a model from survival analysis (accelerated failure time or Cox regression) with an interaction term. When C is a covariate that has k levels, the model would include $k - 1$ terms via indicator variables (sometimes called *dummy variables*), orthogonal polynomials, or splines. To test interaction with C , we would include interactions between X and all of the terms that encode C . These interaction terms can be tested simultaneously using Wald, score, or likelihood ratio tests. Each of these tests produces a statistic that has a χ^2_{k-1} distribution under the null hypothesis that $M_i = M$ in each stratum i .

19.2.3 Testing the null hypothesis

If there is no effect measure modification, pooled estimators of a measure of association can be used to test the null hypothesis of no conditional association between exposure and disease within strata of C . For the Woolf and Mantel-Haenszel estimators, the test statistic is

$$\frac{(M - M_{\text{null}})^2}{\text{Var}(M)},$$

which has a χ_1^2 distribution under H_0 . For the risk difference, $M_{\text{null}} = 0$. For ratio measures, the test is done on the log scale so $M_{\text{null}} = 0$.

19.3 Regression models

A stratified regression model can achieve something similar to the Woolf and Mantel-Haenszel statistics. However, the strata in a regression model are not completely independent as they are in pooled estimators. In a regression model, the strata share information about the association between treatment or exposure X and disease D . When the model does not accurately capture the conditional association between X and D given C , there can be residual confounding or selection bias. Another advantage of stratified regression models is that they can include predictors in addition to C and X .

To test homogeneity in a regression model stratified by C , we can include interaction terms between X and C .

If there is no effect measure modification, we can test the null hypothesis of no conditional association between X and D given C using a Wald, score, or likelihood ratio test of the coefficient on X .

19.3.1 Conditional logistic regression

The conditional logistic regression model that is used to analyze nested case-control studies (see Section 11.5) can also be used to estimate a common odds ratio from case-control data stratified on any confounder or set of confounders C . Let $\text{odds}(p_{si})$ be the odds of disease for person i in stratum (i.e., case-control set) s . Then the conditional logistic regression model assumes

$$\ln \text{odds}(\Pr(D = 1 \mid C = c, X = x)) = \beta_{0c} + \beta x,$$

where β_{0c} is a stratum-specific intercept the stratum with $C = c$ and X is the exposure or treatment. The odds ratio associated with a one-unit increase in X within each stratum of C is e^β .

Consider a matched set with one case and k controls who all have $C = c$, and let p_j the risk of disease in person j . Then the probability that there is one failure and no other failures is

$$\sum_{i=1}^{k+1} \left(p_i \prod_{j \neq i} (1 - p_j) \right) = \sum_{i=1}^{k+1} \frac{p_i}{1 - p_i} \prod_{j=1}^{k+1} (1 - p_j) = \sum_{i=1}^{k+1} \text{odds}(p_i) \prod_{j=1}^{k+1} (1 - p_j).$$

Without loss of generality, we can number the group members so that $i = 1$ is the case. The conditional probability that $i = 1$ is the case given that there is one failure in the group is

$$\begin{aligned} \frac{\text{odds}(p_1) \prod_{j=1}^k (1 - p_j)}{\sum_{i=1}^k \text{odds}(p_i) \prod_{j=1}^{k+1} (1 - p_j)} &= \frac{\text{odds}(p_1)}{\sum_{i=1}^{k+1} \text{odds}(p_i)} \\ &= \frac{e^{\beta_{0c} + \beta x_1}}{\sum_{i=1}^{k+1} e^{\beta_{0c} + \beta x_i}} = \frac{e^{\beta x_1}}{\sum_{i=1}^{k+1} e^{\beta x_i}}. \end{aligned} \quad (19.3)$$

The stratum-specific intercept β_{0c} cancels out.

The likelihood for β is the product of the stratum-specific conditional probabilities in Equation 19.3:

$$L(\beta) = \prod_{i=1}^m \frac{e^{\beta x_i}}{\sum_{j \in R_i^*} e^{\beta x_j}}$$

where R_i^* is the set containing the case and their matched controls. Maximum likelihood estimation yields consistent and asymptotically normal point and interval estimates for β_{true} . This is identical to the Cox partial likelihood from a nested case-control study, except the risk sets are replaced by matched case-control sets and the hazard ratio is replaced by a log odds. Exactly the same regression software can be used to fit both models—only the interpretation of the results is different. This model can be extended to include multiple predictors, including polynomials, splines, categorical variables, and interactions.

19.3.2 Stratified AFT models

In a stratified accelerated failure time (AFT) model, all strata of C have the same underlying failure time distribution (e.g., Weibull, or log-logistic). However, each stratum of C is allowed to have its own baseline rate parameter λ_{0c} and shape parameter γ_c . The other coefficients in the model are interpreted as before. In particular, $e^{-\beta}$ is the common rate ratio associated with a one-unit increase in X within strata of C . These models can be used to estimate a common rate ratio from stratified data.

19.4 R

19.4.1 Stratified Cox model

The Cox model assumes that the hazard of failure at time t is

$$h(t, \beta, x) = e^{\beta_1 x_1 + \dots + \beta_k x_k} h_0(t),$$

where X_1, \dots, X_k are covariates and $h_0(t)$ is the baseline hazard function. A **stratified Cox model** allows different groups to have different baseline hazard functions. Specifically,

$$h(t, \beta, x, c) = e^{\beta x} h_{0c}(t)$$

in the stratum with $C = c$. Although the baseline hazard functions are stratum-specific, a stratified Cox model assumes that all strata have the same coefficient vector β .

In stratum $C = c$, let m_c be the number of distinct failure times, let $t_{1c}, \dots, t_{m_c c}$ denote the distinct failure times, let $R_c(t_{ic})$ denote the risk set in stratum $C = c$ at time t_{ic} , and let x_{ic} denote the covariate value(s) of the person in stratum $C = c$ who fails at time t_{ic} . Then the partial likelihood for a stratified model with K strata and no tied failure times is

$$L(\beta) = \prod_c \prod_{i=1}^{m_c} \frac{e^{\beta x_{ic}}}{\sum_{j \in R_{ic}} e^{\beta x_j}}$$

where the product is over all strata defined by C . The product over the failure times in stratum $C = c$ is just the Cox partial likelihood within the stratum. The different strata share only the coefficients β .

Stratification is a useful extension of the standard Cox model, but it comes at a price. When there is actually a single baseline hazard function, the stratified model is less efficient than an unstratified model. You cannot test the effect of the stratification variable(s), and you cannot compare the model to an unstratified model using a likelihood ratio test or Akaike Information Criterion.

Stratified log-rank test

The log-rank test can also be stratified. The observed and expected number of failures and the variances separately in each stratum and then combine them into a single χ^2 statistic. In this case, the null hypothesis is that the survival functions of the exposed and unexposed are the same within each stratum. Just like the log-rank test is the score test from a Cox proportional hazards model with a single binary covariate X and no ties, the stratified log-rank test is the score test for a stratified Cox model with a single binary covariate and no ties within strata.

Let O_c be the observed number of failures among the exposed in stratum $C = c$, and let E_c and V_c be the expectation and variance of the number of failures among the exposed in stratum c under the null hypothesis. Within each stratum, these are calculated in exactly the same way as in the log-rank test. The sum of the differences between the observed and expected number of failures among the exposed over all strata is

$$U = \sum_c (O_c - E_c).$$

and its estimated variance is

$$V = \sum_c V_c.$$

The stratified log-rank chi-squared statistic is

$$\chi^2_{\text{log-rank}} = \frac{U^2}{V},$$

which has a χ^2_1 distribution under the null hypothesis that the exposed and unexposed have the same stratum-specific survival functions.

19.5 R

Listing 19.1 strat-aft.R

```
## Stratified accelerated failure time (AFT) models

# load R packages
library(survival)

# unstratified log-logistic AFT model
rat_unstrat <- survreg(Surv(time, status) ~ rx + sex,
                      data = rats, dist = "loglogistic")

# stratified log-logistic AFT model for rats data
# The strata() command only allows for different shape parameters.
# To get a truly stratified model, you need to include sex as a predictor.
rat_strat <- survreg(Surv(time, status) ~ rx + sex + strata(sex),
                   data = rats, dist = "loglogistic")
summary(rat_strat)
exp(-coef(rat_strat))
exp(-confint(rat_strat))

# baseline rates for female rats and male rats
lambda_f <- exp(-coef(rat_strat)["(Intercept)"])
lambda_m <- lambda_f * exp(-coef(rat_strat)["sexm"])

# estimated logistic rate ratio (same for males and females)
rr <- exp(-coef(rat_strat)["rx"])
exp(-confint(rat_strat)["rx", ])

# estimated shape parameters
1 / rat_strat$scale
shape_f <- 1 / rat_strat$scale["f"]
shape_m <- 1 / rat_strat$scale["m"]

# estimated odds ratios (constant in a log-logistic AFT model)
or_f <- rr^shape_f
or_m <- rr^shape_m

# residual confounding example
# simulate censored Weibull with different shapes but constant rate ratio
n <- 10000
fail0f <- rweibull(3 * n, shape = .5, scale = 1)
fail1f <- rweibull(n, shape = .5, scale = 1 / 2)
fail0m <- rweibull(n, shape = 2, scale = 1)
fail1m <- rweibull(3 * n, shape = 2, scale = 1 / 2)

fail <- c(fail0f, fail1f, fail0m, fail1m)
cens <- 2
time <- pmin(fail, cens)
event <- ifelse(cens < fail, 0, 1)
x <- rep(c(0, 0, 0, 1, 0, 1, 1, 1), each = n)
male <- rep(c(0, 1), each = 4 * n)
wdat <- data.frame(time = time, event = event, x = x, male = male)
```

Listing 19.2 strat-cox.R

```
## Stratified Cox model

# load R packages
library(survival)

# unstratified Cox model and Nelson-Aalen estimator
unstrat <- coxph(Surv(time, status) ~ rx + sex, data = rats)
summary(unstrat)
unstrat_na <- survfit(unstrat, stype = 2, ctype = 2, conf.type = "log-log",
                     newdata = data.frame(rx = 0, sex = c("f", "m")))

# stratified Cox model and Nelson-Aalen estimator
strat <- coxph(Surv(time, status) ~ rx + strata(sex), data = rats)
summary(strat)
strat_na <- survfit(strat, stype = 2, ctype = 2, conf.type = "log-log",
                   newdata = data.frame(rx = 0))

# plot of stratified and unstratified cumulative hazard estimates
plot(unstrat_na, fun = "cumhaz", lty = "dashed",
     xlab = "Weeks since treatment", ylab = "Cumulative hazard")
grid()
lines(strat_na, fun = "cumhaz", conf.int = FALSE)
legend("topleft", bg = "white", lty = c("solid", "dashed"),
     legend = c("Stratified model", "Unstratified model"))

# unstratified and stratified log-rank tests
survdiff(Surv(time, status) ~ rx + sex, data = rats)
survdiff(Surv(time, status) ~ rx + strata(sex), data = rats)
```

20 Matching in Cohort and Case-Control Studies

For an observational study to compare two groups with respect to a dichotomous outcome variable, the design strategy of matching observational units with respect to a potential confounding variable X is compared with the strategy of selecting independent samples with possible poststratification on X for bias control. ...It is found that proper understanding requires that the prospective and the retrospective study designs be separately considered, and that in certain circumstances the effect of matching on design efficiency is entirely different for the two designs. (Samuels 1981)

When exchangeability (no confounding) and the analytic cohort condition (no selection bias) hold given a set of variables C , then the conditional estimates of risk in the exposed and unexposed in the study sample are unbiased estimates of the causal risks of disease under exposure and no exposure in the eligible population. We have several ways to summarize the causal effect of exposure on disease:

- If there is no effect measure modification on the desired scale, we can use stratified analysis (e.g., Mantel-Haenszel) or a regression model to estimate a common conditional measure of association given C .
- If there is effect measure modification, we can estimate stratum-specific conditional measures of association given C . This can be done nonparametrically or using a regression model with interaction terms for X and C .
- Whether or not there is effect modification, we can use standardization to estimate marginal causal risks of disease. These marginal causal risks can be used to estimate marginal causal effects. If there is no effect measure modification and the measure is collapsible, the standardized measure of association will equal the common conditional measure of association given C .

If the case-control condition holds but not the cohort condition, then our only choice is to estimate conditional odds ratios given C . Depending on the selection of controls, these can approximate conditional risk ratios or hazard ratios given C .

Sometimes C may consist of more than one variable. When we match on multiple covariates (e.g., age and biological sex), we match participants who have similar values for all of the

matching variables. When C has many levels, some strata may have no members from one of the two exposure groups. This can result in estimates that do not converge or have high variance.

Matching can be used to ensure that we have individuals from both exposure or treatment groups in all levels of C . When we match in a cohort study, we ensure that there is at least one individual from both treatment or exposure groups in each level of C . When we match in a case-control study, we ensure that there is at least one case and one control from all levels of C . It turns out that matching has different consequences in cohort and case-control studies:

- In a cohort study, matching is generally used to prevent confounding by ensuring that both exposure or treatment groups have the same distribution of C . It is often not necessary to stratify or standardize by C , except possibly to generalize to the eligible population.
- In a case-control study, matching does not prevent confounding by C . Instead, it is used to improve statistical efficiency in an analysis stratified by C .

Causal graphs can be used to understand these differences. In all cases, it is important to weigh the advantages and disadvantages of matching against those of analytical control for confounding through stratification or weighting.

20.0.1 Matching in a cohort study

In a matched cohort study, matching ensures that the exposure groups have the same distribution of C . If exposure is less common than non-exposure, then we choose one or more non-exposed individuals from the same stratum of C for each exposed individual. Figure 20.1 shows a single-world intervention graph (SWIG) for a cohort study matched on a confounder C . The cohort condition holds given C because $S^x \perp\!\!\!\perp D^x \mid X, C$.




Figure 20.1: SWIG for selection a cohort study matched on a confounder C . Exchangeability and the analytic cohort condition hold given C . Because of matching, both exposure groups have the same distribution of C .

Matching ensures that the distribution of C is the same in both exposure groups and in the study sample, so a crude measure of association based on disease risks is implicitly standardized to this distribution of C . Therefore, adjustment for C is not necessary to estimate the marginal causal effect of X on D in the study sample (i.e., in a standard population with the same distribution of C as the study sample). However, generalization to the eligible population (or to the exposed or unexposed groups in the eligible population) can require adjustment for C if there is effect measure modification or noncollapsibility. If C is conditionally independent of S given $X = 1$, then the distribution of C in the study sample is the same as the distribution of C among the exposed in the eligible population. In this, the marginal causal effect in the study sample is a consistent estimate of the marginal causal effect among the exposed in the eligible population.

20.0.2 Matching on non-confounders

If we remove the edge from C to X in Figure 20.1, then C is associated with D but not a confounder. Because of the path $S^x \leftarrow C \rightarrow D^x$, we still need to condition on C to prevent selection bias. However, this is necessary only because of the path $C \rightarrow S^x$ caused by matching. The result is the same as before: The causal effect of X on D in a standard population with the same distribution of C as the study sample can be estimated without adjustment for C , but generalization to the eligible population requires adjustment for C if there is effect modification or noncollapsibility.

If we remove the edge from C to D in Figure~??, then C is associated with X but not a confounder. In this case, the cohort condition holds without conditioning on C , so no adjustment for C is necessary for estimation of marginal causal effects or generalization to the eligible population.

20.0.3 Matching and efficiency

In a clinical trial, **blocking** refers to assigning treatment within groups defined by baseline variables. In *pairwise blocking*, participants are grouped into pairs based on baseline variables and treatment is assigned to one person in each pair. Blocking usually improves the efficiency of a clinical trial when the blocks are defined by risk factors for disease.

By analogy to blocking in a clinical trial, it is often thought that matching will improve the efficiency of a cohort study. However, Greenland and Morgenstern (1990) showed that this is not always the case. In particular, matching in a cohort study can change the distribution of C in the study sample in a way that increases the variance of the effect estimate. By contrast, blocking never changes the distribution of C in a clinical trial. The key difference is that blocking in a clinical trial is a method of treatment assignment while matching in an observational cohort study is a method of selecting study participants. Matching can increase

or decrease efficiency in a cohort study, and it will almost always make participant selection more difficult.

20.1 Matching in a case-control study

Figure 20.2 shows a SWIG for a case-control study matched on a confounder C . The cohort condition fails because S is a child of D , but the case-control condition holds given C because $S^d \perp\!\!\!\perp X \mid D, C$. It follows that our measure of association must be based on the prevalence of exposure in cases and controls and that we must control for C to avoid selection bias.




Figure 20.2: SWIG for a case-control study matched on a confounder C . The analytic case-control condition holds given C . Because of matching, the case and control groups have the same distribution of C .

In a case-control study, matching ensures that the distribution of C is equal in the case and control groups, not in the exposure groups. Because the exposure groups have different distributions of C , the crude odds ratio cannot be interpreted as a causal effect of exposure within the study sample. The C -conditional odds ratios have a causal interpretation, and they are identical (up to random variation) in the study sample and the eligible population. Away from the null, the C -conditional odds ratios in the eligible population differ from the C -marginal odds ratio in the study sample even when there is no effect modification, so adjustment for C is necessary.

20.1.1 Matching on non-confounders

If we remove the edge from C to X in Figure 20.2, then C is associated with D but not a confounder. Thus, both the marginal odds ratio and conditional odds ratios given C in the eligible population have causal interpretations. Conditioning on the collider at D opens the path $X \rightarrow D \leftarrow C \rightarrow S^d$, so the case-control condition holds only given C . Away from the null, the marginal odds ratios and conditional odds ratios given C in the eligible population differ even when there is no effect modification by C . When there is no effect modification, the conditional odds ratio given C in the eligible population matches the marginal odds ratio

in the study sample. Thus, matching on C is harmful if the marginal odds ratio in the eligible population is of primary interest. Under the null, the case-control condition holds without conditioning on C so no adjustment for C is necessary.

If we remove the edge from C to D in Figure 20.2, then C is associated with X but not a confounder. However, the case-control condition holds only given C because of the path $X \leftarrow C \rightarrow S^d$. When there is no effect modification by C , the marginal odds ratio and conditional odds ratios given C in the eligible population are equal. In the study sample, the marginal odds ratio and conditional odds ratio given C differ away from the null even when there is no effect modification. Under the null, the marginal odds ratios are the same (up to random variation) in the study sample and the eligible population. Thus, adjustment for C is necessary away from the null but not under the null.

20.1.2 Matching and efficiency

In a case-control study, matching improves efficiency by ensuring that there is balance between cases and controls in the strata defined by C . This can improve efficiency even when these strata are not sparse. Earlier, we saw that the power of a case-control study is maximized for a fixed total number of participants when we have equal numbers of cases and controls (Jewell 2003). Because controls are generally easier to find than cases of a rare disease, it is common to enroll 3–5 controls per case. Matching ensures that no strata of C contain only cases, in which case they would be discarded in a Mantel-Haenszel estimate (and possibly in a GLM as well). Although matching on a confounder consistently improves the efficiency of case-control studies, its use must be balanced against the additional difficulty of finding controls and the availability of analytical methods such as stratification and weighting that can control for confounding.

Matching on a non-confounder necessitates a stratified analysis that can lead to a loss of statistical efficiency compared to a non-matched case control study with the same number of participants.

20.2 Overmatching

Matching can be useful, but it can also be harmful. Harmful matching is called **overmatching**, and it takes three forms (Rothman, Greenland, and Lash 2008): matching that reduces statistical efficiency, matching that induces bias, and matching that reduces cost efficiency.

- Statistical efficiency is about the precision of a causal effect estimate achieved with a given total number of participants. In a cohort study, matching prevents confounding but its effect on statistical efficiency can be difficult to predict. In a case-control study, it consistently improves statistical efficiency for a given total number of participants, but it might harm overall efficiency if it leads to a lower total number of participants. It also

necessitates a stratified analysis, which can reduce statistical efficiency if stratification by C would not otherwise be needed.

- Matching on a causal intermediate or a collider can cause bias just like stratifying on a causal intermediate or a collider. Matching should generally be done only on variables that are likely to be important confounders.
- Cost efficiency is about the precision of a causal effect estimate achieved with a given total cost of a study. Some methods of recruiting controls lend themselves naturally to matching by neighborhood, family, friends etc. However, the potential for bias or loss of statistical efficiency should always be balanced against the convenience of control recruitment. It is also important to calibrate the closeness of the matching needed to control confounding. Requiring extremely close matches can greatly increase cost with little improvement in control for confounding or precision.

Listing 20.1 matching-swig-coh.R

```
# DAG for cohort study matched on a confounder

# load R packages
library(dagitty)
library(ggdag, warn.conflicts = FALSE)
library(ggplot2)

# define the DAG
cohort <- dagitty('dag{
  C -> D
  C -> S
  C -> X
  x -> D
  x -> S
}')

# generate data for plotting DAG using ggplot()
# Use geom_dag_label() for adjusted variables to get a box around them.
coordinates(cohort) <- list(x = c(C = 0, X = 0.9, x = 1.1, S = 2, D = 3),
                           y = c(C = 0, X = 0, x = 0, S = -0.5, D = 0))
cohort_dat <- control_for(cohort, c("C", "x"), activate_colliders = FALSE)
label(cohort_dat) <- c("C" = "C", "X" = "X", "x" = "x",
                      "D" = "Dx", "S" = "Sx")
cohort_adj <- filter(cohort_dat, adjusted == "adjusted")
cohort_unadj <- filter(cohort_dat, adjusted == "unadjusted")

# plot DAG with ggplot() to allow for boxes and curved arrows
(ggplot(cohort_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 + coord_equal()
 + geom_dag_label(data = cohort_adj, parse = TRUE, size = 8, fill = NA,
                  label.padding = unit(0.15, "lines"))
 + geom_dag_text(aes(label = label), data = cohort_unadj, parse = TRUE,
                  color = "black", size = 8)
 + geom_dag_edges_arc(curvature = c(0.25, -0.15, 0, 0, 0))
 + annotate("text", x = 1, y = 0.01, size = 8, label = "|")
)
```

Listing 20.2 matching-swig-cc.R

```
# DAG for cohort study matched on a confounder

# load R packages
library(dagitty)
library(ggdag)
library(ggplot2)

# define the DAG
casecontrol <- dagitty('dag{
  C -> D
  C -> S
  C -> X
  d -> S
  X -> D
}')

# generate data for plotting DAG using ggplot()
# Use geom_dag_label() for adjusted variables to get a box around them.
coordinates(casecontrol) <- list(x = c(C = 0, X = 0.9, D = 1.9, d = 2.1, S = 3),
                                y = c(C = 0, X = 0, D = 0, d = 0, S = -0.4))
cc_dat <- control_for(casecontrol, c("C", "d"), activate_colliders = FALSE)
label(cc_dat) <- c("C" = "C", "X" = "X", "x" = "x", "D" = "D",
                  "d" = "d", "S" = "S~d")
cc_adj <- filter(cc_dat, adjusted == "adjusted")
cc_unadj <- filter(cc_dat, adjusted == "unadjusted")

# plot DAG with ggplot() to allow for boxes and curved arrows
(ggplot(cc_dat, aes(x = x, y = y, xend = xend, yend = yend))
 + theme_dag_gray_grid()
 + coord_equal()
 + geom_dag_label(data = cc_adj, parse = TRUE, size = 8, fill = NA,
                  label.padding = unit(0.15, "lines"))
 + geom_dag_text(aes(label = label), data = cc_unadj, parse = TRUE,
                  color = "black", size = 8)
 + geom_dag_edges_arc(curvature = c(0.25, -0.1, 0, 0, 0))
 + annotate("text", x = 2, y = 0.01, size = 8, label = "|")
)
```

References

- Aalen, Odd. 1978. "Nonparametric Inference for a Family of Counting Processes." *The Annals of Statistics* 6: 701–26.
- Aalen, Odd, Ørnulf Borgan, and Håkon Gjessing. 2008. *Survival and Event History Analysis: A Process Point of View*. Springer Science & Business Media.
- Agresti, Alan. 2013. *Categorical Data Analysis*. Third. Vol. 792. John Wiley & Sons.
- Agresti, Alan, and Brent A Coull. 1998. "Approximate Is Better Than 'Exact' for Interval Estimation of Binomial Proportions." *The American Statistician* 52 (2): 119–26.
- Agresti, Alan, and Yongyi Min. 2005. "Frequentist Performance of Bayesian Confidence Intervals for Comparing Proportions in 2×2 Contingency Tables." *Biometrics* 61 (2): 515–23.
- Aitchison, John, and SD Silvey. 1958. "Maximum-Likelihood Estimation of Parameters Subject to Restraints." *The Annals of Mathematical Statistics* 29: 813–28.
- Albert, Adelin. 1982. "On the Use and Computation of Likelihood Ratios in Clinical Chemistry." *Clinical Chemistry* 28 (5): 1113–19.
- Alho, Juha M. 1992. "On Prevalence, Incidence, and Duration in General Stable Populations." *Biometrics* 48 (2): 587–92.
- Altman, Douglas G, Kenneth F Schulz, David Moher, Matthias Egger, Frank Davidoff, Diana Elbourne, Peter C Gøtzsche, Thomas Lang, and CONSORT Group. 2001. "The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration." *Annals of Internal Medicine* 134 (8): 663–94.
- Altshuler, Bernard. 1970. "Theory for the Measurement of Competing Risks in Animal Experiments." *Mathematical Biosciences* 6: 1–11.
- Appleton, David R, Joyce M French, and Mark P J Vanderpump. 1996. "Ignoring a Covariate: An Example of Simpson's Paradox." *The American Statistician* 50 (4): 340–41.
- Baduashvili, Amiran, Arthur T Evans, and Todd Cutler. 2020. "How to Understand and Teach p-Values: A Diagnostic Test Framework." *Journal of Clinical Epidemiology* 122: 49–55.
- Bamber, Donald. 1975. "The Area Above the Ordinal Dominance Graph and the Area Below the Receiver Operating Characteristic Graph." *Journal of Mathematical Psychology* 12 (4): 387–415.
- Bayes, Thomas. 1763. "LII. An Essay Towards Solving a Problem in the Doctrine of Chances. By the Late Rev. Mr. Bayes, FRS Communicated by Mr. Price, in a Letter to John Canton, AMFRS." *Philosophical Transactions of the Royal Society of London* 53: 370–418.
- Bengtsson, Ewert, and Patrik Malm. 2014. "Screening for Cervical Cancer Using Automated Analysis of PAP-Smears." *Computational and Mathematical Methods in Medicine* 2014:

842037.

- Berger, James O, and Thomas Sellke. 1987. "Testing a Point Null Hypothesis: The Irreconcilability of p Values and Evidence." *Journal of the American Statistical Association* 82 (397): 112–22.
- Berkson, Joseph. 1942. "Tests of Significance Considered as Evidence." *Journal of the American Statistical Association* 37 (219): 325–35.
- . 1944. "Application of the Logistic Function to Bio-Assay." *Journal of the American Statistical Association* 39 (227): 357–65.
- . 1946. "Limitations of the Application of Fourfold Table Analysis to Hospital Data." *Biometrics Bulletin* 2 (3): 47–53.
- Bibbins-Domingo, Kirsten, and Alex Helman, eds. 2022. *Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups*. National Academies of Sciences, Engineering,; Medicine (National Academies Press).
- Birnbaum, Allan. 1964. "Median-Unbiased Estimators." *Bulletin of Mathematical Statistics* 11: 25–34.
- Blaker, Helge. 2000. "Confidence Curves and Improved Exact Confidence Intervals for Discrete Distributions." *Canadian Journal of Statistics* 28 (4): 783–98.
- Blumberg, Mark S. 1957. "Evaluating Health Screening Procedures." *Operations Research* 5 (3): 351–60.
- Boos, Dennis D, and Leonard A Stefanski. 2013. *Essential Statistical Inference*. Springer.
- Borgan, Ørnulf, Larry Goldstein, and Bryan Langholz. 1995. "Methods for the Analysis of Sampled Cohort Data in the Cox Proportional Hazards Model." *The Annals of Statistics*, 1749–78.
- Bostrom, RC, HS Sawyer, and WE Tolles. 1959. "Instrumentation for Automatically Pre-screening Cytological Smears." *Proceedings of the IRE* 47 (11): 1895–1900.
- Breslow, NE, NE Day, KT Halvorsen, RL Prentice, and C Sabai. 1978. "Estimation of Multiple Relative Risk Functions in Matched Case-Control Studies." *American Journal of Epidemiology* 108 (4): 299–307.
- Breslow, Norman. 1974. "Covariance Analysis of Censored Survival Data." *Biometrics* 30 (1): 89–99.
- Breslow, Norman E. 1972. "Contribution to Discussion of Paper by DR Cox." *Journal of the Royal Statistical Society: Series B (Methodological)* 34: 216–17.
- Brittain, Erica, James J Schlesselman, and Bruce V Stadel. 1981. "Cost of Case-Control Studies." *American Journal of Epidemiology* 114 (2): 234–43.
- Bross, Irwin. 1954. "Misclassification in 2 x 2 Tables." *Biometrics* 10 (4): 478–86.
- Brown, Lawrence D, T Tony Cai, and Anirban DasGupta. 2001. "Interval Estimation for a Binomial Proportion." *Statistical Science* 16 (2): 101–17.
- . 2003. "Interval Estimation in Exponential Families." *Statistica Sinica* 13: 19–49.
- Brumback, Babette, and Arthur Berg. 2008. "On Effect-Measure Modification: Relationships Among Changes in the Relative Risk, Odds Ratio, and Risk Difference." *Statistics in Medicine* 27 (18): 3453–65.
- Buell, Philip, and John E Dunn Jr. 1964. "The Dilution Effect of Misclassification." *American Journal of Public Health* 54 (4): 598–602.

- Campbell, Donald T. 1957. "Factors Relevant to the Validity of Experiments in Social Settings." *Psychological Bulletin* 54 (4): 297.
- Cheever, David W. 1861. "The Value and the Fallacy of Statistics in the Observation of Disease." *The Boston Medical and Surgical Journal* 63 (24): 476–83.
- Chung, Kai Lai. 2000. *A Course in Probability Theory*. Third. Elsevier.
- Clarke, RD. 1946. "An Application of the Poisson Distribution." *Journal of the Institute of Actuaries* 72 (3): 481–81.
- Clayton, David, and Michael Hills. 1993. *Statistical Models in Epidemiology*. Oxford University Press.
- Clopper, Charles J, and Egon S Pearson. 1934. "The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial." *Biometrika* 26 (4): 404–13.
- Cochran, William G. 1954. "Some Methods for Strengthening the Common χ^2 Tests." *Biometrics* 10 (4): 417–51.
- Cohen, Geoffrey R, and Shu-Ying Yang. 1994. "Mid-p Confidence Intervals for the Poisson Expectation." *Statistics in Medicine* 13 (21): 2189–2203.
- Cohen, I Bernard. 1984. "Florence Nightingale." *Scientific American* 250 (3): 128–37.
- Cole, Philip, and Brian MacMahon. 1971. "Attributable Risk Percent in Case-Control Studies." *British Journal of Preventive & Social Medicine* 25 (4): 242.
- Copeland, Karen T, Harvey Checkoway, Anthony J McMichael, and Robert H Holbrook. 1977. "Bias Due to Misclassification in the Estimation of Relative Risk." *American Journal of Epidemiology* 105 (5): 488–95.
- Cornfield, Jerome. 1951. "A Method of Estimating Comparative Rates from Clinical Data; Applications to Cancer of the Lung, Breast, and Cervix." *Journal of the National Cancer Institute* 11: 1269–75.
- . 1954. "Statistical Relationships and Proof in Medicine." *The American Statistician* 8: 19–21.
- Cornfield, Jerome, William Haenszel, E Cuyler Hammond, Abraham M Lilienfeld, Michael B Shimkin, and Ernst L Wynder. 1959. "Smoking and Lung Cancer: Recent Evidence and a Discussion of Some Questions." *Journal of the National Cancer Institute* 22 (1): 173–203.
- Correa-Villaseñor, Adolfo, Walter F Stewart, Francisco Franco-Marina, and Hui Seacat. 1995. "Bias from Nondifferential Misclassification in Case-Control Studies with Three Exposure Levels." *Epidemiology* 6 (3): 276–81.
- Cox, David R. 1958. "The Regression Analysis of Binary Sequences." *Journal of the Royal Statistical Society Series B: Statistical Methodology* 20 (2): 215–32.
- . 1972. "Regression Models and Life-Tables." *Journal of the Royal Statistical Society: Series B (Methodological)* 34 (2): 187–202.
- Cox, David R, and E Joyce Snell. 1968. "A General Definition of Residuals." *Journal of the Royal Statistical Society: Series B (Methodological)* 30 (2): 248–65.
- Cramér, Harald. 1946. *Mathematical Methods of Statistics*. Princeton University Press.
- Dahabreh, Issa J, and Miguel A Hernán. 2019. "Extending Inferences from a Randomized Trial to a Target Population." *European Journal of Epidemiology* 34 (8): 719–22.
- Dawid, A Philip. 1979. "Conditional Independence in Statistical Theory." *Journal of the Royal Statistical Society: Series B (Methodological)* 41 (1): 1–15.

- Diamond, George A, and James S Forrester. 1983. "Clinical Trials and Statistical Verdicts: Probable Grounds for Appeal." *Annals of Internal Medicine* 98 (3): 385–94.
- Doll, Richard, and Austin Bradford Hill. 1950. "Smoking and Carcinoma of the Lung." *British Medical Journal* 2 (4682): 739.
- Dorn, Harold F. 1959. "Tobacco Consumption and Mortality from Cancer and Other Diseases." *Public Health Reports* 74 (7): 581.
- Dosemeci, Mustafa, Sholom Wacholder, and Jay H Lubin. 1990. "Does Nondifferential Misclassification of Exposure Always Bias a True Effect Toward the Null Value?" *American Journal of Epidemiology* 132 (4): 746–48.
- Duane, Simon, Anthony D Kennedy, Brian J Pendleton, and Duncan Roweth. 1987. "Hybrid Monte Carlo." *Physics Letters B* 195 (2): 216–22.
- Dunn Jr, John E. 1962. "The Use of Incidence and Prevalence in the Study of Disease Development in a Population." *American Journal of Public Health* 52 (7): 1107–18.
- Edwards, Ward, Harold Lindman, and Leonard J Savage. 1963. "Bayesian Statistical Inference for Psychological Research." *Psychological Review* 70 (3): 193–242.
- Efron, Bradley. 1977. "The Efficiency of Cox's Likelihood Function for Censored Data." *Journal of the American Statistical Association* 72 (359): 557–65.
- Efron, Bradley, and David V Hinkley. 1978. "Assessing the Accuracy of the Maximum Likelihood Estimator: Observed Versus Expected Fisher Information." *Biometrika* 65 (3): 457–83.
- Efron, Bradley, and Robert J Tibshirani. 1994. *An Introduction to the Bootstrap*. Chapman & Hall/CRC.
- Elandt-Johnson, Regina C. 1975. "Definition of Rates: Some Remarks on Their Use and Misuse." *American Journal of Epidemiology* 102 (4): 267–71.
- Elm, Erik von, Douglas G Altman, Matthias Egger, Stuart J Pocock, Peter C Gøtzsche, and Jan P Vandenbroucke. 2007. "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies." *The Lancet* 370 (9596): 1453–57.
- Evans, Alfred S. 1973. "Pettenkofer Revisited: The Life and Contributions of Max von Pettenkofer (1818-1901)." *The Yale Journal of Biology and Medicine* 46 (3): 161.
- . 1976. "Causation and Disease: The Henle-Koch Postulates Revisited." *The Yale Journal of Biology and Medicine* 49 (2): 175.
- Fagan, Terrence J. 1975. "Nomogram for Bayes's Theorem." *New England Journal of Medicine* 293 (5): 257.
- Farr, William. 1838. "On Prognosis." *British Medical Almanack* Supplement: 199–216.
- Fay, Michael P. 2010. "Confidence Intervals That Match Fisher's Exact or Blaker's Exact Tests." *Biostatistics* 11 (2): 373–74.
- Fisher, Ronald A. 1922. "On the Interpretation of χ^2 from Contingency Tables, and the Calculation of p." *Journal of the Royal Statistical Society* 85 (1): 87–94.
- . 1935. "The Logic of Inductive Inference." *Journal of the Royal Statistical Society* 98 (1): 39–82.
- Fisk, Peter R. 1961. "The Graduation of Income Distributions." *Econometrica: Journal of the Econometric Society* 29 (2): 171–85.

- Fleming, Thomas R, and David P Harrington. 1984. "Nonparametric Estimation of the Survival Distribution in Censored Data." *Communications in Statistics-Theory and Methods* 13 (20): 2469–86.
- . 2005. *Counting Processes and Survival Analysis*. Vol. 625. John Wiley & Sons.
- Freedman, David A. 2007. "How Can the Score Test Be Inconsistent?" *The American Statistician* 61 (4): 291–95.
- Freedman, Laurence S, Arthur Schatzkin, and Yohanan Wax. 1990. "The Impact of Dietary Measurement Error on Planning Sample Size Required in a Cohort Study." *American Journal of Epidemiology* 132 (6): 1185–95.
- Freeman, Jonathan, and George B Hutchison. 1980. "Prevalence, Incidence and Duration." *American Journal of Epidemiology* 112 (5): 707–23.
- Gail, Mitchell, Roger Williams, David P Byar, Charles Brown, et al. 1976. "How Many Controls?" *Journal of Chronic Diseases* 29 (11): 723–31.
- Garwood, F. 1936. "Fiducial Limits for the Poisson Distribution." *Biometrika* 28 (3/4): 437–42.
- Gelman, Andrew, John B Carlin, Hal S Stern, David B Dunson, Aki Vehtari, and Donald B Rubin. 2014. *Bayesian Data Analysis*. Third. CRC press.
- Goldberg, Judith D. 1975. "The Effects of Misclassification on the Bias in the Difference Between Two Proportions and the Relative Odds in the Fourfold Table." *Journal of the American Statistical Association* 70 (351): 561–67.
- Gompertz, Benjamin. 1825. "XXIV. On the Nature of the Function Expressive of the Law of Human Mortality, and on a New Mode of Determining the Value of Life Contingencies." *Philosophical Transactions of the Royal Society of London* 115: 513–83.
- Greenland, Sander. 1996. "Absence of Confounding Does Not Correspond to Collapsibility of the Rate Ratio or Rate Difference." *Epidemiology* 7 (5): 498–501.
- . 1998. "Probability Logic and Probabilistic Induction." *Epidemiology* 9 (3): 322–32.
- . 2006. "Bayesian Perspectives for Epidemiological Research: I. Foundations and Basic Methods." *International Journal of Epidemiology* 35 (3): 765–75.
- Greenland, Sander, and Hal Morgenstern. 1990. "Matching and Efficiency in Cohort Studies." *American Journal of Epidemiology* 131 (1): 151–59.
- Greenland, Sander, Judea Pearl, and James M Robins. 1999a. "Causal Diagrams for Epidemiologic Research." *Epidemiology* 10 (1): 37–48.
- . 1999b. "Confounding and Collapsibility in Causal Inference." *Statistical Science* 14 (1): 29–46.
- Greenland, Sander, and Charles Poole. 2013. "Living with p Values: Resurrecting a Bayesian Perspective on Frequentist Statistics." *Epidemiology* 24 (1): 62–68.
- Greenland, Sander, and James M Robins. 1986. "Identifiability, Exchangeability, and Epidemiological Confounding." *International Journal of Epidemiology* 15 (3): 413–19.
- . 1988. "Conceptual Problems in the Definition and Interpretation of Attributable Fractions." *American Journal of Epidemiology* 128 (6): 1185–97.
- Greenland, Sander, Stephen J Senn, Kenneth J Rothman, John B Carlin, Charles Poole, Steven N Goodman, and Douglas G Altman. 2016. "Statistical Tests, p Values, Confidence Intervals, and Power: A Guide to Misinterpretations." *European Journal of Epidemiology*

- 31 (4): 337–50.
- Greenland, Sander, and Duncan C Thomas. 1982. “On the Need for the Rare Disease Assumption in Case-Control Studies.” *American Journal of Epidemiology* 116 (3): 547–53.
- Greenwood, Major. 1926. “The Natural Duration of Cancer.” *Reports on Public Health and Medical Subjects* 33: 1–26.
- Gullen, Warren H, Jacob E Bearman, and Eugene A Johnson. 1968. “Effects of Misclassification in Epidemiologic Studies.” *Public Health Reports* 83 (11): 914–18.
- Hanley, James A, and Barbara J McNeil. 1982. “The Meaning and Use of the Area Under a Receiver Operating Characteristic (ROC) Curve.” *Radiology* 143 (1): 29–36.
- Hastings, W Keith. 1970. “Monte Carlo Sampling Methods Using Markov Chains and Their Applications.” *Biometrika* 57 (1): 97–109.
- Herbst, Arthur L, Howard Ulfelder, and David C Poskanzer. 1971. “Adenocarcinoma of the Vagina: Association of Maternal Stilbestrol Therapy with Tumor Appearance in Young Women.” *New England Journal of Medicine* 284 (16): 878–81.
- Hernán, Miguel Á, Sonia Hernández-Díaz, and James M Robins. 2004. “A Structural Approach to Selection Bias.” *Epidemiology* 15 (5): 615–25.
- Hernán, Miguel A., and James M. Robins. 2023. *Causal Inference: What If*. Chapman & Hall/CRC.
- Hill, Sir Austin Bradford. 1965. “The Environment and Disease: Association or Causation?” *Proceedings of the Royal Society of Medicine* 58: 295–300.
- Howard-Jones, Norman. 1973. “Gelsenkirchen Typhoid Epidemic of 1901, Robert Koch, and the Dead Hand of Max von Pettenkofer.” *British Medical Journal* 1 (5845): 103.
- Hurwitz, Eugene S, Michael J Barrett, Dennis Bregman, Walter J Gunn, Paul Pinsky, Lawrence B Schonberger, Joseph S Drage, et al. 1987. “Public Health Service Study of Reye’s Syndrome and Medications: Report of the Main Study.” *JAMA* 257 (14): 1905–11.
- Irwin, JO et al. 1935. “Tests of Significance for Differences Between Percentages Based on Small Numbers.” *Metron* 12 (2): 84–94.
- Jeffreys, Harold. 1946. “An Invariant Form for the Prior Probability in Estimation Problems.” *Proceedings of the Royal Society of London. Series A. Mathematical and Physical Sciences* 186 (1007): 453–61.
- Jewell, Nicholas P. 2003. *Statistics for Epidemiology*. CRC Press.
- Johansen, Søren. 1983. “An Extension of Cox’s Regression Model.” *International Statistical Review* 51 (2): 165–74.
- Kalbfleisch, John D, and Ross L Prentice. 2011. *The Statistical Analysis of Failure Time Data*. John Wiley & Sons.
- Kaplan, Edward L, and Paul Meier. 1958. “Nonparametric Estimation from Incomplete Observations.” *Journal of the American Statistical Association* 53 (282): 457–81.
- Katz, DJSM, J Baptista, SP Azen, and MC Pike. 1978. “Obtaining Confidence Intervals for the Risk Ratio in Cohort Studies.” *Biometrics*, 469–74.
- Keiding, Niels. 1991. “Age-Specific Incidence and Prevalence: A Statistical Perspective.” *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 154 (3): 371–96.
- Kenah, Eben. 2023. “A Potential Outcomes Approach to Selection Bias.” *Epidemiology* 34 (6): 865–72.

- . 2024. “Rothman Diagrams: The Geometry of Confounding and Standardization.” *International Journal of Epidemiology* 53 (6): dyae139.
- Kenward, Michael G, and Geert Molenberghs. 1998. “Likelihood Based Frequentist Inference When Data Are Missing at Random.” *Statistical Science* 13 (3): 236–47.
- Kessel, Elton. 1962. “Diabetes Detection: An Improved Approach.” *Journal of Chronic Diseases* 15 (12): 1109–21.
- King, Aaron A, Edward L Ionides, Mercedes Pascual, and Menno J Bouma. 2008. “Inapparent Infections and Cholera Dynamics.” *Nature* 454 (7206): 877–80.
- Kupper, LL, AJ McMichael, and R Spirtas. 1975. “A Hybrid Epidemiologic Study Design Useful in Estimating Relative Risk.” *Journal of the American Statistical Association* 70 (351a): 524–28.
- L’Abbé, Kristan A, Allan S Detsky, and Keith O’Rourke. 1987. “Meta-Analysis in Clinical Research.” *Annals of Internal Medicine* 107 (2): 224–33.
- Lancaster, H Oliver. 1961. “Significance Tests in Discrete Distributions.” *Journal of the American Statistical Association* 56 (294): 223–34.
- Laplace, Pierre Simon. 1820. *Théorie Analytique Des Probabilités*. Vol. 7. Courcier.
- Le Cam, Lucien. 1953. “On Some Asymptotic Properties of Maximum Likelihood Estimates and Related Bayes’ Estimates.” *University of California Publications in Statistics* 1 (11): 277–330.
- Levin, M L. 1953. “The Occurrence of Lung Cancer in Man.” *Acta-Unio Internationalis Contra Cancrum* 9 (3): 531–41.
- Liddell, FDK, JC McDonald, and DC Thomas. 1977. “Methods of Cohort Analysis: Appraisal by Application to Asbestos Mining.” *Journal of the Royal Statistical Society: Series A (General)* 140 (4): 469–83.
- Lilienfeld, Abraham M. 1959. “‘On the Methodology of Investigations of Etiologic Factors in Chronic Diseases’—Some Comments.” *Journal of Chronic Diseases* 10 (1): 41–46.
- Lusted, Lee B. 1971a. “Decision-Making Studies in Patient Management.” *New England Journal of Medicine* 284 (8): 416–24.
- . 1971b. “Signal Detectability and Medical Decision-Making.” *Science* 171 (3977): 1217–19.
- . 1984. “ROC Recollected.” *Medical Decision Making* 4: 131–35.
- MacMahon, Brian, and William D Terry. 1958. “Application of Cohort Analysis to the Study of Time Trends in Neoplastic Disease.” *Journal of Chronic Diseases* 7 (1): 24–35.
- Makeham, William Matthew. 1860. “On the Law of Mortality and the Construction of Annuity Tables.” *The Assurance Magazine, and Journal of the Institute of Actuaries* 8 (6): 301–10.
- Mantel, Nathan. 1966. “Evaluation of Survival Data and Two New Rank Order Statistics Arising in Its Consideration.” *Cancer Chemotherapy Reports* 50 (3): 163–70.
- Mantel, Nathan, and William Haenszel. 1959. “Statistical Aspects of the Analysis of Data from Retrospective Studies of Disease.” *Journal of the National Cancer Institute* 22 (4): 719–48.
- McCormack, William M, MD Shafiqul Islam, and Md Fahimuddin. 1969. “A Community Study of Inapparent Cholera Infections.” *American Journal of Epidemiology* 89 (6): 658–64.

- McCullagh, Peter, and J A Nelder. 1989. *Generalized Linear Models*. 2nd ed. Chapman & Hall.
- Metropolis, Nicholas, Arianna W Rosenbluth, Marshall N Rosenbluth, Augusta H Teller, and Edward Teller. 1953. "Equation of State Calculations by Fast Computing Machines." *The Journal of Chemical Physics* 21 (6): 1087–92.
- Meydrech, Edward F, and Lawrence L Kupper. 1978. "Cost Considerations and Sample Size Requirements in Cohort and Case-Control Studies." *American Journal of Epidemiology* 107 (3): 201–5.
- Miettinen, Olli. 1976. "Estimability and Estimation in Case-Referent Studies." *American Journal of Epidemiology* 103 (2): 226–35.
- Miettinen, Olli S. 1969. "Individual Matching with Multiple Controls in the Case of All-or-None Responses." *Biometrics* 25 (2): 339–55.
- . 1974. "Proportion of Disease Caused or Prevented by a Given Exposure, Trait or Intervention." *American Journal of Epidemiology* 99 (5): 325–32.
- Miettinen, Olli S, and E Francis Cook. 1981. "Confounding: Essence and Detection." *American Journal of Epidemiology* 114 (4): 593–603.
- Moher, David, Kenneth F Schulz, Douglas G Altman, Matthias Egger, Frank Davidoff, Diana Elbourne, Peter C. Gøtzsche, Thomas Lang, and CONSORT Group. 2001. "The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials." *Annals of Internal Medicine* 134 (8): 657–62.
- Morabia, Alfredo. 2004. "Epidemiology: An Epistemological Perspective." In *A History of Epidemiologic Methods and Concepts*, edited by Alfredo Morabia, 3–125. Springer.
- Morgenstern, Hal, David G Kleinbaum, and Lawrence L Kupper. 1980. "Measures of Disease Incidence Used in Epidemiologic Research." *International Journal of Epidemiology* 9 (1): 97–104.
- Morgenstern, Hal, and Deborah M Winn. 1983. "A Method for Determining the Sampling Ratio in Epidemiologic Studies." *Statistics in Medicine* 2 (3): 387–96.
- Naimi, Ashley I, and Brian W Whitcomb. 2020. "Estimating Risk Ratios and Risk Differences Using Regression." *American Journal of Epidemiology* 189 (6): 508–10.
- Nam, Jun-Mo. 1973. "Optimum Sample Sizes for the Comparison of the Control and Treatment." *Biometrics* 29: 101–8.
- Neal, Radford M. 1996. "Monte Carlo Implementation." *Bayesian Learning for Neural Networks*, 55–98.
- Nelder, John Ashworth, and Robert W M Wedderburn. 1972. "Generalized Linear Models." *Journal of the Royal Statistical Society Series A: Statistics in Society* 135 (3): 370–84.
- Nelson, Wayne. 1969. "Hazard Plotting for Incomplete Failure Data." *Journal of Quality Technology* 1: 27–52.
- . 1972. "Theory and Applications of Hazard Plotting for Censored Failure Data." *Technometrics* 14 (4): 945–66.
- Newcomb, Polly A, Robert G Norfleet, Barry E Storer, Tanya S Surawicz, and Pam M Marcus. 1992. "Screening Sigmoidoscopy and Colorectal Cancer Mortality." *Journal of the National Cancer Institute* 84 (20): 1572–75.
- Newell, David J. 1962. "Errors in the Interpretation of Errors in Epidemiology." *American*

- Journal of Public Health* 52 (11): 1925–28.
- Newell, DJ. 1963. “Note: Misclassification in 2 x 2 Tables.” *Biometrics* 19 (1): 187–88.
- Neyman, Jerzy, and Egon Sharpe Pearson. 1933. “On the Problem of the Most Efficient Tests of Statistical Hypotheses.” *Philosophical Transactions of the Royal Society of London. Series A, Containing Papers of a Mathematical or Physical Character* 231 (694-706): 289–337.
- Oakes, David. 1981. “Survival Times: Aspects of Partial Likelihood.” *International Statistical Review*, 235–52.
- Paneth, Nigel, Ezra Susser, and Mervyn Susser. 2002. “Origins and Early Development of the Case-Control Study: Part 1, Early Evolution.” *Sozial-Und Präventivmedizin* 47 (5): 282–88.
- Paneth, Nigl, Ezra Susser, and Mervyn Susser. 2002. “Origins and Early Development of the Case-Control Study: Part 2, the Case-Control Study from Lane-Claypon to 1950.” *Sozial-Und Präventivmedizin* 47 (6): 359–65.
- Pearce, Neil. 1993. “What Does the Odds Ratio Estimate in a Case-Control Study?” *International Journal of Epidemiology* 22 (6): 1189–92.
- Pearl, Judea. 1993. “[Bayesian Analysis in Expert Systems]: Comment: Graphical Models, Causality and Intervention.” *Statistical Science* 8 (3): 266–69.
- . 1995. “Causal Diagrams for Empirical Research.” *Biometrika* 82 (4): 669–88.
- . 2009. *Causality*. Second. Cambridge University Press.
- Pearson, Karl. 1900. “On the Criterion That a Given System of Deviations from the Probable in the Case of a Correlated System of Variables Is Such That It Can Be Reasonably Supposed to Have Arisen from Random Sampling.” *The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science* 50 (302): 157–75.
- . 1922. “On the χ^2 Test of Goodness of Fit.” *Biometrika* 14 (1/2): 186–91.
- Peto, Richard. 1972. “Contribution to Discussion of Paper by DR Cox.” *Journal of the Royal Statistical Society: Series B (Methodological)* 34: 202–7.
- Pike, MC, and JT Casagrande. 1979. “Re: ‘cost Considerations and Sample Size Requirements in Cohort and Case-Control Studies.’” *American Journal of Epidemiology* 110 (1): 100–102.
- Pratt, John W. 1965. “Bayesian Interpretation of Standard Inference Statements.” *Journal of the Royal Statistical Society: Series B (Methodological)* 27 (2): 169–203.
- Preston, Samuel H. 1987. “Relations Among Standard Epidemiologic Measures in a Population.” *American Journal of Epidemiology* 126 (2): 336–45.
- Rao, C Radhakrishna. 1945. “Information and Accuracy Attainable in the Estimation of Statistical Parameters.” *Bulletin of the Calcutta Mathematical Society* 37 (3): 81–91.
- . 1948. “Large Sample Tests of Statistical Hypotheses Concerning Several Parameters with Applications to Problems of Estimation.” In *Mathematical Proceedings of the Cambridge Philosophical Society*, 44:50–57. Cambridge University Press.
- Ray, Wayne A, Marie R Griffin, and Winanne Downey. 1989. “Benzodiazepines of Long and Short Elimination Half-Life and the Risk of Hip Fracture.” *Jama* 262 (23): 3303–7.
- Ray, Wayne A, Marie R Griffin, William Schaffner, David K Baugh, and L Joseph Melton III. 1987. “Psychotropic Drug Use and the Risk of Hip Fracture.” *New England Journal of Medicine* 316 (7): 363–69.

- Reid, Nancy. 2003. "Asymptotics and the Theory of Inference." *The Annals of Statistics* 31 (6): 1695–2095.
- Remein, Quentin R, and Hugh LC Wilkerson. 1961. "The Efficiency of Screening Tests for Diabetes." *Journal of Chronic Diseases* 13 (1): 6–21.
- Richardson, Thomas S, James M Robins, and Linbo Wang. 2017. "On Modeling and Estimation for the Relative Risk and Risk Difference." *Journal of the American Statistical Association* 112 (519): 1121–30.
- Robert, Christian P, and George Casella. 2004. *Monte Carlo Statistical Methods*. Second edition. Springer.
- Robins, James. 1986. "A New Approach to Causal Inference in Mortality Studies with a Sustained Exposure Periodapplication to Control of the Healthy Worker Survivor Effect." *Mathematical Modelling* 7 (9-12): 1393–1512.
- Robins, James M, and Sander Greenland. 1989. "Estimability and Estimation of Excess and Etiologic Fractions." *Statistics in Medicine* 8 (7): 845–59.
- Rogot, Eugene. 1961. "A Note on Measurement Errors and Detecting Real Differences." *Journal of the American Statistical Association* 56 (294): 314–19.
- Roscoe, John T, and Jackson A Byars. 1971. "An Investigation of the Restraints with Respect to Sample Size Commonly Imposed on the Use of the Chi-Square Statistic." *Journal of the American Statistical Association* 66 (336): 755–59.
- Rose, Geoffrey. 1985. "Sick Individuals and Sick Populations." *International Journal of Epidemiology* 14: 32–38.
- Rosenbaum, Paul R, and Donald B Rubin. 1983. "The Central Role of the Propensity Score in Observational Studies for Causal Effects." *Biometrika* 70 (1): 41–55.
- Rothman, Kenneth J. 1975. "A Pictorial Representation of Confounding in Epidemiologic Studies." *Journal of Chronic Diseases* 28 (2): 101–8.
- . 1976. "Causes." *American Journal of Epidemiology* 104 (6): 587–92.
- . 1978. "A Show of Confidence." *New England Journal of Medicine* 299 (24): 1362–63.
- . 1981. "Induction and Latent Periods." *American Journal of Epidemiology* 114 (2): 253–59.
- Rothman, Kenneth J, Sander Greenland, and Timothy L Lash. 2008. *Modern Epidemiology*. Lippincott Williams & Wilkins.
- Routledge, RD. 1992. "Resolving the Conflict over Fisher's Exact Test." *Canadian Journal of Statistics* 20 (2): 201–9.
- Rubin, Donald B. 1974. "Estimating Causal Effects of Treatments in Randomized and Non-randomized Studies." *Journal of Educational Psychology* 66 (5): 688.
- Rubin, Theodore, Joseph Rosenbaum, and Sidney Cobb. 1956. "The Use of Interview Data for the Detection of Associations in Field Studies." *Journal of Chronic Diseases* 4 (3): 253–66.
- Samuels, Myra L. 1981. "Matching and Design Efficiency in Epidemiological Studies." *Biometrika* 68 (3): 577–88.
- Sartwell, Philip E. 1960. "'On the Methodology of Investigations of Etiologic Factors in Chronic Diseases'—Further Comments." *Journal of Chronic Diseases* 11 (1): 61–63.
- Selby, Joe V, Gary D Friedman, Charles P Quesenberry Jr, and Noel S Weiss. 1992. "A Case–Control Study of Screening Sigmoidoscopy and Mortality from Colorectal Cancer."

- New England Journal of Medicine* 326 (10): 653–57.
- Simpson, Edward H. 1951. “The Interpretation of Interaction in Contingency Tables.” *Journal of the Royal Statistical Society: Series B (Methodological)* 13 (2): 238–41.
- Snow, John. 1855. *On the Mode of Communication of Cholera*. Second edition. John Churchill. <https://wellcomecollection.org/works/uqa27qrt>.
- Sorahan, Tom, and Mark S Gilthorpe. 1994. “Non-Differential Misclassification of Exposure Always Leads to an Underestimate of Risk: An Incorrect Conclusion.” *Occupational and Environmental Medicine* 51 (12): 839–40.
- Stolley, Paul D. 1991. “When Genius Errs: RA Fisher and the Lung Cancer Controversy.” *American Journal of Epidemiology* 133 (5): 416–25.
- Swets, John A. 1973. “The Relative Operating Characteristic in Psychology: A Technique for Isolating Effects of Response Bias Finds Wide Use in the Study of Perception and Cognition.” *Science* 182 (4116): 990–1000.
- . 1988. “Measuring the Accuracy of Diagnostic Systems.” *Science* 240 (4857): 1285–93.
- Swift, Michael Bruce. 2009. “Comparison of Confidence Intervals for a Poisson Mean—Further Considerations.” *Communications in Statistics—Theory and Methods* 38 (5): 748–59.
- Thomas, DC. 1977. “Appendum to ‘Methods of Cohort Analysis: Appraisal by Application to Asbestos Mining,’ by Liddell, FDK, McDonald, JC and Thomas, DC.” *Journal of the Royal Statistical Society: Series A (General)* 140: 469–90.
- Tukey, John W. 1960. “Conclusions Vs Decisions.” *Technometrics* 2 (4): 423–33.
- . 1962. “The Future of Data Analysis.” *The Annals of Mathematical Statistics* 33 (1): 1–67.
- Tunbridge, W M G, D C Evered, R Hall, D Appleton, M Brewis, F Clark, J Grimley Evans, E Young, T Bird, and PA Smith. 1977. “The Spectrum of Thyroid Disease in a Community: The Whickham Survey.” *Clinical Endocrinology* 7 (6): 481–93.
- United States Surgeon General’s Advisory Committee on Smoking. 1964. *Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service*. Public Health Service Publication 1103. US Department of Health, Education,; Welfare, Public Health Service.
- Van de Linde, Patrick Anthony Monteuijs, and Gerald Innes Forbes. 1965. “Observations on the Spread of Cholera in Hong Kong, 1961-63.” *Bulletin of the World Health Organization* 32 (4): 515.
- Van der Vaart, Aad W. 2000. *Asymptotic Statistics*. Cambridge University Press.
- Vandenbroucke, Jan P, Erik von Elm, Douglas G Altman, Peter C Gøtzsche, Cynthia D Mulrow, Stuart J Pocock, Charles Poole, James J Schlesselman, Matthias Egger, and Strobe Initiative. 2007. “Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration.” *Annals of Internal Medicine* 147 (8): W–163.
- Vanderpump, MPJ, WMG Tunbridge, JMI French, D Appleton, D Bates, F Clark, J Grimley Evans, et al. 1995. “The Incidence of Thyroid Disorders in the Community: A Twenty-Year Follow-up of the Whickham Survey.” *Clinical Endocrinology* 43 (1): 55–68.
- Vecchio, Thomas J. 1966. “Predictive Value of a Single Diagnostic Test in Unselected Populations.” *New England Journal of Medicine* 274 (21): 1171–73.
- Verkerk, PH, and SE Buitendijk. 1992. “Non-Differential Underestimation May Cause a

- Threshold Effect of Exposure to Appear as a Dose-Response Relationship.” *Journal of Clinical Epidemiology* 45 (5): 543–45.
- Wacholder, Sholom, Patricia Hartge, Jay H Lubin, and Mustafa Dosemeci. 1995. “Non-Differential Misclassification and Bias Towards the Null: A Clarification.” *Occupational and Environmental Medicine* 52 (8): 557.
- Wald, Abraham. 1943. “Tests of Statistical Hypotheses Concerning Several Parameters When the Number of Observations Is Large.” *Transactions of the American Mathematical Society* 54 (3): 426–82.
- Walker, Alexander M, Johan P Velema, and James M Robins. 1988. “Analysis of Case-Control Data Derived in Part from Proxy Respondents.” *American Journal of Epidemiology* 127 (5): 905–14.
- Walter, Samuel D. 1977. “Determination of Significant Relative Risks and Optimal Sampling Procedures in Prospective and Retrospective Comparative Studies of Various Sizes.” *American Journal of Epidemiology* 105 (4): 387–97.
- Wat, Dennis. 2004. “The Common Cold: A Review of the Literature.” *European Journal of Internal Medicine* 15 (2): 79–88.
- Weibull, Waloddi et al. 1951. “A Statistical Distribution Function of Wide Applicability.” *Journal of Applied Mechanics* 18 (3): 293–97.
- Weiss, Noel S. 2002. “Can the ‘Specificity’ of an Association Be Rehabilitated as a Basis for Supporting a Causal Hypothesis?” *Epidemiology* 13 (1): 6–8.
- Whittemore, Alice S. 1978. “Collapsibility of Multidimensional Contingency Tables.” *Journal of the Royal Statistical Society: Series B (Methodological)* 40 (3): 328–40.
- Wilks, Samuel S. 1938. “The Large-Sample Distribution of the Likelihood Ratio for Testing Composite Hypotheses.” *The Annals of Mathematical Statistics* 9 (1): 60–62.
- Williamson, Tyler, Misha Eliasziw, and Gordon Hilton Fick. 2013. “Log-Binomial Models: Exploring Failed Convergence.” *Emerging Themes in Epidemiology* 10 (1): 1–10.
- Wilson, Edwin B. 1927. “Probable Inference, the Law of Succession, and Statistical Inference.” *Journal of the American Statistical Association* 22 (158): 209–12.
- Winkelstein Jr, Warren. 2009. “Florence Nightingale: Founder of Modern Nursing and Hospital Epidemiology.” *Epidemiology* 20 (2): 311.
- Woolf, Barnet. 1955. “On Estimating the Relation Between Blood Group and Disease.” *Annals of Human Genetics* 19 (4): 251–53.
- Yerushalmy, Jacob. 1947. “Statistical Problems in Assessing Methods of Medical Diagnosis, with Special Reference to X-Ray Techniques.” *Public Health Reports (1896-1970)* 62 (40): 1432–49.
- Yerushalmy, Jacob, and Carroll E Palmer. 1959. “On the Methodology of Investigations of Etiologic Factors in Chronic Diseases.” *Journal of Chronic Diseases* 10 (1): 27–40.
- Yland, Jennifer J, Amelia K Wesselink, Timothy L Lash, and Matthew P Fox. 2022. “Misconceptions about the Direction of Bias from Nondifferential Misclassification.” *American Journal of Epidemiology* 191 (8): 1485–95.
- Yule, G Udny. 1897. “On the Theory of Correlation.” *Journal of the Royal Statistical Society* 60 (4): 812–54.
- Zou, Guangyong. 2004. “A Modified Poisson Regression Approach to Prospective Studies

with Binary Data.” *American Journal of Epidemiology* 159 (7): 702–6.

Zweig, Mark H, and Gregory Campbell. 1993. “Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine.” *Clinical Chemistry* 39 (4): 561–77.

A Calculus